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Preface to “Nutrition and Allergic Diseases” 
Dear reader, 
We are very pleased that the special issue "Nutrition and Allergic Diseases" that appeared in the 
online version of the journal Nutrients in 2017 is now available in the form of a book. 
The expanding world population and the economic growth over the last few decades have 
coincided with a sharp increase in the incidence of inhalant allergies (asthma, rhinitis), atopic dermatitis, 
and food allergies on a global scale. The management of allergic diseases poses a challenge for health care 
budgets. So far, the most significant developments in the management of allergic diseases have been 
obtained in the field of allergy treatment.  
As it is becoming increasingly clear that the development of allergies is linked to our environment 
and diet, which affect our microbiological exposure and microbiota composition, we hope that in the 
coming years more effort will be devoted to preventing, rather than treating, allergies. 
Diet during pregnancy, infancy, and childhood may be of key importance to achieve this goal. For 
this reason, the special issue "Nutrition and Allergic Diseases" is highly relevant as well as timely. We are 
very pleased that many leading scientists in the field have contributed to this book, providing an 
overview of the current trends and developments in nutrition and allergy. Of special note is the fact that 
the effects of nutrition on allergy are not limited to food allergy but are also apparent in inhalant allergies, 
such as asthma and rhinitis. 
We hope you enjoy reading this book! 
Joost van Neerven and Huub Savelkoul 
Special Issue Editors 
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It is clear that the development of IgE mediated allergic diseases is influenced by many factors,
including genetic and environmental factors such as pollution and farming, and also by nutrition.
Nutrition can affect the development of allergies during intrauterine development, after birth during
breastfeeding or bottle feeding, and later after weaning when other foods are introduced. In addition,
food can also be used as a tool to actively prevent (via timing of introduction) manage (hydrolyzed
formula), or even treat (immunotherapy) food allergy (Figure 1).
The purpose of this special issue of Nutrients on nutrition and allergic diseases is to provide an
overview of how nutrition can modify allergies. More specifically the issue addresses the influence
of nutrients and foods present in a normal diet on the development of allergies—and via which
mechanisms they can induce these changes. Several reviews and original papers address these
questions. In this editorial review we will briefly touch upon recent developments in the field to
introduce and position some of the papers in this special issue.
Figure 1. Schematic overview of the influence of nutrition on allergic disease. Nutrition can—in addition
to genetic and environmental factors—play an important role in allergic diseases. Dietary components
present in a normal diet may contribute to prevention of allergies (asthma, rhinitis, dermatitis, atopy
and food allergies), promote the development of allergies (food processing, food allergy), and more
specialized foods can be used for the management or even the treatment of food allergy.
2. Maternal Diet, Breastfeeding, and Infant Nutrition & Allergy
The first 1000 days of life are crucial in the growth and development of infants. Especially during
the first year they have a diet of limited variability, mainly consisting of breastmilk and/or
infant formula, followed by the introduction of normal milk and solid foods. As a consequence,
the composition of these foods has a more prominent effect on immune development than later in life,
when the diet is more varied and the immune system has already matured.
The first contact of infants with nutrition is after conception, when the nutritional status of
the mother can already have an impact on intrauterine development of the fetus. In addition,
maternal diet can also influence breast milk composition. Several papers in this issue focus on
the associations between maternal diets with allergy development later in life. McStay et al. reviewed
studies on folic acid supplementation in pregnant women [9], and noted that folic acid intake may
be linked to childhood allergic disease. On the other hand, other maternal diet components, such as
poly unsaturated fatty acids, probiotics, and prebiotics, may have a protective effect on allergy
development [10–13]. The review by Miles in this issue provides an overview of the current knowledge
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on the intake of fish-derived polyunsaturated fatty acids during pregnancy and atopic eczema in the
first year of life [14].
Several, but not all, studies on the association between breastfeeding and allergy have shown
effects on allergic outcomes [15–17]. One of the factors that may explain the conflicting findings
described above may be the result of differences in breastmilk composition [18]. For example, higher
levels of TGF-β in breast milk have been reported to be associated with lower allergy prevalence [19–22],
although also here there are conflicting reports that did not find this association [20,23]. In this issue,
a review and an original study discuss the relationship between breastfeeding, human breast milk
composition, and the development of allergic diseases [24,25].
When avoidance of food allergens is not possible, as is the case in infants with cow’s milk allergy,
hydrolyzed formula foods are used in the management of cow’s milk allergy to prevent allergic
reactions. For infants that are diagnosed with cow’s milk allergy formula consisting of extensively
hydrolyzed milk, soy or rice protein, as well as amino acid formulas are used as reviewed in [26].
For infants at risk of developing cow’s milk allergy, other milk formulas are available. These consist
of milk proteins that are only partially hydrolyzed. As most of the IgE binding epitopes have been
removed by hydrolysis, these hydrolysates may reduce the risk of developing cow’s milk allergies,
although there is no scientific consensus on its efficacy yet [27,28]. This is also discussed in the review
by VandenPlas et al. in this issue [29].
3. Modulation of Microbiota and Allergy in Early Life
The notion that composition and metabolic activity of the intestinal microbiota affects the
development of allergies has become clearer over the last years [30–33].
The intestinal microbiota can be modulated by non-digestible oligosaccharides (human milk
oligosaccharides in breast milk or prebiotic oligosaccharides), a fiber-rich diet, and by probiotics.
The effects of pre-, pro- and synbiotics on allergies—most notably in eczema—has been the subject
of many studies, reviewed in [34–36]. This is also the subject of the review by Hulshof in this issue,
on the management of atopic dermatitis in children [37]. Likewise, Aitoro et al. discuss the potential of
targeting the gut microbiota in food allergy [38].
Exactly how the microbiota composition influences allergy development is not clear at this
point, but data from animal models strongly suggest a protective role for short chain fatty acids
produced upon fermentation of fiber and oligosaccharides (propionate, butyrate, acetate) [11,39,40].
The molecular mechanisms behind the effect of dietary fiber on allergy via microbiota composition
and metabolic activity are discussed in the review by Wypych and Marsland in this issue [41].
4. Normal Dietary Components and Allergy
After weaning and introduction of milk and solid foods into the diet, additional factors may prevent
or contribute to the development of allergies. Essentially, all dietary antigens are proteins, and therefore
highly digestible diets are recommended for food allergic individuals to reduce the number of intact
antigens reaching the Peyer’s patches. Solid foods associated with lowered allergy prevalence include
fruit and vegetables, vitamins, polyunsaturated fatty acids, and (raw) cow’s milk, but the processing
of foods can possibly also affect allergy development [10,42–50]. These food components, as well as
the effects of food processing, are also addressed in the papers by Hosseini et al. (fruit & vegetables),
Brick et al. (milk and processing), and Teodorowicz et al. (food processing) in this issue [51–53].
5. IgE Antibody Characteristics and the Allergic Phenotype
Finally, processing of foods may influence the allergenicity of these foods [47]. This is discussed
in the paper by Teodorowicz et al. in this issue [53]. Heat processing induces Maillard reactions,
“gluing” carbohydrates to food proteins, which as a result become more immunogenic and probably
also allergenic, thus promoting the development of IgE responses to food allergens.
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At present, no identified antibody characteristics and no identified structural features of IgE
binding epitopes seem to be associated with the phenotype of the food allergic disease. Recent studies
have suggested that IgE directed towards linear epitopes may react with foods in processed forms
(heated and digested), while IgE binding to conformational epitopes may be impaired by such
processing because of changes in allergen tertiary structure. In addition, linear epitopes have been
suggested to potentially be biomarkers for a persistent form of food allergy [54].
6. Food Allergy: Early Introduction and Immunotherapy
Even though nutritional guidelines for food allergy and treatment of food allergies are not the
scope in this special issue, several developments deserve attention and will be mentioned briefly below.
Food allergy is an IgE-mediated reaction to a food, usually during the 2 h following its intake.
It represents a health problem that can lead to life-threatening reactions and can even impair quality
of life. Any food can potentially trigger an allergic response; in fact, more than 170 foods have been
identified as being potentially allergenic, but the vast majority of the clinically diagnosed food allergies
are caused by only a few of these foods. Despite relevant advances in the knowledge of food allergy
during the last decades, gaps in this area are evident, especially in relation to introduction of allergenic
foods and in relation to application of food immunotherapy.
As the prevalence of food allergies in many countries continues to rise, the question remains as to
when to introduce specific allergenic solid foods in infants. The current consensus recommendation
by allergologists is to introduce solid foods after 4 months of age to prevent food allergy. This is
documented by observational studies that later introduction of solid foods is linked to an increased
risk of obesity, gastrointestinal disorders and development of allergy. However, current dietary
guidelines still recommend introduction of solid foods at around 6 months of age. The intent of
these guidelines is to prevent replacing breastfeeding with lower energy and nutrient dense foods
(certainly in malnourished communities) beyond 6 months of age, thereby inducing consequential
malnutrition [55].
However, recent studies indicate that early introduction of food allergens into the diet of young
children, as well as the early introduction of diverse foods may actually prevent food allergy [56–58],
suggesting that immune tolerance can be readily induced to food allergens in early life. The results also
suggest that there is no reason to delay the introduction of the allergenic foods into the infant’s diet
after solid foods have started. Nevertheless, some infants are sensitized to food allergens before any
known ingestion of solid foods and future research needs to focus on strategies to prevent early-life
food allergen sensitization prior to complementary feeding [59].
The results from the Learning Early about Peanut Allergy (LEAP) study [56] have led to
consensus statements from international pediatric, allergy and dermatology societies encouraging
and recommending the early introduction of peanut butter, cooked egg, dairy and wheat products to
infants at (even high) risk of developing food allergy. However, besides effectiveness, safety should
also be considered when introducing potential allergens into the diet [60,61].
Finally, for people who have already developed food allergies, much has been done on the
development of new immunotherapies for food allergy. Safe, specific immunotherapy is not currently
available for IgE-mediated food allergy due to the high risk of anaphylaxis. Oral immunotherapy,
epicutaneous immunotherapy, or sublingual immunotherapy for food allergy are increasingly being
studied, and some innovative approaches have been suggested, such as modification of relevant food
allergens (to make them less allergenic while maintaining their immunogenicity), or combining other
non-specific treatments (e.g., probiotics) to increase efficacy and/or safety [62,63].
7. Conclusions
Our understanding of the influence of nutrition on allergic diseases is increasing steadily.
The papers in this special issue provide an overview of current knowledge in the field and identify
several of the directions in which developments are taking place.
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Abstract: From an evolutionary standpoint, allergy has only recently emerged as a significant health
problem. Various hypotheses were proposed to explain this, but they all indicated the importance of
rapid lifestyle changes, which occurred in industrialized countries in the last few decades. In this
review, we discuss evidence from epidemiological and experimental studies that indicate changes
in dietary habits may have played an important role in this phenomenon. Based on the example of
dietary fiber, we discuss molecular mechanisms behind this and point towards the importance of
diet-induced changes in the microbiota. Finally, we reason that future studies unraveling mechanisms
governing these changes, along with the development of better tools to manipulate microbiota
composition in individuals will be crucial for the design of novel strategies to combat numerous
inflammatory disorders, including atopic diseases.
Keywords: Western diet; nutrients; allergy; microbiota
1. Introduction
Allergy is one of the leading health problems in industrialized countries, affecting around
50 million people in the United States alone, and the number of atopic individuals continues to grow.
The hallmark of this disorder is a strong Th2 response with upregulated levels of the interleukin-4 (IL-4),
IL-5, and IL-13, which leads to enhanced immunoglobulin E (IgE) and IgG1 production, cell recruitment
to the site of allergen exposure, and exaggerated immune responses leading to tissue damage.
From an evolutionary perspective, allergies have only recently appeared as a significant health
problem. Therefore, researchers have long linked their emergence with rapid lifestyle changes, which
occurred in the course of hominine evolution. The “hygiene hypothesis” and its derivatives (the
“old friend” and the “biodiversity” hypotheses) pointed to the reduced exposure to environmental
microorganisms and helminths in industrialized countries nowadays [1–3]. The “toxin hypothesis”
underlined the presence of plant-derived toxins in contemporary foods and skin-care products [4].
Dietary habits are another example of these rapid lifestyle changes and hence, different forms of
“diet hypotheses” have emerged [5–7]. The introduction of animal husbandry and agriculture in the
Neolithic period slowly initiated these shifts. The Industrial Revolution and development of better
tools for food processing further escalated them. As a result, new food items were introduced, such as
refined grains, sugars, and vegetable oils, or manufactured salt. In addition to this, development of a
mechanical reaper in 19th century allowed for increased harvest of grains, which coincided with the
development of steam engine and railroads—prerequisites for grain and cattle transportation. This
created a habit of feeding cattle with grain [8], leading to increased saturated fatty acids (SFA) content
and increased ratio of n-6 to n-3 polyunsaturated fatty acids (PUFAs) in their meat [9,10].
The bloom of the aforementioned foods fundamentally influenced nutritional characteristics of
industrialized regions, increasing glycemic load (potential of food to increase blood glucose and, in
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turn, insulin levels), and altering various parameters, including fatty acid composition (elevating levels
of n-6 PUFAs while reducing that of n-3 PUFAs), macro- and micronutrient intake (decreasing protein
and vitamin/mineral density content, respectively), sodium-potassium ratio (increasing Na+ while
reducing K+ levels), and finally, the fiber content (leading to its severe reduction) [8]. As an outcome,
food in the 20th century substantially differed from what our ancestors consumed. Since these changes
occurred so rapidly on an evolutionary scale, our genome could not have adapted to them. This notion
stands behind the hypotheses that contemporary diet may contribute to development of so-called
“lifestyle diseases”.
Unfortunately, developed countries did very little in the last few decades to spread awareness
of this phenomenon and counteract it. The ubiquitous presence of highly processed, high fat, and
high sugar food and drinks has been a major driver in the development of a so-called “Western diet”,
in which the trends mentioned above are amplified to their extremes. For example, consumption of
refined sugars in the United States increased by 24.5% between 2000 and 1970 while that of refined
vegetable oil increased by 170% between the 1990s and the 1940s [8].
In this review, we will look at the epidemiological and experimental evidence that these changes
may predispose individuals to develop allergies and reason why current trends in dietary habits of
Western civilization might constitute a health threat.
2. Nutrients and Epidemiology of Allergy
One of the earliest notions that nutrients might influence allergic diseases was introduced in
the late 1980s when an association between sodium intake and asthma was reported [11,12]. These
data were backed-up by several other groups studying asthma in both adults and children [13–15],
and although their conclusions were not consistently supported [16–18], they pioneered the notion
that diet may influence development of allergy. Soon after the “sodium hypothesis”, other diet
hypotheses emerged. In 1990, Schwartz and Weiss analyzed data from the Second National Health
and Nutrition Examination Survey, taking into account various antioxidants, including vitamin C.
This study revealed a negative association between vitamin C intake and bronchitis/wheezing [13],
a conclusion that was supported by some, but not all, subsequent studies [19–22]. However, trials
to control asthma progression via dietary vitamin C supplementation brought disappointing results,
questioning the significance of vitamin C in allergy prevention [23,24]. Similar discrepancies were
found for other antioxidants, such as vitamin E, β-caroten, or selenium [19,22,25,26].
Soon after the antioxidant hypothesis, the link between increased intake of n-6 and reduced
consumption of n-3 PUFAs with atopy and asthma was suggested [27–29]. However, as in the
case of the antioxidant hypothesis, observational studies brought inconsistent results, with some
of them supporting it [30–33], some disputing it [34–36], and some even indicating the opposite
correlation [37,38]. Similar to the antioxidant hypothesis, interventional studies aiming to improve
asthma severity via modification of fatty acid intake have been disappointing [5–7].
One factor which might play a significant role is whether the nutrient is assimilated via diet
modification or supplement administration. Observational studies cited in this manuscript relied
on food questionnaires and blood or urine analysis and did not provide information regarding
this issue [13,15,16,18,19,21,26,30,31,33–35,37,38]. Its potential importance is exemplified in the
interventional study by Troisi et al., who dissected the influence of nutrients rich in vitamin C and
E from vitamin C or E supplementation [25]. Interestingly, diet-derived vitamin E was inversely
associated with asthma, while in the case of supplement-derived vitamin E, a positive association was
found. Comparatively, there was no significant influence of diet-derived vitamin C on asthma, while
supplement-derived vitamin C correlated positively with this condition [25]. Comparison of the impact
of diet and supplement-derived nutrients on allergic conditions will be important for future studies.
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3. Milk and Epidemiology of Allergy
Milk is not solely a source of nutrients but contains various other components, such as
immunoglobulin A, cytokines, bacterial metabolites, and, in the case of unpasteurized milk, live
bacteria. Considering this, we are describing the relationship between milk consumption and allergy in
a separate paragraph, starting with the intake of milk from breastfeeding mothers in infancy, followed
by consumption of unpasteurized milk.
3.1. Breastfeeding
Breastfeeding is one of the few features linking dietary habits of people today with that of our
evolutionary ancestors. The sole fact that it is so highly conserved among mammals highlights its
important physiological role. For this reason, it has long been speculated that breastfeeding may protect
against development of atopic diseases. One of the first studies to support this idea was published in
1936 when an inverse relation between breastfeeding and infantile eczema was reported [39]. Since then,
a number of studies supported the protective role of breastfeeding against atopy in infancy [40–44].
Importantly, Saarinen and colleagues followed up on individuals for 17 years, showing that the
protective effect of breastfeeding was maintained during childhood and adolescence [45]. Also,
additional studies focusing on children reached similarconclusions [33,46–48].
However, not all studies confirmed this. In the study by Hide and Gruyer initiated in 1981,
breast-fed children had the same (in the case of asthma) or even increased (in the case of eczema) risk
of developing atopic disease [49]. Also, Wright and colleagues reported that beginning at the age of
6 years, breastfeeding was no longer associated with protection from recurrent wheeze and, in fact,
carried an increased risk in the case of atopic children with asthmatic mothers [50]. No protection
against asthma or even elevated risk for its occurrence was also reported by other studies [51–53]. The
reasons for these discrepancies are not clear, although they might have been caused by variation in milk
composition between individuals. Of note, infant formulas have greatly changed over past decades,
which constitutes another variable to consider. However, many studies cited above were performed in
different decades but reached similar conclusions while others were performed in the same decade
but reached conflicting results. These examples suggest that decade-dependent differences in infant
formula composition may not be a major confounding factor.
In order to clarify the inconsistencies between the studies, meta-analyses of published reports
were undertaken. An analysis of 12 studies concerning bronchial asthma pointed towards an inverse
association between breastfeeding and occurrence of this disease during childhood [54]. Also, an
analysis of 18 studies regarding atopic dermatitis reached similar conclusions, but the effect was
restricted to children with a family history of atopy [55]. Another meta-analysis of six studies
underlined a protective role of breastfeeding in the development of allergic rhinitis [56]. Finally,
the most comprehensive meta-analysis regarding asthma to date, taking into account 117 studies,
found that breastfeeding was a factor reducing the risk of childhood asthma, with the strongest
association in infants (0–2 years) [57].
Collectively, although there is still controversy in the field, most studies conclude that
breastfeeding protects infants and children from developing allergic diseases [58,59]. The underlying
mechanisms are not clear at present but may be associated with immunological components of
breast milk (e.g., immunoglobulin A and its immune complexes, cytokines), antigens (e.g., allergens),
prebiotics (e.g., human milk oligosaccharides), bacteria and bacterial metabolites, and/or others.
Interestingly, many of these components (e.g., IgA [60], human milkoligosaccharides [61], human
milk microbiota [62]) have the potential to influence the microbiota and the homeostasis of infant’s
intestines, which may be of importance for the development of immune tolerance later in life. Detailed
description of these putative mechanisms is beyond the scope of this review. Instead, the reader is
referred to other recent publications in this field [61–66].
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3.2. Unpasteurized Cow’s Milk
It has been well documented that growing up on a farm protects against development of
allergies [67]. One of the proposed factors playing a role in this protection is consumption of
raw milk. Indeed, a cross-sectional survey in rural areas of Austria, Germany, and Switzerland
inversely associated raw milk consumption with asthma, hay fever, and allergic sensitization [68]. This
conclusion has been supported by a cross-sectional multi-center study including almost 15,000 children
from five European countries [69]. Also, similar results were obtained by others. For example,
Wickens and colleagues found a protective effect of unpasteurized milk consumption against atopic
eczema/dermatitis syndrome among farm children from New Zealand [70]. Perkin and Strachan
found that consumption of unpasteurized milk protected against development of eczema and atopy in
rural England [67]. Finally, the GABRIELA study reported an inverse association between raw milk
consumption and asthma, atopy, and hay fever in children from rural areas of Austria, Germany, and
Switzerland [71]. Taken together, there is strong evidence that consumption of raw milk early in life
protects against development of allergies, perhaps even more convincing than the possible protective
effect of breastfeeding. On the other hand, it must be emphasized that raw milk may contain certain
human pathogens, such as Salmonella spp., Campylobacter spp., human pathogenic Escherichia coli,
and Listeria monocytogenes. Therefore, its consumption carries risk for serious infectious diseases and
milk processing (pasteurization or ultra heat treatments) effectively minimizes this risk. For this
reason, raw milk consumption is not a general solution for allergy prevention. Instead, identification
of the mechanisms behind its protective action will be essential for designing novel prophylactic
and therapeutic strategies for allergic diseases. Similarly as in the case of breast milk, various
mechanisms may play a role, including bovine immunoglobulins, cytokines and oligosaccharides [72],
fatty acids [73], miRNA [74], antigens [71], milk microbiota [75], and others. Detailed description of
these potential mechanisms is beyond the scope of this review and has been covered elsewhere [72,76].
4. Dietary Fiber and the Lung Function
Western diets are often rich in fat and processed foods, but low in fiber [8]. For this reason, a
notion that fiber consumption may reduce symptoms of asthma has been hypothesized [77]. This has
been based upon studies using mouse models (discussed in the next chapter) as well observational
studies linking fiber intake with improved lung function [78–81]. Kan and colleagues were the first
to observe a positive association between fiber intake and better lung function in chronic obstructive
pulmonary disease (COPD). Statistically significant trends were found for total fiber intake, cereal
fiber, and fruit fiber [78]. Similar conclusions were reached by Varasso et al., who found a negative
association between total and cereal fiber intake and the risk of newly diagnosed COPD [79]. An
inverse association between dietary fiber and impaired lung function was also found in the case of
asthma. Berthon and colleagues compared dietary intake patterns between patients suffering from
severe persistent asthma and healthy individuals. Interestingly, a positive association was found for fat
(total and monounsaturated fatty acids) and sodium intake while an inverse correlation was observed
for fiber and potassium intake [80]. Finally, Root et al. surveyed 15,567 American subjects for their
dietary habits and correlated calculated macronutrient intake with their lung function. Total calories
as well as saturated fatty acids were inversely associated with the pulmonary function [measured
by the ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC)], while for
dietary polyunsaturated fatty acids, long-chain omega-3 fatty acids, dietary fiber, and animal protein,
a positive correlation was found [81]. Given the above evidence, Halnes and co-workers hypothesized
that high-fiber meal challenge may ameliorate symptoms in asthmatic patients. They recruited
29 individuals with stable asthma and divided them in two groups: 17 patients were challenged with a
soluble fiber meal and 12 of them with a control meal. Interestingly, patients receiving a soluble fiber
meal had decreased levels of several airway inflammation biomarkers 4 hours post-challenge, including
exhaled nitric oxide, sputum total cell, neutrophil, lymphocyte, and macrophage counts as well as
sputum IL-8 protein concentration. Intriguingly, these changes correlated with increased expression
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of GPR41 and GPR43 in the sputum of these patients, suggesting the mechanistic basis for these
beneficial changes [77]. The possible importance of GRP41 and GPR43 in triggering anti-inflammatory
mechanisms downstream of fiber intake will be discussed in detail in the next chapter.
In conclusion, various nutrients have been proposed in the past to influence risk for allergy
development and many epidemiological studies have been launched to investigate their impact.
Although “diet hypotheses” are still controversial, it seems that certain nutrients may indeed confer
protection, especially in the case of consumption of raw milk. However, epidemiological studies
regarding many other nutrients are scarce, including intake of dietary fiber, which has dramatically
reduced over the last centuries. In the next section, we will discuss the potential role for dietary
fiber intake in protection against diseases, including allergy, based on experimental data using
mouse models.
5. Dietary Fiber, Short-Chain Fatty Acids, and Susceptibility to Diseases: Lessons Learned from
Animal Studies
Anti-inflammatory properties of butyrate, a short-chain fatty acid produced by fermentation
of soluble fibers by commensal bacteria in the gut, have long been recognized. Although initially
proposed to exert its function through restoration of energy metabolism in colonocytes [82], later
research rather supported its immunomodulatory properties, based on experiments in vitro [83–86].
Apart from the butyrate, in vitro anti-inflammatory properties of other short-chain fatty acids, such as
propionate and acetate, have also been proposed [87].
An important step towards unraveling the mechanisms behind short-chain fatty acids (SCFA)
action came with identification of G-protein-coupled receptors GPR41 and GPR43 as their extracellular
receptors [88,89]. The physiological importance of this finding was first highlighted in a study showing
that the protective role of acetate in a mouse model of colitis was dependent on GPR43 [90], although
this did not appear to be the case in a mouse model of allergic inflammation, where the effects of
acetate did not require GPR43 [91]. Similar discrepancy was observed in the case of propionate. While
exerting its anti-inflammatory properties via GPR43 in a mouse model ofcolitis [92], in a mouse model
of allergic airway inflammation it was GPR41 but not GPR43 that played a major role [93]. The reasons
for these differences are not clear. Finally, GPR109a has been reported as a low-affinity receptor for one
of the short chain fatty acids, butyrate [94], and the physiological importance of this finding has been
demonstrated in a mouse model of colitis [95,96] and food allergy [97].
Regardless of the surface receptor responsible for the initial recognition of short-chain fatty acids,
many studies have focused on downstream mechanisms mediating their anti-inflammatory properties.
For example, propionate and butyrate were shown to induce differentiation of regulatory T cells
in vitro and in vivo and this process coincided with increased histone H3 acetylation inTregs [92], or
more specifically, of Foxp3 regulatory elements [98,99]. Smith and colleagues proposed that propionate
acts directly via GPR43 on colonic Tregs to induce these effects [92]. However, Arpaia et al. pointed
out that in the case of butyrate, in addition to imprinting epigenetic effects directly on Tregs, it may
also endow dendritic cells with superior capacity to drive differentiation of this subset [99]. Similar
conclusions were drawn by Singh and colleagues who demonstrated that colonic dendritic cells (DCs)
and macrophages from GPR109a-deficient mice were defective in inducing Treg cell differentiation
in vitro [95]. Interestingly, in the mouse model of airway allergic inflammation, anti-inflammatory
properties of propionate were not linked to Treg cells but rather to DC function, since propionate
treatment in vivo did not affect Treg cell numbers but impaired the ability of dendritic cells to drive
Th2 responses [93]. Finally, Macia et al. implicated inflammasome activation as a mechanism through
which short chain fatty acids confer protection in a dextran sulfate sodium (DSS)-induced mouse
model of colitis [96].
The mechanisms behind anti-inflammatory properties of acetate are also controversial.
Furusawa et al. [98] and Arpaia et al. [99] suggested that acetate, unlike propionate and butyrate,
lacks HDAC inhibitory properties and fails to induce Treg differentiation in vitro and in vivo. In the
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study by Fukuda et al., the authors suggest that the protective effects of acetate in their model of
enteropathogenic infection may rely on its ability to induce anti-apoptotic and anti-inflammatory gene
expression in colonic epithelial cells as well as on its capacity to increase transepithelial electrical
resistance [100]. However, Thorburn and colleagues reached different conclusions based on their
model of allergic airway inflammation. They observed increased acetylation levels of histones at the
Foxp3 promoter, elevated numbers of Treg cells and their enhanced suppressive activity upon feeding
mice with acetate in the drinking water. Importantly, they concluded that the protective effect of
acetate in their model of allergic inflammation was dependent on this subset of cells, as Treg depletion
abrogated its beneficial role [91].
Since short-chain fatty acids are mostly products of bacterial fermentation of nutrients, the
question regarding the interplay between SCFA production, diet, and microbiota composition has been
raised. In a study from our group, some light onto these complex interactions was shed. Mice fed on a
high fiber diet had increased ratio of Bacteroidetes/Firmicutes abundance in the gut and lungs and this
coincided with increased cecal and serum levels of SCFA [93]. A similar observation was reported in
the study by Thorburn and colleagues [91]. Of note, Bacteroidetes are known to be efficient at fermenting
fiber into SCFAs, supporting a causative relationship between increased SCFA and the increase of
Bacteroidetes. Nevertheless, since SCFA may also be produced by other phyla, the importance of
Bacteroidetes increase in these models should be investigated further. Overall, it is important to note
that high fiber diet protected mice against allergic airway inflammation, underlining that protective
effects of SCFA are not restricted to the gut, but can influence other peripheral tissues [91,93].
The importance of high fiber diet-induced microbiota changes has also been implicated in a
mouse model of colitis [96]. The authors linked the protective role of high fiber diet in this model
with inflammasome activation. Interestingly, re-colonization of germ-free mice with microbiota from
mice fed on a high fiber diet resulted in increased levels of IL-18 secretion and caspase-1 activity in
comparison to the control group [96]. Further insights into the diet-microbiota-SCFA axis were gained
by Tan and colleagues [97]. First, they noted that high fiber diet, which protected mice against peanut
allergy, changed intestinal microbiota composition and increased levels of SCFA. In order to dissect
the impact of these two factors, they re-colonized germ-free mice with fecal matter from mice fed on
low-fiber or high fiber diets and showed that the latter were protected against peanut allergy despite
having similar levels of SCFA. This indicated that the protective effect of fiber feeding in this model
was not due to these metabolites. However, SCFA supplementation was also able to confer similar
protection. Therefore, the authors propose that two mechanisms play a role upon feeding mice with
a high fiber diet. Importantly, the effects of this diet relied on epithelial GPR43 and immune cell
GPR109a, since feeding GPR43 or GPR109a-deficient mice with high fiber diet no longer protected
mice against peanut allergy [97].
6. Dietary Fats and Susceptibility to Diseases
As previously mentioned, Western diet contains elevated levels of dietary fats [8]. For this
reason, it has long been hypothesized that higher fat intake might be implicated in elevated risk
for disease occurrence, including allergy. High fat diet-induced obesity could have a significant
contribution to this. Indeed, a positive association between obesity and allergy is well documented in
epidemiological studies [101–104] as well as in animal models of allergy [105–108]. Description of the
current knowledge regarding this issue is beyond the scope of this review. Instead, the reader is referred
to several recent reviews in this field [109–112]. However, it could be hypothesized that high fat diet
enhances susceptibility to allergy independently of obesity. Increased free fatty acid release itself could
be immunomodulatory and influence disease susceptibility. The effects of high fat meals independently
of obesity have been shown in asthmatic patients. In the study by Wood et al., non-obese asthmatic
patients receiving a high-fat meal had increased levels of TLR4 mRNA and neutrophils in their sputum
cells in comparison to subjects receiving a low-fat meal [113]. In an animal model of allergy, although
pups born from mothers fed on a high fat diet did not have increased body weight or blood glucose
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levels, they displayed a more severe anaphylaxis score after oral sensitization to peanut protein [114].
This study underlined transgenerational effects of high fat diet independently of major confounders,
such as obesity or diabetes; however, the exact components of a high fat diet which could imprint these
changes were not defined. Saturated fatty acids, which are major components of a high fat diet, could
be involved, as their pro-inflammatory potential is well established [115]. Polyunsaturated omega-6
fatty acids could also contribute to this, as they have been described to enhance allergic responses in
mouse models of asthma [116–118]. Finally, monounsaturated fatty acids are also candidates, as they
constitute a major component of high fat diets, although their immunomodulatory potential in the
context of allergy remains unexplored.
Overall, high fat diet may influence susceptibility to allergy through obesity or directly through
nutritional composition. Regarding the latter, dietary fatty acids contained within the diet have the
potential to induce pro-inflammatory responses. Decreased content of dietary fiber in high fat diets
may at the same time lead to downregulation of anti-inflammatory pathways, further escalating the
imbalance between pro- and anti-inflammatory responses. Further research is needed to establish
the potential of dietary components of high fat diets to influence allergic responses and decipher the
molecular mechanisms they trigger.
7. Conclusions and Perspectives
Lifestyle changes, which most rapidly occurred in the last century, have been proposed to
increase susceptibility to allergies. The hygiene hypothesis suggested the role of decreased contact
with environmental microbes and helminths in this phenomenon, while diet hypotheses pointed
towards the importance of changes in dietary habits. The microbiota seems to be a common
component of these two views, as it is shaped by various external factors, including environmental
microorganisms and diet (Figure 1). Given the vast impact the microbiota exerts on immune responses
and susceptibility to diseases, it is crucial to integrate both views and understand how environmental
cues influence microbiota composition. Unraveling this may lead to clearer distinctions between
pathogenic and beneficial species and indicate ways to manipulate them. This holds promise for the
development of novel therapeutic approaches targeting the microbiota for prevention and treatment of
inflammatory disorders.
Environmental microbes Diet 
Microbiota composition 
Disease susceptibility 
Figure 1. The cross-talk between environmental microorganisms, diet and microbiota composition and
its impact of disease susceptibility.
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Abstract: The gut microbiota plays a pivotal role in immune system development and function.
Modification in the gut microbiota composition (dysbiosis) early in life is a critical factor affecting the
development of food allergy. Many environmental factors including caesarean delivery, lack of breast
milk, drugs, antiseptic agents, and a low-fiber/high-fat diet can induce gut microbiota dysbiosis,
and have been associated with the occurrence of food allergy. New technologies and experimental
tools have provided information regarding the importance of select bacteria on immune tolerance
mechanisms. Short-chain fatty acids are crucial metabolic products of gut microbiota responsible for
many protective effects against food allergy. These compounds are involved in epigenetic regulation
of the immune system. These evidences provide a foundation for developing innovative strategies to
prevent and treat food allergy. Here, we present an overview on the potential role of gut microbiota
as the target of intervention against food allergy.
Keywords: cow’s milk allergy; diet; immune tolerance; dysbiosis; probiotics; short chain fatty
acids; butyrate
1. Introduction
During the last several decades, a changing patterns in the epidemiology of food allergy [FA]
have been observed, with an increased prevalence, severity of clinical manifestations, and risk of
persistence until later ages [1]. Atopic family history, ethnicity, atopic dermatitis (AD), and related
genetic polymorphisms have been associated with FA development [2]. Although genetic factors may
predispose individuals to the development of FA among selected individuals, they cannot explain the
changes in epidemiology over this short time frame, suggesting that environmental factors promote
FA [3]. FA develops following loss of immune tolerance, which results in allergic sensitization and
subsequent disease manifestation and progression.
The initial exposure to food allergens occurs predominantly via the gastrointestinal tract or skin.
An impaired skin barrier could lead to increased transcutaneous passage of antigens and subsequent
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sensitization. An association between the early onset of AD and development of FA has been shown [4].
In the gastrointestinal tract, the two main factors influencing immune tolerance are dietary factors and
microbiota composition and function [5]. Kim et al. demonstrated that under normal physiological
conditions, macromolecules from the diet induce the bulk of regulatory T cells (Tregs) development,
which is essential for suppressing a default immune response to dietary antigens [5]. Observational
studies have suggested that the early introduction of peanut [6], egg [7], or cow’s milk [8] may prevent
the development of allergy to these foods. A randomized controlled trial (Learning Early about
Peanut Allergy, LEAP) showed that the early consumption of peanut in high-risk infants with severe
eczema, egg allergy, or both reduced the development of peanut allergy by 80% by 5 years of age [9].
The Persistence of Oral Tolerance to Peanut (LEAP-On) study showed that the absence of reactivity is
maintained in these subjects [10].
The gut microbiota could be defined as the trillions of microbes that collectively inhabit the gut
lumen [4,11], and increasing evidence shows that altered patterns of microbial exposure [dysbiosis]
early in life can lead to FA development by negatively influencing immune system development [12].
Thus, the gut microbiota could be considered a potential target for preventive and therapeutic
intervention against FA. Recent studies have reported the efficacy of intervention in the gut microbiota
against FA.Here, we review the current understanding of the potential role of gut microbiota as
potential target against FA.
2. Importance of Microbial Exposure for the Development of Immune Tolerance
Immune tolerance is the state of unresponsiveness of the immune system to substances or
tissues that have the potential to induce an immune response. Tolerance is achieved through both
central tolerance and peripheral tolerance mechanisms [13]. The exact mechanisms involved in the
development of immune tolerance have not been not fully defined [14]. Current evidence suggests
that the gut microbiota and its metabolites (mainly short chain fatty acids), together with to exposure
to dietary factors in early life, critically influence the establishment of immune tolerance to food
antigens [5] (Figure 1). Germ-free mice are unable to achieve immune tolerance to food antigens [15].
During the early stage of post-natal life, development of the gut microbiota parallels maturation
of the immune system [16]. During vaginal delivery, infants receive their first bacterial inoculum
from the maternal vaginal tract, skin tissue, and often fecal matter, exposing the immature immune
system of newborns to a significant bacterial load [17]. Maturation of a healthy gut microbiota in early
life allows for a change in the Th2/Th1 balance, favoring a Th1 cell response [18], while dysbiosis
alters host-microbiota homeostasis, favoring a shift in the Th1/Th2 cytokine balance toward a Th2
response [19]. Gut microbes induce the activation of Tregs which are depleted in germ-free mice [20].
Microbiota-induced Tregs express the nuclear hormone receptor RORγt and differentiate along a
pathway that also leads to Th17 cells; while in the absence of RORγt in Tregs, there is an expansion
of GATA-3-expressing Tregs, as well as conventional Th2 cells, and Th2-associated pathology is
exacerbated [21]. Moreover, it has been demonstrated that under normal physiological conditions,
macromolecules obtained via the diet induce Treg cell development in the small intestinal lamina
propria, which is essential for suppressing the default strong immune response to dietary antigens [5].
The presence of both diet- and microbe-induced populations of Treg cells may be required to induce
complete tolerance to food antigens [5].
It has been speculated that microbiota can activate MyD88 signaling in the lamina propria and
follicular dendritic cells (DCs) [22]. Mucosal plasma cells, upon induction by DCs, produce secretory
IgA (sIgA). The sIgA system is considered important in the pathogenesis of FA. Delayed development
of IgA-producing cells or insufficient sIgA-dependent function at the intestinal surface barrier appears
to contribute substantially to FA [21]. This agrees with previous study of minor dysregulations of
both innate and adaptive immunity (particularly low levels of IgA) in children with multiple FAs [23].
Furthermore, the gut microbiota stimulates DCs in the Peyer’s patches to secrete transforming growth
23
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factor (TGF)-β, C-X-C motif chemokine ligand 13, and B-cell activating protein, which leads to IgA
production and class switching [24].
 
Figure 1. Immune tolerance network in the intestinal lumen: interaction between microbiome and
the gut immune system in early-life. The immune tolerance network is mainly composed by the
well-modulated activity of different components: gut microbiota (without gut microbiota, it is not
possible to achieve oral tolerance); dietary factors (mainly dietary peptides, as amino acids are unable
to drive immune tolerance); epithelial cells; dendritic cells; and regulatory T cells. Food antigens
and intestinal microbiota constitute the majority of the antigen load in the intestine. CX3CR1+ cells
(likely macrophages) extend dendrites between intestinal epithelial cells, sample antigens in the gut
lumen, and transfer captured antigens via gap junctions to CD103+CCR7+ dendritic cells (DCs). This
subset of DCs migrates from the lamina propria to the draining lymph nodes, where the DCs express
transforming growth factor-β (TGFβ), retinoic acid (RA), interleukin-10 (IL-10) and also express the
enzyme indoleamine 2,3-dioxygenase (IDO), thereby inducing naïve CD4+ T cells to differentiate into
regulatory T (Treg) cells. Macrophages also appear to secrete IL-10, leading to Treg cell proliferation.
Treg cell express integrin α4β7, which results in homing to the gut where Treg cells may dampen the
immune response. CD103+ DCs also sample antigens that pass through the epithelial barrier via M
cell-mediated transcytosis or by extending a process through a transcellular pore in an M cell. Recent
evidence suggests a role for regulatory B cells in activating Tregs after stimulation with microbial
factors recognized by Toll-like receptors. B cell clones expressing antibodies specific for food allergen
may undergo isotype switching in secondary lymphoid organs with the aid of follicular T helper (TFH)
cells. Food tolerance is associated with IgA. For a broader prospective, the complex interaction between
intestinal contents and immune and non-immune cells creates an environment that favors tolerance by
the inducting IgA antibodies and Tregs, which produce IL-10, a molecule crucial for the induction of
tolerance to food antigens.
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Accordingly, it has been recently demonstrated that dietary elements, including fibers and vitamin
A, are essential for the tolerogenic function of CD103+ DCs and maintenance of mucosal homeostasis,
including IgA production and epithelial barrier function [25].Moreover, in experimental studies, some
mice are protected from the development of FA (non-responders) compared with animals showing
marked systemic FA symptoms after immunizations [26,27]. This differential immune response is
associated with a distinct microbiota composition in mice with a non-responding phenotype [28].
Recent findings have also suggested that neonatal gut microbiome dysbiosis promotes CD4+ T cell
dysfunction associated with allergy [29] and supports age-sensitive interactions with microbiota [30].
Early-life may be a key “window of opportunity” for intervention given the age-dependent association
of the gut microbiome and FA outcomes [31].The microbiota also promotes B cell receptor editing
within the lamina propria upon colonization [32]. Regulatory B (Breg) cells are characterized by
their immunosuppressive capacity, which is often mediated by interleukin (IL)-10 secretion, but also
IL-35 and TGF-β production [33]. An additional immunoregulatory role is the up-regulation of IgG4
antibodies during differentiation to plasma cells. Several studies have demonstrated a potential role
for Breg in the induction and maintenance of the tolerance mechanism [34–36]. Several types of Bregs
with distinct phenotypic characteristics and mechanisms of suppression have been described [34–36];
therefore, additional studies are necessary to understand the effective role of Bregs in oral tolerance.In
addition, there is a body of data reporting the activation of non-immune pathways in food oral
tolerance. Data suggest that a healthy gut microbiota may protect against allergic sensitization
by affecting enterocyte function and regulating its barrier-protective properties. Similarly, innate
lymphoid cells (ILCs) that are abundant in mucosal and barrier sites are involved in these defence
mechanisms [37]. While several subsets of ILCs have been identified, particular attention has been
given to ILC3 and its interactions with the microbiota. Among other factors, these cells produce IL-22,
a cytokine of central importance in maintaining tissue immunity and physiology via its pleiotropic
action in promoting antimicrobial peptide production, enhancing epithelial regeneration, increasing
mucus production, and regulating intestinal permeability [38]. How the microbiota affects the turnover
of ILC3 remains unclear, but recent evidence supports that defined commensals preferentially impact
this subset. Particularly, Clostridia-induced IL-22 has been demonstrated to be an innate mechanism
by which the microbiota can regulate the permeability of the epithelial barrier and contribute to
protection against food allergen sensitization [15]. In contrast, gut microbiota dysbiosis induces
alterations in intestinal epithelial function resulting in aberrant Th2 responses toward allergic, rather
than tolerogenic, responses [39].
3. Gut Microbiota in FA
Epidemiological studies have established a correlation between factors that disrupt the microbiota
during childhood and immune and metabolic conditions later in life. Several factors responsible for
dysbiosis have been associated with the occurrence of FA, such as caesarean delivery [40], lack of breast
milk [41], drug use (mainly antibiotics and gastric acidity inhibitors) [42], antiseptic agent use, and low
fiber/high fat diet [43] (Figure 2). Emerging data from human studies link the use of antimicrobial
agents to the increasing prevalence of FA. Neonatal antibiotic treatment reduced microbial diversity
and bacterial load in both fecal and ileal samples and enhanced food allergen sensitization [15]. Even
low-dose early-life antibiotic exposure can lead to long-lasting effects on metabolic and immune
responsiveness [44]. Maternal use of antibiotics before and during pregnancy, as well as antibiotic
courses during the first months of life, are associated with an increased risk of cow’s milk allergy
(CMA) in infants [45].
Data characterizing the microbiota of patients with FA are still preliminary because of multiple
environmental stimuli that profoundly influence the composition of the gut microbiota [46]. Some
studies have failed to identify differences in infant microbiota according to later allergic status, or
have found different changes in gut microbiota depending on the cases and groups of subjects.
Although compelling evidence for the association of gut microbiota dysbiosis with FA is emerging,
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heterogeneities in study design, including sampling time points, methods used to characterize the
microbiota, and different allergic phenotypes under study, make it difficult to establish a clear
correlation between specific bacterial taxa and allergy development. To better identify microbiota
changes associated with the emergence of FA, well-phenotyped birth cohorts are needed with long-term
follow up.
First studies using bacterial cultures showed that infants allergic to cow’s milk had higher total
bacteria and anaerobic counts [47]. There was no association between culturable bacteria and food
sensitization by 18 months of age in three cohorts of European infants [48]. Kendler et al. found no
association between culturable gut bacteria and sensitization to food including milk, egg, peanut,
and hazelnut [49].Pyrosequencing technology can identify approximately 80% more bacteria in the
gut than those identified by conventional culture-based methods, revealing the high complexity
and diversity of the gut microbiota.Recent evidence suggests that gut dysbiosis precedes FA and
influences during early life affected the subsequent development of allergic disease [50]. Nakayama et
al. profiled the fecal bacteria compositions of allergic and non-allergic infants and correlated changes
in gut microbiota composition with allergy development in later years [51]. They found that in
the allergic group, the genus Bacteroides at 1 month and genera Propionibacterium and Klebsiella at 2
months were more abundant, while the genera Acinetobacter and Clostridium at 1 month were less
abundant than in the non-allergic group [51]. Additionally, the relative abundance of total Proteobacteria,
excluding genus Klebsiella, was significantly lower in the allergic than in the non-allergic group at
the age of 1 month. Allergic infants with high colonization of Bacteroides and/or Klebsiella showed
less colonization of Clostridium within the major phylotypes, suggesting antagonism between these
bacterial groups in the gut. Bacteroides are sensitive to short-chain fatty acids (SCFAs), particularly
under low pH conditions [52], suggesting that the observed antagonism is attributable to an SCFA
produced by Clostridium [52]. Azad et al. found that an increased Enterobacteriaceae/Bacteroidaceae ratio
and low Ruminococcaceae (Clostridia class) abundance, in the context of low gut microbiota richness in
early infancy, are associated with subsequent food sensitization, suggesting that early gut dysbiosis
contributes to subsequent development of FA [53]. A low level of microbial diversity with reduced
Clostridiales, and increased Bacteroidales have been also observed in the gut microbiota of allergic
patients [54].
Cross-sectional studies comparing the intestinal microbial composition of food allergies in healthy
subjects have also been performed. Fecal microbial composition was assessed using 16 S rRNA
sequencing to determine the differences between children with FA (n = 17 with IgE-mediated FA,
n = 17 with non-IgE-mediated FA) and healthy controls (n = 45) [55]. There was no difference in
microbial diversity between groups. Subjects with IgE-mediated FA showed increased levels of
Clostridium sensu stricto and Anaerobacter (Clostridia class) and decreased levels of Bacteroides and
Clostridium XVIII. Levels of C. sensu stricto were also correlated with the levels of IgE [56]. Chen et al.
recently showed that children with food sensitization in early life have an altered fecal microbiota and
lower microbiota diversity compared to healthy controls. Children with food sensitization showed
significantly decreased numbers of Bacteroidetes and a significantly increased number of Firmicutes
compared to healthy children. The most differentially abundant taxa in children with food sensitization
were characterized by increased abundances of Clostridium IV and Subdoligranulum (Clostridia class)
and decreased abundances of Bacteroides and Veillonella (Clostridia class) [56]. Recently, enriched taxa
from the Clostridia class and Firmicutes phylum were observed in children with a more favourable
CMA disease course [57]. Accordingly, a low abundance of some sub-taxa belonging to Clostridia may
be associated with the development of FA. The Clostridia class has become one of the largest genera of
bacteria, and presently contains more than 100 species. Some Clostridia groups possess pathogenic
species; however, most Clostridia have a commensal relationship with the host [58].In agreement with
this view, a pivotal study by Atarashi et al. showed that the spore-forming component of gut microbiota,
particularly clusters IV and XIVa of the genus Clostridium, promoted Tregs accumulation in the colonic
mucosa. Colonization of mice by a defined mix of Clostridium strains provided an environment rich
26
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in TGF-β and affected the number and function of colonic Tregs expressing the Foxp3 transcription
factor (Foxp3+ Tregs) [59]. Foxp3+ Tregs play a critical role in oral tolerance [60]. In a subsequent study,
Atarashi et al. isolated 17 strains within Clostridia clusters XIVa, IV and XVIII from a human fecal
sample and demonstrated that these strains affect Tregs differentiation, accumulation and function in
mouse colon [61].
Many bacterial metabolites are an important communication tools between the host immune
system and commensal microbiota, establishing a broad basis for mutualism [62]. Among these,
SCFAs are among the most abundant, and play a critical role in mucosal integrity, and local and
systemic metabolic function, and stimulate regulatory immune responses [63–65]. Clostridia species
belonging to cluster IV and XIVa are prominent source of SCFAs in the colon. SCFAs have been
implicated in the regulation of both the proportions and functional capabilities of colonic Tregs [62],
which, in some studies, has been specifically attributed to butyrate production by spore-forming
Clostridiales [63]. Moreover, SCFAs can increase epithelial barrier functions, as measured by fluorescein
isothiocyanate-dextran permeability assay, in a GPR43-dependent manner [25] or through the
stabilization of hypoxia-inducible factor-alpha, particularly by butyrate [66]. Therefore, SCFAs can
promote the barrier functions of the intestine, suggesting another protective role of butyrate against FA.
In FA children compared to healthy subjects, different levels of fecal SCFAs, particularly butyrate, have
been described [67–69]. As recently demonstrated, dysbiosis in Faecalibacterium prausnitzii is associated
with AD, but it was shown that the presence of subspecies is more associated with AD than with
the species overall [70]. Dysbiosis results in the suppression of high-butyrate-producer subspecies,
leading to a reduction in overall butyrate production. Thus, different types of dysbiosis may share the
same metabolic features leading to similar effects in term of SCFAs or of other metabolites levels that
could facilitate the occurrence of FA. Interestingly, substantial correlations exist between the 16S rRNA
profile, predicted metagenome, and metabolome of neonatal fecal samples, indicating a deterministic
relationship between the bacterial community composition and metabolic microenvironment of the
neonatal gut [29].It is also crucial that studies move beyond cataloguing of bacteria and toward
functional characterization and mechanistic understanding. Metatranscriptomic studies will provide
information regarding not only which bacteria and bacterial genes are present in a sample, but also
the transcriptional activity of the community [71]. Metabolomics can reveal how bacterial metabolites
facilitate interactions with the host and how they may influence the health state of the host [72,73].
Fine-level characterization of bacterial species can help reveal the function of the microbiome, which
is affected by interactions among closely related bacteria that may compete for the same niche but
have distinct activities. Together, these studies will provide a high-resolution picture of bacteria-host
interactions that can lead to disease.Moreover, studies on germ-free mice may enable more precise
determination of how microbial imbalances result in disease.
4. Modulation of the Gut Microbiota in FA
Primary prevention via microbiota-directed therapy is particularly appealing for potentially
decreasing the incidence of FA. Children exposed to farm environments show a decreased risk for the
development of allergic disease [74,75]. Although it has not been proven, a plausible explanation for
the protective effect of early-life farm exposure is the role of microbiota, as individuals exposed to a
farm environment exhibit a different microbial composition than those with other lifestyles [76]. Other
epidemiologic factors protective against FA include having older siblings and pet exposure in early
life [77]. Pet ownership is associated with a high microbial diversity in the home environment [78].
A recent study examining the influence of dietary patterns on the development of FA at the age
of two years suggests that dietary habits influence FA development by changing the composition
of the gut microbiota [43]. During infancy, breast milk provides various benefits to the new-born.
Oligosaccharides, which are enriched in breast milk, favour the colonization of the SCFA-producing
bacteria Bifidobacterium spp. [79]. Breast milk plays a critical role in the maturation of the gut
microbiota by providing an initial source of commensal bacteria to the infant [80]. It has been recently
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demonstrated that higher levels of TGF-β2 in breast milk are associated with an increased relative
abundance of several bacteria, including members of Streptococcaceae and Ruminococcaceae, and lower
relative abundance of distinct Staphylococcaceae taxa [81]. One intervention that can modify the gut
microbiota most significantly is diet, either by introducing new species or bacterial genes or by
modulating the abundance of existing microbes in the community [82]. It has been demonstrated that
an infant diet consisting of high levels of fruits, vegetables, and home-prepared foods was associated
with fewer FA [43] (Figure 2). A high-fiber diet favours the outgrowth of bacteria capable of fermenting
dietary fibers, such as Bifidobacterium and Lactobacillus, followed by an increase in serum SCFA levels.
Neonatal prebiotic supplementation studies have failed to demonstrate any effect of prebiotics on the
development of FA, but showed positive results for other allergic manifestations such as eczema [83].
Figure 2. Environmental and lifestyle factors related to microbial exposure and their putative effect on
the risk of developing food allergy.
Probiotics, defined as ingested microbes that provide health benefits to the host [84], may be
beneficial by changing the microbiota. Recently published guidelines for atopic disease prevention from
the World Allergy Organization concluded that there is a likely benefit to using probiotics in preventing
eczema in children with a family history of allergic disease, but the evidence is very low in quality [85].
The most important factor in using probiotics against allergy is that this effect on the immune system
is strain-specific. Thus, the results of studies for a selected bacterial strain cannot be adopted to other
probiotic strains [84].Selected probiotics, such as Lactobacillus rhamnosus GG (LGG), were found to
lower the risk of eczema when used by women during the last trimester of pregnancy, by breastfeeding
mothers, or when given to infants [86].Studies examining the efficacy of currently available probiotics
in treating FA have yielded conflicting results. It was recently demonstrated that oral immunotherapy
supplemented with the probiotic L. rhamnosus CGMCC 1.3724 led to peanut unresponsiveness in 82%
of allergic children [87]. In one randomized, double-blind, placebo-controlled study of infants with
challenge-proven CMA, administration of Lactobacillus casei CRL431 and Bifidobacterium lactis Bb12 for
12 months did not affect the acquisition of tolerance to cow’s milk [88]. In contrast, we demonstrated
in different studies that an extensively hydrolyzed casein formula (EHCF) containing LGG accelerated
the development of tolerance acquisition in infants with CMA and reduced the incidence of other
allergic manifestations [89–91]. When we compared the fecal microbiota of infants receiving this
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tolerance-inducing probiotic-supplemented formula to that obtained from infants receiving EHCF
alone, we found significant positive correlations between the abundance of butyrate-producing genera,
and an increase concentration of fecal butyrate [68]. The mechanisms of action of butyrate are multiple,
but many of these involve epigenetic regulation of gene expression by inhibiting histone deacetylase
(HDAC). Inhibition of HDAC 9 and 6 increased FoxP3 gene expression, and the production and
suppressive function of Tregs [92]. We demonstrated that the use of EHCF+LGG induces stronger
epigenetic regulation of Th1 and Th2 cytokines genes as revealed by the significantly different levels of
promoter region methylation [93]. Similar results were obtained by examining the FoxP3 Treg-specific
demethylated region (TSDR) methylation profile. FoxP3 TSDR demethylation and expression were
significantly higher in children treated with EHCF+LGG compared to in children treated with other
dietary strategies [94]. These results strongly suggest that acting on gut microbiota composition and
function can have long-term protective effects in children with FA.
5. Conclusions
Our understanding of the role of gut microbiota in the development of FA continues to evolve.
Larger studies, preferably longitudinal birth cohort studies with more homogenous designs, are
needed to clarify the presence or absence of a defined dysbiotic signature associated with FA.
In addition, larger interventional trials are required to evaluate the roles of different probiotic strains
in modulating gut microbiota composition and function. Integrating these findings with epigenetics
and metabolomics data enable the development targeted microbiota with innovative approaches to
prevent and manage FA.
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Abstract: The pathophysiology of atopic dermatitis (AD) is multifactorial and is a complex
interrelationship between skin barrier, genetic predisposition, immunologic development, skin
microbiome, environmental, nutritional, pharmacological, and psychological factors. Several
microbial modulations of the intestinal microbiome with pre- and/or probiotics have been used in
AD management, with different clinical out-come (both positive, as well as null findings). This review
provides an overview of the clinical evidence from trials in children from 2008 to 2017, aiming to
evaluate the effect of dietary interventions with pre- and/or pro-biotics for the treatment of AD.
By searching the PUBMED/MEDLINE, EMBADE, and COCHRANE databases 14 clinical studies
were selected and included within this review. Data extraction was independently conducted by two
authors. The primary outcome was an improvement in the clinical score of AD severity. Changes
of serum immunological markers and/or gastrointestinal symptoms were explored if available.
In these studies some dietary interventions with pre- and/or pro-biotics were beneficial compared
to control diets in the management of AD in children, next to treatment with emollients, and/or
local corticosteroids. However, heterogeneity between studies was high, making it clear that focused
clinical randomized controlled trials are needed to understand the potential role and underlying
mechanism of dietary interventions in children with AD.
Keywords: atopic dermatitis; children; mucosal immune development
1. Introduction
Worldwide, the most common inflammatory skin disease is atopic dermatitis (AD) with
a prevalence of 10–20% in children [1]. In 60% of these children, the onset of AD occurs early in life,
before one year of age [2]. Pediatric AD can be characterized by its relapsing-remitting nature and the
overall severity is mild in most of these young children [3]. The pathophysiology is multifactorial with
a complex interrelationship between skin barrier development, genetic predisposition, immunological
development, skin microbiome composition, and environmental, nutritional, pharmacological, and
psychological factors. Whether or not AD is a primarily driven barrier dysfunction or a primarily
inflammatory skin disease remains open for debate. Taking into account the recent understanding of
the complex role of host microbial development in early life, new insights on regarding the role of
microbial modulation in AD development during infancy may be hypothesized.
Nutrients 2017, 9, 854 34 www.mdpi.com/journal/nutrients
Nutrients 2017, 9, 854
1.1. Host–Microbiome Development and Nutrition
The first contact of mucosal tissues to external microbiota is crucial in the establishment and
maturation of the mucosal, as well as systemic, immune systems [4,5]. In particular, the first year of
life is essential for programming the immune system. The development of barrier function and the
immune system are influenced by environmental factors, such as feeding patterns, antibiotic use by
the mother during delivery, or postnatal use of antibiotics by the neonate [6]. Proper understanding
of the protective and programming effects of a healthy immune and microbiome development may
provide opportunities to reduce the risk of development of AD. Any discordance between the early
developmental requirements of the infant’s immune system may contribute to the development of
allergic diseases [7]. A recent COCHRANE systematic review of five clinical trials (952 participants)
concluded that avoiding major allergens in the maternal diet (during gestation/lactation) does not
protect against development of AD in the infant during the first 18 months of life [8]. This study also
concluded that there was insufficient evidence that prolonged exclusive breast feeding was protective
against AD. Early sensitization to food allergens through breast milk, skin contact, and/or inhalation
occurs and may explain why some infants show an allergic response to specific proteins despite having
never ingested it [7]. An additional influencing factor in allergy development is the timing of solid food
introduction. For instance, infants starting with solid food introduction at four or five months of age
had a lower risk for AD development (Odds ratio = 0.41, 95% Confidence interval, 0.20–0.87) compared
to infants which were exclusively breastfed [9]. However, except maybe for peanut allergy, strong
evidence is lacking to decide whether the age of complementary food introduction should be four or
six months in order to prevent the development of allergy [5]. Although scientific evidence is limited,
it has been suggested that timing of the start and type of nutrition (i.e., breastfeeding/infant formula)
during solid food introduction influences the development of allergic diseases [10]. The question,
however, remains whether observed effects are derived from direct interaction with immune cells,
or indirectly through alterations in the microbiome composition and change in derivatives thereof,
followed by immune changes [11]. The microbial composition is involved in the development of
the regulatory T cell response and thereby plays a key role in immune development [12]. Within
in vitro assays it has been shown that the addition of specific oligosaccharides during dendritic cell
development induces a regulatory T cell response potentially of benefit in an allergic setting [13].
Moreover, dietary supplementation with specific prebiotic oligosaccharides has been shown to reduce
the risk of developing allergies in infants [14]. Therefore, during early life it seems likely that specific
components can contribute to the normal immune development via multiple direct and indirect
pathways, thereby reducing the risk of allergic manifestations.
1.2. Development of Skin and Microbiome in Early Life
The composition and diversity of the skin microbiome shows a unique habitat per location,
especially within children. The skin microbiome composition may be affected by different factors
including age, sex, and microbial antigen exposure. Skin microbiota of neonates varies by the mode of
delivery, but the differences become less apparent with age in early childhood [15,16]. The composition
is also dependent on pH, temperature, Ultraviolet (UV) exposure, natural moisturizing factors (NMFs),
and can easily change over time [17]. Specific changes in the skin microbiome have been associated
with AD and other allergic manifestations [18]. AD has been associated with early life colonization
of Staphylococcus aureus (S. aureus). A reduced bacterial diversity in the skin microbiome is of major
importance in AD pathogenesis [19]. Only 5% of the skin microbiome in non-atopic individuals
is colonized with S. aureus, compared to 39% in non-lesional skin and 70% in lesional skin of AD
patients [20,21]. Although within a birth cohort it was shown that 10 infants with AD at the age of
12 months were not colonized with S. aureus before their first AD manifestation [22], colonization and
infection with S. aureus has been associated with increased IgE responses, food allergy, and severity
of AD skin disease [23,24]. In addition to the bacterial composition, the fungal and viral community
differences are also associated with allergic manifestations such as rhinitis and asthma, as well [25,26].
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This underscores the complexity of the host-microbe balance induction, as well as the sensitivity
towards modulations herein [27].
Although whether or not AD is primarily driven by microbial dysbiosis leading to barrier
dysfunction remains a key question, the skin barrier is hampered in AD. Within infants the skin
has a higher ability to restore itself as a barrier. This adaptive flexibility results in unique properties of
infant skin [28]. In a recent meta-analysis of genome-wide association studies of more than 15 million
genetic variants in 21,399 cases and 95,464 controls, 10 new loci associated with AD risk were identified,
bringing the total susceptibility loci until to 31 at the time of this publication [28–30]. Children
with AD have changes in their skin barrier due to filaggrin deficiency or tight-junction dysfunction,
which allows the penetration of irritants, allergens, and bacteria, leading to inflammation [31,32].
1.3. Immune Deregulation within AD
In AD, the skin barrier function is compromised, allowing penetration of environmental factors,
such as irritants, allergens, and bacteria, leading to inflammation and/or allergic sensitization [33,34].
Skin barrier dysfunction induces the release of several inflammatory factors, including thymic stromal
lymphopoietin (TSLP) and other cytokines and chemokines, which trigger inflammation in the skin [35].
These pro-inflammatory mediators (including chemokines) are released by the affected keratinocytes
to attract leukocytes to the site of inflammation [36,37]. The characteristic leukocyte migration into
the skin is driven by excessive chemokine production at the site of inflammation. Several chemokines
(classically characterized within the Th1-type of response: CXCL9, CXCL10, and CXCL11; the Th2-type
response: CCL-17, CCL22; and for inflammation: CCL-20) have been associated with an AD phenotype
comprising complex pathology [38]. Studies on the pathology of early paediatric AD are limited and
correlation of disease activity has been shown with only a few serum biomarkers (i.e., CCL17, CCL22,
CCL27, and IgE) in infants [38,39]. Recently, profound immune activation in non-lesional skin in
paediatric patients with AD has also been detected [38]. While little is known about the alterations
in skin-derived immunity and skin barrier function that occur during the early-onset phase of AD,
Th2 (IL-13, IL-31, and CCL17), Th22 (IL-22 and S100As), and some Th1-skewing (IFN-γ and CXCL10)
have been detected in the skin, which is also observed in adults [38]. An increase in recruited Th2
cell populations classically leads to the increased production of interleukins IL-4, IL-5, and IL-13,
which may be locally involved in the induction of IgE and eosinophil activation [39]. However,
the identification of the trigger in AD development is still very complex.
1.4. Current Understanding in the Specific Microbial Modulations in AD
Due to the potential role of the microbiome in children with AD and development in early
childhood, this seems a promising time frame for effective nutritional interventions including those
with pre- and/or probiotics. In 2008 a comprehensive COCHRANE review (analysing 10 clinical trials
(up to April 2008 (781 children)) concluded that overall probiotics in general seem not to be effective
as a treatment of AD [40]. On the contrary, a modest role for probiotic interventions in paediatric
dermatitis was suggested [41,42], as well as within later studies regarding pre- and/or probiotic
interventions [43]. As stated by the recent meta-analysis by Kim et al. [44], the difference between
age and severity of AD as measured by scoring of childhood atopic dermatitis (SCORAD) should
be taken into account when analysing the impact of microbial modulations. Collectively, there was
a large heterogeneity between trials complicating the comparison between specific species, strains,
dosage, duration, time or age, and clinical outcomes. The aim of this review is to give an overview of
the results of recently performed clinical intervention studies published after the COCHRANE review
in 2008 until June 2017, studying the effect of microbial modulations for treatment of AD in children.
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2. Methods
2.1. Search Strategy
To identify clinical dietary intervention studies with prebiotics/probiotics and/or synbiotics
in children with AD, from birth up to 18 years of age, the PUBMED/MEDLINE, EMBASE,
and COCHRANE databases have been searched. Since the COCHRANE review included all clinical
trials up to April 2008, the literature search started from 2008 to June 2017. The following keywords
were used: (probiotics OR prebiotics OR synbiotics) AND (atopic dermatitis OR eczema).
2.2. Study Selection
Published clinical intervention studies were included within this review meeting the following
criteria: clinical studies with a dietary intervention with prebiotic(s) and/or probiotic(s), all participants
were human, more specifically children from birth up to 18 years of age, all children with AD before
the start of intervention, only studies with a clinical outcome for AD severity, studies published in
the last 10 years, written in English, and presenting original data. A total of 75 abstracts have been
retrieved through the database searches. Two authors independently checked the fulfilment of the
inclusion criteria for this review by screening titles and abstracts and excluded studies that obviously
did not fulfil the inclusion criteria. Seventy-three were published between April 2008 and 2017. A total
of 59 from the 73 studies were excluded for this review, due to different outcomes than the inclusion
criteria for this overview. The majority of these clinical studies had prevention of AD or other allergic
manifestations as the primary outcome (N = 31). Other reasons to exclude studies were: no clinical
AD outcome value, only gastrointestinal outcomes, safety studies, or genetic outcomes. In addition,
three long-term follow-up studies were excluded. Finally the reference lists of the positively identified
articles were checked for additional clinical studies and led to one additional study.
2.3. Data Extraction
Data extraction was independently conducted by two authors and cross-checked to avoid errors.
Disagreements were resolved through consensus and, when needed, using the opinion of a third
author. Details of the study were recorded: methods, objectives, study population, age of children
with AD, inclusion and exclusion criteria, mild-to moderate-to severe AD, mean SCORAD scores,
specific dietary intervention, strain and dosage of prebiotics and or probiotics, control diet, duration
of intervention, number of randomized children in each group, clinical outcome of AD severity and
change in AD severity (using primarily the AD scoring system SCORAD [45]). In addition, if available,
the immunological outcomes, as well as the gastrointestinal outcomes, were included.
3. Results
3.1. Study Characteristics
The literature search resulted in 75 clinical intervention studies and, after inclusion, 13 studies
could be used. One publication included two different types of interventions; open label versus
randomized control using the same probiotic strain. Therefore, those two clinical studies will be
mentioned separately in this overview. The study characteristics of the 14 selected clinical trials
(N = 1008 children with AD) are summarized in Table 1 [43,46–57].
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3.2. Specific Dietary Intervention
Since the results of clinical intervention studies in the past showed inconclusive results of
prebiotics and/or probiotics in the treatment of AD, it was hypothesized that the beneficial effects of
prebiotics and probiotics are strain- and dose-dependent. Lactobacillus and Bifidobacterium are the two
most investigated bacterial species in allergy research. Again, a wide variety in the dietary intervention
studies was found in the clinical trials between 2008 and 2017 (Table 1). In total, 12 included trials
were randomized controlled trials (RCTs) which had a total of 601 AD children in the treatment
groups and 444 AD children in the control groups. The two additional clinical trials provided
an open label intervention and were conducted with 63 children with AD. Not one intervention
study used the same strain of probiotics or the same combination with prebiotics. More specifically,
five RCTs provided synbiotic mixtures [43,47,49,50,55], four RCTs provided only one probiotic as
dietary intervention [52,54,56,57], two RCTs provided more than one probiotic strain within the
study [48,53], one trial explored the effect of prebiotics only [46], and the two open label studies were
conducted with only one probiotic strain [51,57].
3.3. Effect of Dietary Intervention on Clinically-Detected AD Severity
In total, 12 out of the 14 studies reported the severity in AD using SCORAD. Three of the five
RCTs with synbiotic intervention showed significant AD improvement by reduction of AD severity
after dietary intervention compared to control diet [49,50,55]. The remaining two synbiotic RCTs
showed a significant reduction of SCORAD score in both groups [43,47]. Improvement of AD severity
was shown in three out of the four RCTs with one probiotic strain [52,54,57]. In addition, the result
of the two open label intervention studies with one strain of probiotics is an improvement in AD
symptoms [51,57]. Additionally, the RCT with the highest enrolment of children with AD (N = 220),
showed an improvement in AD severity compared to the control group [53]. The trial of Gore et al.
with two strains of probiotics showed a reduction of the SCORAD score in both groups [48]. The
prebiotic trial showed improvement of AD severity in both groups [46]. In addition, the RCT with
synbiotic intervention showed improvement of AD severity (SCORAD score). In the trial of van der
Aa et al., a subgroup analysis of AD infants with elevated IgE levels showed a greater SCORAD score
reduction in the synbiotic group [43]. A previous study also showed that synbiotic interventions
may have beneficial effects, especially in AD with elevated IgE [58]. Taking IgE further into account,
Shafiei et al. found no differences in comparing SCORAD scores in the IgE and non-IgE AD infants [47].
In contrast to Wang et al., who included only AD children with at least one positive skin prick test or
at least one elevated specific IgE level within their study, showed improvement in AD [53], suggesting
an important role for IgE.
3.4. Additional Effect of Dietary Interventions
Knowing the complexity of development in early life, some studies provide additional exploratory
markers within the different RCTs. Three RCTs showed changing levels in cytokines IL-4 and/or IFN-y,
which were significantly lower after intervention or did not show any change [51–53]. Additionally,
changes in serum chemokine markers were detected, showing significant changes in two [54,57]
groups, and no significant differences between groups in another study [43]. Some studies showed
changes in IgE levels, but no significance between treatment and control [43,48,53]. In addition to
serum markers, a few studies provide additional data on the effect of dietary intervention cellular
composition [50]. For instance, the eosinophil count was significantly lower between groups in one
study [52], and over time in one other study [55]. In three studies no immunological data was available,
which may be due to the young age of infants included in those studies [46,47,51]. Only three RCTs
reported on faecal bacterial counts after dietary intervention; all, however, confirmed changes in gut
microbial composition after dietary intervention. Gastrointestinal symptoms, such as stool consistency
and diaper dermatitis, were also positively influenced in the treatment group compared to control
after the specific dietary interventions [43,46].
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3.5. Treatment Duration and Time of Intervention
Within the identified clinical intervention studies, the treatment duration was variable, ranging
from eight weeks up to six months [43,46–57]. There seemed to be no association between the
duration of dietary intervention and the outcome of clinical improvement of AD. The trials indicating
improvement of AD in both groups had intervention periods of eight or 12 weeks [43,46,48].
The effective duration of dietary intervention remains unclear. In two trials included in this review,
a positive beneficial effect on AD severity remained detectable after the intervention period [53,55].
4. Discussion
This review summarizes the clinical outcome on AD severity among children receiving dietary
intervention with or without prebiotics, probiotics, or synbiotics. It presents an overview of data from
2008 to June 2017 regarding the use of the specific dietary interventions in the treatment of AD in
children, from birth up to 18 years of age available to date. As in earlier studies and meta-analyses
published up to 2008, overall, strong evidence to clarify insights into the role of pre-, pro-, and
synbiotics in treatment of AD is lacking, which may be due to high heterogeneity among the trials.
Moreover, the outcome on AD severity seems to depend of multiple factors, including age, season, UV
exposure, the use of local corticosteroids, number of AD exacerbations, etc.
Within the clinical intervention studies included in this review, several confounding factors need to
be considered when interpreting the results. For example, since it is unethical to withhold AD children
AD treatment with emollients and/or topical steroids, most studies provided treatment simultaneously
with the dietary intervention. However, not all trials reported the amount and frequency of topical
steroid use and, therefore, it is not clear if children in the treatment group were using the same amount
of topical steroids as in the control groups. Within future studies, the method of randomisation,
as well as amount and frequency of used topical steroids, should be reported. Although in some
trials a decrease of local steroid use was mentioned, the effect of nutritional intervention compared to
pharmacological treatment may both influence the AD severity score. For clinical outcome comparisons,
the SCORAD score is validated for AD severity, but it is known to be difficult to assess in young
infants, providing possible inter-observer variability. Moreover, due to the relapsing-remitting nature
of AD in these young children (which occurs randomly in time), this may complicate the evaluation of
AD severity and the impact of nutritional intervention effects in time. Recently, the evaluation on AD
measurements provided recommendations about scoring AD severity, providing an interesting tool for
future research. These include SIS (skin intensity score) (paediatric version), POEM (patient-oriented
eczema measure), SCORAD (Severity Scoring of Atopic Dermatitis index), SA-EASI (self-administered
eczema area and severity index score), and adapted SA-EASI, which are currently the most appropriate
instruments to assess AD and, therefore, should be recommended as core symptom instruments in
future clinical trials [59].
With the knowledge that both the child’s microbiome and mucosal immunity evolves from infancy
into early childhood, the age of inclusion in a study of AD is of utmost importance. In infants the
cheeks are a typical preferred site of AD and the nasal tip is usually spared. After one year of age,
a change of AD sites is more prone to the antecubital and popliteal fossa. Possible explanation for this
change is change in the diversity in the skin microbiome and changes in skin barrier function in early
life. Nevertheless the age of inclusion was within the dietary intervention studies, which may explain
the differing results. Hypothesizing that the first year of life is the essential period for programming the
mucosal immune system, this may also be the preferred time to prevent the development of AD with
microbial modulations. However, as shown within some recent meta-analyses with a specific focus
on the clinical evidence from dietary intervention studies, it was concluded that dietary intervention
during pregnancy, or lactation in the mothers, or in the early life of the infant led to a decreased risk
of AD development, but not the development of other allergies [60–62]. It should be noted that the
overall evidence is low due to the inconsistent results among studies. In order to investigate and
understand the mechanisms involved in immune modulation capacities of microbiota by dietary
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interventions on clinical outcome severity of AD in childhood, the consistency between trials must
increase. Therefore, criteria should be formulated on how to conduct future studies in this field in
order to be able to compare clinical trial outcomes, so that subsequently reliable and valid advice can
be given to implement dietary interventions in the management of AD.
5. Conclusions
Identifying high-risk children for atopic manifestations and AD children who can benefit
from these microbial modulations seems highly relevant. Moreover, a better understanding of the
contributing factors, such as the skin microbiome, faecal composition, and biomarkers of skin barrier
function, leading to changes within serum biomarker profiles would be of great value for a more
individualized therapeutic approach in AD management in children. In addition, to overcome the
problem of heterogeneity of the studies and therefore the limitation of comparing clinical trial outcomes,
an international committee of experts should focus on definitions of outcome measures, treatment
duration, administration of the product, etc. Since the development and evolution of each child’s
microbiome starts from infancy up to childhood, an early life dietary intervention (in pregnancy
and/or in infancy) seems preferable. Further standardized clinical research is, however, necessary to
gain more insight into specific strains, prebiotics and timing for optimal intervention. By combining
the individual factors of a child with AD, as mentioned above, it may be possible to eventually match
the clinical needs with the best dietary management option available.
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CCL CC chemokine ligand (−17, −20, −22, −27)
CXCL CXC chemokine ligand (−9,−10,−11)




IgE Immunoglobulin E (total, specific)
IL Interleukin (−4, −5, −13, −22, −31)
IFN Interferon (−γ)
NMF Natural moisturizing factors
POEM Patient-oriented eczema measure
RCT Randomized controlled trial
SA-EASI Self-administered eczema area and severity index score
SASSAD Six Area, Six Sign Atopic Dermatitis severity score
SIS Skin intensity score
SCORAD Scoring atopic dermatitis score, clinical tool for scoring AD severity
SC Stratum corneum
TEWL Trans epidermal water loss
Th- T helper cell type (1, 2, 17, 22)
TIS Three Item Severity score
TJ Tight junction
TSLP Thymic stromal lymphopoietin
UV Ultraviolet
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Abstract: Since the early 1990s, maternal folic acid supplementation has been recommended prior
to and during the first trimester of pregnancy, to reduce the risk of infant neural tube defects.
In addition, many countries have also implemented the folic acid fortification of staple foods,
in order to promote sufficient intakes amongst women of a childbearing age, based on concerns
surrounding variable dietary and supplementation practices. As many women continue to take folic
acid supplements beyond the recommended first trimester, there has been an overall increase in
folate intakes, particularly in countries with mandatory fortification. This has raised questions on
the consequences for the developing fetus, given that folic acid, a methyl donor, has the potential
to epigenetically modify gene expression. In animal studies, folic acid has been shown to promote
an allergic phenotype in the offspring, through changes in DNA methylation. Human population
studies have also described associations between folate status in pregnancy and the risk of subsequent
childhood allergic disease. In this review, we address the question of whether ongoing maternal
folic acid supplementation after neural tube closure, could be contributing to the rise in early life
allergic diseases.
Keywords: allergic disease; epigenetics; folate; folic acid; maternal diet; pregnancy
1. Introduction
The dramatic increase in childhood allergic disease is now a serious public health issue in
high-income countries [1–4]. Current evidence points to a multifactorial aetiology with a complex
genetic predisposition, interacting with key environmental factors, including dietary changes. Both
epidemiologic and mechanistic studies have linked specific and general consequences of recent dietary
intake patterns, to biological effects in early life, including early immune dysregulation, an enhanced
predisposition to inflammation, and inappropriate responses to normally harmless ubiquitous antigens,
such as allergens, in very early life. The impact of diet is complex and is influenced through changing
food sources and changes in specific nutrient intakes, with secondary immune and metabolic effects.
These nutritional factors (including folate) have the potential to induce persistent developmental
changes in gene expression through epigenetic modifications, and thereby, alter developing immune
pathways, organ systems, and subsequent disease predisposition [5–7].
The developing fetus is highly responsive to environmental cues. One of the best described
examples is the ability to modulate metabolic activity in response to the maternal nutrient
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supply—activating gene modules that conserve energy when maternal nutrition is restricted [8].
While these short term adaptations may provide short term advantages, they may also increase the
risk of long term disease [8]. Some epigenetic modifications may also prompt early onset disease, such
as allergic disease [9], although the evolutionary drivers of these adaptations are not well understood.
In this context, there has been a focused interest on specific nutrients that are known to have direct
effects on the epigenetic pathways that control gene expression during early development, such
as folate.
Epigenetic mechanisms are finely coordinated processes that regulate the expression of genes,
without alterations in the underlying gene sequence [10]. This includes DNA methylation, histone
modifications, and non-coding RNAs, which coordinate gene expression to allow a responsive interface
between the genes and the environment. Variations in the nutrient status can alter the epigenome,
for example folate, which in addition to a myriad of biological actions, plays an essential role in the
methylation of the universal methyl donor S-adenosylmethionine (SAM), and critically influences
methionine metabolism pathways, protein synthesis and metabolism, cell multiplication, and tissue
growth [11]. Changes in methyl donor activity of DNA methyl transferase enzymes, and an increased
methylation of CpG sites of specific regions of DNA and associated changes in the chromatin structure,
can silence gene transcription, thereby altering cellular activities [12].
Maternal nutrition is a critical factor, not only in providing the nutrient building blocks for fetal
development, but also in steering the patterns of fetal gene expression that dictate the phenotype,
patterns of metabolic and physiological responses, and future disease risk [13], even though subtle
shifts in the profile of the nutrient supply. In this way, the epigenetic effects of maternal nutrition on
fetal immune development are likely to be an important factor in the risk of allergic disease, particularly
as differences in immune function can already be detected at birth, in those who go on to develop the
disease [14]. This demonstrates lasting effects of in utero exposures on immune development, but also
provides a window of opportunity for preventing immune-related diseases, and reversing the rising
disease burden [7,15,16].
The hormonal milieu of pregnancy promotes tolerance at the materno-fetal interface, including
immune regulatory responses and Type 2 T helper cell (TH2) responses, to protect the fetus from Type 1
T helper cell (TH1) alloantigen responses [17]. Fetal responses to allergens and other environmental
exposures develop during this period, and are similarly TH2-skewed [17]. Specific regulatory responses
in utero [18] have also been shown to be modified by the maternal environment [19]. Thus, variations
in maternal environmental conditions may strongly set the scene for how the newborn responds
to the postnatal environment, including the capacity to dampen inflammatory responses and to
down-regulate TH2 responses in the postnatal period [20]. Disruption of these aspects of early immune
regulation may interfere with normal TH1 maturation in the postnatal period, and lead to an allergic
phenotype [21].
Of immediate relevance here are the antenatal effects of folate, shown to promote allergic
predisposition in animal studies. Specifically, a landmark murine asthma model demonstrated that
maternal folic acid supplementation promoted allergic airway disease in the offspring, by modifying
DNA methylation and the expression of fetal genes associated with the development of an allergic
phenotype [22]. Moreover, these epigenetic changes and the disease predisposition were inherited by
the second generation. These biological actions of folic acid, together with epidemiological associations
between infant allergic disease and maternal folate consumption in humans (below), raise questions on
the unintended consequences of ongoing folic acid supplementation during pregnancy, potentially at
higher than recommended requirements, after the window of risk for neural tube defects has passed.
Here, we examine world-wide changes in public health strategies, aimed at improving folic acid
status over the past 25 years, and summarise the current evidence for a link between maternal folic
acid supplementation during pregnancy and the development of childhood allergic diseases. This
is based on a literature search for studies investigating the relationship between maternal folic acid
supplement use in pregnancy, folate status, and childhood allergic disease outcomes; together with
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changes in folate- and folic acid-related public health strategies. The electronic databases of PubMed,
Medline, Cochrane Library, and Google Scholar were searched, to identify articles published before the
end of August 2016, using multiple combinations of the following search terms: allergic disease, atopy,
epigenetics, DNA methylation, folate, folic acid, maternal diet, and pregnancy. Reference lists of recent
review articles and key studies were also examined, to identify any other relevant studies not found
during the initial database search. Multiple publications from some of the cohorts were examined, for
potential overlapping participants and results. All relevant studies were included in this review.
2. Folate Requirements in Pregnancy
Folate requirements increase in pregnancy, in order to meet the maternal and fetal metabolic
needs, and greater DNA synthesis and rapid cell division, during fetal development. An inadequate
periconceptional maternal folate status has been associated with neural tube defects, such as spina
bifida and anencephaly, highlighting the importance of entering pregnancy with adequate folate
stores [23]. The international reference range for folate levels during pregnancy have been derived
from 10 studies; seven studies relating to serum folate levels and three studies relating to red
cell folate for the use of clinicians interpreting laboratory results [24]. These have been set using
5th to 95th percentile laboratory analyte values for red cell folate, for the first, second, and third
trimesters of pregnancy, and are 137–589 ng/mL, 94–828 ng/mL, and 109–663 ng/mL, respectively;
and 2.6–15.0 ng/mL, 0.8–24.0 ng/mL, and 1.4–20.7 ng/mL, respectively, for serum folate. The target
for women of reproductive age is a level of red cell folate >906 nmol/L, to maximally reduce the risk of
neural tube defects [23,25]. There is no target reference value for serum folate in women of reproductive
age, due to a lack of epidemiological evidence for deriving these levels. Dietary reference values for
folic acid intake during pregnancy vary internationally, with estimated daily average requirement
values of 250 μg in the United Kingdom (UK); 370 μg in Japan; 400 μg in Europe; and 520 μg in
Australia, United States (US), Canada and New Zealand.
3. History of Folic Acid Supplementation
Investigations into the therapeutic benefit of folic acid commenced in the 1930s, when Wills and
colleagues investigated the treatment of tropical megaloblastic anaemia with yeast and marmite, and
identified the presence of an unidentified bioactive factor [26]. The consumption of yeast extract, which
contains folic acid, to nourish pregnant women, was also promoted from the 1930s [27]. In the 1950s
and 1960s, researchers found that treatment with folic acid supplementation prevented megaloblastic
anaemia in pregnancy [28,29]. Recommendations for utilising prophylactic folic acid treatment of
pregnant women to prevent folate deficiency-related anaemia followed, and were implemented
at a hospital located in Staffordshire (England) in around 1958, and in some ante-natal clinics in
Britain by the late 1960s [29–31]. It was also recommended in the US, by the Manual of Standards in
Obstetric-Gynaecologic Practice, from 1965.
Early research into folate deficiency in pregnancy and adverse pregnancy outcomes of fetal
abnormalities, suggested a beneficial effect of folic acid supplementation in pregnancy and the risk
of neural tube defect outcomes, only emerged in the 1960s [32,33]. Evidence of “periconceptional”
folate status, emerged during the late 1980s and early 1990s [34–39]. A meta-analysis examining the
protective effect of daily folic acid supplementation (alone or in combination with other vitamins
and minerals) in preventing neural tube defects, when compared with no interventions/placebo
or vitamins and minerals without folic acid in randomized trials, found a risk ratio of 0.28, and a
95% confidence interval of 0.15 to 0.52 [40].
During the past two decades, folate recommendations to prevent neural tube defects have been
implemented in many regions of the world for women who are pregnant, planning a pregnancy, and
of childbearing age. Early recommendations were made by the US in 1991, the UK in 1992, Canada in
1993, and Australia in 1994. Daily 400 μg folic acid supplementation recommendations for women of a
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reproductive age, and those planning a pregnancy, have now been adopted world-wide, and were
endorsed by the World Health Organisation (WHO) in 2006.
4. Time Trends in Folic Acid Supplementation Practices
Folic acid supplementation rates have been found to vary over the last few decades. Public health
education has been shown to increase the use of folic acid in planned pregnancy [41], although, research
indicates that folic acid supplementation rates are increased amongst higher socioeconomic status (SES)
groups, and that primary prevention strategies specifically targeting folic acid supplementation, even
when supported with public health promotional activities, do not reach some socially disadvantaged
groups, who are potentially at the greatest risk [42–45]. In particular, this includes younger women,
those who are less educated, on low incomes, minority ethnic populations, and/or those with an
unplanned pregnancy. A recent study from China supports this point. It found that pregnant women
taking folic acid supplements after the first trimester, were more likely to be older, from urban areas,
and have had a higher level of education, than those women who were not taking supplements in late
pregnancy [46].
5. Dietary Intake of Folate from Food Sources
A recent systematic review and meta-analysis of dietary micronutrient intakes from food sources
alone during pregnancy in developed countries [47], reported that the median dietary folate intakes
(interquartile ranges) were 190 (190–232) μg/day for Australia/New Zealand, 334 (292–367) μg/day
for the USA/Canada; 280 (260–315) μg/day for Europe, 217 (184–265) μg/day for the UK, and
276 (271–284) μg/day for Japan. Dietary intakes were consistent across the whole of the gestation
for each geographical region. Importantly, estimated folate intakes were 13% to 63% less than each
respective country’s dietary folate intake recommendations; reinforcing the need for pregnant women
to take folic acid supplements.
6. Folic Acid Food Fortification
The limitations of relying on consumer-driven supplementation as the primary public health
approach, led to the consideration of other folic acid-related policies, in order to achieve more
equitable folate status in women of reproductive age. To address this, in addition to the existing folate
recommendations and preventive health campaigns, some countries introduced voluntary and/or
mandatory food fortification [48,49]; including developed economies such as Australia, Canada,
Finland, Ireland, New Zealand, Norway, South Africa, the UK, and the US; and developing economies
such as Brazil, Chile, China, and Costa Rica. Voluntary fortification of bread and breakfast cereal
commenced in the UK from the mid to late 1980s. Both Canada and the US introduced similar
mandatory fortification of all cereal flour food products into regulations in 1996, with the enactment
of fortification by 1998. The US mandatory fortification requires all cereal grain to be fortified with
folic acid, at 140 μg/100 g of grain food. Following these mandatory fortification initiatives, the
effectiveness on the reductions in neural tube defect rates in the US and Canada, were around 50% and
54%, respectively [50]. Mandatory folic acid fortification of food has now been introduced in around
79 countries world-wide.
The governments of Australia and New Zealand implemented voluntary folate fortification of
some foods in the mid-1990s, with manufacturers primarily fortifying breakfast cereals and bread
products [49,51]. Following this, a 30% reduction in neural tube defects was reported in Western
Australia; likely reflecting the combined influence of a folate promotion project and voluntary
fortification measures [52]. Similar reductions in neural tube defects were reported in other countries,
following mandatory folic acid fortification of staple foods, including Chile (43% reduction after
2000) [53], Brazil (35% reduction after 2004) [54], and South Africa (30% reduction) [55].
Evidence that the prevalence of neural tube defects was higher in Australia and New Zealand
than the US, the UK, and Canada, led to the Australian and New Zealand Food Regulation Ministerial
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Council determination that neural tube defects posed a public health issue of sufficient severity,
warranting a mandatory fortification approach. This led to the mandatory fortification of bread-making
wheat flour with folic acid that came into effect in Australia in September 2009, with a two year phase-in
period from 2007. A recent evaluation of this measure found significant reductions in the rates of
neural tube defects of 14% in the states for which data were available, and 74% amongst the offspring of
Australian Indigenous women in the same states. At this time, New Zealand delayed implementation
of this food standard, mainly due to both industry and political issues [48]. Some countries, for
example Sweden, have not introduced any fortification of foods, opting instead for a precautionary
approach to minimise the risk of unintentional consequences [48].
7. Dietary Intake and Folate Status Post Folic Acid Food Fortification
In Australia, the aim of the mandatory folic acid fortification was to increase folic acid intake by
100 μg/day [56]. After the commencement of mandatory fortification, folic acid intake in the target
population group of women of reproductive age, was estimated to have increased by 159 μg/day,
when calculated using dietary modelling based on measured folic acid levels in bread samples in
2010 [56]. There was an expectation that folic acid supplementation would still be required to meet
the required folate status for preventing neural tube defects [57]. The most recent Australian national
dietary folate intake data, recorded by the Australian Health Survey in 2011/12, captured dietary
intake of folate post fortification in Australia, including natural folate in food, and folic acid intake from
fortified foods and supplements [58]. The mean daily intake for females aged 14–18 years, 19–30 years,
and 31–50 years was 559.6 μg/day, 536.3 μg/day, and 529.4 μg/day, respectively. Dietary intakes were
influenced by consumption of the fortified foods, which is dependent on the variations in dietary
patterns of subgroups in the population. Current popular low carbohydrate diets, and low grain-based
diets, may impact on some consumers’ fortified bread consumption [59], and hence lower their overall
dietary folate intake.
The Australian Health Survey, conducted in 2011/12 [58], was the first national collection of
biomedical results of folate status collected post implementation of mandatory folic acid fortification.
Nutrient biomarker results reported median serum folate levels of 33.6 (interquartile range 26.5,
40.7) nmol/L, and mean red cell folate levels of 1601.0 (1366.0, 1848.4) nmol/L, for women of
reproductive age (16–44 years of age). Nearly half of the female population surveyed (48.1%) had a
serum folate level greater than 35.0 nmol/L; and 16.5% had a level greater than 45.0 nmol/L. These
levels are in the upper range of the international reference range of 3–47 nmol/L [24]. Notably, a
recent Canadian study found that folate levels post mandatory food fortification, were above the
normal reference ranges for early and late pregnancy, and over twice the folate target range for
women of reproductive age, with geometric mean (95% CI) red cell folate levels in early pregnancy
(12–16 weeks) of 2417 nmol/L (2362, 2472), and late pregnancy (at delivery, 38–42 weeks) of
2793 nmol/L (2721, 2867) [60].
8. Timelines of Changing Folate Status and Increasing Prevalence of Allergic Diseases
The increased prevalence of childhood allergic diseases, including allergic rhinoconjuctivitis,
eczema, and asthma, has been well-documented since the 1990s; although, for some countries that
previously reported a high prevalence of asthma symptoms, the rates may now have plateaued or
decreased [4,61]. This decrease in asthma prevalence is not consistent with the suggested role that
folate supplementation may play in the development of asthma from animal studies. In a recent global
survey of both developed and developing countries, the food allergy prevalence rates for children
aged <5 years from nine countries with oral food, varied from 1% in Thailand, through to 10% in
Australia, challenging proven food allergy data [4]. The rates of hospital emergency food-related
anaphylaxis admissions have also increased in the UK, the US, and Australia, since 1990 [1]. The
increase in food-related anaphylaxis admissions rates for 0–4 years old in Australia has occurred in
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parallel with the timeframes of implemented Australian folic acid related initiatives, although it should
be highlighted that this does not imply any evidence of association (Figure 1).
Figure 1. Food-related anaphylaxis hospital admissions rates (per 100,000 population per year) of
children aged 0–4 years in Australia between 1998/99 and 2011/12, and the timing of Australian folic
acid public health measures. Source: Adapted from Mullins, R.J. et al. [1].
9. Observational Studies Investigating the Relationship between Maternal Folic Acid
Supplementation and/or Folate Status during Pregnancy and Childhood Allergic Disease
Ten publications [62–71] reporting the findings of the relationships between folic acid
supplementation and/or folate status in pregnancy, and allergic disease outcomes in children, were
identified. These studies encompassed folic acid supplementation use at differing time periods during
pregnancy. To date, there have been no randomised, controlled trials investigating the effect of folic
acid supplementation during pregnancy on childhood allergic disease outcomes. The observational
studies differed in the investigated allergic disease outcomes; the methods used to determine the
disease outcomes, such as clinical history (parental reported symptoms, parental reported diagnosis by
medical practitioner, medical practitioner diagnosis); sensitization using skin prick tests and allergen
specific IgE; and the “at risk” status of the children, due to the family history of allergic disease. The
study time periods also cross decades; with differing levels of folic acid supplementation use, dietary
folate intakes, and different folic acid food fortification policies. None of the studies were conducted in
countries where there is a mandatory folic acid fortification in place.
9.1. Periconceptional and First Trimester Folic Acid Supplementation
The relationship between preconception and first trimester folic acid supplementation, or folate
status in early pregnancy and allergic disease in children, has been investigated in two prospective
mother and child birth cohort studies. In the Netherlands, the maternal plasma folate status at
13.5 ± 2.0 weeks’ gestation, of >16.2 nmol/L, was associated with and increased prevalence of
atopic dermatitis outcomes in children up to 4 years of age [67]. This study recruited pregnant
women residing in the Netherlands from the year 2000 onwards, at a time when dietary folate
intakes may have been influenced by voluntary food fortification. A Norwegian study found that
maternal-reported first trimester folic acid supplementation use, was associated with an increased
risk of maternal-reported wheeze in children at 18 months of age [66]. Folate rich diets and folic acid
supplementation in pregnancy recommendations, were the initiatives implemented in Norway during
the study recruitment period.
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9.2. Folate Status and/or Folic Acid Supplementation at Some Time during Pregnancy
In a recent Finnish study, folate intake and folic acid supplement use during pregnancy, were
associated with an increased risk of a cow’s milk allergy in the offspring [70]. Finland had no voluntary
folic acid fortification in place at the time of this study. In the Netherlands, folic acid use during
pregnancy was associated with an increased risk of respiratory wheeze at the age of one year, but not
at two-eight years; however, there was no association with other allergic diseases, such as asthma and
eczema [62]. In a separate birth cohort study in the Netherlands, researchers found no association
with asthma, wheeze, eczema, atopic dermatitis, and specific IgE sensitization, at multiple follow ups,
between three months and six-seven years [69]; although, there was an association between higher
maternal folate levels measured at around 35 weeks gestation, and a reduced asthma risk in offspring
aged six-seven years. Dietary folate exposure may have been influenced by voluntary food fortification
in The Netherlands at this time.
A South Korean cohort study of pregnant women at 12 to 28 weeks gestation, found that
serum folate at a level of ≥9.5 ng/mL, was associated with a reduced risk of maternal-reported
atopic dermatitis in offspring at 24 months; although, no relationship was found for late pregnancy
(29–42 weeks gestation) [68]. This finding is contrary to the other studies described here, adding to
the uncertainty of the potential role of folic acid supplementation on allergy development. This may
reflect differences between countries. Also of interest in this study [68], is that higher serum folate
levels were associated with increased levels of the immunoregulatory cytokine IL-10 in cord blood.
9.3. Second and Third Trimester Pregnancy Folic Acid Supplementation
Publications from those studies examining later pregnancy folate supplementation and allergic
disease in the offspring outcomes, have also reported variable results (Table 1). These longitudinal
studies provide evidence from cohorts of mother-child pairs across England, Norway, and Australia.
An English study found no association between maternal folic acid supplementation at 18 weeks
and childhood atopy; although, there was some evidence of an association between maternal folic acid
supplementation at 32 weeks and a child’s genotype (T allelle), and childhood atopy [64]. This is the
earliest of the studies described here, where the cohort study time period occurred after voluntary
permission to fortify bread and breakfast cereal in the mid/late 1980s, and prior to the 1992–1993 folic
acid supplementation recommendations in the UK.
In a Norwegian cohort study, no association between late pregnancy folic acid supplementation
use (after 12 weeks), and childhood allergic disease outcomes, was found; whereas, in a case control
study nested in the same cohort, the risk of asthma was found to be increased in children at three years
of age, with increasing quintiles of maternal plasma folate levels at 18 weeks [65,66]. Norway had
dietary folate recommendations for pregnancy, but there was no fortification of food in place at the
time of these studies.
Intriguingly, two Australian cohort studies found positive associations between folic acid
supplementation in late pregnancy and the risk of asthma at 3.5 years [71]; and between higher
doses of folic acid (>500 μg/day) from supplements in the third trimester and eczema at 12 months,
along with a reduced risk of sensitization for fetal serum folate levels between 50 to 75 nmol/L after
adjusting for confounders, including maternal allergy [63]. Only voluntary fortification of some food
was implemented in Australia at the time of these studies.
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The limitations of observational epidemiological studies should be highlighted here, given that
the statistical significance of associations does not infer causality. Many of the observational studies
were reliant on maternal-reported folic acid supplementation use and parental-reported allergic disease
outcomes, which are subject to reporting bias. There is a lack of randomised clinical trials investigating
the effect of the single dietary exposure of folic acid supplementation use during the second and
third trimester of pregnancy. Randomisation of exposures is critical for accounting for the multiple
confounding modifiable environmental factors that have been identified as potentially influencing the
in-utero environment and related allergic disease outcomes in children, including other nutritional
factors, such as vitamin D, gut microbiota, smoking, rural environments, pet keeping, and high
SES-related health seeking behaviours [5,7,13,16].
10. Epigenetic Effect of Folate on Immune Gene Regulation
Following the hallmark study by Hollingsworth et al., in 2008, [22] demonstrating the
transgenerational effects of folic acid on epigenetic regulation, and the predisposition to allergic disease,
there has been intense interest in the effects of folate on immune development. In a randomised,
controlled trial of healthy subjects (n = 20), where participants were allocated a daily folic acid
supplement of 1.2 mg over a 12 week period (n = 10, 70% female), or a placebo (n = 10, 80% female),
the folate status was found to influence the proteome, including the proteins involved in immune
function [72]. Maternal use of folic acid supplements around the time of conception, has been found to
be associated with increased methylation of genes in their children, such as insulin-like growth factor 2
(IGF2) in early childhood [73].
Recently, DNA methylation signatures from mononuclear blood cells, were found to predict
clinical food allergy in infants aged 11–15 months [74]. Another study identified the longitudinal stable
methylation differences in CD4+ T cells, from 12 month old infants with a diagnosed food allergy,
highlighting the potential for epigenetic changes in these cells to influence the allergy phenotype
via changes during T-cell development [75]. Interestingly, there is also evidence linking whole
blood-isolated DNA methylation profiles and an active cow’s milk allergy; therefore indicating the
potential of a link between the epigenetic changes in DNA methylation and the findings of the Finnish
association study described above. In an epigenome-wide association study in US children, using
DNA from whole blood samples, the methylation of gene loci was identified as being associated with
a cow’s milk allergy [76]. A study of children in the Netherlands also found general hypermethylation
in DNA regions, identified as being involved in immunological pathways of children, which challenge
the proven cow’s milk allergy evidence, when compared to controls [77]. Mononuclear cells from
children with a cow’s milk allergy have also been found to have distinct differences in the DNA
methylation profiles for TH2- (IL-4, IL-5) and TH1(IL-10, IFN-γ)-associated cytokine genes, when
compared to controls (healthy children) and tolerant children who had outgrown their previous cow’s
milk allergy [78]. Collectively, these observations emphasise the need to better understand the impact
of folic acid supplementation practices on aspects of fetal development, including the immune system.
It is important to note the limitations of this review described above; and frame the current extent of
the evidence base as being mainly derived from animal and observational epidemiological studies,
with some emerging evidence from DNA methylation studies.
11. Conclusions
Folic acid acts as a methyl donor, with the capacity to alter the methylation of DNA. In animal
studies, folic acid has been found to modify gene expression, linked to the development of allergic
disease in offspring. These actions of folic acid, coupled with results from several human population
studies, provide some foundation to bring into question the role of folic acid exposure in late pregnancy
in the development of allergic disease in children, after the critical period of time for protection against
neural tube defects. However, the epidemiological cohort study results are conflicting, and there is a
significant lack of conclusive human trials, including in folate-replete populations. The likelihood of
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a multifactorial aetiology of allergic diseases in children, further highlights the need to examine this
potential hypothesis using a randomised control trial study design, in order to better understand the
clinical plausibility of this epigenetic role of folic acid supplementation in late pregnancy. Given the
global trend of increasing allergic disease prevalence, this field of research is of interest to researchers,
health practitioners, and food regulators alike; and has important research translation potential for
informing food policy and health communication decision making.
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Abstract: The role of breastfeeding in improving allergy outcomes in early childhood is still unclear.
Evidence suggests that immune mediators in human milk (HM) play a critical role in infant immune
maturation as well as protection against atopy/allergy development. We investigated relationships
between levels of immune mediators in colostrum and mature milk and infant outcomes in the first
year of life. In a large prospective study of 398 pregnant/lactating women in the United Kingdom,
Russia and Italy, colostrum and mature human milk (HM) samples were analysed for immune
active molecules. Statistical analyses used models adjusting for the site of collection, colostrum
collection time, parity and maternal atopic status. Preliminary univariate analysis showed detectable
interleukin (IL) 2 and IL13 in HM to be associated with less eczema. This finding was further
confirmed in multivariate analysis, with detectable HM IL13 showing protective effect OR 0.18
(95% CI 0.04–0.92). In contrast, a higher risk of eczema was associated with higher HM concentrations
of transforming growth factor β (TGFβ) 2 OR 1.04 (95% CI 1.01–1.06) per ng/mL. Parental-reported
food allergy was reported less often when IL13 was detectable in colostrum OR 0.10 (95% CI 0.01–0.83).
HM hepatocyte growth factor (HGF) was protective for common cold incidence at 12 months OR 0.19
(95% CI 0.04–0.92) per ng/mL. Data from this study suggests that differences in the individual
immune composition of HM may have an influence on early life infant health outcomes. Increased
TGFβ2 levels in HM are associated with a higher incidence of reported eczema, with detectable
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IL13 in colostrum showing protective effects for food allergy and sensitization. HGF shows some
protective effect on common cold incidence at one year of age. Future studies should be focused on
maternal genotype, human milk microbiome and diet influence on human milk immune composition
and both short- and long-term health outcomes in the infant.
Keywords: colostrum; human milk; immune modulators; immunologically active molecules;
cytokines; growth factors; health outcomes; immunological outcomes
1. Introduction
Increasing rates of allergy/atopy are of great concern with children bearing the greatest burden of
this increase [1]. Long-term disease and health outcomes have been associated with multiple factors
but, in particular, maturation of the immune system and immune-mediated diseases have been linked
to later metabolic disorders such as cardiovascular disease [2]. Whilst there is evidence to suggest
that the maternal environment in pregnancy has an impact on subsequent development of immune
system in their offspring [3], early nutrition in the first two years of life, a rapid period of infant growth
and development, is also believed to impact short- and long-term health. A plethora of evidence
exists describing the multiple benefits of breastfeeding for both the mother and the infant, yet the
mechanisms by which they confer these benefits remain to be fully elucidated.
Human milk (HM) contains a large variety of active immune components [4], which are
present in differing concentrations [5], yet no comprehensive study has delved into the influences of
maternal characteristics on immune composition of HM. We may expect HM to contain all necessary
immunological components in the amounts needed for an appropriate infant immune development.
Abundance of immune active molecules in HM represents a major difference when compared with any
formula milk available. Further, little is known about the immune composition’s influence on short-
and long-term health outcomes.
It can be expected that HM composition may naturally change as a response to a number of
environmental and genetic factors. HM immune components may influence immunological health
outcomes but linear relationships between HM composition and subsequent health outcomes should
be evaluated with care, due to potential confounding. Previously reported differences in HM immune
composition between the countries and within the same populations provide evidence of volatility
and reasons behind it remain unclear.
Amongst immunologically active molecules studied in HM, transforming growth factor β (TGFβ)
is the most well described. HM contains all the isoforms of TGFβ, with TGFβ2 being the most
dominant; accounting for 95% of the total TGFβ [6]. Protective effects of TGFβ on gut mucosal
inflammation have been shown in animal models [7]. This protective effect may be explained by
promotion of IgA production and induction of oral tolerance [8,9]. Oddy and Rosales systematically
reviewed human milk TGFβ ability to influence infantile immunological outcomes [10]. Most of the
studies included in the analysis found a statistically significant association between higher TGFβ
concentration in HM and reduced risk of atopic diseases in the child. The authors suggested that TGFβ
found in the milk may play a role in homeostasis maintenance in the intestine, regulating inflammation
and subsequently promoting oral tolerance which may reduce the risk of allergy development.
Cytokines are one of the major classes of immune components in HM [11] but they are present
in low concentrations; therefore, there is some doubt as to whether they have significant biological
activity sufficient to modify health outcomes. On the other hand, growth factors are detected in much
higher quantities in both colostrum and mature milk [12] and may therefore have a more potent
influence in facilitating immunity maturation, as has been shown in both animal models [13] and
human studies [14,15].
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Hepatocyte growth factor (HGF) is a less-studied component that is also present in HM in
high amounts, comparable with those of TGFβ [12,16,17], but has received less attention. HGF
levels in human colostrum are 20 to 30 times higher when compared to paired maternal serum [16],
suggesting that this growth factor is actively secreted into breast milk and may have an important
role in early immune development. HGF is assumed to be in such high concentrations to facilitate
proliferation, angiogenesis and intestinal tissue maturation via paracrine and endocrine signaling [12,17].
Accumulated knowledge from animal model studies suggests that HGF may also play a role in airway
hyper-responsiveness and airway remodeling in allergic asthma [18–20] which highlights potential
importance of this immune active molecule for human milk research.
We aimed to assess the impact of maternal and environmental factors in relation to colostrum and
mature human milk immune active components composition and health outcomes at the age of six
and twelve months.
2. Materials and Methods
2.1. Study Setting, Eligibility Criteria, and Ethics
The investigations and sample collection have been conducted following ethical approval by
Ethics committees in three countries participating in the study: West London Rec 3 (UK) (Ref. number
10/H0706/32) and all paperwork has been completed according to the hospital R & D Joint Research
Office (UK) (JROSM0072) policy; the Ethical Committee of the Azienda Ospedaliera di Verona (Italy)
(approval No. 1288), and the Moscow Institute of Paediatrics and Child Health of the Ministry of
Health of the Russian Federation (Russia) (approval No. 1-MS/11). All women provided written
informed consent.
Women were enrolled at antenatal and postnatal units of 3 participating centers: Maternity
Hospital No. 1, Moscow, Russia; St. Mary’s Hospital, London, UK; G.B. Rossi Hospital, Verona, Italy.
Details of recruitment are described in full elsewhere [21].
2.2. Medical Records and Interview
Following enrolment, participants underwent allergy skin prick testing (SPT) and answered a
10-minute interview-based questionnaire regarding their medical history. Exposure variables recorded
were selected based on a detailed review of known determinants of HM composition [22]. Information
collected from the recruited women included: parity; age; mode of delivery; details of residence
environment, such as mould presence at home, regular contact with animals and/or pets at home;
exposure to tobacco smoke (smoker or living in household with smoker or self-reported passive
smoker); any reports of infections during pregnancy. We also obtained information on maternal dietary
preferences—fish, fresh fruit, and probiotic intake. Participant medical records were reviewed by study
personnel to extract relevant health information which was not available from questionnaires, prior to
breast milk analysis. SPT was undertaken using the following solutions: Histamine 1% Positive Control,
Glycerol Negative Control, House Dust Mite (Dermatophagoides pteronyssinus), Cat (Felix domesticus),
Grass Pollen, Birch pollen, Peanut, Hazelnut, Egg (all from Stallergenes, SA 92160 Anthony, France),
and Cow’s milk (ALK-Abello, Hǿrsholm, Denmark). SPT was performed by standard technique using
1 mm lancets (ALK-Abello, Hǿrsholm, Denmark), and were read at 15 min. Allergic sensitization was
defined as a wheal ≥3 mm to at least one allergen, in the context of a wheal ≥3 mm to histamine and
no wheal to the negative control.
2.3. Human Milk Sampling
Participants were given sterile tubes to collect their own colostrum (once in the first 6 days of life)
and mature HM (once at 4–6 weeks postpartum). Instructions were given for collection of samples
by manual expression or by collecting the drip from the contra-lateral breast during feeding [23].
Colostrum samples were frozen at −50 ◦C to −80 ◦C within 12 h of collection. HM samples were
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collected at home, transported to participating units by study staff, and frozen at −50 ◦C to −80 ◦C
within 12 h of collection. It has been previously demonstrated that storage for 6 months at either
−20 ◦C or −80 ◦C did not influence the concentration of immune active factors in human milk [24].
After thawing, samples were centrifuged at 1500× g for 15 min at 4 ◦C. The lipid layer was removed
with a pipette and aqueous fraction was analysed for immune modulators [25]. All milk samples were
transported to London at −70 ◦C where the samples were stored at −80 ◦C until analysis.
2.4. Electro-Chemiluminescence
We used electro-chemiluminescence to measure immune mediators in colostrum and breast milk
samples for Th1 and Th2 cytokines, HGF, and TGFβ1-3 (MesoScale Discovery, Rockville, MD, USA).
Laboratory experiments were run according to manufacturer’s protocol, using an eight-point standard
curve. Assays were run in duplicate with no dilution used for Th1 and Th2 cytokines (IL2, IL4,
IL5, IL10, IFNγ, IL12, IL13) and HGF, and 1:2 dilution for TGFβ assays, following pilot experiments
which showed that TGFβ2 levels in undiluted milk samples were often greater than the upper limit
of detection. For TGFβ analysis, samples were acidified by the addition of 1N HCl to colostrum or
mature milk. Acidified samples were then neutralised by addition of 20 μL of 1.2 NaOH, 0.5 HEPES.
Assays were run in duplicate, and mediator levels were excluded where the CV was >25%.
2.5. Health Outcomes
The infants’ health outcomes were assessed at the age of 6 months by means of a phone
questionnaire and at one year of age by a questionnaire during the follow-up visit. All questions were
carefully explained to the mothers. All health outcomes were self-reported by the mother except atopic
sensitization which was assessed by skin prick test. Information on fever, wheeze, common cold,
eczematous rash, reflux and vomiting cumulative incidence, food allergy/sensitivity or intolerance
incidence were solicited.
Common cold was defined as at least one episode of runny nose or cold lasting for a minimum of
3 days. Cough/wheeze outcome was defined as at least one episode of recurrent cough or wheezing
prior to assessment at one year of age. Eczema symptoms were considered present if the child had
ever had a characteristic itchy eczematous rash intermittently at any time during the last 6 months.
Parental-reported food allergy was defined as food allergy/sensitivity or intolerance incidence reported
by the parents within the first 12 months of life. An infant was considered to be atopic if s/he had
positive control wheal of ≥3 mm and any of the allergen-induced wheals being ≥3 mm greater than
negative control.
For exclusive breastfeeding, the World Health Organisation (WHO) recommended definition
“that the infant receives only breast milk” was used. No other liquids or solids are given—not even
water—with the exception of oral rehydration solution, or drops/syrups of vitamins, minerals or
medicines” [26].
2.6. Statistical Analysis
We assessed the probability of infants to develop particular health outcomes (presented as a binary
variables) depending on potential determinant, using a binomial GLmulti (GLM) and LASSO (Least
Absolute Shrinkage and Selection Operator) analyses. The resulting term importance was plotted in
order to graphically visualize the effects of determinants. Such plots provide a graphical representation
of importance estimate or relative evidence weight of candidate determinants. These weights are
computed as the sum of the relative evidence weights of all possible models in which the term appears.
Sensitivity analysis was performed for both methods and all models; a different number of variables
were included to make sure that those selected had a real and credible effect on the outcome.
Health outcomes assessed using models were: fever, eczema, food allergy/sensitivity/intolerance
assessed at 6 months. Common cold incidence, reflux and/or vomiting, and cough/wheeze were
assessed both at 6 and 12 months. Influence of immune active molecules level in colostrum and mature
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HM in conjunction with potential confounding factors was analysed in relation to health outcomes at
the age of 6 and 12 months. The most reliable information was available for eczema, cough/wheeze
and food allergy at 6 months and common cold at 12 months, these data were used as health outcomes
for the statistical modelling.
The following determinants of health outcomes were included into the models: levels of growth
factors in colostrum and mature human milk, detectability of cytokines in colostrum and breast
milk, site of collection, colostrum collection time, maternal atopic status, delivery type, infant gender.
Prior to inclusion, descriptive statistics, cross-tables, correlation and descriptive statistical tests were
performed on each determinant to describe the importance of each variable and identify which may
be the most useful in explaining and predicting a particular health outcome. Human milk immune
active molecules assessed were presented as levels of HGF, TGFβ1, TGFβ2, TGFβ3, and cytokines
(IL2, IL4, IL5, IL10, IFNγ, IL12, IL13) detectability. As cytokines are detected in human milk in low
concentrations, data were transformed into binary variable (detectable vs. undetectable) to increase
statistical analysis power. Data on cytokine detectability can be found elsewhere [21].
Statistical analysis was performed using R statistical package version 3.1.0 (R Core Team. R:
A language and environment for statistical computing. R Foundation for Statistical Computing,
Vienna, Austria). As a first step, univariate analysis and correlation matrix were used, followed by
multivariate analysis which included modelling, using LASSO and GLM.
3. Results
3.1. Study Population
A total of 481 mothers were recruited into the study from June 2011 to March 2012 from the birth
centres and antenatal and postnatal units of secondary and tertiary hospitals from three countries,
located in Northern Europe, Eastern Europe, and the Mediterranean area. Of 481 women, 398 (UK
n = 101, Russia n = 221, Italy n = 76) provided samples and were included in this study. The 83 mothers
unwilling or unable to provide colostrum samples were not evaluated further.
Demographic data of the participants is described in full elsewhere [21]. Data on co-variates
included into multivariate statistical analysis and health outcomes is presented in Table 1. Significant
differences between groups were seen for most variables recorded. Maternal allergic sensitization
(highest in UK), tobacco smoke exposure (highest in Russia), rate of infant allergic sensitisation (highest
in Italy), parental-reported food allergy and common cold (highest in Russia), and parental-reported
cough and wheeze (highest in UK), all differed significantly. Rates of maternal atopy, parity and infant
gender did not differ for health outcomes assessed (Tables A1, A3, A5 and A7).
Table 1. Characteristics of study participants and health outcomes between sites of collection.
Characteristics UK Russia Italy
p-Value
(Three Countries)
Maternal allergic sensitisation * 35/94 (37) 22/156 (14) 9/40 (23) <0.01 a
Male gender 54/101 (53) 118/216 (55) 41/76 (54) 0.98 a
Primiparous women 55/100 (55) 93/216 (43) 29/75 (39) 0.06 a
Household tobacco smoke exposure 30/99 (30) 135/218 (62) 25/76 (33) <0.01 a
Parent-reported eczema 20/81 (25) 69/210 (33) 5/47 (11) <0.01 a
Infant allergic sensitisation * 3/43 (7) 4/156 (3) 7/35 (20) <0.01 a
Parent-reported food allergy 15/80 (19) 103/210 (49) 3/47 (6) <0.01 a
Parent-reported common cold 50/101 (50) 117/221 (53) 28/74 (38) <0.01 a
Parental-reported cough/wheeze 29/101 (37) 43/221 (21) 13/74 (28) 0.02 a
a Pearson χ2 test has been used. Data shown are (n/(%)) for all binary variables presented; * Defined as skin prick
test wheal ≥3 mm to at least one of a panel of common allergens.
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3.2. Associations between Determinants and Infant Health Outcomes
When unadjusted levels of growth factors and detectability of cytokines were assessed, we found
that detectable IL13 and IL2 in breast milk were significantly less often associated with eczema at
6 months. In contrast, TGFβ2 in breast milk was associated with eczema, but this did not reach
statistical significance. Lower levels of HGF were found in colostrum of the mothers of infants
who subsequently developed common cold at 12 months of age. No other factors were found to be
associated with any health outcome (Tables A1–A8).
When multivariate analysis was performed, “Best” statistical model for each outcome highlighted
those factors having the most significant influence on a particular outcome. All results are adjusted
for the site of collection as a potential confounder. The average importance of the variables for a
particular health outcome across all possible models visualised is shown in Figure 1. All factors found
to be important at least in a single model and any significant associations with health outcomes are
presented in Table 2.
Figure 1. “Best” statistical model for each outcome: (A) eczema; (B) food allergy; (C) common cold;
(D) cough/wheeze. Each model highlights those factors having the most significant influence on
a particular outcome development, out of all determinants assessed. These are relative evidence
weights of the covariates, with scale between 0 and 1.0 (equivalent of 0% to 100%). These weights
are computed as the sum of the relative evidence weights of all models demonstrating presence of
a particular determinant out of all models assessed in which the covariate appears. All results are
adjusted. Col. stands for colostrum; BM-mature breast milk.
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3.2.1. Associations between Maternal Factors/Environment and Health Outcomes
Maternal/environmental determinants reviewed were not found to be important for health
outcomes development. At least one episode of common cold at the age of 12 months was reported
less often OR 0.02 (95% CI 0.01–0.23) by mothers living in Moscow. Country of sample collection was
not associated with parental-reported food allergy OR 0.13 (95% CI 0.01–1.46) and OR 2.07 (95% CI
0.47–9.02) for Verona and Moscow respectively.
3.2.2. Association between Collection Site and Colostrum/Breast Milk Composition
Among the studied variables, three were associated with eczema development at 6 months
postpartum. Infants having breast milk with higher levels of TGFβ2 were at significantly higher risk
OR 1.04 (95% CI 1.01–1.06) of eczema development. In contrast, if detectable levels of IL13 were present
in HM, it was associated with a reduced risk OR 0.18 (95% CI 0.04–0.92) of eczema development.
These results confirm the outcomes of the univariate analysis. In our cohort, boys tended to have
eczema less often OR 0.2 (95% CI 0.05–0.84) compared with girls. Children fed colostrum with
detectable levels of IL13 in colostrum were found to be less likely OR 0.1 (95% CI 0.01–0.83) associated
with parental-reported food allergy at the age of 6 months.
HGF concentration in breast milk was associated with less common cold development OR 0.19
(95% CI 0.04–0.92). No determinants were found to be associated with cough/wheeze development at
the age of 12 months. There is some tendency for HGF to be associated with a higher risk of cough or
wheeze development, but results did not reach significance OR 1.89 (95% CI 0.94–3.78).
There was no association between any factor and infant allergic sensitisation at one year of age.
It may be explained by a very small sample size as only 14 babies from the three cohorts developed
allergic sensitisation.









































Average importance of the determinants for a particular health outcome during the first year of life, across all
possible models. Data for exposures shown to be important presented as OR (95% CI). NI-determinant has not been
found to be important for the particular health outcomes development. Statistically significant results presented in
bold. GLM = GLmulti; HM = human milk; HGF = Hepatocyte growth factor; TGFβ = transforming growth factor β.
4. Discussion
Mothers from the three geographical regions studied live in very different environments, have
differences in diet, lifestyle and it is necessary to take into account many factors which may potentially
influence human milk composition as well as health outcomes. In contrast to other studies, we included
a large number of potential determinants, adjusting the results to the site of collection as a potential
confounder making the results more robust.
The aim of the study was to investigate whether peptide regulatory factors in human milk
impacted infant health outcomes. Despite limitations, the results suggest that variability of human milk
composition has an effect on parental-reported eczema, food allergy, and common cold development.
The results support the concept that IL13 and HGF have protective effects and TGFβ2 may act as a risk
factor, which may explain the diversity of results from epidemiological studies on the health-promoting
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effects of breastfeeding with regards to allergic diseases. Further, many studies attempted to evaluate
colostrum and human milk composition influence on atopy and/or allergy development in the first
years of life and produced conflicting results [23,27–29].
As TGFβ is an important regulatory cytokine suppressing both Th-1 and 2 activity, it appears
counter-intuitive that high levels are associated with increased risk of eczema development. However,
eczema is primarily a condition of impaired skin barrier function with allergic sensitization being a
secondary phenomenon. Our findings suggest that higher concentrations of TGFβ2 in mature human
milk are associated with significantly increased risk of eczema reported by the age of 12 months.
Some studies support this observation, having found increased TGFβ1 and TGFβ2 in colostrum
associated with the eczema onset in infants [6,28,29]. However, conflicting results have come from
other studies [23,27,30–32]. It is not known why TGFβ might have an adverse effect on eczema,
but it may be related to a particular isoform influence. A known classic example of TGFβ isoform
differences has been observed in cutaneous scarring experiments done on animal models [33]. In these
experiments mammalian embryos showed healing with no scarring and full skin recovery [34] with
the expression of high levels of TGFβ3. In contrast, low levels of TGFβ1 and 2 [35] as well as similar
TGFβ3 function have been demonstrated in human scarring physiology [36]. These pathways suppress
immune surveillance in the skin such that infections break down the already genetically susceptible
tissue. TGFβ family proteins are known for their diversity in biological functions, including migration
of normal and abnormal cells, as shown in cancer research [37]. This may be a mechanism behind
an association between the levels of TGFβ2 in HM and eczema. High concentrations of TGFβ2 may
represent a biomarker that may predict risk of eczema in breastfed infants. This provides the initial
inflammatory trigger to establish skin inflammation. Only a small number of children in our cohort
were sensitized, which does not allow for an accurate assessment of a decreased barrier function;
however, TGFβ may be impacting the skin barrier independent of allergy. However, the most likely
explanation is that TGFβ in HM is a key factor, playing an important role in gut integrity maintenance
as well as oral tolerance induction [38,39].
Detectable IL13 in mature milk reduced the risk of parent-reported eczematous rash development,
whilst detectability of this cytokine in colostrum seems to have a similar association with food
allergy/sensitivity/intolerance reported by the mothers at six months of age. This is the first study to
report this association between IL13 in colostrum/human milk and eczema and/or food adverse events
in children at 12 months of age. Eczema is not primarily an allergic condition but a heterogeneous
disease. It may be speculated that a combination of TGFβ and IL13 may lead to TH1 responses
impairment. The high IL-13 in colostrum fits well with the presumed impact on Immunoglobulin
(Ig) E production but the counter effect of detectable levels in mature milk may be irrelevant as they
are so low as to have little if any biological significance. Although maternal-reported events are a
subjective measure and risk of bias is increased, these data should be validated on larger cohorts of
high-risk infants.
Most studies agree that levels of other human milk immune active molecules, cytokines in
particular, are not associated with atopy and/or allergy development in early life [23,27,29,30].
Only 14 infants developed allergic sensitisation in our cohort, which therefore provided insufficient
statistical power to analyse for any associations.
Human milk has been shown to be beneficial for infants in part by providing high concentrations
of immune active molecules which are associated with a decreased incidence of neonatal respiratory
infections as well as long-term outcomes, such as wheeze and/or asthma [40]. Gdalevich and Mimouni
provided a meta-analysis suggesting protective effects of exclusive breastfeeding in the first months
of life on later asthma development [41]. However, the difficulty in combining data is that the
wheeze/asthma phenotype differs between studies. Further, it is known that most early life wheezers
do not subsequently develop persistent asthma.
Our data did not show any significant association of colostrum and/or HM immune active
molecules with parent-reported cough or wheeze episodes at 12 months of age. It is known that a
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large proportion of infants suffer asymptomatic infections during the first year of life [42]. There was
also no association between human milk composition and common cold reported at 6 months of age.
However, when assessed at one year of age, HGF levels in HM were associated with reduced incidence
of common cold reported at 12 months of age. HGF is known for its ability to provide protection
during inflammatory diseases, directly targeting macrophages or lymphocytes [20]. Animal research
showed that HGF administration stimulates intestinal cell proliferation resulting in intestinal growth
induction [43]. HGF may well act in a similar fashion when transferred in high amounts into infants’
gut. This finding shows that HGF as a component of human milk may not only play a very important
role during the very first days of life, providing infant gut immunity development and maturation, but
it is also capable of influencing long-term health outcomes. However, we cannot rule out a reversed
causative relationship, due to the presence of common cold viruses which may lead woman to express
higher quantities of HGF into their milk, in order to protect the offspring.
The main strength of this study is that it is one of the largest to date, assessing immune active
molecules in colostrum and mature milk. The main limitation of this study is recruitment of women
from the general population. As a consequence, very few babies developed eczema. According to UK
working party criteria, recurrent rash development reported by the mother is not the most accurate
and precise criteria to use. An apparent weakness of this study is that all immunological outcomes
were reported by the parents and not based on healthcare professional diagnosis. Mothers tend to
over-report health outcomes, such as food allergy in their children, but childhood eczema can be
accurately reported by caregivers [44]. The same applies to common cold symptoms as retrospective
parental reporting can be inaccurate. Another weakness is that health outcomes were reported by the
parents at 6 and 12 months only, with most of the data coming from 6 months. We also did not collect
HM on a multiple occasion at many time points, which would be required for the assessment of the
actual intake of immune active molecules depending on the duration of breastfeeding.
Our data suggests that another factor substantially increasing the risk of eczematous rash
development is the gender of the baby, with girls at higher risk. This result is in agreement with the
International Study of Asthma and Allergies in Childhood (ISAAC) phase three data [45], although
usually prevalence of eczema during the first year of life varies slightly when compared with older age
groups. Differences in perception of eczema by women living in different countries and participating
in our study could also play some role in reporting. Some of the previous studies have shown that
gender long term does not seem to play a significant role in risk of developing atopy, eczema [42,46]
and allergic rhino-conjunctivitis.
5. Conclusions
In this large international cohort study of HM immune composition, we found an important
association between HM constituents and infant health outcome. Our hypothesis is at least in part
confirmed but will require more detailed evaluation of environments. We have also confirmed that
variations in levels peptide regulatory factors in human milk do associate with different infant health
outcomes. As we focused on an un-selected general population cohort, the power to detect effects on
allergy outcomes was limited. Despite this, higher TGFβ and IL13 did associate with eczema. This
will require confirmation in a high-risk cohort and could indicate targets for trial of interventions to
prevent atopic diseases.
Future research assessing human milk composition association with immunological health
outcomes should include international collaborative studies with strict harmonisation of sampling,
storage and analysis protocols between the sites. There is a need in studies, for evaluating human
milk immune composition with samples collected at multiple time points prospectively. The only
way forward is to bring different research groups together in an attempt to map human milk
composition, highlighting differences between the countries and finding associations between human
milk immunology and health outcomes.
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Appendix A
Table A1. Univariate analysis demonstrating demographic data and difference in colostrum and HM
cytokine detectability for eczema as a health outcome.
Categorical Variables No Eczema (n = 244) Eczema (n = 94) p-Value
Demographics
Positive maternal atopy 42 (22.2%) 16 (35.5%) 0.735
Gender (male) 122 (50.8%) 57 (61.3%) 0.111
Multiparity 137 (57.3%) 47 (98.6%) 0.422
Immune active molecules
Detectable HM IL13 45 (37.8%) 9 (23.8%) 0.002
Detectable Col IL13 52 (24.6%) 16 (36.8%) 0.598
Detectable HM IL2 31 (26.1%) 4 (10.6%) 0.001
Detectable Col IL2 33 (15.6%) 8 (18.4%) 0.355
Pearson χ2 test or Fisher’s exact test (if appropriate) were used for this analysis. Statistically significant differences
(p < 0.05) appear in bold.
Table A2. Difference in crude levels of growth factors (ng/mL) for eczema as a health outcome.
Numeric Variables No Eczema (n = 244) Eczema (n = 94) p-Value
HM TGFβ2, median (IQR) 13.57 (14.717) 17.48 (25.619) 0.087
Col TGFβ3, median (IQR) 1.52 (2.513) 2.04 (2.570) 0.169
Col HGF, median (IQR) 2.11 (5.239) 2.52 (6.540) 0.371
HM HGF, median (IQR) 0.79 (0.602) 0.76 (0.745) 0.834
Col TGFβ2, median (IQR) 41.80 (73.124) 47.69 (81.280) 0.663
HM TGFβ3, median (IQR) 0.254 (0.220) 0.302 (0.200) 0.663
Wilcoxon test was used for this analysis. Statistically significant differences (p < 0.05) appear in bold.
Table A3. Univariate analysis demonstrating demographic data and difference in colostrum and HM
cytokine detectability for food allergy as a health outcome.
Categorical Variables No Food Allergy (n = 216) Food Allergy (n = 121) p-Value
Demographics
Maternal atopy 44 (25.1%) 14 (14.7%) 0.067
Gender (male) 111 (51.9%) 67 (56.8%) 0.457
Multiparity 119 (56.7%) 63 (52.9%) 0.591
Immune active molecules
Detectable HM IL13 33 (33.7%) 21 (25.9%) 0.337
Detectable Col IL2 46 (25.1%) 22 (21.4%) 0.565
Detectable HM IL2 22 (22.4%) 13 (16.0%) 0.376
Detectable Col IL13 24 (13.0%) 17 (16.5%) 0.530
Pearson χ2 test or Fisher’s exact test (if appropriate) were used for this analysis. Statistically significant differences
(p < 0.05) appear in bold.
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Table A4. Difference in crude levels of growth factors (ng/mL) for food allergy as a health outcome.
Numeric Variables No Food Allergy (n = 216) Food Allergy (n = 121) p-Value
HM TGFβ2, median (IQR) 13.765 (24.656) 13.616 (12.434) 0.984
Col TGFβ3, median (IQR) 1.718 (2.704) 1.531 (1.854) 0.494
Col HGF, median (IQR) 2.082 (5.436) 2.419 (6.199) 0.437
HM HGF, median (IQR) 0.843 (0.769) 0.731 (0.539) 0.066
Col TGFβ2, median (IQR) 0.289 (0.216) 0.275 (0.207) 0.909
HM_TGFβ3, median (IQR) 0.289 (0.216) 0.275 (0.207) 0.909
Wilcoxon test was used for this analysis. Statistically significant differences (p < 0.05) appear in bold.
Table A5. Univariate analysis demonstrating demographic data and difference in colostrum and HM
cytokine detectability for cough/wheeze as a health outcome.
Categorical Vars No Cough/Wheeze (n = 251) Cough/Wheeze (n = 85) p-Value
Demographics
Positive maternal atopy 38 (19.7%) 18 (24.0%) 0.541
Gender (male) 128 (51.4%) 48 (58.5%) 0.320
Multiparity 132 (54.3%) 50 (58.8%) 0.554
Immune active molecules
Detectable HM IL13 40 (29.4%) 14 (33.3%) 0.771
Detectable Col IL2 51 (24.4%) 17 (22.1%) 0.849
Detectable HM IL2 26 (19.1%) 9 (21.4%) 0.825
Detectable Col IL13 31 (14.8%) 10 (13.0%) 0.800
Pearson χ2 test or Fisher’s exact test (if appropriate) were used for this analysis. Statistically significant differences
(p < 0.05) appear in bold.
Table A6. Difference in crude levels of growth factors (ng/mL) for cough/wheeze as a health outcome.
Numeric Vars No Cough/Wheeze (n = 251) Cough/Wheeze (n = 85) p-Value
HM TGFβ2, median (IQR) 12.891 (15.595) 21.725 (20.910) 0.090
Col TGFβ3, median (IQR) 1.523 (1.932) 1.890 (3.2648) 0.193
Col HGF, median (IQR) 2.115 (5.413) 2.337 (6.36) 0.564
HM HGF, median (IQR) 0.729 (0.615) 0.859 (0.769) 0.153
Col TGFβ2, median (IQR) 41.274 (64.585) 54.094 (96.060) 0.283
HM_TGFβ3, median (IQR) 0.274 (0.200) 0.314 (0.395) 0.283
Wilcoxon test was used for this analysis. Statistically significant differences (p < 0.05) appear in bold.
Table A7. Univariate analysis demonstrating demographic data and difference in colostrum and HM
cytokine detectability for common cold as a health outcome.
Categorical Vars No Common Cold (n = 143) Common Cold (n = 130) p-Value
Demographics
Positive maternal atopy 20 (19.0%) 26 (24.1%) 0.469
Gender (male) 76 (54.3%) 69 (53.9%) 1.000
Multiparity 81 (57.9%) 66 (52.0%) 0.399
Immune active molecules
Detectable HM IL13 28 (31.5%) 13 (21.3%) 0.237
Detectable Col IL2 27 (22.5%) 28 (25.9%) 0.862
Detectable HM IL2 16 (18.0%) 8 (13.1%) 0.501
Detectable Col IL13 20 (16.5%) 16 (14.8%) 0.654
Pearson χ2 test or Fisher’s exact test (if appropriate) were used for this analysis. Statistically significant differences
(p < 0.05) appear in bold.
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Table A8. Difference in crude levels of growth factors (ng/mL) for common cold as a health outcome.
Numeric Vars No Common Cold (n = 143) Common Cold (n = 130) p-Value
HM TGFβ2, median (IQR) 13.0121 (11.823) 15.67338 (24.983) 0.324
Col TGFβ3, median (IQR) 1.9393452 (2.453) 1.7625169 (4.183) 0.977
Col HGF, median (IQR) 3.4656324 (8.459) 1.997605 (5.249) 0.009
HM HGF, median (IQR) 0.7281423 (0.660) 0.8027212 (0.556) 0.910
Col TGFβ2, median (IQR) 44.1042 (71.380) 42.36296 (77.730) 0.462
HM_TGFβ3, median (IQR) 0.288506 (0.216) 0.2748667 (0.207) 0.909
Wilcoxon test was used for this analysis. Statistically significant differences (p < 0.05) appear in bold.
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Abstract: There is conflicting evidence on the protective role of breastfeeding in relation to the
development of allergic sensitisation and allergic disease. Studies vary in methodology and definition
of outcomes, which lead to considerable heterogeneity. Human milk composition varies both
within and between individuals, which may partially explain conflicting data. It is known that
human milk composition is very complex and contains variable levels of immune active molecules,
oligosaccharides, metabolites, vitamins and other nutrients and microbial content. Existing evidence
suggests that modulation of human breast milk composition has potential for preventing allergic
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diseases in early life. In this review, we discuss associations between breastfeeding/human milk
composition and allergy development.
Keywords: breastfeeding; human milk; allergy; allergic diseases; oligosaccharides; microbiome;
cytokines; thymus
1. Introduction
Over the last few decades there has been a worldwide steady increase in the prevalence of
allergic diseases [1]. Commensurate with a decrease in infectious diseases, allergy has become a
considerable health/economic burden, most notably in relatively more affluent countries [2]. However,
similar trends are starting to be seen in the developing world [3]. Explanations for this virtual allergy
pandemic are not entirely clear but the “hygiene hypothesis” [4] remains the most widely quoted
theory, explaining allergic disease rise as a mutually counter-regulatory interaction between the
immune response to infection and that associated with allergy. Urban affluent lifestyles have been
associated with significantly reduced infant exposure to bacterial infection and an altered commensal
microbiome leading to a default allergic pattern of immune responses to common environmental
ostensibly harmless antigens/allergens. Earlier birth order and/or fewer number of siblings, late or no
attendance in day care facilities, and reduced exposure to pets [5] are among factors most commonly
associated with allergic disease development. The apparent importance of rural environment exposure
has been demonstrated in the study by Sozanska and co-authors [6], showing dramatic changes in
community lifestyle leads to increased risk of allergy development. The accession of Poland to the
European Union and changes in agricultural policies have resulted in an increase in prevalence of
allergic diseases over an eight-year period. Within this timeframe, population contact with domestic
animals and unpasteurised milk consumption has significantly declined while allergy rates have risen.
Although the “hygiene hypothesis” provides a mechanistically credible explanation for the rise
in allergy prevalence, other societal factors have been brought forward, such as dramatic changes in
dietary preferences over the past few decades. The less frequent consumption of fresh fruit, vegetables
and fish has lowered fibre intake, and altered omega-3 and omega-6 polyunsaturated fatty acid
(PUFA) ratios. Other environmental factors include lack of ultraviolet exposure leading to vitamin D
insufficiency, greater exposure to air pollutants such as volatile organic compounds, diesel particulates
and ozone, and even, increased exposure to chemical contaminants from packaged foods. Allergy is
therefore, perceived as a “modern malady” prompting clinicians, researchers and policy makers
around the globe to search for effective primary prevention [7]. Preventative strategies are particularly
important for children at high risk of allergy development [8,9], with one or both parents being
allergic [10]. It is suggested that the “window of opportunity” for allergy prevention is somewhere
within the timeframe between conception and the first six months after birth [7,11,12]. As virtually all
association studies do not discriminate between exposures of the mother during pregnancy, and/or
lactation, or those directly affecting the infant, it is not possible to attribute a more exact timing of the
“window”. It is perhaps more likely that a sequence of events during pregnancy and the early months
of life combine to alter the risk of allergic sensitization and subsequent disease.
Human milk (HM) should be the main source of nutrition during a critical period of metabolic and
immune programming, driven in part by its effects on intestinal function. Accumulated data suggests
that a wide range of bioactive factors: such as proteins, polyunsaturated fatty acids, oligosaccharides,
microbial content, metabolites, and micronutrients [13] present in HM can influence the infant’s gut
immune maturation. Chronic allergic diseases are linked with the altered functioning of the innate and
adaptive immune systems [14] and evidence suggests that it can be influenced using interventional
strategies [15]. Recent research shows that various maternal exposures, such as immunisation,
dietary patterns, vitamin D, ω-3 fatty acids and/or probiotics, may influence HM composition and
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thereby affect infant health. HM composition varies over time from delivery, within and between
women, and even within the same feed, which may in part, explain some of the conflicting results of
general observational studies regarding the provision of breastfeeding. Although HM constituents
will be critical in influencing a range of other aspects of breastfeeding, such as its “exclusivity”,
the close physical contact during nursing and time of weaning may also have important implications
for health and development. However, results are inconsistent between studies, and there is no
clear understanding of the pathways linking the intervention with effects on HM composition and
health outcomes.
This review summarises existing evidence on breastfeeding and human milk composition in
relation to allergic disease development.
2. Breastfeeding and Immunological Outcomes
Many aspects of breastfeeding can potentially influence its health effects [16]. These include
duration of breastfeeding, maternal diet during lactation [17], and age at complementary food
introduction [18–20], which can all differentially affect how breastfeeding may act on child health
and immune development. Breastfeeding alters a child’s gut microbiome and subsequent immune
development [21,22] and influences risk of respiratory infections through maternal antibody
transfer [21]. It also impacts childhood nutrient intake such as vitamin D. The latter nutrient has
been of particular interest because there are vitamin D receptors on many immune active cells and
most notably on regulatory T-cells. Insufficiency is associated with reduced T-cell regulation of
immune hyper-sensitive responses [23]. Data from some studies suggests that breastfeeding may
impact immune organ functioning, with a difference in thymus involution seen between breastfed and
formula fed children (discussed in more detail in Section 2.3).
It is well established that breastfeeding confers protection against both short-term adverse
outcomes including reduced morbidity and mortality from neonatal infections) and long-term
events including reduction in blood pressure, type 2 diabetes, increased IQ and better educational
achievements in later life (even when adjusted for family socio-economic status [24]) [25]. A World
Health Organisation (WHO) report suggests that there is a lower long term morbidity from
gastrointestinal and allergic diseases in infants who were exclusively breastfed for 6 months in
comparison to non-breastfed children [26]. Moreover, breastfeeding seems to play an important role at
a time of complementary food introduction. Thus, during introduction of gluten into the infant diet it
may reduce the risk of coeliac disease, suggesting important interactions between BM components,
dietary antigens, and gut associated lymphoid tissue (GALT) [27]. However, this protective
effect on coeliac disease remains uncertain, as studies have produced conflicting evidence [28].
Similar associations of reduced allergy in infants who have continued being breastfed during weaning
have been reported [29]. Based on these data, current UNICEF and WHO recommendations are “every
infant should be exclusively breastfed for the first six months of life, with continued breastfeeding for
up to two years or longer” [30].
Despite some high-quality research, there is conflicting evidence on the protective role of
breastfeeding in relation to many non-communicable diseases, including immunological (allergic
and autoimmune) outcomes. It has been hypothesised that the mixed results may be in part
due to variations in HM composition as it is known to contain a large variety of immune active
components [13] which are present in differing concentrations [31]. Which factors are able to provide
sufficient influence on short and long-term health outcomes in infants is still a matter of discussion,
despite a number of studies attempting to address this question.
2.1. Importance of Breastfeeding Duration
When evaluating the relationship between breastfeeding duration and health outcomes it is
important to have clear definitions for breastfeeding duration. It is usually defined as total breastfeeding
duration, the time between birth and complete cessation of breastfeeding; while exclusive breastfeeding
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duration is the time between birth and first introduction of a non-breastmilk feed. Feeding expressed
breastmilk, fresh or frozen, by bottle, and use of donor breastmilk, given directly or fresh or frozen by
bottle, are variably included within these definitions of total or exclusive breastfeeding, depending
on the focus of the research study. Use of the term exclusive breastfeeding is problematic in that
it combines two separate interventions—timing of first solid (‘complementary’) food introduction,
and use of a breastmilk substitute (formula milk). In general the evidence that early formula milk
introduction is not optimal for development of infants health is stronger than the evidence that early
complementary food introduction causes harm. It also depends on the type of allergy developed and
exposure of allergens involved. This discrepancy has been highlighted by recent data showing that
early complementary food introduction has defined health benefits—recent studies show that the
phenomenon of oral tolerance induction, known for over 100 years to occur in animal experiments,
also occurs in humans [7,29,32–34]. Oral tolerance occurs when early and sustained feeding of a food
antigen reduces risk for developing food allergy to that antigen. This phenomenon has been shown to
occur in humans for the two most common food allergies affecting young children: egg and peanut
allergy [34]. However it is important to underline that tolerance development was only demonstrated
in the per protocol and not ITT group in the latter study and further research is needed to make
definitive conclusions.
This first sign that early introduction of complementary foods may be beneficial to infant health,
suggests that future studies will need to more clearly distinguish timing of infant formula introduction
and timing of complementary food introduction when evaluating relationships between exclusive
breastfeeding duration and allergic disease risk.
2.2. Breastfeeding and Allergic Diseases
At the beginning of the last century, Grulee and Sanford suspected a link between HM
substitute feeding and a higher incidence of eczema [35]. Since then many prospective and
retrospective observational studies have tested breastfeeding associations with the onset of
allergic disease, providing mixed results for eczema [19–21,36–49] sensitisation [21,37,42,46–58] and
asthma [19–21,36,42,47,48,59–66]. Messages culminating from these studies range from a protective
effect of breastfeeding [67], to a higher risk of atopy [68], or no significant effect [69]. Despite the
conflicting evidence, several clinical societies have made recommendations regarding the duration
and type of breastfeeding. As mentioned above, the WHO recommends exclusive breast feeding for at
least 6 months in all infants with continued breastfeeding up to 2 years or longer if a mother wishes to
do so [30].
The first efforts to systematically review existing evidence on breastfeeding associations with
the selected eczema [70] and asthma [71], were made by Gdalevich and Mimouni two decades
ago. Later, additional systematic reviews and meta-analyses were undertaken, assessing worldwide
evidence [26,72,73], or focusing on data from developed countries [74]. The main challenge in the
meta-analyses of these data was significant heterogeneity in the definitions of breastfeeding, which are
not always consistent with WHO recommendations, and in phenotyping of for health outcomes. In the
most recent systematic review which was published just two years ago [75], Lodge and colleagues
reported on 4 different definitions of eczema, food allergy and asthma, and 3 definitions of allergic
rhinitis used across studies [75], with differing breastfeeding exclusiveness and duration creating even
more uncertainty.
Assessment of breastfeeding’s potential to prevent allergic disease in observational studies is
not an easy task as several factors, such as socioeconomic status, positive allergy family history, early
exposure to pets and timing of solid food introduction, alongside variations in HM composition, are
all sources of bias. Prospective randomised studies are needed to provide solid evidence of causal
relationships, however such studies would be unethical. The sole large randomized controlled trial used
an innovative approach in a country with a very low breast feeding rate and investigators randomised
mothers to a breast feeding promotion group or continued standard practice. The intervention
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significantly increased breast feeding rates and facilitated evaluation of the breastfeeding associations
with health outcomes in Belarus [76]. There was a reduced risk of early eczema (Odds Ratio (OR) 0.54,
95% CI 0.31–0.95) with breastfeeding but no long-term protection against eczema, allergic rhinitis and
asthma at 6.5 years of age, despite the long duration and exclusivity of breastfeeding observed in this
trial [77]. However, the extent to which WHO recommendations delayed introduction of non-milk
food sources at a critical period where tolerance induction may be important to prevent allergy is
uncertain [78].
2.2.1. Eczema
Most of the studies assessing breastfeeding impact on eczema development come from the
cross-sectional studies or birth cohorts. The major weakness of collected data is related to a long
retrospective recall period and lack of adjustment for potential confounding factors, such as allergy
family history [75]. Authors of The International Study of Asthma and Allergies in Childhood (ISAAC),
a large observational study assessing more than two hundred thousand children worldwide, failed to
find evidence of a breastfeeding protective effect on eczema development at 6–7 years of age (OR 1.05,
95% CI 0.97–1.12), but reported some protection against severe eczema (OR 0.79, 95% CI 0.66–0.95) [79].
Outcomes of a systematic review and meta-analysis, covering literature up to 2014, suggested that
children below 2 years of age who were exclusively breastfed for more than 3–4 months were are at
lower risk (OR 0.74, 95% CI 0.57–0.97) of eczema development; however, this protective effect was no
longer evident after the age of 2 (OR 1.07, 95% CI 0.98–1.16) [75]. The authors highlighted a potential
high risk of bias from smaller studies showing more significant protective effects.
2.2.2. Food Allergy
Studies assessing the association between breastfeeding and food allergy contribute conflicting
results, with some cohort studies reporting a reduced risk of food allergy development in a
general population [80,81] and in high risk children [82], with others suggesting a greater risk after
breastfeeding [83,84]. The most recent meta-analysis showed no statistically significant association
between breastfeeding and food allergy development (OR 1.02, 95% CI 0.88–1.18). Assessment of food
allergy is not straightforward in the context of a clinical trial, as the gold standard for confirming
the diagnosis is the double-blind food challenge, which is not always a viable option for study
participants. In many studies, a combination of a clinical history and skin prick test (SPT) or serum IgE
testing is used as surrogate markers of a diagnosis of food allergy with inevitable high heterogeneity.
Hence, the primary goal for future research should be harmonization of the outcome definition [75].
Recent clinical trials showing benefits in early food introduction (from 3 to 4 months of age), in parallel
with breastfeeding, may indicate a worthwhile strategy to decrease risks of food allergy development.
This has been driven by recent studies, such as the Learning Early About Peanut Allergy (LEAP) and
Enquiring About Tolerance (EAT) trials [29,33], suggesting that in some children, early introduction
(before child age 6 months) of peanut and/or egg protein reduces the risk of allergy to these foods [7].
2.2.3. Asthma
More than 15 years ago, Gdalevich and Mimouni reported a link between breastfeeding and
lowered asthma prevalence in children (OR 0.70, 95% CI 0.60–0.81) [71]. This association has been
further confirmed in two subsequent meta-analyses (OR 0.78, 95% CI 0.74–0.84] [73] and OR 0.88, 95%
CI 0.82–0.95 [75]). Biological plausibility or coherence in published evidence for a role of breastfeeding
in protecting against asthma development includes its demonstrated benefit in reducing the number of
respiratory tract infections in early infancy, especially among infants in middle- and low-income
countries [75]. In addition, exclusive breastfeeding reduces the duration of hospital admission,
risk of respiratory failure and the requirement for supplemental oxygen in infants hospitalized with
bronchiolitis [85,86]. Some of the described protective effects may be mediated through an antiviral
mechanism or non-specific enhancement/maturation of the infant immune system.
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However, there is significant heterogeneity (study design, outcome definition, country
development) between studies reporting an inverse association between breastfeeding infants and
asthma development. Some of the differences can be explained by variations in the definitions
for breastfeeding exclusivity and duration, and methods to diagnose asthma in children [87]. It is
known that many infants who wheeze in the first years of life do not develop asthma in later life [88],
but wheeze is often used as the diagnostic marker of asthma. There are several notable large prospective
birth cohorts, such as Avon Longitudinal Study of Parents and Children (ALSPAC) [50], Prevention
and Incidence of Asthma and Mite Allergy (PIAMA) [89] and the cross-sectional International Study
of Asthma and Allergies in Childhood (ISAAC) [90] study, with data from these studies considered
of higher quality [75]. The protective effects of breastfeeding on asthma are more apparent in recent
studies, perhaps due to improvements in methodology [73,75]. It is worth noting that subgroup
analysis shows a greater protective effect of breastfeeding in middle to low income countries where
allergy is less common [75]. It seems likely that the major effect is on respiratory infection induced
wheeze rather than atopic asthma. Future studies will need to phenotype and endotype asthma
more precisely.
2.3. Breastfeeding, Thymus and Immunity
The thymus is an essential organ for generation of T cell immunity and tolerance. Lymphoid
progenitors from the bone marrow migrate to the thymus, where a series of stringent positive and
negative selection processes take place [91]. These processes are important for the production of
functional T cells, which are able to recognize and respond to foreign/microbial antigens presented
by the MHC in the periphery, but also Foxp3+ regulatory T (Treg) cells, which mediate immune
tolerance to self and a variety of self and foreign antigens [92]. Not surprisingly, thymic aplasia as
seen in DiGeorge syndrome is associated with immune deficiency and immune dysregulation [93].
Furthermore, in all vertebrates the thymus naturally shrinks in size with age. This process of thymic
involution is poorly understood to date [94] but impacts directly on thymic output [95].
Thymic size can also be influenced by a variety of factors. Prenatally, maternal factors such as
preeclampsia has been associated with reduced thymic diameter [96], although the mechanism and the
consequences of this need to be further investigated. Postnatally, various events such as acute stress
are known to reduce the thymic size [97].
Breastfeeding on the other hand, has been associated with increased thymic size. At 4 months of
age, the thymus size (as assessed by ultrasound) in exclusively breast-fed infants was more than double
the size of formula fed infants, an effect that persisted at least until 10 months of age [98]. A further
study revealed that persistent breast feeding between 8 and 10 months also correlated with increased
thymus size in a “dose dependent” manner [99]. Although the immune implication of this remains
unclear, a subsequent study showed a correlation between breast feeding and peripheral CD4 and
CD8 T cell counts and proportion [100]. The importance of thymic tissue for T cell immunity is further
supported by a study showing that partial or total thymectomy in infants undergoing cardiac surgery
was associated with lower T cell numbers and immunoglobulin levels later in life [101]. The mechanism
by which breastfeeding may influence thymus size is unclear. However, one study conducted in rural
Gambia suggested that the reduced thymic size and output in exclusively breastfed infants born in the
“hungry season” compared to “harvest season” was associated with reduced Interleukin 7 (IL7) levels
in the breast milk [102]. As IL7 is critical for thymopoiesis [103], it seems plausible that this cytokine
may influence thymic size. However, other breast milk cytokines and metabolic components need to
be considered as well.
In addition, breast milk is known to shape the infant’s gut microbiome [104]. The gut microbiome
is the main source of bacterial metabolites such as short chain fatty acids, which have been shown to
play a central role in T cell development and differentiation [105]. Hence, a mechanistic explanation
implicating a beneficial role of breastfeeding on the infant’s gut microbiome may be an alternative
explanation for enhanced thymic size in breastfed infants.
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Overall, evidence suggests that breastfeeding influences thymic size. However, evidence is lacking
regarding the mechanism and the immune impact of this observation. Future longitudinal cohort
studies are required to address this. These studies should include good measures of thymic output
such as assays of T cell receptor excision circles (TREC) and thorough immune phenotyping of T cell
subsets, gut microbiome profiling as well as good clinical data on immune outcomes.
3. Human Milk Composition and Allergy
Human milk is the earliest and should be the only source of nutrition during first few months of
life, a crucial period for infant immune system development and metabolic programming for lifelong
health and development. Many biologically active components are found in HM, and there is some
evidence, arising from the studies in humans, suggesting maternal exposures can change both HM
composition and subsequent infant health outcomes [78,106–108].
3.1. Human Milk Immunological Composition
Variations in breast milk immune composition (and the infant’s response to HM immune
constituents) may also explain some of the conflicting results of studies evaluating whether prolonged
exclusive breast-feeding can prevent allergic disease [109,110]. Human milk is a “soup” full of immune
active factors, including leukocytes (polymorphonuclear neutrophils, monocytes/macrophages,
lymphocytes), which potentially may influence immunological outcomes in infancy and early
childhood. It contains over 250 potentially immunologically active proteins, including a wide variety
of cytokines, inflammatory mediators, signalling molecules, and soluble receptors [13], as well as
prebiotic oligosaccharides: polyunsaturated fatty acids (PUFAs) [111]: and a diverse microbiome [112],
all of which are involved in complex interactions which could influence immune outcomes.
Colostrum (early human milk, produced during the first days of life) is very rich in
immunologically active molecules that are present in much higher concentrations than mature
HM [106,113–116]. The levels of growth factors in colostrum decline very rapidly, which may be
partially explained by increasing dilution, as in the first days of life the infant’s volume requirements
are low [116]. As HM matures, the relative concentrations of the immunologically active molecules
decrease as the volume and nutritional requirements of the infant increase.
There is only limited literature on the relationship between maternal diet (including intervention
trials), human milk immunological composition, and allergy development [117,118]. The main studies
are summarised in Tables 1 and 2.






Fish Oil and Fresh
Fish
Hawkes 2001 [119] Fish oil supplementation 5 weeks no significant influence on TGF-β1 and TGF-β2
Dunstan 2004 [120] Fish oil supplementation 3 days no significant influence on IgA and sCD14 levels
Urwin 2012 [121] Farmed salmonsupplementation 1, 5 and 28 days
no significant influence on TGF-β1, TGF-β2
and sCD14
Probiotics
Bottcher 2008 [122] Probiotic supplementation(L. reuteri) 3 days and 1 month
↓ TGF-β2 and ↑ IL-10 (borderline significance) in
3 day samples
no difference in IgA, SIgA, TGF-β1, TNF, sCD14
in 1 month samples
Prescott 2008 [123] Probiotic supplementation(L. rhamnosus or B. lactis) 7 days
↑ TGF-β1 in HM from B. lactis group
no significant influence on IL6, IL10, IL13, IFN-γ,
TNF-α, sCD14, total IgA
Boyle 2011 [124] Probiotic supplementation(L. rhamnosus) 7 and 28 days
↓ sCD14 and IgA levels in HM from L. rhamnosus
GG group
no significant influence of on TGF-β1
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(L. rhamnosus and B. lactis)
colostrum (after birth)
and 1 month
↑ IL-2, IL-4, IL10 TNF-α and total n-3 fatty acids
in probiotic group
no significant influence on IFN-γ and IL6
Kuitunen 2012 [126]
Probiotic supplementation
(A combination of 2 species
of L. rhamnosus, B. breve and
P. freudenreichii)
0–3 days and 3 months ↑ IL-10 and ↓ casein IgA antibodies inprobiotics group
Savilahti 2015 [127]
Probiotic supplementation
(A combination of 2 species
of L. rhamnosus, B. breve and
P. freudenreichii)
0–3 days and 3 months no significant influence on sCD14, HBD2and HNP1–3
Other Interventions
Linnamaa 2013 [128] Blackcurrant seed oil after delivery and3 months
↑ IFN-γ and ↓ IL-4 in blackcurrant seed oil group
no significant influence on IL-5, IL-10, IL-12 and
TNF levels
Nikniaz 2013 [129] Synbiotic 3 and 4 months ↑ IgA and TGF-β2 in synbiotic groupno significant influence on TGF-β1
“↑”—stands for increased levels of a particular factor and “↓”—stands for decreased levels of a particular factor.
Table 2. Human milk immunological composition and allergy development.
Study Allergic Outcomes
Assessed
Relationship between Human Milk Composition and Outcomes
Human Milk




(up to 12 months)
↑ TGF-β1 and TGF-β2
(colostrum) higher post weaning-onset atopic disease




(up to 2 years)
Salivary IgA
(up to 2 years)
Eczema (up to 2 years)
IL-4, IL-5, IL-6, IL-8, IL-10, IL-13,
IL-16, IFN-γ, TGF-β1, TGF-β2,
RANTES, eotaxin or SIgA
(colostrum and 1 month HM)
no significant influence on atopy and/or allergy
Oddy 2003 [133] Asthma-like symptoms(up to 12 months)
↑ TGF-β1 (2 weeks HM)
TNF-α, sCD14 and IL10
(2 weeks HM)
lower risk of wheeze in infancy




(up to 4 years)
Eczema (up to 4 years)
↓ IgA casein antibodies and




(up to 12 months)
Allergic sensitisation
(up to 2 years)
Wheezing (up to 2 years)
TGF-β1, IL-10, IL-12 and sCD14
(1 month HM)





(up to 2 years)
Eczema (up to 2 years)
↓ TGF-β2 (colostrum)
lower incidence of sensitisation during the first
2 years of life





(up to 5 years)
Eczema (up to 5 years)
Allergic sensitisation
(up to 2 years)
↑ TGF-β2 (3 month HM)
IL-10 and TGF-β2 (3 month HM)
higher risk of allergic disease and eczema at
2 years of age
no significant association with allergic outcomes




(up to 12 months)
infants in the highest quartile of
IL-5 and IL-13 (2 weeks HM)




(up to 12 months)
Allergic sensitisation
(up to 12 months)
TGF-β1, sCD14, total IgA
(7 and 28 days HM)
no significant association with any of the atopic
manifestations
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Relationship between Human Milk Composition and Outcomes
Human Milk
Composition Factors Outcome of Influence
Orivuori 2014
[138]
Eczema (up to 4 years)
Asthma (up to 6 years)
Allergic sensitisation
(up to 6 years)
↑ sIgA (2 months HM)
TGF-β1 (2 months HM)
sIgA (2 months HM)
lower eczema incidence up to the age of 2 years
no significant association with the outcomes
no significant association with atopy or asthma




(up to 5 years) ↑ sCD14 (3 months HM)
higher incidence of allergic sensitisation and
eczema
Jepsen 2016 [58]
Eczema (up to 3 years)
Recurrent wheeze
(up to 3 years)
↑ IL-1β (1 month HM)
CXCL10, TNF-α, CCL2, CCL4,
CCL5, CCL17, CCL22, CCL26,
TSLP, IL17, CXCL1, CXCL8,
TGF-β1 (1 month HM)
lower eczema incidence up to the age of 3 years





(up to 6 months)
Wheeze (up to 6 months)
Food allergy
parental-reported
(up to 6 months)
↑ TGF-β2 (1 month HM)
detectable IL-13 (colostrum)
detectable IL-13 (1 month HM)
HGF, TGF-β1, TGF-β3, IL-2,
IL-4, IL-5, IL-10, IFN-γ, IL-12
(colostrum and 1 month HM)
higher risk of eczema
lower risk of food allergy
lower risk of eczema
no significant association with eczema, wheeze
or food allergy
“↑”—stands for increased levels of a particular factor and “↓”—stands for decreased levels of a particular factor
3.1.1. Immune Composition and Allergy
Among the immunological markers assessed in HM, TGF-β is probably the most studied to date.
The systematic review by Oddy and Rosales assessed relationships between TGF-β in human milk
and immunological outcomes in infants and children [140]. Two-thirds the studies selected for this
review found an association between higher TGF-β1 or TGF-β2 levels in colostrum or mature milk and
reduced risk of atopic outcomes in the infant. The authors suggested that TGF-β found in human milk
may play a role in homeostasis maintenance in the intestine, regulating inflammation and subsequently
promoting oral tolerance which may reduce the risk of allergy development [140].
A few studies focused on eczema, found increased TGF-β1 and/or TGF-β2 in HM associated with
this skin disease onset in infants [122,126,130,139]. However, contrasting results of other studies do
not allow final conclusions on the influence of TGF-β on eczema development [132,135,137,138]. Oddy
and co-authors reported increased TGF-β1 levels in breast milk to have some protective effect against
wheeze development in infancy [133] but this conflicts with two other large cohort studies [135,138].
As it is assumed that TGF-β has biological relevance and is active in the infant gut [141], these results
suggest that TGF-β plays an important role and may be a missing component of progression from
allergic sensitisation to allergy disease in early life, but inconsistency in results prevents us from
making any definitive statements. Differences in the outcomes can be affected by the stage of lactation
when samples were collected.
Another immune active molecule that is of interest is soluble CD14, a bacterial pattern recognition
receptor for cell wall components such as lipopolysaccharide. It is primarily expressed on the surface
of monocytes, macrophages and neutrophils as membrane CD14 [142,143] but is also found in HM in
its soluble form—sCD14. In all the studies levels of sCD14 in HM were very high as this immune active
molecule is amongst those immune factors actively excreted into HM. CD14 may play an important
role, providing protection against subsequent allergy manifestation [144–146]. More than a decade
ago, Jones and co-authors showed that low sCD14 levels in mature milk were associated with eczema
development [131] and then Savilahti reported similar trends for colostrum [134]. Later studies,
however, failed to reproduce these results and did not report any protective effect of this soluble
receptor on eczema [135,137]. The conflict between the outcomes of the studies may be a consequence
of a difference in CD14 genotype with breastfeeding being associated with a decreased risk of atopic
sensitisation in children with a CT/CC genotype [52]. We now recognise eczema as a consequence of
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genetically determined skin barrier defects with allergy being a likely secondary outcome. Phenotyping
and genotyping eczema in relation to breast feeding therefore becomes a priority.
There is a general agreement between studies suggesting that levels of other human milk immune
active molecules, cytokines in particular, are not associated with atopy and/or allergy development
in early life [126,132,135,137]. The only outlying results come from the recent paper by Jepsen and
co-authors, suggesting that high levels of IL1β in mature milk are associated with lower risk of eczema
by the age of 3 [58] and Jarvinen et al. showing that networks of pro-inflammatory and regulatory
cytokines in HM are associated with tolerance to cow’s milk [147]. As many cytokines exist in very low
concentrations in HM, the sensitivity of the assays is critical and many studies report a high proportion
of undetectable levels in their samples [58,148,149]. This may explain lack of conclusive data on HM
cytokines association with immunological outcomes. Furthermore, if there are only trace levels of
these mediators they are unlikely to have significant biological activity. Future studies will need to
assess biological activity alongside assays of concentrations.
Most of the studies were aimed at allergic sensitisation, eczema, early wheezing and/or asthma
and allergic rhinitis development as the main phenotypic outcomes which allow for some comparison.
However, significant methodological heterogeneity between the studies, especially with regards to the
stage of HM collection and outcome definitions, are the main obstacles on the way to any meta-analysis
of up to date data in this field. Despite these difficulties it is apparent that certain factors of interest
in HM may play a role in allergic sensitisation and/or allergy prevention. The most promising HM
components are TGF-β, sCD14, and particularly their relationship with HM oligosaccharides (HMOs)
and microbiome, interactions which have not been extensively studied and may represent a prime area
for future research. In view of the large number of potentially immune-active constituents in breast
milk, investigation of only a limited range of constituents may well produce conflicting results. There is
a lack of studies, attempting to assess HM as a whole, rather than focusing on single components.
In other words, the “soup” is likely more important than individual ingredients.
3.1.2. Potential for Immunological Composition Alteration via Dietary Interventions
Given the observations discussed above there is the intriguing possibility for interventions
which modify maternal immunity to impact infant immune responses and allergic disease in
offspring [131,134]. With the development of the ‘hygiene hypothesis’ many focused their research on
the protective effects of environmental exposures during pregnancy and early life, during a period of
time when infant gut colonization and maturation of the immune system takes place. Despite a number
of birth-cohort studies, the ability to change human milk composition remains a “grey area” in existing
knowledge and more hypothesis driven research is required before large population intervention trials
can begin.
Existing data provides evidence that HM composition is highly variable within the same
individual and between women. It has been shown that maternal lifestyle (dietary habits,
physical activity, place of residence) can have a significant influence on HM biologically active
components [106–108,116]. These findings have motivated a number of intervention trials aiming to
prevent allergy development in early infancy.
There are many trials of probiotic administration, as single-entity products of a specific strain or
mixtures, in the prevention of allergy development, with cumulative meta-analytic evidence suggesting
some protection against eczema [150]. Prescott et al. observed higher levels of TGF-β1 and IgA in
human milk of mothers receiving B. lactis HN019 probiotics, and higher IgA levels alone in those
receiving L. Rhamnosus HN001. In contrast probiotic supplementation did not seem to have an effect
on the rest of BM immunological profile (IL-13, IFN-γ, IL-6, TNF-a, IL-10 and sCD14) [123]. Two other
studies of probiotic use during pregnancy reported no effect on TGF-β levels in HM [124,151] and
they were in opposition to findings by Rautava and co-authors [152]. Heterogeneity of methods again
confounds attempts at meta-analysis.
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Another potential intervention approach is the use of prebiotics. Prebiotics are non-digestible
food components that may confer benefit by providing the substrates for normal bacterial growth the
gut. It is more common now to see prebiotics added to formula milk. It is unclear whether prebiotics
are capable of modifying HM composition or influencing subsequent allergy development in both
high risk and general populations [153].
PUFAs (e.g., ω-3 and ω-6 fatty acids) are an essential part of HM composition and, as a logical
investigation, researchers have attempted to influence PUFA levels in HM by means of intervention,
selecting fish oil or whole fish as a main source of PUFA. Some of these studies also evaluated HM
immunological composition. Data from several intervention trials showed no apparent evidence for
the impact of fish consumption on immune active molecules in HM [119–121]. Another source rich in
ω-3 and ω-6 fatty acids is blackcurrant seed oil. A Finnish study reported lower levels of IL-4 and
increased IFN-γ in HM following black currant seed oil consumption, with no differences in IL-5,
IL-10, IL-12 and TNF levels, in comparison to an olive oil fed group [128].
Overall, there is some evidence that probiotic [123,124,152] administration to pregnant and
lactating women, or a diet with a high fish intake [121] alters breast milk immune composition.
Although the specific changes identified are not always correlated with clinical outcomes, maternal
supplementation during pregnancy and lactation to enhance human milk “quality” may have a
beneficial influence on health outcomes, and modulation of breast milk composition is one possible
mechanism [154] (see Table 2).
3.2. Human Milk Oligosaccharides
3.2.1. The Fascinating Complexity of Human Milk Oligosaccharides
Unique to HM is the complexity and abundance of HMOs consisting of both short-chain as
well as long-chain oligosaccharide structures in a unique ratio based on molecular size (roughly 9:1
respectively). Together with specific metabolites derived from bacterial fermentation, the HMOs play
a key role in microbiome development and building a healthy immune system, creating a fit and
resilient immune system in early and later life [155]. It is important to realize that the complex HMO
composition is determined by genetic polymorphisms and activity of the secretor fucosyltransferase2
gene (FUT2), the Lewis gene (FUT3), and is regulated by glycosyl-transferases within the mammary
gland. Differences in genetically determined glycosyl-transferase patterns affect HMO amount and
composition between mothers and during lactation [156]. The presence or absence of α1,2-linked
fucosylated epitopes in secretions, including saliva and milk, defines secretor and non-secretors
respectively. Consequently, the secretor-phenotype distribution differs among populations [157,158].
The provision of secretor type related complex mixtures of HMOs, have been associated with a direct
protection against infections [159] and may be linked to a reduction in allergic disease incidence in
breast-fed infants later in life [46].
The basic HMO structure is fucosylated and/or sialylated, resulting in respectively neutral and
acidic oligosaccharide structures within short- as well as long-chain structures. In addition to the
inter-individual genetic variation, the total HMO concentration varies during lactation which normally
provides the optimal needs over time. Colostrum contains approximately 20–25 g/L HMOs, whereas
mature HM has declining HMO concentrations to 5–15 g/L [160,161]. 2′-Fucosyllactose (2′-FL) is a
disaccharide which is thought to be the most abundant oligosaccharide with a concentration ranging
from 0.06 to 4.65 g/L [157,158]. Each HMO is structurally unique and effects of individual structures
may not be universal to all HMOs, therefore understanding the balanced complex mixture is of
considerable importance.
Although the protective capacity of HM against infections within infants is clearly observed,
the possible benefit for the prevention of immune related disorders such as allergy remains
controversial [135,162,163]. Any discordance between the early developmental requirements for an
infant’s immune development and the dynamic nature of HM constituents may possibly contribute to
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the development of allergic diseases [162]. Whether observed effects are derived from direct interaction
with immune cells or indirectly through the alterations in microbiome composition and change in
derivatives thereof remains unknown. It is clear however, that the microbiota composition and activity
can have an influence on the development of allergy, more specifically regulatory T cell development
is strongly influenced by the microbial composition, and therefore subject to modulation by dietary
intervention and specific oligosaccharides [164–166]. Several studies have shown that the composition
of the gut microbiome differs significantly between those with allergy and/or allergic disease and
those without [167–171]. How a microbiome composition becomes dysbiotic and thereby leads to the
development of immune related disorders such as allergy is hitherto not fully understood; however,
it is thought that early-life ecological succession of mucosal colonization occurs concomitantly with
development, expansion, and education of the mucosal immune system [172]. Indeed, gnotobiotic
mouse studies have demonstrated that there is a critical window of time for immune development,
after which intestinal immune development cannot be fully achieved [173–175].
3.2.2. Shaping the Microbial Balance in Early Life
The question of how optimal early-life microbial ecological succession occurs is a topic of intense
interest. Once HMOs are formed, only those bacteria that possess the necessary enzymes (incl. glycosyl
hydrolases) can cleave and utilize these oligosaccharides [176]. Members of the Bacteroidaceae and
Bifidobacteriaceae families have been shown to consume HMOs, including several Bifidobacteria which
have the sialidases and glycosidases necessary to internalize and catabolize HMOs [177–181]. What this
means is that for breast-fed infants, bifidobacteria have the capability to preferentially colonize the infant
GI tract by the third month of life [177]. In addition, it was recently shown in a mouse study that the
combination of B. infantis with HMO decreased GI inflammation and permeability [182]. Other mouse
studies revealed that oral administration of Bifidobacteria is able to modulate inflammation associated
with allergy [171,183,184]. However, the total HM oligosaccharide composition is likely to be very
important and it should be realized that individual oligosaccharides in HM might have their own
unique function on microbes, immune cells and epithelial cells.
Given that maternal secretor status impacts the bifidobacterial community structure of the infant
gut [185], it can be hypothesized that a combination of HMOs with specific bacteria are able to modulate
gut immunity and gut integrity. Additional roles of fucosylated and sialyated HMOs are related to the
common structural motifs they share with glycans on the gut epithelia that are known receptors for
pathogens. It is thought that HMOs competitively interact with pathogens, preventing adhesion and
biofilm formation on the gut epithelium [186–188]. Together with their ability to only be fermented by
specific bacteria, HMOs therefore play an important role in shaping early gut microbial succession.
The nature of this succession, and exactly how different oligosaccharides function in this context, are
questions that remain to be elucidated.
As previously discussed, there have been conflicting reports regarding the relationship between
breastfeeding and development of allergy [19,117,189,190], and it may be that it is the combination of
oligosaccharides and bacteria that shape immunity. Indeed, it was recently reported that infants born
by caesarean section with a high risk of allergies had a lower risk of IgE-associated eczema at 2 years,
but this association was not observed at 5 years [46]. In addition, prebiotic oligosaccharides together
with Bifidobacteria have recently shown in caesarean-delivered infants to be able to modulate the
microbial composition which was associated with the emulation of the gut physiological environment
observed in vaginally delivered infants [191,192]. Moreover, epidemiological studies have frequently
shown that there is a clear associational link between perinatal factors, such as breastfeeding, caesarean
delivery, and antibiotic use, and the programming of intestinal inflammatory disorders. However,
more work needs to be done to fully understand how HMOs and allergy development are related.
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3.2.3. HMOs Are Directly Involved in Early Life Immune Development
How the complete mixture of and/or specific HM oligosaccharides are able to beneficially
regulate gut microbiota composition, maintain gut integrity, and most importantly, enhance mucosal
immunity to establish a balanced immune development is not completely understood. Because of
the multiple different structures within authentic HMOs, several distinct receptors and pathways
are thought to play an important role within the direct immune modulating role of HMOs. Direct
interaction has recently been shown (by using glycan microarray technology) between glycan-binding
proteins expressed on the epithelial cells and cells of the innate immune system to specific HMOs.
For instance, 2′-Fucosyllactose and 3-fucosyllactose were shown to bind human DC-SIGN (Dendritic
cell-specific intercellular adhesion molecule-3-grabbing non-integrin), a C-type lectin receptor
present on the surface of both macrophages and dendritic cells. Moreover, the involvement of
a set of glycan binding receptors including the C-type lectin receptors and Toll-like receptors
(TLR) has been identified [193–195]. The direct binding of 2′FL to human DC-SIGN has been
shown to be fucose-specific and DC-SIGN signaling seems to be influenced, leading to alteration
in pro-inflammatory cytokine response in a TLR specific fashion [196,197]. In addition, it has
long been known that human galectins expressed by intestinal epithelial cells also interact with
oligosaccharides [198]. However, the exact mechanisms of how HMOs are able to alter the biological
function of these human cells are still unknown.
Only a few limited studies have focused on the immune-modulatory effects of individual HMOs
within infants and in animal studies, and have suggested anti-inflammatory and immune regulatory
potential, but the mechanism by which specific HMOs may influence the risk for allergy development
is currently not known [199]. Supplementation of the diet with 2′FL or 6′SL did not show any effect on
the levels of allergen specific Immunoglobulin (Ig)E or IgG1 in sensitized or challenged mice. Dietary
supplementation with specific oligosaccharides providing some of the functional benefits of HMOs,
have been shown to reduce the risk of developing allergies in infants [200,201]. Recent data suggest
that the onset of IgE-associated allergic manifestations, (but only in infants with a high hereditary
risk for allergies and born by C-section) might be associated with FUT2-dependent oligosaccharide
composition in breast milk consumed by these infants [46]. These mechanisms collectively include
but may not be limited to the pathogen decoy capacity of specific HMOs, the prebiotic effect on the
microbiome composition, the modulation of the SCFA production which in turn supports the barrier
integrity and/or through direct immune modulatory functions [202]. However, further clinical studies
are needed to support either one of these mechanisms to identify the full potential of HMOs within the
early life immune development.
Within the last few years an interesting increase in understanding and knowledge regarding the
presence and effects of HMOs and composition has been achieved. Consequently, with expansion of
these studies and progress in biotechnology, the potential of adding HMOs to the complex mixture of
prebiotic oligosaccharides in infant formulas are increasing. However, in order to decide which to add,
in which concentration, composition and combination to prevent and treat allergy development in
early life, as well as later in life, clearly needs additional study.
3.3. Human Milk Microbiota
Early microbial colonization is essential for infant’s metabolic and immunological development [203].
Cumulative evidence suggests a direct link between microbial colonization and the risk of
non-communicable diseases in later life, including allergies [204,205]. After birth, the transfer of
microbiota continues during lactation, and is considered to be the cause of differences in gut microbiota
between exclusively breastfed and formula fed infants during the first months of life [206]. In the
recent years the presence of a HM microbiome has been confirmed, with a variety of microbes and
their associated genes and antigens transmitted to the infant during breastfeeding [112]. Available
data show that HM contains approximately 103–105 viable bacteria per mL [207,208].
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Initially, the presence of microbes in human milk was evaluated by use of culture-dependent
techniques and isolates belonged to Staphylococcus, Streptococcus, and Lactobacillus and Bifidobacterium
species, which have been used as probiotics in intervention trials [209]. With the development and
application of culture-independent techniques including next-generation sequencing, it has become
clear that HM contains a much more diverse variety of bacteria, including other lactic acid bacteria,
such as Enterococcus, Lactococcus and Weissella; typical inhabitants of the oral cavity, such as Veillonella
and Prevotella; bacteria usually found in the skin, like Propionibacterium, and other Gram negatives,
e.g., Pseudomonas, etc., [112,210–212]. In a recent systematic review, a core of predominant organisms
was described, which includes Staphylococcus, Streptococcus and Propionibacterium [213]. These genera
are universally predominant in human milk, regardless of different potential confounding factors,
such as sampling, geographic location or analytical methods [213].
There is still scarce information about the influence of environmental and perinatal factors on
HM microbiota composition [214]. Some studies reported that geographical location [112,204,206,215],
delivery mode [207,208], maternal body mass index (BMI) [211,216] or antibiotic intake [217] would
have an impact on HM microbiota. However, others did not find similar effect with regards to other
perinatal factors [218]. Furthermore, an imbalance in the normal bacterial composition of HM can
lead to the overgrowth of specific opportunistic pathogens and lead to mammary infection, such as
lactational mastitis [219,220].
The origin of HM bacteria is currently unknown. A number of hypotheses have been proposed:
(1) human milk microbiota could derive from the mother’s skin, and the infant’s oral cavity during
suckling; (2) an internal route, the “entero-mammary pathway” has been proposed and suggests that
bacteria from maternal gut could be taken up by immune cells and transported via blood stream or
lymphatic system to the mammary gland [221]; (3) specific microbes were detected in the human breast
tissue, which may also supply microorganisms to the milk [222,223].
Human milk microbes hypothesised to play a key role as early gut colonizers, likely
contribute to the immune system development and maturation [224,225]. Alterations or divergent
antibodies/microbiota transferred via HM may affect an infant’s immune development. Lower
proportions in the Bifidobacterium genus have been observed in HM from allergic mothers [226].
The gut microbiome from allergic children also differs from non-allergic in composition and
diversity [226]. Recently, altered immune responses towards gut microbiota were observed as early as
1 month postpartum, in exclusively breastfed children who subsequently developed allergies [227].
Relationships between HM components (HMOs, fatty acids, immunological constituents, etc.) and
allergy development in infants have been recently receiving increased attention [46,60,139,228–230].
Several studies reported that allergic disease and asthma are less common in children exposed to
unpasteurized cow’s milk (CM), which is a source of viable microorganisms [231]. Therefore, bacterial
communities of HM could also be taking part in the protection of infants against allergic diseases,
acting as a natural probiotic, and this requires further elucidation. However, unpasteurized CM also
contains many immune active constituents with close sequence homology to those found in HM. These
could also potentially explain the benefits of raw CM. Existing data suggests that some Lactobacillus
and Bifidobacterium strains have been linked to allergy protection, in particular against eczema [150].
It is worth noting, however, that eczema is not synonymous to allergy, as discussed in other sections
of the manuscript. This highlights a need in precision of outcome definitions alongside pheno- and
endo-typing infant outcomes. As these genera can be found in HM, it is, therefore, plausible that their
transfer to the infant during breastfeeding could provide immunological protection, although more
work is needed to confirm this link.
The potential protective effect of HM bacteria against allergic diseases development has not been
properly studied and future research should also investigate HM bacterial recognition by the immune
system. Better knowledge would help to understand the importance of maternal transference of
altered immune responses towards microbiota during breastfeeding, and their potential influence on
allergy development during infancy. However, it is rather difficult to establish causal relationships
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between HM microbiome and its role in protection against allergic diseases. It is impossible to rule out
the probability of an epi-phenomenon, and future research should tackle cause-effect relationships.
Further analysis based on state-of-the-art, next-generation sequencing methods will be crucial in
understanding the association between bacterial diversity inherited through breastfeeding and an
infant’s potential allergy development.
In clinical trials, oral administration of bacterial strains to lactating mothers showed modulatory
effects both on human milk composition and on the infant’s gut. It was shown that Lactobacillus reuteri
intake led to its detection in the mother’s milk and infant faeces [210]. Similarly, another study
studied the effect of supplementation with L. rhamnosus to reduce the risk of allergy development
when given to women during pregnancy and lactation [232]. Probiotic intake during pregnancy and
lactation also induced specific changes in the infant Bifidobacterium colonization and influenced HM
microbiota composition compared with those receiving placebo [233]. Recently, the effects of perinatal
probiotic supplementation on the HM composition have been reinforced, leading to changes in its
microbiota, including Bifidobacterium and Lactobacillus sp., and also functional components of HM,
such as oligosaccharides (HMO) and lactoferrin [234].
Protective effects of certain Lactobacillus and Bifidobacterium strains on eczema development have
been previously reported [235,236]. Their ability to provide protection against other allergic diseases
has also been described, although results are conflicting and existing evidence does not support their
use for allergy prevention. The beneficial effect on eczema has been proved [150], but the causality is
still unclear. As eczema is a consequence of a skin barrier defect, the possibility of protection due to
direct effects of short-chain fatty acids on skin rather than immune modulation cannot be excluded.
If strong relationships between specific HM microorganisms and allergic diseases are further confirmed,
prebiotics and probiotics could be used to improve HM composition and infant microbiota modulation.
3.4. Human Milk Micronutrients
While breastfeeding is recommended as the sole source of infant nutrition up to 6 months of age by
WHO [237], there are caveats that an adequate maternal diet is required in conjunction with sufficient
volumes of milk that can be transferred to the infant [237]. Lactating women and infants have a greater
physiological demand for micronutrients and are therefore at higher risk of adverse consequences
with insufficiency. Despite HM containing a multitude of micronutrients that are the infant’s sole
source in early life, comprehensive methodical research has not been carried out in this area [238].
Further, many HM micronutrients differ between women, such as Vitamin A and group B vitamins,
which are influenced by maternal dietary intake (Table 3). Owing to this variation and the limited
number of studies that often use small participant numbers, frequently suffer from lack of control for
stage of lactation, fail to record maternal supplementation, and have inconsistent sampling, robust
reference ranges for HM micronutrients do not exist. To add fuel to the fire, various methods have been
employed such as microbiology and radioisotope dilution with the recent addition of chromatography,
coupled with UV, fluorometric and mass spectrometry detection making comparisons even more
challenging. Only recently has there been a concerted effort to shed light on questions such as
variation within feeding, circadian rhythms and the impact of maternal supplementation. This lack
of research likely explains conflicting results and has subsequently hampered the determination of
recommended daily intakes for infants [239]. The other potential explanation is failure to consider the
timing of deficiencies. Transfer of nutrients to the foetus during pregnancy is likely equally, if not more
important, than HM composition. During the first trimester of pregnancy, programming of growth
trajectories will have a profound effect on foetal and infant requirements for micronutrients. Keeping
in mind the “Developmental Origins of Health and Disease” (DOHaD) hypothesis, which suggests
fetal developmental ‘plasticity’ and discordance between intra- and extra-uterine exposures produces
the greatest adverse effects [240].
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Table 3. Human milk micronutrients known to be influenced by maternal diet. The range of
mean concentrations is given for mature milk. Reference [241]—”Handbook of Milk Composition”








K 0.12–0.98 ug/dL [241–243] Tocopherol (vit E) 207–366 ug/dL [244–246]
D 0.008–0.62 ug/dL[242,246–248]
Retinol (Vit. A) * 40–485 μg/L [242,245,249]
Water Soluble Vitamins
Thiamin (vit B-1) 21.1–228 ug/L [249–251] Folate 53–133 ug/L [241,252,253]
Riboflavin (vit B-2) 0.03–0.35 mg/L [249,251]
Niacin (vit B-3) 68.7–260 ug/L [251,254]
Vit B-6 0.06–0.31 mg/L[241,249,251,255]
Cobalamin (vit B-12) 85–970 ng/L [249,255,256]
Ascorbic acid (vit C) 35–105 mg/L [241,246,249]
Pantothenic acid (vit B-5) 2.0–2.5 mg/L [241,251]
Choline 144–258 mg/L [241,257]
Minerals
Selenium 3–60 ng/mL [241,249,258,259] Zinc 0.68–12 ug/mL [241,245,260–262]
Iodine 9–250 ug/L [241,249,263–265] Copper 0.006–0.5 ug/mL [241,245,253]
Iron 0.3–0.9 ug/mL [245,262,266]
Calcium 259–300 mg/L [241,245,262]
Phosphorus 130–170 mg/L [241,245,262]
Magnesium 30.5–31.4 mg/L [241,245]
Sodium 111–300 mg/L [241,245,262]
Potassium 380–630 mg/L [241,245,262]
Chromium 0.15–0.8 ng/mL [241,247,253]
Chloride 453–690 mg/L [241,262]
Manganese 0.33–125 ng/mL [241,245,253,262]
* Vit.—Vitamin.
3.4.1. Vitamin A
A number of HM vitamins are influenced by maternal diet including vitamin A, which plays a
major role in both growth and immune function. In a small study of lactating Bangladeshi women
(n = 18) intensive sampling showed that the most appropriate sample should be taken from a pumped
volume from a full breast and that there was a small but significant circadian variation that disappeared
when milk fat was accounted for. Further, vitamin A content increased significantly with acute
supplementation [254]. Vitamin deficiencies in the infant included adverse outcomes such as severe
respiratory and gastrointestinal infections, as well as increased morbidity and mortality [267]. In a
mouse model, maternal supplementation during lactation prevented allergic airway inflammation and
had a protective effect on oral tolerance induction [268]. This finding is consistent with a meta-analysis
of human studies that shows dietary intake of vitamin A to have either a beneficial association in
asthma prevention or no association [269]. In contrast, direct neonatal supplementation in human
neonates appears to increase the risk of atopy and wheezing, particularly in females [270]. It is
speculated that HM borne vitamin A reduces allergy via promotion of intestinal crypt development
and a reduction of gut permeability without impacting the digestion of milk [16,268]. Future studies
will serve to shed light on the protective mechanisms of HMvitamin A.
3.4.2. B Vitamins
In general, group B vitamins concentration of HM is also strongly related to maternal intake and
levels respond to dietary supplementation [271,272]. Levels of HM B vitamins are based on samples
from women in established lactation, as thiamin, vitamin B-6, and folate are lower, and vitamin B-12
higher in the first few weeks of lactation (transitional milk) [272], whereas, in established lactation the
levels of all B vitamins remain relatively stable [246]. Importantly, maternal depletion impacts infant
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status to varying degrees depending on the vitamin and the levels of the vitamin. Further, complicating
the picture is the lack of global documentation on the prevalence of HM vitamin B deficiency.
Studies investigating relationships between vitamin B and infant allergy are also scant with one
study showing no relationship between wheeze or eczema in infants (16–24 months) and maternal
intake of folate, vitamin B12, vitamin B6, and vitamin B2 during pregnancy [273].
3.4.3. Vitamin D
Vitamin D is a steroid hormone produced by skin exposure to ultraviolet light and has many
important roles such as maintaining bone health via the regulation of calcium and phosphorus
absorption. It also plays a role in the innate and adaptive immune system. Due to the ubiquitous
reduction in the time spent outdoors, maternal HM concentrations of vitamin D (25-Hydroxyvitamin
D) are often deficient. Since HM vitamin D levels are positively related to maternal serum
concentrations [274–276] there are serious concerns regarding the vitamin D status of exclusively
breastfed infants, evidenced by a resurgence in the diagnosis of rickets [277]. Maternal daily vitamin D
supplementation of 400–2000 IU of vitamin D/day increases HM concentrations and subsequently
infant 25-Hydroxyvitamin D status [278]. Hence, the current recommendations of the American
Academy of Pediatrics is that all breastfed infants be supplemented with 400 IU/day of oral vitamin D
from birth [279].
It is not clear whether vitamin D intake during pregnancy and lactation lowers the risk of infant
allergies. In a number of studies, high maternal vitamin D levels have been associated with increased
risk of eczema, asthma, food allergy or sensitization to food allergens [280–282] while others report
reduced risk of allergic outcomes [269,283–286] or no relationship [286–288]. An interesting study
on a large Finnish cohort found that maternal vitamin D intake from food was associated with
reduced risk of cow’s milk allergy (CMA) while supplementation of both vitamin D and folic acid
was associated with increased risk of CMA [289]; however, it is likely that other lifestyle factors have
contributed to this finding. Comparisons of these studies are limited due to differences in study design,
methodologies, supplementation, time of measurements, along with a lack of information regarding
lactation. The other issue is the reported non-linear relationship between allergy outcomes in relation
to vitamin D levels with very low and very high levels increasing the risks. The optimal level for
immunological health is still to be defined and this may well differ dependent on stage in pregnancy
and the age of the infant. Supplementation of lactating women and monitoring of their infants for
allergy has yet to be carried out and may yield different results as seen with vitamin A. Hence,
due to the limited and conflicting evidence, the World Allergy Organization has not recommended
supplementing women in pregnancy or lactation as an allergy preventative strategy [290].
3.4.4. Iron
Iron levels in HM are relatively low (0.3 mg/L), but this micronutrient is highly bio-available to
the infant with absorption rates ranging between 16% and 50%, which is higher than that available
from formula feeds [291]. The reported prevalence of iron deficient anemia is <2% up to 6 months
and 2–3% between 6 and 9 months in European infants [291]. Therefore, infant supplementation
is generally not recommended in the first 6 months of life with the exception of infants of diabetic
mothers and low birth weight infants that have low iron stores [266,292]. However, it is recommended
that the first complementary foods are rich in iron [293]. A recent study has found as many as a third
of healthy fully breastfed infants are iron deficient or have iron deficiency anaemia at 5 months of
age [294]. Supplementation of breastfed infants (1–6 months) with 7.5 mg per day of ferrous sulfate
resulted in higher haemoglobin concentration and higher mean corpuscular volume at 6 months of age
than those not supplemented [295]. Better visual acuity and greater Bayley Mental and Psychomotor
Developmental Indices were also recorded at 13 months in supplemented infants. Thus, the American
Academy of Paediatrics recommends that exclusively breastfed term infants and those receiving more
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than half of their daily feeds as breast milk be supplemented with oral iron at 1 mg/kg per day from
4 months of age [296].
Adequate iron is essential for both normal infant neurodevelopment [266] and immune protection
yet is the most common global micronutrient deficiency worldwide [297] with infants and children at
high risk due to the high demand for rapid growth. Very few studies have investigated the relationship
of infant iron status and immunological outcomes with one case-control study showing no difference
in infant status with respect to eczema [298].
3.4.5. Zinc
Infants and children have high requirements for zinc due to rapid growth and tissue synthesis.
Zinc deficiency is not uncommon (>20%) particularly in infants/children less than 5 years of
age [299,300]. Symptoms of zinc deficiency include growth retardation, altered immune function and
gastrointestinal effects such as diarrhea. Those infants/children at highest risk are those consuming
a combination of breast milk and a predominantly plant-based diet of low zinc content as well as
prematurity and low birth weight. [301]. HM zinc content is not related to maternal zinc status and
in developed settings, zinc intake from HM is considered adequate provided the mother is able to
generate enough milk for her infant [301]. However, infant zinc supplementation is often indicated in
low resources settings and those where complementary foods are low in zinc [301].
Again, research into the relationship between infant zinc intake during lactation and allergy is
scarce. Of note a case control study has shown that zinc status is lower in those infants with eczema
compared to their matched controls [298], which is more likely a direct effect on skin barrier rather
than immune responses.
3.4.6. Summary
Micronutrients are important part of the HM composition, but there is a only small body of
evidence that their intake during early life may be related to allergy. In order to establish firm
relationships future research will need to consider sampling and measurement methods of HM.
This includes importance of adjustment for timing—pregnancy vs. lactation; foetal and infant growth
trajectories; and includes better clinical outcome definition. It is also possible to measure dose
(rather than concentration) by employing methods such as test weighing [302] to further improve the
quality of subsequent studies.
3.5. The New Frontier: Human Milk Glycoproteins and Metabolites
Metabolomics is one of the newest “omics” sciences which has been integrated into HM study
using a top-down systems biology approach to explore and unravel the genetic-environment-health
paradigm [303]. Metabolomics, or the study of metabolites, is useful to elucidate the complex
interactions of HM constituents, and to understand the physiological state of HM in various stages of
lactation [304] and in response to infection. Metabolomics, together with other the “omics” such as
proteomics and glycomics and genomics can enable us to understand this complex and dynamic
relationship. Several complementary analytical platforms such as nuclear magnetic resonance
(NMR), capillary electrophoresis (CE), liquid or gas chromatography (LC or GC) coupled with mass
spectrometry (MS) have been used to profile the composition of HM [305,306]. Recent study by
Andreas et al. has identified 710 metabolites in HM using various modified extraction methods, such as
Folch extraction and single-phase extraction using methanol and methyl tert-butyl ether (MTBE) [305].
Besides characterizing the HM metabolome, temporal changes in metabolites across stages
of lactation can be tracked to demonstrate the adaptation of breasts to meet the nutritional and
developmental requirements of the growing infant. Using LC- and GC-MS methods, Villasenor et al.
reported increases in several fatty acids such as linoleic and oleic acid, from the first to the fourth
week postpartum in full-term infants, while cholesterol, fucose and α-tocopherol levels declined [306].
In NMR-based analyses, Wu et al. reported decreases to phosphocholine and glycerol-phosphocholine
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concentrations after the first month of lactation that coincided with an elevation in levels of choline,
a compound essential for the neonate’s growth and neuronal development [307]. Whereas, Sundekilde
et al. characterized and compared 51 metabolites including HMOs, in preterm and full-term milk
up to 100-days post-partum [304,308]. Lacto-N-difucohexaose I, 3′-sialyllactose and 6′-sialyllactose
were identified to be higher in preterm milk compared to term milk [304]; these HMOs have been
implicated in the onset of necrotizing enterocolitis in rat pups [309] and infants [310]. Recent studies
have revealed strong associations between HM metabolites (including HMOs) and the microbiota of
the infant’s gut [311]; this content was covered in earlier sections of this review.
The hygiene hypotheses have expanded our understanding of how allergic disease originates
during infancy. Equally important and likely in response to our microbial environment is the role
of breastfeeding in promoting tolerance to antigens and subsequently reducing the incidence of
allergy and asthma [312,313]. This protection is potentially related to bioactive compounds such as
secretory immunoglobulin A (sIgA) and TGF-β, present in colostrum and mature human milk that
provide protection during the time when the infant’s own immune responses are immature. TGF-β is
discussed in the earlier sections of this review and this section will focus on a few constituents of HM in
relation to infant infection and inflammation as follows: 2 glycoproteins, secretory immunoglobulin A,
and lactoferrin, and low molecular weight compounds such as lactose, choline and anti-inflammatory
short-chain fatty acids. Increasingly, we are appreciating the anti-infective and anti-inflammatory
roles of HM microbiota to directly influence the infant’s gut microbiome, and of HMOs which drive
the growth of microbes to shape gut immunity. These interactions between HM metabolites, the
gut microbiome and allergic disease are reviewed in more detail by Kumari and Kozyrskyj [314]
and Julia et al. [315]. The expanded role for antimicrobial proteins/peptides in HM, as breakdown
products of lactoferrin, will only be briefly mentioned in this section.
3.5.1. Secretory Immunoglobulin A (sIgA)
Secretory Immunoglobulun A (sIgA) is the principal immunoglobulin on human mucosal surfaces
which blocks microorganisms and toxins from attaching to mucosal epithelial cells. While oral
administration of monoclonal antigen-specific IgA prevents infection with bacterial and viral
pathogens, in its natural polyclonal state, non-specific sIgA protects against gastrointestinal and
respiratory infections [316]. In colostrum, levels of non-specific sIgA reaching 12 g/L are not
uncommon, and they decrease to 1 g/L in mature milk [317]. The HM transfer of sIgA from mother to
an infant provides protection against infection by binding pathogens and stimulating gut microbes
until the infant immune system takes over to produce sufficient sIgA levels [318]. It also has an
important role in the development of oral tolerance to gut microbiota. Fecal sIgA concentrations
reach a peak of 4.5 mg/g feces at 1 month of age in exclusively breastfed infants (fed some formula
immediately after birth); they decline to 1.5 mg/g of feces at 5 months of age where they remain for the
duration of infancy [319]. In exclusively formula-fed infants, however, fecal sIgA concentrations peak
at 1.5 mg/g feces, drop to 1 mg/g feces at 3 months, then reach comparable levels to breastfed infants
at 9 months of age. Much higher sIgA levels have been observed 1 week after birth with exclusive
breastfeeding [320]. Low levels of non-specific faecal IgA in infants were among the first associated
with a higher risk of allergy [321].
The production of intestinal IgA commences around 1 month after birth when low levels of fecal
sIgA can be detected in non-breastfed infants [322]. Hence, sIgA in colostrum has been likened to an
immune booster, a beneficial attribute that varies by maternal characteristics and can be impacted by
medical intervention. Residual country variation in colostrum sIgA levels has been reported, even after
accounting for collection time, and maternal parity, smoking, fruit and fish consumption, and allergen
sensitization [323]. Cesarean delivery was independently associated with reduced sIgA colostrum
levels in this study. Breakey et al. reported lower HM sIgA levels in time periods before and after
respiratory or gastrointestinal infections in 8-month old infants of a traditional population living in
rural Argentina [324].
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As evident by the presence of fecal IgA in exclusively formula-fed infants, full-term infants
produce substantial levels of their own IgA within 3 months after birth [325]. However, the highest
IgA levels are seen in exclusively breastfed infants and they increase in direct proportion to the “dose”
of HM (exclusive, partial versus no breastfeeding) provided to the infant. At this age, the likelihood of
C. difficile colonization in gut microbiota was reduced by 75% among infants with fecal IgA levels [326]
in the highest tertile, independent of parity, birth mode and breastfeeding status. While C. difficile
presence in the infant gut is not uncommon, it is a marker for lowered colonization resistance to
pathogenic bacteria and has been found to be associated with future allergic disease [327,328]. Hence,
BM and infant sIgA have an important role in reducing C. difficile colonization. Furthermore, infant
fecal IgA levels are noted to be inversely associated with infant serum levels of IgE and lower binding
of IgA to Bacteroides species increases risk for asthma at age 7 [227,321].
3.5.2. Lactoferrrin
Lactoferrin is a large molecular weight glycoprotein that is also present in colostrum and transition
milk, and at higher levels than in mature milk [329]. Lactoferrin participates in host defense against
microbial pathogens by binding bacterial membranes, binding iron and making it less available for
microbial growth, down-regulating tumor necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β)
production, and stimulating the maturation of lymphocytes [330]. Peptide breakdown products of
lactoferrin have specific direct antibacterial and antifungal activity.
Higher lactoferrin levels were seen in HM preceding and following an infectious episode in the
rural infants of the Breakey et al. study [324]. Since this association with infection was in the opposite
direction to that seen for sIgA secretion in the same infants, the study authors proposed that lactoferrin
“responds” to an infection. Lactoferrin is detected in infant feces. Mastromarino et al. found fecal
bifidobacteria and lactobacilli concentrations in newborns to be positively correlated with fecal lactoferrin
levels soon after delivery [329]. Due to reported associations between child atopy with reduced and not
elevated lactobacillus abundance in the infant gut [331], it is interesting that Zhang et al. found eczema
and atopic sensitization at 6 months (but not later) to be more likely in infants of mothers with higher
HM levels of lactoferrin at 6 weeks after birth [332]. Upper respiratory tract infections were less likely
when children were 1 or 2 years of age with higher HM lactoferrin. Clearly, the interactions between
anti-infective and anti-inflammatory effects of this HM protein are complex and require further study.
3.5.3. Low Molecular Weight Metabolites
Milk Fatty Acids
Milk lipids are principal macronutrients in HM and account for over 50 % of the infant energy
daily intake requirements. Polyunsaturated fatty acids (PUFAs), more specifically the omega-3
(ω-3) fatty acids: docosahexaenoic (DHA) and eicosapentaenoic (EPA), have been shown to have
anti-inflammatory effects in chronic inflammatory diseases, such as asthma [333]. Several specialized
pro-resolving mediators such as resolvin and protectin, are synthesized from ω-3 fatty acids by
lipoxygenase and cyclooxygenase in Th2-cytokine-stimulated macrophages and airway epithelial
cells of human and murine origin [334,335]. These mediators have anti-inflammatory properties and
demonstrated suppressive effects on allergic asthma [336].
More recently, the short-chain fatty acids (SCFAs), acetate, butyrate and propionate, have gained
interest as mediators of allergic inflammations. They are produced by gut microbes and are used
as an energy source by gut epithelial cells (colonocytes) and after absorption, by the liver for
gluconeogenesis [314]. Increasingly, inflammation is being viewed as a by-product of the metabolic
activity of gut microbiota from evidence that SCFAs are altered in children who are or become
overweight or atopic. New evidence shows that maternal SCFA levels during pregnancy can directly
impact the health of infants. Thorburn et al. observed that when a high-fibre diet was consumed
during pregnancy, maternal serum acetate (but not other SCFA) levels were higher [337]. Lower serum
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levels of acetate during pregnancy were associated with wheeze in infants. In a follow-up murine
model experiment, feeding dams acetate during pregnancy and the immediate postpartum period
reduced the development of allergic airway inflammation in offspring.
SCFAs are the first metabolites produced by the gut microbiota of newborns, with synthesis
increasing rapidly after birth [338]. In the few published studies, total SCFA levels are elevated in the
gut of formula-fed versus breastfed infants born at term gestation, yet relative to other SCFA, acetate
levels are highest with exclusive breastfeeding [314,339]. Since microbiota have been detected in HM
and breastfeeding influences SCFA levels in infants, it is quite plausible that HM contains SCFA. In our
pilot comparison of HM across 5 countries, butyrate and acetate were detected by NMR spectroscopy
in HM collected 1 month after vaginal delivery in women who had not received antibiotics. Tan et al.
have observed a reduction in food allergy and total serum IgE levels in mice treated with acetate and
butyrate, but not propionate in drinking water [340]. This protection against food allergy was not
observed in the absence of gut microbiota, suggesting that in addition to SCFAs, a cascade of other
signaling molecules are required to prevent sensitization to food antigens [341].
Choline
Choline is a component of the non-protein nitrogen in human milk and is an important metabolite
for lipid synthesis and in the neurodevelopment of the infant [342]. The circulatory concentration of
free choline, phosphocholine, glycerophosphocholine in breastfed infants is positively correlated with
the choline contents of consumed HM [343]. Ozarda et al. has demonstrated that the water-soluble
choline content of early HM at 1 to 3 days postpartum was positively associated with maternal serum
C-reactive protein (CRP) levels [344]. Since serum CRP is typically elevated during active infection or
acute severe inflammatory processes [345,346], the Ozarda study suggests that HM choline content is a
response to low-grade inflammation in the nursing mother. In fact, higher intake of dietary choline in
adults has been independently associated with a reduction in inflammatory markers, namely with
lowered levels of serum CRP, interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α) [347], although
the exact cause of this association remains unclear. Of interest, in the Ozarda et al. study, both HM
levels of choline and serum CRP were higher after caesarean versus vaginal delivery, differences
which could not be attributed to the weight, height or body-mass index of breastfeeding women [344].
It is of particular interest considering known notable associations between delivery by C-section and
increased risk of allergic diseases development [348].
Lactose
Lactose is the main component of the carbohydrate portion of HM and induces innate immunity
by up-regulating gastrointestinal antimicrobial peptides that protect the infant’s gut against pathogens
and regulate gut microbial homeostasis [349]. As such, the lactose concentration in HM increases
after closure of the tight junctions at the initiation of lactation [350]. Before the infant can absorb
lactose for energy use, it is broken down to glucose and galactose by β-galactosidase lactase in the
small intestine [351]. Infant lactose intolerance is not common, as lactase is tightly regulated in infant
and is then progressively down regulated in most children by 2 to 3 years of age [317]. As lactase
activity decreases, the lactose moiety remains intact and then reaches the large intestine, where it is
metabolized by gut microbes. This fermentation process produces hydrogen, methane, carbon dioxide
and lactate [352], molecules which have the potential to cause bloating, abdominal cramps, nausea and
symptoms typical of lactose intolerance. This lactose-lactase system is suggested to act as a biological
timer, controlling birth spacing in human and eventual weaning. Noteworthy is that lactase deficiency
is more prominent in those of Asian, South American and African descent [317]. However, there is no
high-quality research providing a link between the lactose and allergic diseases development.
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4. Breastfeeding/Human Milk Research Unmet Needs
Hitherto in this state-of-the-art review two predominant approaches were presented in the field
of breastfeeding and HM research, with some studies assessing the impact of breastfeeding on health
outcomes, while others testing putative associations between HM composition and the development
of non-communicable disease in general, and allergy in particular. There is an evident lack of studies
combining both, which therefore does not elaborate on the reasons for breastfeeding being beneficial
in some children, with no effect, or even conferring a higher risk of allergy development, in the others.
Furthermore, each field of study had its own methodologic challenges.
We pointed out that various methods of quantifying breastfeeding (exclusive breastfeeding versus
supplementation, feeding duration categorization), differences in assessing outcomes (self-report
versus clinical measures), and the timing of outcome assessment have all contributed to the inconsistent
results of association studies and intervention trials. In addition, the role of breastfeeding may vary
in importance depending on characteristics of the infant, such as age and mode of delivery. When
comparing the impact of breastfeeding on gut microbiota in neonates versus infants, Levin et al.
reported greater variance in microbial composition explained by breastfeeding at 6 months than at
1 month of age [353]. Before 3 months of age, the impact of caesarean section (CS) on gut microbial
composition has been found to be stronger than breastfeeding [353,354] and to be independent
of breastfeeding status [353,355]. On the other hand, findings from the Canadian Healthy Infant
Longitudinal Development birth cohort suggest that early breastfeeding may modify intrapartum
antibiotic prophylaxis and CS-associated dysbiosis of the gut microbiome later in infancy [355]. Hence,
in addition to correctly applying breastfeeding definitions, separating ante- from postnatal influences,
better phenotyping allergy outcomes and utilizing “big data” to study the impact of clusters of HM
components, assessment of infant subgroups is required for a more precise recommendations to be
made about breastfeeding according to maternal characteristics (i.e., asthmatic status, allergic history,
parity, etc.) and delivery mode.
We have also shown that HM has a very complex composition, consisting of a wide range of
immunologically active markers, oligosaccharides, live microorganisms, micronutrients, metabolites
and many other bioactive compounds. Human milk composition is dynamic and variable. Early milk
is particularly rich in its constituents and they undergo rapid change during the very first days of
life. Country differences are also apparent, but not fully explainable at this stage, indicating that
women living in different geographic locations may have distinct human milk profiles. The impact of
HM composition on allergic disease development in children is still a matter of discussion as studies
continue to produce conflicting results. In view of the vast number of crucial components in human
milk, investigation of a single or limited range of constituents may well lead to confusing outcomes.
An appealing thesis is that lactating women can be characterized according to specific and individual
constituents of their milk, called “lactotypes”. Future studies should investigate the possibility of
a lactotype phenotype in a large number of nursing women by analyzing human milk for multiple
constituents at a time and looking for associations with a variety of immunologic phenotype and
outcomes (Figure 1).
Methodological differences in the detection of constituents are also a major issue in HM studies,
which makes it challenging for meta-analyses to be undertaken. HM composition comparisons
between populations or countries should consider strict harmonisation of sampling, storage and
analysis protocols, especially for the timing of sampling, and the collection of samples from lactating
women with similar characteristics. Such studies would reduce variations caused by differences
between populations and between sampling methods, although variation in storage time of milk
samples could not be controlled in this way.
There are number of unmet research needs in breastfeeding and HM research (Box 1) which have
arisen during the development of this manuscript and should be addressed in the future research.
Addressing these needs would lead to a better understanding of the links between breastfeeding/HM
composition and allergic disease development in infancy and childhood.
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Figure 1. Maternal, environmental and human milk composition factors influence on immunological
outcomes in child.
Box 1. Unmet research needs in breastfeeding and human milk research.
 Large and well-standardised studies of HM composition (integrated data on immune markers, HMOs,
PUFAs, microbiome and metabolites), defining lactotypes and assessing variation between women residing
in different countries
 Application of omics approaches (metabolomics, proteomics, genomics, etc.) to highlight the most
important components of HM in relation to allergic diseases
 Studies evaluating biological activity of a specific components within HM
 Randomised trials of breastfeeding interventions with long-term follow-up for allergic disease development
 Randomised trials of early weaning (3–4 months) using different dietary approaches
 Large cohort studies which combine assessments of breastfeeding influence on allergy development with
the constituent analysis of HM samples
 Development of a new intervention strategies for HM composition modification and indirect preventative
effect on allergy prevention
 Relevance of a geographical location/lifestyle/diet and its’ influence on the composition of human milk
should be assessed in more detail and research should account for these important confounders
As evidence accumulates from HM research, it will address some of these gaps to better inform policy
makers, clinicians and nursing mothers. Future studies must continue to apply sound methodological
approaches [356], as well as to incorporate new technologies and bring a “patient-centered”
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individualised approach to their application. Emerging laboratory and analytical methods will facilitate
the inclusion of data on the human milk microbiome and metabolome as likely mechanistically
important components of breastfeeding and these findings must be investigated for their roles
in the developmental origins of health and disease (DOHAD) [154]. As allergic sensitization
and allergy associated diseases are increasingly common and constitute the commonest group
of common conditions afflicting young people, they provide the best opportunity to investigate
DOHAD hypotheses.
5. Conclusions
Allergic diseases such as eczema, food allergy and asthma are the commonest chronic diseases
of childhood in many countries, and there is evidence that early life events, such as variations in
breastfeeding patterns, maternal diet, environmental and microbial exposures may be important
in their development. There remain a number of hurdles to overcome before we come to a clear
understanding on how to translate these associations into clinical practice because association is
not synonymous with cause and effect. The possibility that interventions which modify maternal
immunity can impact infant immune responses by changing HM composition is in part supported by
associations between HM composition and immunological outcomes.
Complexity and variability in human milk composition (and known infant’s response to many
of HM constituents) may also explain some of the conflicting results of studies evaluating the effect
of prolonged exclusive breastfeeding and the prevention of allergic disease development. Future
research needs to account for different environmental exposures and use systematic methodologies to
characterize variations in human milk composition in relation to well-defined clinical and immune
outcomes during childhood. Statistical approaches using cluster analysis should be implemented more
frequently, in order to define the role of lactotypes, consisting of immune active molecules, PUFA’s,
microbiome composition. Understanding the relationship between HM composition and development
of non-communicable diseases, and particularly allergy, may allow us to establish a new paradigm in
allergy prevention research—namely modulation of HM composition via maternal dietary and other
interventions, in order to promote healthy infant immune development.
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Abstract: Early-life nutrition is an important modifiable determinant in the development of a child’s
immune system, and may thereby influence the risk of allergic sensitization and atopic diseases.
However, associations between overall dietary patterns and atopic diseases in childhood remain
unclear. We examined associations of diet quality in early life with allergic sensitization, self-reported
physician-diagnosed inhalant and food allergies, eczema, and asthma among 5225 children
participating in a population-based cohort in the Netherlands. Diet was assessed during pregnancy,
infancy, and childhood using validated food-frequency questionnaires. We calculated food-based
diet quality scores (0–10 or 0–15), reflecting adherence to dietary guidelines. At age 10 years, allergic
sensitization was assessed with skin prick tests. Information on physician-diagnosed inhalant and
food allergies, eczema, and asthma was obtained with questionnaires. We observed no associations
between diet quality during pregnancy and allergic sensitization (odds ratio (OR) = 1.05 per point
in the diet score, 95% confidence interval (CI): 0.99, 1.13), allergies (0.96, 95% CI: 0.88, 1.04), eczema
(0.99, 95% CI: 0.93, 1.06), or asthma (0.93, 95% CI: 0.85, 1.03) in childhood. Also, diet quality in infancy
or childhood were not associated with atopic outcomes in childhood. Our findings do not support
our hypothesis that a healthy dietary pattern in early life is associated with a lower risk of allergic
sensitization or atopic diseases in childhood.
Keywords: diet quality; allergic sensitization; allergy; eczema; asthma; pregnancy; infants; cohort
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1. Introduction
The prevalence of childhood atopic diseases, such as eczema and food allergy, has increased in the
recent decades [1]. These diseases have a substantial impact on the quality of life of those affected [2].
Genetic background is one of the factors associated with atopic diseases, but given the rapid increase
in the prevalence, environmental risk factors, including geographic area and lifestyle factors may play
a substantial role in the development of allergies and other atopic diseases [3–5]. Early-life nutrition is
an important modifiable lifestyle factor that influences the development of a child’s immune system [6].
Suboptimal nutrition during pregnancy, infancy, or childhood may interrupt the maturation process
of the immune system from fetal life until childhood [6,7], which may increase sensitization and
thereby the risk of atopic diseases in childhood. There has been great interest in early-life dietary
exposures in relation to atopic diseases, with studies focusing on breastfeeding [8], timing of solid
food introduction [9,10], food allergen avoidance [11,12], or intake or blood levels of specific nutrients
during pregnancy or in infancy [13–16]. Although these specific nutritional factors may indeed be
relevant for atopic health, these factors may also represent an overall dietary pattern. Individuals do
not consume one specific nutrient or food at a time, but a variety of nutrients combined in foods
and meals that may interact. Studying overall dietary patterns takes these potential interactions into
account [17] and may be more applicable in clinical practice.
A few previous studies examined dietary patterns in relation to atopic diseases. So far, most
studies mainly focused on a Mediterranean diet in pregnant women or children in relation to atopic
diseases [18–20]. However, findings are inconsistent and most of these studies only examined
self-reported atopic diseases, such as asthma or allergic rhinitis [18–20]. Assessing atopy using
skin prick tests may be more sensitive and less affected by measurement error, but only a few
studies examined associations between dietary patterns and objectively measured atopy. A study in
Spain observed an inverse association between a Mediterranean diet during pregnancy and atopy
in childhood [21], whereas other studies did not observe associations of either data-driven dietary
patterns [22,23] or predefined dietary patterns (i.e., Mediterranean diet score and Alternate Healthy
Eating Index) [23] during pregnancy with atopy in children. A few other studies focused on early
childhood dietary patterns in relation to atopic outcomes. For example, a nested case-control study
in the United Kingdom found better adherence to a dietary pattern including high intakes of fruits,
vegetables, and home-prepared foods in two-year-old children without food allergy than children
who did have a diagnosis of food allergy [24]. Recently, a population-based cohort in Singapore
reported an inverse association of a dietary pattern high in noodles and seafood at the age of one year
with allergic sensitization to house dust mite at the ages of 18 months and five years, but not with
self-reported eczema or rhinitis [25]. Finally, results from other population-based cohorts, including
previous analyses in our cohort, showed positive associations of a Western dietary pattern with
self-reported asthma symptoms in children aged 3–4 years [26] and 8–11 years [27], but not with
allergic sensitization measured by skin prick tests [27]. These previous studies examined diet at
different points in early life, focused on different types of dietary patterns, and did not adjust for diet at
other points in childhood. In addition, previous studies mainly focused on a traditional Mediterranean
diet or examined data-driven dietary patterns, which may not represent actual healthy diets and which
cannot be extrapolated to other populations because these patterns are population-specific.
Therefore, we aimed to examine the associations between predefined dietary patterns based on
Dutch dietary guidelines (i.e., diet quality) during pregnancy, infancy, and childhood with allergic
sensitization, inhalant and food allergy, eczema, and asthma in mid-childhood. In addition, we
examined whether associations of early-life diet were independent of diet at other time points,
including current child diet, and whether associations differed between boys and girls, by maternal
history of atopic diseases, and between those who received breastfeeding for at least four months
exclusively, partially, or not at all.
120
Nutrients 2017, 9, 841
2. Methods
2.1. Study Design and Population
This study was embedded in the Generation R Study, an ongoing population-based prospective
cohort from fetal life onward in Rotterdam, the Netherlands [28]. Pregnant women with an expected
delivery date between April 2002 and January 2006 were invited to participate. Parents of all participating
children provided written informed consent and medical ethical approval was obtained from the
medical ethical committee of Erasmus University Medical Center, Rotterdam (MEC 198.782/2001/31,
2001). Further information on the design of the Generation R Study is available elsewhere [28].
In total, parents of 5225 children provided consent, had dietary data for at least one time point
(i.e., during pregnancy, infancy, or childhood) and had valid data for at least one of the outcome
variables (i.e., sensitization, allergy, eczema, or asthma). Because data on dietary intake at the different
time points and the atopic outcomes were not complete for all participants, the population for analysis
varied per specific analysis (n: between 2519 and 3776) (Supplemental Figures S1–S3).
2.2. Dietary Intake during Pregnancy
Dietary intake in early pregnancy (median 13.6 weeks of gestation (interquartile range (IQR)
12.4–16.2)) was assessed using a semi-quantitative food-frequency questionnaire (FFQ). The FFQ
included foods that were frequently consumed in the Dutch population and was modified for use in
pregnant women. Energy intakes were calculated using data from the Dutch Food Composition Table.
The FFQ was validated against three 24-h recalls among 71 pregnant women living in Rotterdam.
Intra-class correlation coefficients for macronutrient intakes ranged from 0.5 to 0.7.
We applied a previously developed predefined food-based diet quality score for pregnant women,
reflecting adherence to dietary guidelines, as described in detail elsewhere [29]. Briefly, this diet
quality score included continuous scores on 15 components: high intake of vegetables, fruit, whole
grains, legumes, nuts, dairy, fish, tea; ratio whole grains of total grains, and ratio soft fats (i.e., soft
margarines) and oils of total fat; low intake of red meat, sugar-containing beverages, alcohol, salt;
and folic acid supplement use in early pregnancy. The maximum score for each component was 1,
resulting in an overall sum-score ranging from 0 to 15. A higher score represented a better diet
quality [29]. More details on the included components and cut-offs are described in Supplemental
Table S1 and elsewhere [29].
2.3. Dietary Intake in Infancy
Dietary intake of the children at a median age of 12.9 months (IQR 12.7–14.0) was assessed using
a semi-quantitative FFQ, which was developed specifically for Dutch 1-year-old children and filled
out by the parents [30,31]. Energy and nutrient intakes of the children were calculated using the Dutch
Food Composition Table. The FFQ was validated against three 24-h recalls among 32 children and
reasonable to good intra-class correlation coefficients for nutrient intake of 0.4 to 0.7 were found [30,31].
We applied a previously constructed predefined diet quality score for preschool children [30].
As described in detail elsewhere [30], this continuous score reflected adherence to dietary guidelines
for preschool children and included ten components, resulting in an overall sum-score ranging from 0
to 10, with a higher score representing a healthier diet [30]. More details on the included components
and cut-offs are described in Supplemental Table S2 and elsewhere [30].
2.4. Diet Quality in Childhood
Dietary intake in childhood at a median age of 8.1 years (IQR 8.0–8.2) was assessed with
a semi-quantitative FFQ, as described in detail elsewhere [32,33]. The FFQ developed for Dutch
children in this age group and was filled out by the parents. Energy intakes were calculated using data
from the Dutch Food Composition Table. The FFQ was validated for energy intake using the doubly
labelled water method (Pearson’s r = 0.62) [33].
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We applied a previously developed diet quality score for school age children [32], with a similar
scoring system as used for the pregnant women and infants. This child diet quality score included
ten components, resulting in an overall diet quality sum score ranging from 0 to 10. More details
on this diet quality score and the included components are described in Supplemental Table S3
and elsewhere [32].
2.5. Allergic Sensitization and Atopic Diseases
Children visited our research center at a median age of 9.7 years (IQR 9.6–9.9). Sensitization to
inhalant (including house dust mite, 5-grass mixture, birch, cat, and dog) and food (including peanut,
cashew nut, hazelnut, and peach) allergens was assessed by skin prick tests using the scanned area
method [34]. Histamine dihydrochloride (10 mg/mL) was used as a positive control in duplicate
and a saline solution (NaCl 0.9%) as a negative control. Skin responses were measured 15 min after
applying allergens to the skin by measuring the area of the wheal (mm2). An area that was ≥40% of the
histamine response was considered positive [35]. Children with a positive skin response to any of the
allergens were categorized as ‘any allergic sensitization’. We further categorized children into inhalant
allergic sensitization and food allergic sensitization. In addition, questionnaires including questions
adapted from the International Study of Asthma and Allergies in Childhood core questionnaire [36]
were used to obtain information on physician-diagnosed inhalant (‘Was your child ever diagnosed
by a physician with an allergy to pollen (hay fever)/house dust mite/cat/dog?’) (no; yes) and food
allergies (‘Was your child ever diagnosed by a physician with an allergy to cashew nut/peanut?’)
(no; yes). Based on these questions, we dichotomized children into ‘any allergy’ (no; yes). Finally,
we further categorized children into ‘sensitization to any allergen and any allergic symptom’ versus
‘no sensitization and no symptoms’. Information on ever eczema and asthma at the age of 10 years
was obtained with the same questionnaire (‘Was your child ever diagnosed by a physician with
eczema/asthma?’) (no; yes).
3. Covariates
At enrollment in the study, maternal height and weight were measured and body mass index
(BMI) was calculated (kg/m2). Questionnaires were used to obtain information on educational level of
the mother (low; high), net household income (<2200 or ≥2200 Euros/month), parity (nulliparous;
multiparous), prenatal pet exposure (yes; no), and whether mothers drank alcohol (never; until
pregnancy was known; continued drinking occasionally; continued drinking frequently), smoked
(never; until pregnancy was known; continued smoking during pregnancy), and used folic acid
supplements (no; started in first ten weeks; started periconceptional) during pregnancy. We used
questionnaires to obtain information on maternal history of atopic disease, including allergy (hay
fever/house dust mite/food), eczema, or asthma. If a mother reported to have any of these outcomes,
we categorized her as having a history of atopic disease.
Information on child’s date of birth and sex was obtained from medical records. The child’s
ethnic background (Dutch; non-Dutch) was defined based on the country of birth of the parents, which
was obtained with questionnaires at enrollment. Information on breastfeeding during the first four
months (never; partial; exclusive) was obtained via postnatal questionnaires. Exclusive breastfeeding
was defined as receiving breastmilk only for at least four months. Timing of solid food introduction
in the first year of life (<3; 3–6; ≥6 months) was obtained from the FFQ administered in infancy.
Questionnaires were used to obtain information on day care attendance in the first year of life (≤24 or
>24 h/week).
4. Statistical Analyses
Non-linearity of associations of diet quality during pregnancy, infancy, or childhood with all
atopic outcomes was explored using natural cubic splines (degrees of freedom = 3). As no indications
for non-linear associations for the main models were found, all analyses were performed using models
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assuming linearity. Multivariable logistic regression analyses were used to analyze the associations
of either diet quality during pregnancy, infancy, or childhood with allergic sensitization and atopic
diseases around the age of 10 years. All associations were analyzed in three models with stepwise
adjustment for potential confounders based on previous evidence. The first model was adjusted for
child’s ethnic background, sex, age at outcome assessment, and total energy intake. The second model
was additionally adjusted for several socioeconomic and lifestyle factors, including maternal BMI
at enrollment, maternal educational level, household income, parity, prenatal pet exposure, alcohol
intake during pregnancy, smoking during pregnancy, folic acid supplements during pregnancy, and
maternal history of atopic disease. In the final model, we examined whether associations of diet quality
in pregnancy, infancy, or childhood with allergic sensitization and atopic diseases were independent of
diet at the other two time points by additionally adjusting them for each other. Breastfeeding, child’s
sex, child’s ethnic background, and maternal history of atopic diseases were separately examined as
potential effect modifiers by including interaction terms in the models.
As sensitivity analyses, we repeated our analyses restricted to participants with a Dutch ethnic
background only to reduce the risk of residual confounding by ethnicity, since the FFQs were developed
for a Dutch population. Also, we repeated our analyses excluding children with any allergic disease
in the first year of life for the analyses on infant and child diet quality. In addition, we examined
associations of diet quality with the combination of sensitization and allergic symptoms versus no
sensitization or symptoms as outcome. Furthermore, we examined whether associations of early-life
diet quality with allergic sensitization and atopic diseases were independent of the other outcomes by
adjusting associations with atopic diseases for allergic sensitization and vice versa. Finally, to verify
that any associations of the overall diet quality scores were not driven by any specific component of
the score, we repeated the main analyses excluding one component from the diet score at a time.
To reduce potential bias due to missing values on some of the covariates (ranging from 0 to 30.1%),
these variables were multiple imputed (n = 10 imputations). Diet quality scores at different time
points were treated as either exposure or confounders in the different models. When diet quality was
included as a confounder, multiple imputed values of diet quality scores were used and when diet
quality was the exposure of interest, the non-imputed variable was used. The results presented are
the pooled regression coefficients of the 10 imputed datasets. All statistical analyses were carried out
using the statistical software program SPSS statistics version 21.0 (IBM Inc., Armonk, NY, USA).
5. Results
5.1. Population Characteristics
Characteristics of the study population are presented in Table 1. The majority of the children
had a Dutch ethnic background (63.7%), and half of the children were girls (50.8%). Mean (±SD) diet
quality score during pregnancy was 7.7 (±1.6) out of theoretical range of 0 to 15, mean diet quality
score in infants was 4.3 (±1.4) out of 10, and mean diet quality in 8-year-old children was 4.5 (±1.2) out
of 10. None of the participants (either pregnant women or their children) reached the maximum diet
quality score. In total, 26.0% of the children were sensitized to one or more allergens, with 25.6% of all
children being sensitized to an inhalant allergen and 5.7% to a food allergen. A physician diagnosed
allergy was reported for 11.1% of the children, with a total of 10.6% of the children diagnosed with an
inhalant allergy and 1.9% with a food allergy. Eczema was present in 20.0% of the children, and 8.3%
of the children had asthma.
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Table 1. Characteristics of the study population (n = 5225).
N (%), Median (IQR), or Mean (SD)
Maternal characteristics
Age at enrollment, years 31.7 (28.4–34.4)
Total energy intake, kcal/d (n = 4069) 2047 (1670–2439)
Diet quality score (n = 4069) 7.7 (1.6)
Educational level, higher 2751 (52.7%)
Household income, ≥2200 Euros per month 3234 (61.2%)
Parity, nulliparous 3027 (57.9%)
Prenatal pet exposure, yes 1800 (34.4)
Alcohol intake during pregnancy
Never 2040 (39.0%)
Until pregnancy was known 722 (13.8%)
Occasionally during pregnancy 1949 (37.3%)
Frequently during pregnancy 514 (9.8%)
Smoking during pregnancy
Never 3978 (76.1%)
Until pregnancy was known 484 (9.3%)
Continued during pregnancy 763 (14.6%)
Folic acid supplement use
No 1084 (20.8%)
Started in the first 10 weeks of pregnancy 1745 (33.4%)
Started periconceptional 2395 (45.8%)
History of atopic disease, yes 2116(40.5%)
Infant characteristics
Sex, female 2652 (50.8%)
Ethnic background, Dutch 3331 (63.7%)
Age at dietary assessment, months (n = 2796) 12.9 (12.7–13.9)
Total energy intake, kcal/d (n = 2796) 1261 (1058–1505)
Diet quality score (n = 2796) 4.3 (1.4)
Breastfeeding
Never 508 (9.7%)
Four months partially 3401 (65.1%)
Four months exclusively 1315 (25.2%)
Child characteristics
Age at dietary assessment, years 8.1 (8.0–8.2)
Total energy intake, kcal/d (n = 4066) 1461 (1240–1702)
Diet quality score (n = 4066) 4.5 (1.2)
Age at outcome assessment, years 9.7 (9.6–9.9)
Any allergic sensitization (n = 3911) 1357 (26.0%)
Inhalant allergic sensitization 1335 (25.6%)
Food allergic sensitization 298 (5.7%)
Any allergy (n = 4577) 579 (11.1%)
Inhalant allergy 554 (10.6%)
Food allergy 97 (1.9%)
Ever eczema (n = 4598) 1046 (20.0%)
Ever asthma (n = 4616) 432 (8.3%)
Values are means (±standard deviation (SD)) for continuous variables with a normal distribution, or medians
(interquartile range (IQR)) for continuous variables with a skewed distribution, and absolute numbers (percentages)
for categorical variables and are based on imputed data. Missing values for educational level (5.0%), household
income (18.9%), parity (2.8%), prenatal pet exposure (20.6%), alcohol intake (during pregnancy (14.2%), smoking
during pregnancy (17.1%), folic acid supplement use (28.2%), history of atopic disease (17.2%), child ethnic
background (0.2%), and breastfeeding (30.1%) were multiple imputed (n = 10 imputations).
5.2. Diet Quality during Pregnancy
Associations of diet quality during pregnancy and allergic sensitization in children are presented
in Table 2. In model 1, we observed a statistically significant association for inhalant allergic
sensitization (OR = 1.06, 95% CI: 1.01, 1.12) (model 1, Table 2). However, this association was no longer
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statistically significant after adjustment for socioeconomic and lifestyle factors. In model 3, which was
our main model, we observed no associations between diet quality during pregnancy and food allergic
sensitization (OR = 1.04, 95% CI 0.92, 1.17) in children at the age of 10 years (model 3, Table 2). In line
with our findings for allergic sensitization, we observed no statistically significant associations with
self-reported physician-diagnosed inhalant (OR = 0.94, 95% CI: 0.88, 1.00) or food allergies (OR = 1.11,
95% CI: 0.91, 1.35), eczema (OR = 0.99, 95% CI: 0.93, 1.06), or asthma (OR = 0.93, 95% CI: 0.85, 1.03) in
10-year-old children (model 3, Table 2).
Table 2. Associations of diet quality in pregnancy with allergic sensitization and allergic diseases in
childhood at the age of 10 years.
OR (95% CI) Per 1 Point Higher Diet Quality Score
Model 1 Model 2 Model 3
Any allergic sensitization (n = 1019/2960) 1.06 (1.00, 1.11) 1.06 (0.99, 1.13) 1.05 (0.99, 1.13)
Inhalant allergic sensitization (n = 1002/2960) 1.06 (1.01, 1.12) 1.06 (0.99, 1.13) 1.06 (0.99, 1.13)
Food allergic sensitization (n = 224/2960) 1.04 (0.94, 1.14) 1.04 (0.92, 1.16) 1.04 (0.92, 1.17)
Any allergy (n = 449/3588) 0.96 (0.90, 1.03) 0.96 (0.88, 1.04) 0.96 (0.88, 1.04)
Inhalant allergy (n = 427/3588) 0.95 (0.89, 1.00) 0.94 (0.88, 1.00) 0.94 (0.88, 1.00)
Food allergy (n = 69/3588) 1.06 (0.91, 1.24) 1.04 (0.86, 1.25) 1.11 (0.91, 1.35)
Ever eczema (n = 840/3600) 1.03 (0.98, 1.08) 1.00 (0.94, 1.06) 0.99 (0.93, 1.06)
Ever asthma (n = 319/3610) 0.91 (0.84, 0.98) 0.94 (0.86, 1.03) 0.93 (0.85, 1.03)
Values are odds ratios with 95% confidence intervals (CIs) from logistic regression analyses, for allergic sensitization
or atopic disease per 1 point higher diet quality score. Numbers (n) represent cases/total population with valid data
included in the analyses. Bold values represent p-value < 0.05. Model 1: Sex, ethnic background, age at outcome
assessment, total energy intake. Model 2: Maternal BMI at enrollment, maternal educational level, household
income, parity, prenatal pet exposure, alcohol intake during pregnancy, smoking during pregnancy, folic acid
supplements during pregnancy, maternal history of atopic disease, breastfeeding. Model 3: Diet quality in infancy
and childhood.
5.3. Diet Quality in Infancy
Associations of diet quality in infancy and allergic sensitization and atopic diseases in children
are presented in Table 3. For diet quality in infancy, similar null findings were observed for inhalant
allergic sensitization (OR = 0.99, 95% CI: 0.92, 1.06) and for food allergic sensitization (OR = 0.98,
95% CI: 0.86, 1.12) in model 3). Also, no associations were observed with inhalant (OR = 0.96, 95% CI:
0.87, 1.05) or food allergies (OR = 0.84, 95% CI: 0.70, 1.05) or with eczema or asthma in children around
the age of 10 years (Table 3).
Table 3. Associations of diet quality in infancy with allergic sensitization and allergic diseases in
childhood at the age of 10 years.
OR (95% CI) Per 1 Point Higher Diet Quality Score
Model 1 Model 2 Model 3
Any allergic sensitization (n = 823/2456) 1.00 (0.94, 1.06) 1.00 (0.94, 1.07) 0.99 (0.92, 1.06)
Inhalant allergic sensitization (n = 808/2456) 1.00 (0.94, 1.07) 1.00 (0.94, 1.07) 0.99 (0.92, 1.06)
Food allergic sensitization (n = 173/2456) 0.99 (0.93, 1.05) 0.99 (0.87, 1.12) 0.98 (0.86, 1.12)
Any allergy (n = 316/2519) 0.94 (0.87, 1.02) 0.94 (0.86, 1.03) 0.94 (0.86, 1.04)
Inhalant allergy (n = 302/2519) 0.95 (0.87, 1.04) 0.96 (0.87, 1.05) 0.96 (0.87, 1.05)
Food allergy (n = 58/2519) 0.84 (0.68, 1.03) 0.82 (0.67, 1.01) 0.84 (0.70, 1.05)
Ever eczema (n = 586/2543) 1.00 (0.97, 1.04) 1.00 (0.93, 1.07) 1.00 (0.93, 1.08)
Ever asthma (n = 236/2542) 0.95 (0.86, 1.05) 0.96 (0.86, 1.06) 0.96 (0.86, 1.07)
Values are odds ratios with 95% confidence intervals (CIs) from logistic regression analyses, for allergic sensitization
or atopic disease per 1 point higher diet quality score. Numbers (n) represent cases/total population with valid data
included in the analyses. Model 1: Sex, ethnic background, age at outcome assessment, total energy intake. Model 2:
Maternal BMI at enrollment, maternal educational level, household income, parity, prenatal pet exposure, alcohol
intake during pregnancy, smoking during pregnancy, folic acid supplements during pregnancy, maternal history of
atopic disease, breastfeeding. Model 3: Diet quality in pregnancy and childhood.
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5.4. Diet Quality in Childhood
Table 4 presents associations of diet quality in childhood with the allergic outcomes. We observed
no associations of diet quality in childhood with inhalant allergic sensitization (OR = 1.03,
95% CI: 0.96, 1.11) or food allergic sensitization (OR = 1.00, 95% CI: 0.88, 1.15) in childhood (model 3,
Table 4). Similar null findings were observed for inhalant allergy (OR=1.05, 95% CI: 0.95, 1.15), food
allergy (OR = 0.86, 95% CI: 0.69, 1.05), eczema (OR = 1.02, 95% CI: 0.95, 1.10), and asthma (OR = 1.03,
95% CI: 0.93, 1.15) (Table 4).
Table 4. Associations of diet quality in childhood with allergic sensitization and allergic diseases in
childhood at the age of 10 years.
OR (95% CI) Per 1 Point Higher Diet Quality Score
Model 1 Model 2 Model 3
Any allergic sensitization (n = 1012/3017) 1.03 (0.97, 1.10) 1.04 (0.97, 1.11) 1.03 (0.96, 1.11)
Inhalant allergic sensitization (n = 994/3017) 1.04 (0.97, 1.11) 1.04 (0.97, 1.12) 1.03 (0.96, 1.11)
Food allergic sensitization (n = 218/3017) 0.99 (0.93, 1.06) 0.99 (0.87, 1.13) 1.00 (0.88, 1.15)
Any allergy (n = 463/3750) 1.00 (0.92, 1.09) 1.02 (0.94, 1.12) 1.04 (0.95, 1.14)
Inhalant allergy (n = 445/3750) 1.00 (0.92, 1.09) 1.03 (0.94, 1.12) 1.05 (0.95, 1.15)
Food allergy (n = 79/3750) 0.88 (0.72, 1.06) 0.85 (0.69, 1.04) 0.86 (0.69, 1.05)
Ever eczema (n = 850/3766) 1.02 (0.98, 1.05) 1.01 (0.95, 1.09) 1.02 (0.95, 1.10)
Ever asthma (n = 335/3776) 0.97 (0.92, 1.02) 1.01 (0.91, 1.12) 1.03 (0.93, 1.15)
Values are odds ratios with 95% confidence intervals (CIs) from logistic regression analyses, for allergic sensitization
or atopic disease per 1 point higher diet quality score. Numbers (n) represent cases/total population with valid data
included in the analyses. Model 1: Sex, ethnic background, age at outcome assessment, total energy intake. Model 2:
Maternal BMI at enrollment, maternal educational level, household income, parity, prenatal pet exposure, alcohol
intake during pregnancy, smoking during pregnancy, folic acid supplements during pregnancy, maternal history of
atopic disease, breastfeeding. Model 3: Diet quality in pregnancy and infancy.
5.5. Additional Analyses
Associations were not statistically significantly different between Dutch and non-Dutch children
for any of the outcomes (p-for-interaction >0.1). In line with this, sensitivity analyses restricted to
children with a Dutch ethnic background only resulted in similar effect estimates as observed in
the whole population (Supplemental Tables S4–S6). An exception was that among children with
a Dutch ethnic background only, a higher diet quality during pregnancy was associated with a higher
likelihood of inhalant allergic sensitization. However, we interpret this as a chance finding, since
there was no association with any of the other outcomes; the interaction with ethnicity was not
statistically significant; and because this finding would not remain if we would take into account
multiple testing (p = 0.02). Also, analyses excluding children with any allergic disease in the first year
of life resulted in similar findings (Supplemental Tables S7 and S8), except for an inverse association
of diet quality in infancy with food allergy (OR = 0.64, 95% CI: 0.43, 0.95, p = 0.03), but not with any
of the other outcomes. Analyses with a combination of allergic sensitization and allergic symptoms
as the outcome (n = 642) versus no sensitization and symptoms (n = 1699) resulted in similar null
findings (Supplemental Table S9). Additional adjustment for the other outcome variables did not
affect the results (Supplemental Tables S10–S12). Also, excluding one component from the diet scores
at a time, or additional adjustment for introduction of solid foods and day care attendance in the
first year of life did not affect the results. We observed a significant interaction (p = 0.03) of infant
diet quality with sex on food sensitization, and of infant diet quality with breastfeeding on eczema
(p = 0.03), but not on any of the other outcomes (p-for-interaction ranging from 0.1 to 0.9). For none
of the associations, we observed a significant interaction for maternal history of atopic diseases or
child’s ethnic background (p-for-interaction >0.1). Stratification by sex suggested effect estimates in
different directions (boys: OR = 0.88, 95% CI: 0.73, 1.06, model 3, girls: OR = 1.10, 95% CI: 0.91, 1.32,
model 3), but none statistically significant. Similarly, after stratification by breastfeeding, no significant
associations were observed in the different groups.
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6. Discussion and Conclusions
In this large population-based study, we aimed to examine the associations between diet quality
during pregnancy, infancy, and childhood with allergic sensitization, physician-diagnosed inhalant
and food allergy, eczema, and asthma in mid-childhood. Overall, we observed no associations of
overall diet quality during either pregnancy, infancy, or childhood with allergic sensitization or atopic
diseases in children around the age of 10 years.
6.1. Interpretation and Comparison with Previous Studies
Although we observed a few associations of diet quality with atopic outcomes in our sensitivity
analyses, these were not consistent and do not remain if multiple testing would be taken into account.
In addition, the effect estimates were similar as observed in the main analyses. Our finding of a higher
diet quality in infancy with lower odds of food allergy in additional analyses warrants caution and
needs further study, as the prevalence of food allergy in these analyses is low (n = 18).
Previous studies mainly reported on associations of one particular time point in childhood
(e.g., either pregnancy, infancy, or childhood) with different atopic outcomes. In this study, we
examined diet at three different time points in early life. Although some previous studies observed
an inverse association of overall diet during either pregnancy or infancy with atopic outcomes in
childhood [21,25], we did not observe such associations. This is in line with a previous study in the
United Kingdom that also observed no associations of data-driven dietary patterns in pregnancy with
asthma or atopy in children around the age of seven years [22]. A recent systematic review suggested
that a Mediterranean diet during pregnancy may only have an inverse association with asthma in
the offspring in their first year of life, but not afterwards [19]. The longer time window between
exposure and outcomes, and the measurement of atopic outcomes at the age of 10 years may therefore
explain the absence of an association in our study, as children may outgrow some atopic diseases
as they become older [37] and diet may have no long-term effects. Indeed, previous analyses in our
cohort showed a positive association of adherence to a ‘Western-like’ dietary pattern in early life with
asthma-related symptoms such as wheezing at the ages of three and four years [26], whereas we
did not observe associations of diet quality with asthma at the age of 10 years in the current study.
This suggests that any potential association between early-life diet and atopic outcomes may take place
within a short term and may not persist into later childhood.
However, studies with shorter time windows between exposure and outcome also report
inconsistent findings. Several cross-sectional studies examined associations of a predefined
Mediterranean dietary pattern in childhood with allergic outcomes [18,19]. Inverse associations
were reported in some of these studies, for example for diet in children aged six to seven years [38] and
10 to 12 years [39]. A study in the United Kingdom observed a positive association of a Western dietary
pattern, which was high in processed foods, at the age of eight years with asthma, but no associations
with allergic sensitization at the ages of eight and 11 years [27]. Finally, another study observed no
associations of children’s adherence to a Mediterranean diet at the age of 6.5 years with atopy at the
same age [21].
In addition to the time window of measurements, geographic area and cultural differences may
play a role in the inconsistent associations observed in the different studies. A meta-analysis suggested,
for example, that a Mediterranean diet may only be protective for atopic symptoms among children in
the Mediterranean area [18]. A possible explanation for this may be the use of different Mediterranean
diet indices, which may reflect slightly different food products. Also, a recent study in Singapore
reported that a dietary pattern which was particularly high in fish and other seafood such as shellfish,
at the age of one year was associated with less allergic sensitization to house dust mite at the ages of
18 months, but also at the age of five years [25]. The high fish intake may have driven the observed
association. However, children and adults in the Netherlands have a relatively low fish and shellfish
intake [40] and low variability. Therefore, these food groups do not drive large variations in our diet
quality scores [30]. In addition, our diet quality scores were based on dietary guidelines, whereas
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most previous studies examined indices based on a traditional Mediterranean diet or data-driven
dietary patterns and did not take into account dietary guidelines. However, these dietary patterns are
population-specific and may not represent actual healthy diets. The absence of an association in our
study may suggest that specific foods or nutrients, such as fish or fatty acids, rather than overall dietary
patterns may be more relevant for the prevention of atopic outcomes in children. Further studies in
specific populations are needed to confirm this.
6.2. Strengths and Limitations
The strengths of this study are its population-based, prospective design, the inclusion of a large
number of participants, and the availability of numerous covariates. Also, we had detailed information
on allergic sensitization to several common allergens relevant for school-age children, measured with
skin prick tests. For these tests, we used the scanned area method to determine the wheal area, which
is considered to be more accurate than measuring the average wheal diameter, and is recommended
for use in academic research [34]. Furthermore, we analyzed overall dietary patterns, and not just
single nutrients, which takes into account the interactions between different nutrients [17], and we had
dietary data available at several time points throughout early life.
Several limitations of this study should also be considered. First, dietary intake during pregnancy,
infancy, and childhood were assessed with FFQs, which are prone to measurement errors [41].
However, FFQs are commonly used in large epidemiological studies and have been shown to rank
participants accurately according to their dietary intake [41]. In addition, in our study, we used
validated, extensive, population-specific FFQs [30,31,33]. Although allergic sensitization was measured
objectively using skin-prick tests, our other atopic outcomes were assessed with questionnaires filled
out by the parents, which may have resulted in some misclassification. These questionnaires included
questions on physician-diagnosed inhalant or food allergies, eczema, and asthma by any physician, but
with no further details. However, we expect any misclassification to be unrelated to the exposure and
therefore only resulting in random information bias. Furthermore, results for the associations of diet
quality with objectively assessed allergic sensitization with skin prick tests and the self-reported atopic
diseases were consistent. Despite that we were able to adjust the analyses for several confounders,
some may not have been measured perfectly and there may be other possible confounding factors that
we did not have available. Finally, most of the participants included in our study had a Dutch ethnic
background, were, on average, highly educated, and had a high household income, which may limit
the generalizability of our findings to other populations. However, in our sensitivity analyses restricted
to participants with a Dutch ethnic background only similar results were obtained, suggesting no large
bias due to ethnic background.
In conclusion, our findings suggest that overall diet quality in early life, either during pregnancy,
infancy, or childhood, is not associated with the risk of allergic sensitization or atopic diseases in later
childhood. Specific nutrients rather than overall dietary patterns may be more relevant for atopic
outcomes in children and require further study.
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Abstract: The prevalence of food allergy in childhood appears to be increasing in both developed and
transitional countries. The aim of this paper is to review and summarise key findings in the prevention
and management of food allergy, focusing on the role of dietary components and nutritional habits
in the development and optimal functioning of the immune system. Essential fatty acids, zinc
and vitamin D are likely to enhance the anti-inflammatory and antioxidative barrier and promote
immunologic tolerance. Additionally, nutritional components such as pre- and probiotics represent a
novel research approach in the attempt to induce a tolerogenic immune environment. For all these
reasons, the traditional avoidance diet has been, in recent years, completely reconsidered. New
findings on the protective effect of an increased diversity of food introduced in the first year of life on
allergic diseases are consistent with the hypothesis that exposure to a variety of food antigens during
early life might play a role in the development of immune tolerance. Accordingly, therapeutic (and
even preventive) interventions should be planned on an individual basis.
Keywords: food allergy; children; diet diversity; adequate nutrition
1. Introduction
Food allergy (FA) represents a substantial health problem in childhood. The prevalence appears
to be increasing in both developed and transitional countries, however a true increase has been
difficult to demonstrate [1]. Over 90% of food allergies are caused by eight common allergens; namely:
eggs, peanuts, cow’s milk, soy, nuts, shellfish, fish, or wheat [2]. On the whole, food allergy affects
approximately 6% of infants younger than three years [2], and prevalence decreases over the first
decade. The cumulative incidence of food hypersensitivity over a 10-year period is 6.7% (95% CI:
5.2–8.4%); 3.0% (95% CI: 1.8–4.2%) had IgE-mediated food allergy and 0.6% (95% CI: 0.07–1.3%) had
non-IgE-mediated food allergy/food intolerance [3]. A systematic review from the European Academy
of Allergy and Clinical Immunology concluded that food allergy prevalence in Europe ranges between
0.1 and 6.0% [4]. The Institute of Medicine report states that the prevalence of food allergies in children
ranges between 1.1 and 10.4% [1]. Food-allergic infants commonly present with symptoms and signs
of atopic eczema, gastrointestinal symptoms and/or recurrent wheezing [5]. Diet plays a crucial role in
both the prevention and management of food allergy. A number of factors, including the maternal diet,
the microbiome and early life feeding, have been investigated for the prevention of allergic diseases [6].
The aim of this paper is to review and summarise key findings in the prevention and management of
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food allergy, with particular reference to nutrients of concern (fats, micronutrients), gut flora (including
the role of pre- and probiotics), early-life feeding and formula choice in cow’s milk allergy.
2. Prevention of Food Allergy: The Role of Nutrition in the Development and Optimal
Functioning of the Immune System
Allergy results when there is a breakdown in normal “tolerance” mechanisms, which leads to
inappropriate and detrimental immune responses to normally harmless substances, including food
allergens such as cow’s milk protein, eggs, nuts, or shellfish [7]. At birth, the immune system is
immature, but it develops with age, antigen stimulation, and appropriate nutrition [8]. In addition,
bacterial colonisation occurs during the first weeks of life, and interactions between intestinal flora
and the developing mucosa result in further development of immune responses and oral tolerance [7].
Nutrition plays a key role in the development, maintenance, and optimal functioning of immune
cells. Nutrients, such as zinc and vitamin D and nutritional factors, such as pre- and probiotics, can
influence the nature of an immune response and are important in ensuring appropriate functioning of
the immune system, as described in the paragraphs below.
2.1. Fat
Appropriate fat intake may become seriously compromised in allergen-restricted diets and may
be further influenced by the “westernized” dietary practices. The role of fat on the immune system
can be divided into the role of saturated vs. unsaturated fats and the particular role of the essential
fatty acids.
2.1.1. Saturated vs. Unsaturated Fats
It has been reported that typical western diets rich in protein and saturated fat and low in complex
carbohydrates may negatively affect the diversity of the gut microbiome [9]. This was supported
by David et al. [10], showing that an animal-based diet high in protein and fat, with very little
fibre intake, resulted in increased abundance of bile-tolerant microorganisms (Alistipes, Bilophila, and
Bacteroides) and decreased levels of Firmicutes that metabolize dietary plant polysaccharides (Roseburia,
Eubacterium rectale, and Ruminococcus bromii) within a five-day period. A recent review also concluded
that the amount, type (e.g., unsaturated vs saturated), and mixture of dietary fats can dramatically
shift gut microbial community membership and function [11]. In addition, high fat, high sugar diets
also affect the gut barrier function in mice, as demonstrated by high horseradish peroxidase (HRP)
influx, lower portal vein endotoxin levels and decreased goblet cell numbers [12]. The gut barrier
function may be permanently affected in non-IgE mediated food allergies, and temporarily affected
during allergen exposure in IgE mediated food allergies [13,14].
2.1.2. Essential Fatty Acids (EFAs)
EFAs are important immune regulators. Linoleic acid (LA), the parental n-6 polyunsaturated
fatty acid (PUFA), is converted into arachidonic acid (AA) by fatty acid elongase and desaturase,
and subsequently may give origin to pro-inflammatory and pro-allergic lipid mediators, whose
collective name is eicosanoids [15]. In contrast, α-linolenic acid (ALA), an n-3 PUFA, is converted
in the mammalian body to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which
are subsequently converted into anti-inflammatory and/or pro-resolving lipid mediators (such as
resolvins and protectins). EPA forms the precursors of the 3 series of prostaglandins and the 5 series of
leukotrienes, which are biologically less powerful than the corresponding derivatives which form the
n-6 compounds. Because n-3 and n-6 PUFAs compete for the same metabolic pathways, an increase of
n-3 PUFA, parallel to a decrease of n-6 PUFA intake, might theoretically reduce the onset of human
immunologic conditions, including allergies, thanks to the replacement of AA with EPA and DHA in
the membranes of inflammatory cells. EFA, including long-chain PUFAs, may be consumed as part
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of the normal diet through breast milk, formula and food, or as supplements at any stage in the life
cycle [15].
The fatty acid status is of particular concern in infants and children. Essential fatty acids (EFA)
promote the renewal of the protective hydrolipidic film layer of the skin and, accordingly, an altered
EFA metabolism has been associated with the pathogenesis of atopic dermatitis (AD). Moreover,
the clinical spectrum of EFA deficiency may range from mild skin irritation to life-threatening
conditions [16].
In spite of intensive research in the field, a recent systematic review [17] concerning the role of
dietary PUFAs in the development of allergy shows that PUFA supplementation in infancy seems
not to affect infant incidence, childhood incidence or childhood prevalence of food allergy (GRADE
level of evidence: very low; GRADE, Grading of Recommendations Assessment, Development and
Evaluation) in infants up to two years of age, even taking into account a moderate heterogeneity
between studies that reported infant incidence of food allergy (3 studies; 915 infants; RR (risk ratio)
0.81, 95% CI 0.56–1.19%, I2 (fraction of variance due to heterogeneity) = 63%; RD (risk difference)
0.02, 95% CI: 0.06–0.02%, I2 = 74%). However, while well-documented immunomodulatory effects of
n-3 PUFAs (both in vitro and in vivo) highlight the potential role in preventing and treating allergic
disease, larger longitudinal intervention studies are clearly warranted to confirm this observation [18].
2.2. Zinc
Children with food hypersensitivity have increased amounts of mastocytes, eosinophils and
neutrophils in the digestive tract. Persistent exposure to allergen can lead to chronic inflammatory
changes of mucous membrane and increased production of reactive oxygen species (ROS) [19]. Excess
ROS should be neutralized by components of the antioxidative barrier. Therefore, all disturbances
of enzymatic and non-enzymatic mechanisms of this barrier lead to many unfavourable reactions,
including oxidation of cell membrane lipids. Zinc is an essential trace element and it is needed
for various cellular functions; specifically, it is a cofactor of many enzymes, including superoxide
dismutase (SOD), which play an important role in maintaining the oxidative-antioxidative balance.
A study performed in 134 children with food allergy, aged 1 to 36 months, showed that children with
food allergy had significantly lower concentrations of zinc, and therefore a weakened antioxidative
barrier [19]. To our knowledge there are no randomized controlled trials (RCTs) investigating zinc
supplementation and allergic outcomes.
2.3. Vitamin D
The classical role of Vitamin D is, in fact, related to calcium homeostasis and bone health. However,
over the last decade, the effects of vitamin D on the innate and adaptive immune system have been
investigated and expanded [20]. The active form of the vitamin, i.e., 1,25(OH)2D (calcitriol), has
effects on epithelial cells, T cells, B cells, macrophages and dendritic cells. It stimulates innate immune
responses by enhancing the chemotactic and phagocytotic responses of macrophages, as well as the
production of antimicrobial proteins such as cathelicidin. This action plays a role in maintaining
mucosal integrity by stimulating junction genes. Nevertheless, the potential effect of vitamin D on
Th1/Th2 adaptive immune response is of interest and related to food allergy [21–23]. Almost all cells
of the adaptive immune system express the vitamin D receptor, making them also capable of being
vitamin responsive. When specifically considering a potential role for vitamins in food allergy, vitamin
D has been shown to affect several mechanisms that promote immunologic tolerance, including T
regulatory cell function and the induction of tolerogenic dendritic cells. However, clinical trials on
vitamin D supplementation in children and the possible role in preventing food allergy are lacking.
A systematic review of vitamin D supplementation for the prevention of allergic diseases found no
evidences about the protective role of this nutrient in children, but the currently available data are
poor [24].
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2.4. The Role of Prebiotics, Probiotics and Microbiota in the Prevention of Food Allergy
The innate immune system has the ability to modulate adaptive immune responses to food
proteins. Therefore, the type of gastrointestinal microbiota of the newborn and the preservation
of intestinal permeability is crucial for preventing the development of food allergies. The dietary
modulation of nutritional factors through pre-, pro- and synbiotic preparations represent a novel
research hypothesis and a challenge for dietitians and paediatric allergists. The modulation of the
immune system using functional foods is a promising research hypothesis in the attempt to induce a
tolerogenic immune environment [16].
2.4.1. Prebiotics
Prebiotics have been defined as “non-digestible food components that beneficially affect the host
by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon
and thereby improving host health”, and recently redefined as “a selectively fermented ingredient that
allows specific changes, both in the composition and/or activity in the gastrointestinal microbiota that
confers benefits” [25]. In December 2016, the panel of experts convened by the International Scientific
Association for Probiotics and Prebiotics (ISAPP) suggested a new definition, i.e., “a substrate that is
selectively utilized by host microorganisms conferring a health benefit” [26]. Based on the body of
available evidence, the Guidelines for Atopic Disease Prevention (GLAD-p) panel concluded that it is
likely that prebiotic supplementation in infants reduces the risk of developing recurrent wheezing and
possibly also the development of food allergy. However, there is very low certainty that there is an
effect of prebiotics on other outcomes, other than an indirect effect due to its effect on the microbiome.
In fact, their activity can be affected by many individual factors, (e.g., host’s microbiota or the genetic
predisposition to diseases). Environmental factors such as diet or antibiotics can also influence the use
of prebiotics [26].
2.4.2. Probiotics
Probiotics are living microorganisms that have been proposed as immune-modulators of the
allergic response by affecting phagocytosis and production of pro-inflammatory cytokines, and thus
have been advocated as therapeutic and preventive interventions for allergic diseases [27]. They
are present in everyday food (not only in yoghurt or fermented milk, but also in cheese—either
hard or soft—and also in less expected sources such as kefir, miso soup or tempeh) and they are a
common exposure in almost everyone’s life [27]. The probiotic effects of complex oligosaccharides in
human milk promote the establishment of a bifidogenic microbiota which, in turn, induces a milieu
of tolerogenic immune responses to foods. Earlier studies suggested a positive effect of probiotic
interventions on atopic dermatitis, but meta-analyses have failed to confirm it.
The new World Allergy Organization (WAO) guidelines determined that it is likely that probiotic
supplementation in infants reduces the risk of developing eczema and suggested that probiotics should
be recommended in mothers of high-risk infants and in infants at high risk of allergic disease, where
“high risk for allergy in a child” is defined as having a biological parent or sibling with an existing or
history of allergic rhinitis, asthma, eczema, or food allergy [27]. The recommendations are conditional,
and based on very low-quality evidence, with no specific recommendation regarding strains, dose,
treatment duration etc.
In terms of tolerance development in those with established food allergy, one study from Australia
performed oral immunotherapy (OIT) to peanut in combination with Lactabillus GG, showing that
89.7% of the study participants in this arm were desensitized to peanut. The authors speculate that this
protective effect may be seen because of the possible effect of the probiotic on T regulatory cells [28].
Further scientific confirmation is required to include probiotics and prebiotics in the therapeutic plans.
Practical implications and how this should be incorporated in advising food allergy sufferers are
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also unclear in terms of advising regular intake of foods high in short-chain fructo-oligo saccharides,
fermented foods and yoghurts.
3. The Role of Allergen Intake and Dietary Diversity in Prevention of Food Allergy
3.1. Allergen Intake
Measures to prevent allergy and food allergy have traditionally included maternal allergen
avoidance during pregnancy and/or lactation, periods of exclusive breast feeding and avoidance
of potential allergens, including food and environmental antigens, during the first year of life and
beyond [29]. The value and significance of food avoidance for preventive purposes has been completely
reconsidered in recent years.
On the contrary, an ideal age to introduce potentially allergenic foods into an infant’s diet has
been debated for the past 2 decades, particularly in high-income countries where allergic disease has
become highly prevalent. Initial approaches to primary prevention of food allergy largely focused
on “avoidance” strategies. In 2000 [30], practice guidelines generally recommended that allergenic
foods (such as egg, cow’s milk, and peanut) be avoided during the first 1 to 3 years of life. As data
accumulated from both observational studies and experimental models, it became apparent that
avoidance practices may not be beneficial.
Given the increasing interest in the role of time of introduction of allergic food into the infant diet
(the so-called “window of opportunity”) and the risk of allergic diseases, intervention trials evaluating
the intake of food, as milk, egg, peanuts, etc., during the first year of life have been performed.
For instance, a recent RCT found no evidence that regular egg intake from age 4 to 6.5 months
substantially alters the risk of egg allergy by age 1 year in infants who are at hereditary risk of allergic
disease and had no eczema symptoms at study entry [31]. These findings are generally supportive
of other data in high-risk patients showing a risk-reducing benefit for early egg introduction, and
risk-reducing benefit for early peanut introduction [32]. The EAT study [33] also showed a reduced risk
in the general population using the per protocol analysis, but not the intention to treat analysis. For
peanut, clinical practice guidelines in the US have incorporated these findings and do recommend early
peanut introduction in the first year of life for high- and standard-risk children [34]. However, despite
some evidence for early introduction of egg, the US guidelines only made recommendations regarding
peanut intake, and concluded that there was not enough evidence to suggest early introduction of
egg. Surprisingly, the UK COT report [35], published very recently, suggested that all foods should
be introduced after a period of exclusive breast feeding from 6 months and that there is no need to
introduce peanut or egg differently from other foods. It seems as if despite the data from recent RCTs
on peanut and egg, the weaning debate will continue, as there is still no consensus about the age
of introduction of these foods. The only consistent messages are: start weaning once the infant is
developmentally ready; don’t delay introduction of allergens: once they are introduced into the diet,
continue to feed them.
3.2. Diet Diversity and Other Related Factors
3.2.1. Dietary Diversity
Recent findings on the protective effect of an increased diversity of food introduced in the first
year of life on allergic diseases (asthma, atopic dermatitis, food allergy and atopic sensitisation) are
consistent with the hypothesis that exposure to a variety of food antigens during early life might be
important for the development of immune tolerance [36–38].
The microbiome plays an important role in ensuring the gut wall integrity and regulation of the
immune system. Diet diversity has been shown to reduce allergic diseases [36,38]. It may well be
that the more diverse diet leads to a more diverse microbiome [39], and that natural microbial load of
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food enhances this process [40]. This in turn may improve the gut wall integrity and regulation of the
immune system, but human trials are needed to confirm this theory.
3.2.2. Food Production
Food production and cooking methods, inclusive of canning, putting food in pouches, producing
“ready to eat” foods, may affect the natural microbioal load of food and hence the immune system as it
may affect the microbiome and, possibly, the allergic response.
Lang et al. [40] reported that the microbial load of different diets (e.g., USA diet vs. vegan diet)
differs due to the foods excluded and cooking methods used. Chaturvedi, et al. [41] reported that the
natural microbial load of fruits and vegetables differ between groups from a different socio-economic
status. In addition, Venter and Maslin reported an association between an increase in baby food sales
and allergic diseases [42], underlining that commercial baby foods are sterile and that the diversity
of ingredients and nutrient content is variable. All these factors highlight that the foods we eat
(irrespective of their nutrient content) may affect the immune system and perhaps development and
management of allergic diseases.
3.2.3. Healthy Diet
It is unclear at present what a “healthy diet” in terms of allergy prevention and management
means, and if a healthy diet as we know it (20% protein, 50% carbohydrate, 30% fat) has any relevance
in allergy prevention. Currently, either the healthy eating index [43] or a Mediterranean-style diet [44]
is being used as a proxy measure for healthy eating. Research using the healthy eating index tool,
specific to the pregnancy diet, found no association between overall healthy eating score and recurrent
wheeze in infants at the age of 3 years [43], and this was confirmed in another study by Moonesinghe et
al. focusing on eating patterns in pregnancy and allergic diseases [45]. In addition to these two studies,
two review papers addressed the issue of the Mediterranean diet on allergy prevention. Venter et al.
summarised studies during pregnancy [46]. Three observational studies have investigated the role of
the Mediterranean diet on allergy outcomes. One study showed a possible increased risk for the infant
to develop allergic disease [47], one showed a reduction in wheeze [48], and another study showed no
effect on allergy prevention [49]. Mediterranean style eating patterns shows more promising effects
with reduction in asthma/wheezing symptoms seen but no effect on other allergic symptoms [44].
More studies are therefore needed with well-defined criteria for healthy eating to study its effect on
allergy prevention.
3.2.4. Other Factors
More recently, the role of advanced glycosylated end products in food and the direct effect on
the Th2 immune system and the microbiome has been described [50]. One mouse model study also
questioned the role of emulsifiers on the gut microbiome. This study showed that a diet high in
emulsifiers destroyed the epithelial mucous layer in the gut, altered gut microbial composition and
promoted inflammation [51].
4. The Role of Diet in the Management of Food Allergy
The cornerstone of the nutritional management of food allergies is an individualized allergen
avoidance management plan. In children, the main goals are to prevent the occurrence of acute and
chronic symptoms by avoiding the offending food(s), whilst providing an adequate, healthy and
nutritionally balanced diet and maintaining optimal growth; ideally, under the guidance of a trained
dietitian [52]. Complete avoidance of the allergen is still required by some, but latest developments
in food allergy have indicated that some individuals with food allergies tolerate baked forms of milk
and egg [53]. Additionally, complete avoidance of all nuts is not necessarily recommended anymore,
and only those nuts reacted to should be eliminated from the diet [54]. In addition to nutritional
consequences of food allergy, it is known that children and families with food allergies experience a
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decreased quality of life across a number of domains, which can create anxiety and lead to avoidance
of social situations [55–58]. Hence, it is suggested that liberalisation of the diet, when appropriate and
safe, will increase both quality of life and nutritional intake.
4.1. Cow’s Milk Allergy
Exclusion of any food group can result in a nutritionally deficient diet, but the elimination of milk
and products in infancy is particularly likely to cause nutritional deficiencies [59] and deserves special
emphasis. Cow’s milk proteins (CM) are among the first foods introduced into an infant’s diet, and
accordingly they represent one of the first and most common causes of food allergy in early childhood.
Cow’s milk allergy generally requires a strict exclusion diet, usually for the first year of life. This
exclusion of a main food group occurs at a critical time in the development of food preferences and
eating habits. The management of CMA (cow’s milk allergy) in infants and young children requires
individualized advice regarding avoidance of cow’s milk, including advice to breastfeeding mothers
and/or guidance on the most appropriate specialized formula or milk substitute [60]. In many cases,
micronutrient supplements will also be required; however, their usage is not always intuitive with
both under- and over-supplementation occurring [61].
Cow’s milk proteins could induce an allergic reaction: in particular beta-lactoglobulin (BLG),
included in the whey fraction, is not present in human milk, and is therefore is considered the principal
component involved in the etiology of the disease. During the production of infant formula, only the
processes of extensive hydrolysis, ultrafiltration or an enzymatic cleavage result in truly hypoallergenic
formulas [16].
4.1.1. Choice of Formula in CMA
The nutritional value of a milk substitute must be taken into account at ages lower than 2 years
of life, when such a type of food is needed and may represent the only source of nutrients in
the first months of life [16]. As breast milk composition differs both in component ratios and
structure from other milks, the composition of infant formula should serve to meet the particular
nutritional requirements and to promote normal growth and development of the infants for whom
they are intended [62,63]. When a replacement formula is needed, allergologists can avail themselves
of different types of formula [64]. The alternative formulas considered for CMA are extensively
hydrolysed whey or casein formula (eHWF or eHCF), and amino acid-based formula (AAF), which
are considered to be of low antigenic potential and are therefore preferred in highly allergic children.
The unpalatable taste of hydrolysed formulas has often been associated with reduced intakes and
a consequent growth faltering in infants fed these types of formula, particularly in the first year of
life [59].
In recent years, an alternative explanation has been proposed based on the content of free amino
acids (FAAs) in hydrolysed formulas, added to complete their biologic value. Glutamic acid, in
particular, has been suggested to downregulate appetite during feeding by interacting with specific
receptors in the oral cavity and gastrointestinal tract. However recent studies have shown no negative
effect of feeding AA formulas in infants; on the contrary, they may be beneficial for growth [65].
Other studies have demonstrated that dietary management with extensively hydrolysed
casein-based formula (eHCF) supplemented with the probiotic Lactobacillus rhamnosus GG (LGG)
results in a higher rate of tolerance acquisition in infants with CMA than in those treated with
eHCF without supplementation or with other non-casein-based formulas. The mechanistic basis
for this effect could be the possible influence of eHCF+LGG on the strain-level bacterial community
structure of the infant gut [66]. However, randomised controlled trials to date have not yielded
sufficient evidence to recommend probiotics for the primary prevention of allergic disorders. Indeed,
the Nutrition Committee of the European Society for Paediatric Gastroenterology Hepatology and
Nutrition (ESPGHAN) does not support routine supplementing with probiotics in infant formulas [67].
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Soy protein-based formula may be an option in infants older than 6 months who do not accept
the bitter taste of an eHCF, or in cases in which the higher cost of an eHCF is a limiting factor [68].
However, soy formulae have nutritional disadvantages. Absorption of minerals and trace elements
may be lower because of their phytate content. They also contain appreciable amounts of isoflavones,
with a potentially weak estrogenic action that can lead to high serum concentrations in infants. Also,
the possible derivation from genetically modified soy should be considered. Hence, the European
Society of Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) and the American
Academy of Pediatrics (AAP) recommend that cow’s-milk-based formulas should be preferred over
soy formulas in healthy infants, and soy protein-based formulas should not usually be used during
the first 6 months of life [68].
Other mammal’s milks, those of, goats, ewes, mares, donkeys, or camels, have been proposed
as substitutes in the management of CMA in infants and children, but are NOT recommended, due
to either nutritional issues, cross-reactions or both. The Diagnosis and Rationale for Action against
Cow’s Milk Allergy (DRACMA) guidelines state that milk allergens of various mammalian species
cross-react [16]. The greatest homology is found between cow’s, buffalo’s, sheep’s and goat’s milk
proteins. Proteins in their milks have less structural similarity with pig, horse, donkey, camel and
dromedary. Goat’s, buffalo’s and ewe’s milk are particularly not recommended by the World Allergy
Organization due to cross-reactivity with cow’s milk [16]. The tolerance of other mammalian milks
needs to be further investigated in clinical trials, and there are some concerns about their chemical
composition and sanitation. In conclusion, either amino acid-based formulas or eHCFrepresent the
most available solutions for allergic infants who are no longer breast-fed. The therapeutic interventions
should therefore be indicated on an individual basis.
5. Conclusions
Food allergy represents a significant health burden at either an individual and population level
worldwide. Recent guidelines for the prevention of food allergies advocate that there is no need to
delay the introduction of allergenic foods once weaning has commenced. In terms of food allergy
management (end even prevention), individualised strategies should be implemented. These strategies
will include developmental readiness to be weaned, prevalence of particular food allergies in certain
countries, family eating patterns and availability of physician and dietetic care.
Care should be taken to ensure adequate intake of nutrients, particularly in relation to cow’s milk
allergy, when selecting a suitable hypoallergenic formula. There is emerging evidence regarding the
role of fats (particularly EFAs), pre-/probiotics, commercial foods, healthy eating and micronutrients
on food allergy. A better understanding of how nutrients and other aspects of food, food patterns and
food preparation may affect the immune system and allergy outcomes is required to best advise those
at risk of developing food allergies and those with current food allergies.
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67. Lis-Święty, A.; Milewska-Wróbel, D.; Janicka, I. Dietary strategies for primary prevention of atopic—What
do we know? Dev. Period Med. 2016, 20, 68–74. [PubMed]
68. Koletzko, S.; Niggemann, B.; Arato, A.; Dias, J.A.; Heuschkel, R.; Husby, S.; Mearin, M.L.; Papadopoulou, A.;
Ruemmele, F.M.; Staiano, A.; et al. Diagnostic approach and management of cow’s-milk protein allergy in
infants and children: ESPGHAN GI Committee practical guidelines. J. Pediatr. Gastroenterol. Nutr. 2012, 55,
221–229. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Prevention and Management of Cow’s Milk Allergy
in Non-Exclusively Breastfed Infants
Yvan Vandenplas
Kidz Health Castle, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium;
yvan.vandenplas@uzbrussel.be; Tel.: +32-2-477-5780; Fax: +32-2-477-5784
Received: 11 April 2017; Accepted: 30 June 2017; Published: 10 July 2017
Abstract: Introduction: The prevention and management of cow milk allergy (CMA) is still
debated. Since CMA is much less frequent in breastfed infants, breastfeeding should be stimulated.
Method: Literature was searched using databases to find original papers and reviews on this topic.
Results: Hydrolysates with a clinical proof of efficacy are recommended in the prevention and
treatment of CMA. However, not all meta-analyses conclude that hydrolysates do prevent CMA or
other atopic manifestations such as atopic dermatitis. There are pros and cons to consider partially
hydrolysed protein as an option for starter infant formula for each non-exclusively breastfed infant.
A challenge test is still recommended as the most specific and sensitive diagnostic test, although a
positive challenge test does not proof that the immune system is involved. The Cow Milk Symptom
Score (CoMiSS™) is an awareness tool that enables healthcare professionals to better recognize
symptoms related to the ingestion of cow milk, but it still needs validation as diagnostic tool.
The current recommended elimination diet is a cow milk based extensive hydrolysate, although rice
hydrolysates or soy infant formula can be considered in some cases. About 10 to 15% of infants
allergic to cow milk will also react to soy. Mainly because of the higher cost, amino acid based
formula is reserved for severe cases. There is no place for infant formula with intact protein from
other animals as cross-over allergenicity is high. During recent years, attention focused also on the
bifidogenic effect of prebiotics and more recently also on human milk oligosaccharides. A bifidogenic
gastrointestinal microbiome may decrease the risk to develop allergic disease. The addition of
probiotics and prebiotics to the elimination diet in treatment may enhance the development of
tolerance development. Conclusion: Breastfeeding is the best way to feed infants. Cow milk based
extensive hydrolysates remain the first option for the treatment of CMA for the majority of patients,
while amino acid formulas are reserved for the most severe cases. Rice hydrolysates and soy
infant formula are second choice options. Partial hydrolysates with clinical proof of efficacy are
recommended in some guidelines in the prevention of CMA and allergic disease in at risk infants,
and may be considered as an option as protein source in starter infant formula.
Keywords: cow milk allergy; hydrolysate; infant formula; functional gastrointestinal disorder;
prevention; treatment
1. Introduction
This manuscript discusses the prevention and management of cow’s milk allergy (CMA) in
non-exclusively breastfed infants. CMA is an adverse health effect arising from a specific immune
response that occurs reproducibly on exposure to a protein present in cow milk. Breastfeeding is the
first choice feeding for infants, and allergic and functional gastrointestinal disorders occur more often
in non-exclusively breastfed than in breastfed infants. The prevalence of allergic diseases involving
the gastrointestinal (GI) tract, respiratory tract and the skin is likely to be rising worldwide [1]. Food
allergy is a growing health concern in the westernized world with approximately 6% of children
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suffering from it [2]. CMA is one of the most frequent causes of food allergies in young children with
an estimated prevalence between 1.9% and 4.9% in the first year of life [3,4]. Whether there has also
been an increase in CMA has not been thoroughly studied [5]. According to a report from Denmark,
CMA is up to half of the allergic children immunoglobulin E (IgE) mediated [6]. The risk to develop
allergic disease is multifactorial. Recent evidence suggests that low blood vitamin D level is a risk
factor for food allergy; vitamin D deficiency predisposes to GI infections, which may promote the
development of food allergy. Several data suggest that serum 25-hydroxyvitamin D levels are often
insufficient in children with asthma, atopic dermatitis, and food allergy [7]. There is no evidence
that supplementation of poly-unsaturated fatty acids in infancy has an effect on infant or childhood
allergy, asthma, dermatitis/eczema or food allergy [8]. Many infants present with symptoms related
to milk ingestion. The most frequent symptoms and signs related to CMA are listed in Table 1. Both
IgE and non-IgE mediated CMA exist. Allergic symptoms must be reproducible. The involvement
of the immune system in non-IgE mediated allergy is difficult to demonstrate. Non-IgE mediated
allergy is the cause of symptoms in a subset of patients with “hypersensitivity”. Sometimes the
symptoms caused by ingestion of milk are very likely to be immune mediated, as in the case of atopic
dermatitis improving during a cow milk elimination diet. However, in the case of GI symptoms, such
as regurgitation, constipation or general symptoms such as crying or distress, the involvement of
the immune system cannot (easily) be demonstrated. . It is likely that there is overlap between the
latter and functional GI symptoms. Experts agreed that the likely prevalence for colic, regurgitation,
and functional constipation is 20%, 30% and 15%, respectively [9]. The perception of parents that an
infant may have cow milk related symptoms is much greater than the reported incidence of CMA
since parents report an incidence of up to 17% [10]. The relationship between some of these common
symptoms of infancy and CMA is not clear. The best example may be upper respiratory tract symptoms
which can seldom be related to CMA, but most frequently are caused by viral infections. It is only in
a minority of infants that functional GI symptoms such as regurgitation, constipation and colic are
of allergic origin. Intolerance is the consequence of lactase deficiency, the brush border enzyme that
digests lactose, the predominant sugar in milk, and is almost always secondary to another condition
in young infants. The meaning and definition of a “hypo-allergenic formula” varies in different
parts of the world. While in Europe a “hypo-allergenic formula” means a formula that contains
hydrolyzed protein and thus a reduced allergenicity, the American Academy of Pediatrics defined it
as a formula that is effective in the treatment of at least 90% of the children with CMA, with a 95%
confidence interval. It has to be recognized that an extensive hydrolysate is “tolerated” by the vast
majority of CMA-patients but that such an elimination diet is not really “treatment” as the elimination
diet does not change the immune response. Oral immunotherapy or anti-IgE actually modify the
individual propensity to react to cow’s milk and are therefore therapeutic. However, since most
literature, including guidelines, recommend the use of extensive hydrolysates as first choice in the
management, “treatment” is used in this context.
Tolerance of cow milk will have developed in 85% to 90% of the infants with CMA by the age of
three years. High IgE levels predict a longer persistence of allergic reactions to cow milk. In particular,
GI symptoms show a good prognosis, suggesting again an overlap between functional GI symptoms
and CMA [3,6]. However, most of the information on the natural evolution of CMA comes from
tertiary care or specialized centers and only the most severe cases are seen in these centers. This means
that data on the natural evolution of CMA at the primary healthcare level are missing.
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Table 1. Symptoms and signs related to CMA.
General
• Anaphylaxis
• Food protein induced enterocolitis syndrome (FPIES; shock-like symptoms with severe metabolic acidosis,
vomiting and diarrhea)
Gastro-Intestinal
• Failure to thrive, anorexia, refusal to feed, early satiety
• Dysphagia, dyspepsia
• Abdominal pain, colic
• Nausea, regurgitation, emesis
• Diarrhea with or without protein loss or bleeding
• Constipation with or without perianal rash
• Iron-defeiciency anemia due to occult blood loss
Respiratory
• Respiratory distress
• Runny nose, chronic coughing
• Wheezing/stridor
Dermatological
• Urticaria, atopic eczema, angioedema.
2. Methods
The PubMed and Cochrane Library databases were searched up to July 2016. The searches were
limited to human studies and to studies published in English. Only published data were considered.
3. Prevention
The allergic march describes the order in which atopic disease develops, starting with atopic
dermatitis followed by asthma to end with rhinoconjunctivitis [11]. The development of atopic disease
is influenced by environmental and genetic, thus epi-genetic, confounders.
Two meta-analyses including selected papers on one partial hydrolysate conclude that selected
partially and extensive hydrolyzed infant formula may prevent the development of atopic dermatitis
and possibly that of CMA [12,13]. Boyle et al concluded in a meta-analysis including much more
trials (37 compared to 11 and 15 [14]) that overall there was no consistent evidence that partially or
extensively hydrolysed formulas reduce risk of allergic or autoimmune outcomes in infants at high
pre-existing risk of these outcomes [14]. Odds ratios for eczema at age 0–4, compared with standard
cows’ milk formula, were 0.84 (95% confidence interval 0.67 to 1.07) for partially hydrolysed formula;
0.55 (0.28 to 1.09) for extensively hydrolysed casein based formula; and 1.12 (0.88 to 1.42) for extensively
hydrolysed whey based formula [14]. A large study with a negative outcome with a different partial
whey hydrolysate than the one included in the above mentioned two meta-analyses contributes largely
to these findings [15]. These findings also suggest that outcomes obtained with one hydrolysate may
not be extrapolated to another hydrolysate, and that findings are hydrolysate-specific. According
to Boyle et al, there is no evidence to support the health claim approved by the US Food and Drug
Administration that a partially hydrolysed formula could reduce the risk of eczema nor the conclusion
of the Cochrane review that hydrolysed formula could allergy to cows’ milk [14]. This is only partially
confirmed by the recent Cochrane review reported that in infants at high risk of allergy not exclusively
breast fed, very low-quality evidence suggests that prolonged hydrolysed formula feeding compared
with CMF feeding reduces infant allergy and infant CMA ([16] -Cochrane review withdrawn). Studies
have found no difference in childhood allergy and no difference in specific allergy, including infant and
childhood asthma, eczema and rhinitis and infant food allergy [16]. Although extensively hydrolyzed
formulas (eHF) can be used in prevention, they are not considered as first option as they are much
more expensive that partially HF (pHF). Because of their bitter taste, eHF have a poor palatability.
In theory, the allergenic epitopes are destroyed in the manufacturing process of eHF. pHF has been
developed to decrease the amount of epitopes that possibly induce sensitization, while still having
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peptides of sufficient immunogenicity to induce oral tolerance. Only these pHF can be recommended
for prevention for which there are sufficient clinical data to support their efficacy, which are missing
for the majority of the commercialized pHFs. Some guidelines recommend the use of pHFs in “at risk”
infants, which are defined as infants born in a family in which at least one of the family members
(parents, brother, sister) has atopic disease. There is no consensus if this diagnosis of atopic disease
should be “doctor confirmed” or not. As a consequence of the ongoing debate some countries (e.g.,
Japan, UK, Finland, Australia) do not recommend the use of pHF to prevent allergy. There is no place
for infant formula with intact protein from different origin in the prevention of allergic disease. Soy
protein infant formula has no place in the prevention of atopic disease.
Epidemiological data show that about half of the infants that will develop allergy are not part
of this “at risk” group [17]. This is due to the fact that although the risk is lower in the non-at risk
group, the number of infants in the non-at risk group is much larger. In other words: guidelines
recommend today prevention only for half of the infants that will develop atopic disease, and not for
the other half. A recent analysis from the 15 year follow-up of the two German birth cohorts GINI-plus
and LISA-plus reported for the first time that parental allergic diseases increase the risk of childhood
allergic diseases, especially for asthma, independent on whether the first onsets was before or after the
birth of a child [18]. Knowledge on the long-term effects of pHF on growth and body composition
outcomes in healthy infants later in life is still limited [19]. There are some indications that hydrolysed
protein results in metabolic responses more distinctly different from those of human milk and different
metabolic organ development compared to intact protein [19,20]. However, FDA and EFSA regulatory
authorities consider a partially hydrolysed protein source as a protein source that can be used in starter
infant formula, irrespective of the fact if there would be some prevention of allergy or not. All studies
with pHF show no or some benefit, but never an increased risk for adverse effects. So the question
should be asked is pHF should not be considered as the best second choice infant feeding for every
infant, at least for those pHFs with clinical data supporting their efficacy (Figure 1), irrespective of
the fact if there is a preventive effect on allergy or not. Opponents to this viewpoint state that breast
milk contains intact protein, and a pHF does not. This is true. But: breast milk contains also proteases,
digesting protein. The role of these proteases is yet unknown. And breast milk does not contain intact
cow milk protein, but contains cow milk peptides. The digestion of partially hydrolysed protein may
result in different metabolites than intact protein. Whether this is clinically relevant or not, is yet
unknown. Overall, it is the opinion of the author that a partially hydrolysed protein may be considered
as an option as protein source of a starter formula for every non-exclusively breastfed infants. It then
becomes a cost/benefit discussion, which is difficult because cost of formula does vary substantially
from country to country [19].
Figure 1. Proposed dietary options according to breastfeeding and/or family history of atopic disease.
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4. Symptoms and Diagnosis
Symptoms related to cow milk intake develop usually within the first two months after its
introduction and it is unusual for CMA to develop in a child older than one year of age [21]. Symptoms
can be separated in IgE and non-IgE mediated, and according to literature the distribution can be
estimated fifty-fifty [21]. Many infants develop symptoms in two or more organ systems. Typical IgE
mediated symptoms include urticaria, angioedema, vomiting, diarrhea and anaphylaxis. Dermatitis
and rhinitis can be IgE and non-IgE mediated. Vomiting, constipation, hemosiderosis, malabsorption,
villous atrophy, eosinophilic proctocolitis, enterocolitis and eosinophilic esophagitis are non-IgE
mediated reactions. In addition, respiratory symptoms such as chronic rhinitis and asthma may be
caused by CMA [22]. Irritability, fuzziness and colic are sometimes the only symptoms of CMA [3,23].
Whether diagnostic investigations such as IgE, specific RAST and skin prick tests should be performed
depends on local facilities and routines, but they are not routinely recommended in the guidelines [3,21].
Total IgE is not helpful in the diagnosis of CMA, but the IgE level is related to the development of
tolerance: the lower the total IgE, the more rapidly tolerance develops [21]. Specific IgE and skin
prick tests may contribute to confirm the suspected diagnosis, although false positive results do
exist. The atopy patch test, which is popular in France, has not been considered as a recommended
diagnostic test in guidelines [3,21]. Negative test results do not exclude allergy [3]. Other diagnostic
tests are only possible in specialized laboratories or indicated in very distinct clinical conditions, such
as mucosal biopsies in infants presenting with blood in their stools. There is no place for the (expensive)
determination of IgG4-antibody levels as these are considered to demonstrate contact of the immune
system with the antigens but do not suggest an allergic reaction [3,21,23].
A symptom-based score, the Cow Milk Related Symptom Score (CoMiSSTM) has recently been
developed to raise awareness of symptoms related to the ingestion of cow milk [24]. A challenge test is
likely to be positive in 80% of patients if an initial score of more than 12 decreases to less than half with
an eHF [25]. Therefore, it is hoped that, when it is validated, the CoMiSSTM may become a valuable
diagnostic tool [24].
The majority of the guidelines accept an open challenge in infants suspected of CMA, although
a double-blind challenge test is considered to be the gold standard for diagnosing CMA [3,21,23].
Standardized procedures on how to perform a challenge test have been published (Table 2) [3,21,23].
A challenge test should always be performed under medical supervision, but it does not have to be
systematically performed in a hospital environment. Hospitalization is recommended if it is suspected
that acute, severe or unpredictable symptoms could occur [3]. Parents are often reluctant to perform a
challenge test, because it will make the allergic child sick again. In addition, the results of a challenge
are often difficult to interpret. While immediate reactions are relatively easy to pick up, delayed
reactions are more difficult to detect. A group of experts published a standardized double-blind
placebo-controlled food challenge [24]. This certainly has the merit to be scientifically sound but has
the disadvantage to be difficult to apply in daily practice in not experienced centers or at primary
health care level. Specifically for a cow's milk challenge, European experts have proposed an open
prolonged challenge: after a half day challenge under medical supervision, the patient returns home
and parents need to continue the challenge by providing a sufficient daily intake of at least 200 mL of
milk per day [3,21]. Indeed, about half of the children will develop a delayed reaction, which will only
be picked up if the parents are collaborating and the follow up is adequate. Double-blind challenge
tests cover only the first part of the challenge test, which is under medical supervision.
Table 2. Example of standardized protocol for open challenge test.
• Drop of formula on the lips
• If there is no reaction after 15 min, the formula is given orally and the dose is increased stepwise (0.5, 1, 3,
10, 30, 50 to 100 mL) every 30 min
• Additional observation for at least 2 h
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If negative, the infant should drink at least 200 m of cows’ milk-based infant formula each day
for the next 2 weeks and the parents should be contacted daily by a healthcare professional or should
contact a healthcare professional if symptoms occur so that a late reaction can be documented.
5. Treatment
The vast majority of infants with suspected CMA will be formula-fed and present with a
combination of the symptoms listed in the CoMiSS™ [24]. Guidelines recommend an elimination
diet with a whey or casein-based eHF with clinical proof of efficacy for two to four weeks
as the first option [3,23] (Table 3). The CoMiSS™ score can contribute to quantify clinical
improvement. Hydrolysates strengthen the epithelial barrier, modulate T-cell differentiation and
decrease inflammation [26]. Some studies suggest a role for hydrolysates in manipulating pathogen
recognition receptors signaling as underlying mechanism. Peptides from hydrolysates have been
shown to bind to TLR2 and TLR4 and influence cytokine production in epithelial cells and macrophages.
Current insight suggests that hydrolysates may actively participate in modulating the immune
responses in subjects with and those at risk to develop CMA [26]. If the symptoms do not improve,
then CMA is unlikely. The percentage of patients tolerating the eHF will depend on the selection of
patients. In eHFs, most of the nitrogen is present as free amino acids and peptides <1500 kDa [27].
During CMA treatment, allergenic peptides may be potentially harmful. Therefore, peptides that
have reduced allergenicity but are capable to induce tolerance are recommended. The World Allergy
Organization Diagnosis and Rationale for Action against Cow’s Milk Allergy (WAO-DRACMA)
guidelines recommend cow milk based eHF over soy infant formula in IgE-mediated CMA [10]. Amino
acid based formula (AAF) is recommended if formula-fed infants present with the rare condition of
anaphylaxis and in eosinophilic esophagitis, or when the child does not tolerate to the eHF and CMA
is a likely diagnosis (because failure of eHF has been reported) or when the cost/benefit analysis is in
favor of the AAF [3,21]. However, eHFs have been reported to be effective in adults with eosinophilic
esophagitis caused by cow milk [28]. If a strict AAF diet does not result in an improvement of the
symptoms, the patient does not suffer CMA. In case of anaphylaxis, the long-term management
of such infants should include a challenge with an eHF before cow milk is (re-)introduced. This
should be carried out after 6 to 9 months or when the infant is one year old and always in a hospital
environment [3,23].
Table 3. Recommended therapeutic options according to different guidelines for different symptoms
and signs of cow's milk allergy.
Australia [29] Dracma [10] Espghan [3]
1st choice 2nd choice 1st choice 2nd choice 1st choice 2nd choice
GI syndromes eHFsoy (if >6 months)
AAF
eHF eHF AAF eHF AAF
proctocolitis eHF AAF eHF AAF
Eos Eso AAF AAF AAF
Immediate FA eHFsoy (if >6 months)
AAF
eHF eHF AAF/Soy eHF AAF
FPIES eHF AAF eHF AAF eHF AAF
Atopic eczema eHFsoy
AAF
eHF eHF AAF/Soy eHF AAF
urticaria eHF AAF/Soy eHF AAF
Constipation eHF AAF
Heiner syndrome AAF eHF
If an eHF is not available, if the infant refuses to drink it or if it is too expensive, a rice hydrolysate
or a soy infant formula are considered as second choices. Since pHF has longer peptides than eHF,
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pHF may trigger symptoms in sensitized infants (3,10,23). Therefore, a cow milk based pHF is not
suitable for treating CMA. While eHF needs to be tolerated by >90% of patients, pHF will be tolerated
by less than half of infants with CMA [3].
Thickened eHF and AAF are commercially available [30,31] to treat simultaneously CMA and
infant regurgitation. Whether an eHF is thickened or not seems not to be relevant in CMA; however,
when the challenge test is negative, the thickened eHF is more effective in reducing regurgitation than
the non-thickened [30]. Up to now allergic reactions to the thickening agent in these formulas have not
been reported.
Partial and extensively rice hydrolyzed formula are commercialized and, in some parts of the
world, soy (hydrolyzed) infant formula also exists. Since rice hydrolysates are relatively new, they
are not (yet) considered in published guidelines. The clinical efficacy of rice hydrolysates, partial and
extensive, seems excellent [32,33]. Rice hydrolysates are free of CMP allergens. Rice hydrolysates are
less expensive than cow milk based eHF. The content of arsenic in rice may be a safety issue limiting
the use of rice. There is an FDA warning against the use of rice in infants and young children regarding
rice feed thickeners and rice cereals. Therefore the arsenic content in rice based infant formula should
be determined and declared on the label [34]. The arsenic content in infant formula is reported to be
within the safety limits. Other mammalian milks such as sheep milk and goat milk are not indicated
in the treatment of CMA [3]. Infant formulas based on goat milk are on the market in a substantial
number of countries, but the high incidence of cross-reactivity in CMA patients results in the fact that
they cannot be recommended for infants with CMA [35]. Significant cross-sensitization to milk proteins
derived from kosher animals exist in patients allergic to CMP, but far less so than the milk proteins
tested from non-kosher animals [35,36]. Camel and mare milk have not been evaluated as possible
options [37–39], but ass milk in particular has been shown to be effective in treating CMA [40,41].
The DRACMA guidelines even recommend donkeys milk as third option in constipation due to CMA.
However, none of these alternative options fulfill the nutritional and compositional requirements for
infant formula and as a result they cannot be recommended in the treatment of CMA. Consumption
of unprocessed cow milk in young infants protects against respiratory infections [42]. However,
unprocessed cow milk can as well not be recommended in infants for nutritional reasons. The epitopes
in raw, cooked or baked milk differ [43] as baked milk was reported to be tolerated in patients with
eosinophilic esophagitis as presentation of CMA [43]. Although use of hypoallergenic baked milk in
oral immune therapy is a promising therapy, care must be taken before its administration in baked
milk-reactive patients because of the risk for anaphylaxis and only limited increase in challenge
threshold attained [44].
Soy infant formula has existed for longer than one century, but its popularity varies greatly [23].
The Agence Française de Sécurité Sanitaire des Aliments drew attention to the presence of isoflavones
and their unknown impact on infant health. Isoflavones have been shown to induce estradiol-like
effects in animal models [45]. The American Academy of Pediatrics reviewed the literature and
summarized that 10% to 14% of infants with CMA will become soy-sensitized, with a higher incidence
in non-IgE mediated CMA than in IgE mediated CMA [46]. According to a recent meta-analysis,
the prevalence of soy allergy was 0.5% in the general population, but the prevalence of sensitization
after the use of soy infant formula was 8.7% [47]. Therefore, it seems logic today to recommend a
clinically tested eHF as first option in the management of CMA, and to recommend rice hydrolysates
as a second option and soy as third option.
A lack of effective and approved treatment has led to strict avoidance of the culprit food proteins
being the only standard of care [2]. Several food immunotherapies are being developed; these
involve oral, sublingual, epicutaneous, or subcutaneous administration of small amounts of native or
modified allergens to induce immune tolerance [2,48]. Oral immunotherapy is a promising but still
experimental method to treat children with cow’s milk allergy [49]. The approach generally follows
the same principles as immunotherapy of other allergic disorders and involves the administration
of small increasing doses of food during an induction phase followed by a maintenance phase with
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regular intake of a maximum tolerated amount of food [50]. Most research has been conducted with
oral immunotherapy due to its efficacious and relatively safe profile but remains an investigational
treatment to be further studied before advancing into clinical practice [2,48]. Determination of IgE
and IgG4 epitope binding may contribute to select candidates for oral immune therapy [51]. Oral
immune therapy carries significant risk of allergic reactions [51]. The ability of oral immune therapy to
desensitize patients to particular foods is well-documented, although the ability to induce tolerance
has not been established [51]. Recent data suggest that oral immune therapy may induce long term
tolerance in half of the children [52]. Markers of allergy such as blood eosinophils and serum IgE
decreased and milk-specific IgG and IgG4 increased during oral immune therapy [49]. Adipokines,
leptin and resistin, which functionally are cytokines linked to Th1-type response, increase during oral
immune therapy [49]. The high frequency of allergic adverse reactions of the various approaches
highlighted the need of refinements in the strategies. A careful review of the patients who received
food oral immune therapy in controlled trials confirmed that adverse events were not rare but that
~90% of children could achieve an effective desensitization [53]. A promising strategy for preventing
IgE cross-linking and thus enhancing safety of immune therapy, while still activating T cells, is the
use of tolerogenic peptides [2]. Additional bigger, multicentric and randomized-controlled studies
must answer multiple questions including optimal dose, ideal duration of immunotherapy, degree of
protection, efficacy for different ages, severity and type of food allergy responsive to treatment [48].
The procedure remains investigational and should be performed only by trained physicians, especially
in the pediatric setting [53]. Immunotherapy for food allergy is still not ready for the clinic, but current
and upcoming studies are dedicated to collect enough evidence for the possible implementation of
allergen-SIT as a standard treatment for food allergy [2].
6. Gut Microbiota
The role of the GI microbiota in food allergy has been a topic of major interest since many years.
Oral tolerance is the consequence of a systemic absence of a response to dietary antigens. Early infancy
is a window during which gut microbiota may shape food allergy outcomes in childhood [54]. Dietary
antigens and intestinal microbiota are known to make up the majority of the antigen load in the
intestine. The GI microbiome plays a strong role in the orientation of the immune response [55].
Food allergy is associated with alterations in the gut microbiota or dysbiosis early in life that may
be predictive of disease persistence versus tolerance acquisition [56]. Qualitative and quantitative
differences in the composition of the gut microbiota between infants who will and infants who
will not develop allergy are demonstrable before the development of any clinical manifestations of
atopy [57,58]. Gut microbiome composition at age 3 to 6 months was associated with acquisition
of tolerance to milk proteins by age 8 years, with enrichment of Clostridia and Firmicutes in the
infant gut microbiome of subjects with resolved CMA [54]. Metagenome functional prediction
supported decreased fatty acid metabolism in the gut microbiome of subjects whose CMA resolved [54].
As a consequence, bacterial taxa within Clostridia and Firmicutes could be studied as probiotic
candidates for milk allergy therapy [54]. Data obtained in murine models of food allergy suggest that
microbial therapy with protolerogenic bacteria such as certain Clostridial species holds promise in
future applications for prevention or therapy of food allergy [59]. Extrapolation from in vitro data
suggests that supplementing infant formulas such as eHF with prebiotics or probiotics (Lactobacillus
(L.) rhamnosus GG, Bifidobacteria (B.) breve) may offer an additional benefit [60].
6.1. Prebiotics
Dietary supplementation with short chain galacto-oligosaccharides (scGOS), long chain
fructo-olgosaccharides (lcFOS) and/or pectin-derived acidic oligosaccharides during sensitization
effectively reduce allergic symptoms but differentially affect mucosal immune activation in
whey-sensitized mice [61]. A beneficial effect of prebiotics on the development of atopic dermatitis
in a high risk population of infants was shown for the first time in this paper [62]. Although the
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mechanism of this effect requires further investigation, it appears likely that oligosaccharides modulate
postnatal immune development by altering bowel flora and have a potential role in primary allergy
prevention during infancy [63]. These findings were confirmed by demonstrating that early dietary
intervention with oligosaccharide prebiotics has a protective effect against both allergic manifestations
and infections [64]. Later, this effect was also shown in non-at-risk infants [63]. The observed
dual protection lasting beyond the intervention period, up to the age of five years, suggests that an
immune modulating effect through the intestinal flora modification may be the principal mechanism
of action [60,63]. This mechanism has now been demonstrated [64].
The addition of lactose to an eHF is able to positively modulate the composition of gut microbiota
by increasing the total fecal counts of L/B and decreasing that of Bacteroides/Clostridia [65]. The
positive effect is completed by the increase of median concentration of short chain fatty acids, especially
for acetic and butyric acids demonstrated by the metabolomic analysis [66]. However, the ESPGHAN
Committee on Nutrition concluded in 2011 that there was insufficient evidence to recommend the use
of prebiotics in infant formula to prevent atopic disease [67]. But, based on GRADE evidence to decision
frameworks, the WAO guideline panel suggests using prebiotic supplementation in not-exclusively
breastfed infants and not using prebiotic supplementation in exclusively breastfed infants [68]. Both
recommendations are conditional and based on very low certainty of the evidence [68].
Human milk oligosaccharides (HMOs) are a group of complex sugars that are highly abundant
in human milk, but currently not present in infant formula. Literature indicating that HMOs play a
major beneficial and facilitating role in the development of the infant’s microbiome and thus immune
development is abundant and unequivocal. However, there are over 100 different HMOs, with specific
properties and functions. HMOs are not digested by the infant and serve as metabolic substrates for
select microbes, contributing to shape the infant gut microbiome. HMOs provide a main substrate
to help shape the infant’s gut microbiota and affect the maturation of the intestinal mucosal immune
system [69]. Higher HMO diversity at the age of one month was associated with lower total and
percentage fat mass [69]. At the age of 6 months, each 1-μg/mL increase in lacto-N-fucopentaose was
associated with a 1.11-kg lower weight and a 0.85-g lower lean mass [69]. These findings support the
hypothesis that differences in HMO composition in mother's milk are associated with infant growth
and body composition [69].
HMOs act as soluble decoy receptors that block the attachment of viral, bacterial or protozoan
parasite pathogens to epithelial cell surface sugars, which may help prevent infectious diseases in the
gut and also the respiratory and urinary tracts. HMOs alter host epithelial and immune cell responses.
Secretor milk contains higher concentrations of total and fucosylated HMOs than does nonsecretor
milk. These HMO concentrations can be correlated to the health of breastfed infants in order to
investigate the protective effects of milk components [70]. HMOs have the potential to selectively
enrich the beneficial intestinal microbiota in breast-fed infants. Infants that received human milk with
low Lacto-N-fucopentaose III concentrations were more likely to become affected with cow’s milk
allergy when compared to high LNFP III-containing milk (odds ratio 6.7, 95% CI 2.0–22) [71].
Up to now, only a limited number of HMOs have been synthetized and studied in infant
formula, showing beneficial results. It is however unclear if a single HMO is more beneficial for
the infant’s immune system development than the artificial prebiotic oligosaccharides such as galacto-
and fructo-oligosaccharides.
6.2. Probiotics
The administration of probiotics may contribute to the restoration of the healthy equilibrium
of the GI microbiota and contribute to the efficacy of an elimination diet in CMA. Probiotics are
known to cross-talk with the intestinal immune cells. Probiotic bacteria have different modes of
action in the intestinal lumen: they hydrolyze peptides that are potentially antigenic to non-antigenic
peptides; they decrease the intestinal permeability and, as a consequence reduce the penetration of
antigens from the gut lumen to the systemic circulation; they stimulate the local production of IgA
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and they regulate local inflammatory responses and stimulate the differentiation and growth of the
GI mucosa [41]. Administration of L GG to children under the age of 2 years suffering from eczema
and with a challenge-proven food allergy has been shown to result in a significant decrease in the
eczema score [72]. A formula supplemented with L GG also decreased GI symptoms in infants with
eczema [73]. A cow milk challenge in allergic infants resulted in an increase of fecal IgA levels and a
decrease of the TNF-α level compared to a placebo [74]. L. GG has been shown to substantially increase
the memory B cells and stimulate interferon-γ secretion in infants with CMA and with IgE-associated
dermatitis, but not in healthy infants [75]. These findings support the hypothesis that infants with an
atopic predisposition may have an aberrant pattern of intestinal microbiota and this explains why the
beneficial effects of probiotics are only seen in this group [76]. In infants with colitis, supplementing a
casein eHF with L. GG significantly enhanced the recovery of the inflammation in the colonic mucosa
in comparison to the same hydrolysate without the probiotics [76]. In the group that received the
probiotic, fecal calprotectin and the number of infants with ongoing occult blood in stools after one
month were significantly smaller [77]. The primary goal in the treatment of CMA is, of course, for the
symptoms to disappear. However, the second, and almost equally important objective, is to acquire
oral tolerance. As an eHF supplemented with L casei CRL431 and B lactis BB-12 failed to accelerate
tolerance, this effect may be strain specific [78]. In a trial that compared an eHF without and with L
GG, a double-blind placebo-controlled food challenge (at least 1.4 × 107 CFU/100 mL) was negative
in 15/28 (53.6%) infants without L. GG and in 22/27 (81.5%, p = 0.027) with L. GG. These findings
may prove innovative in the therapeutic approach to treating infants with CMA by accelerating the
acquisition of tolerance [79].
Consumption of probiotic milk products was related to a reduced incidence of atopic eczema and
rhinoconjunctivitis, but not associated to the incidence of asthma by 36 months of age [80].
Most tolerant infants showed a significant increase in fecal butyrate levels, and those taxa that
were significantly enriched in these samples [81], exhibited specific strain-level demarcations between
tolerant and allergic infants. Data suggest that a casein eHF with L. GG promotes tolerance in infants
with CMA, in part, by influencing the strain-level bacterial community structure of the infant gut [81].
Perinatal probiotic administration is safe in long-term follow-up [82]. Children receiving L.
rhamnosus GG perinatally tended to have decreased allergy prevalence [82]. The subgroup analysis
based on the type of treatment suggested that both L. alone and L. with B. are protective against atopic
dermatitis (OR = 0.70, p = 0.004; OR = 0.62, p < 0.001). Probiotics seem to have a protective role in atopic
dermatitis prevention if these are administered during the pre- and postnatal period in both general
and allergic risk populations [82]. However, the ESPGHAN Committee on Nutrition concluded in 2011
that there was insufficient evidence to recommend probiotics to prevent atopic disease [67]. However,
considering all critical outcomes in this context, the WAO guideline panel determined that there is
a likely net benefit from using probiotics resulting primarily from prevention of eczema. The WAO
guideline panel suggests: (i) using probiotics in pregnant women at high risk for having an allergic
child; (ii) using probiotics in women who breastfeed infants at high risk of developing allergy; and
(iii) using probiotics in infants at high risk of developing allergy [83]. Probiotic compounds may
contain hidden allergens of food and may not be safe for subjects with allergy to cow milk or hen’s
egg [84,85].
Post-sensitization administration of non-digestible oligosaccharides and Bifidobacterium breve
M-16 V were shown to reduce allergic symptoms in mice [86]. Studies demonstrate that an AAF with
synbiotics is safe and well tolerated and promotes normal growth when fed to healthy full-term infants
as the sole source of nutrition and is hypoallergenic in subjects with CMA [87].
7. Conclusions
The diagnosis of CMA is still a challenge. Cow milk based eHF remains the recommended and
preferred therapeutic choice, while AAF is reserved for the most severe cases. Rice hydrolysates
and soy informant formulas are second choice options. Manipulation of the gut microbiotica may
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enhance the development of oral tolerance. Hydrolysates, in particular pHF with proven efficacy, may
become a protein source in starter infant formula. Since the efficacy of hydrolysates in the prevention
of allergic disease is debated, some guidelines recommend these formulas in infants at risk for atopic
disease, while other meta-analyses and some countries do not recommend the use of these formulas
in prevention. However, it is obvious that these formulas do not harm. Similar, although the clinical
evidence for a benefit of additional prebiotics or HMOs and/or probiotics is limited, supplementation
of hydrolysates should be considered as adverse effects have not been reported.
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Abstract: A causal link between increased intake of omega-6 (n-6) polyunsaturated fatty acids
(PUFAs) and increased incidence of allergic disease has been suggested. This is supported by
biologically plausible mechanisms, related to the roles of eicosanoid mediators produced from
the n-6 PUFA arachidonic acid. Fish and fish oils are sources of long chain omega-3 (n-3) PUFAs.
These fatty acids act to oppose the actions of n-6 PUFAs particularly with regard to eicosanoid
synthesis. Thus, n-3 PUFAs may protect against allergic sensitisation and allergic manifestations.
Epidemiological studies investigating the association between maternal fish intake during pregnancy
and allergic outcomes in infants/children of those pregnancies suggest protective associations, but the
findings are inconsistent. Fish oil provision to pregnant women is associated with immunologic
changes in cord blood. Studies performed to date indicate that provision of fish oil during pregnancy
may reduce sensitisation to common food allergens and reduce prevalence and severity of atopic
eczema in the first year of life, with a possible persistence until adolescence. A recent study reported
that fish oil consumption in pregnancy reduces persistent wheeze and asthma in the offspring at ages
3 to 5 years. Eating oily fish or fish oil supplementation in pregnancy may be a strategy to prevent
infant and childhood allergic disease.
Keywords: allergy; asthma; eczema; polyunsaturated fatty acid; omega-6; omega-3; inflammation;
eicosanoid; resolution; early life origins
1. Introduction
Epidemiological studies strongly suggest that early life environmental exposures are important
determinants of health and disease in later life [1,2]. Nutrition has been identified as one important
exposure that influences early development and later outcomes [3,4]. Considerable development of
the human immune system occurs in utero and in the weeks and months after birth [5–7], and there is
evidence that early immune development can be influenced by nutritional factors [8]. Epidemiological,
ecological, and case-control studies have associated differences in the patterns of exposure to
omega-6 (n-6) and omega-3 (n-3) polyunsaturated fatty acids (PUFAs) with differences in the incidence
and prevalence of atopic sensitisation or its clinical manifestations (allergies, atopic eczema, hayfever,
allergic asthma) [9,10]. A molecular and cellular mechanism has been proposed to explain this
association [9,10], thus making a causal relationship between fatty acid exposures and risk of allergic
disease. In this article, the mechanisms that are proposed to underlie the causal link between early
exposure to n-6 or n-3 PUFAs and altered risk of developing allergic diseases will be described, as will
the literature relating early exposure to the different PUFAs to allergic diseases or to relevant immune
outcomes. This is an update of an earlier discussion of this topic [11].
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2. Polyunsaturated Fatty Acids: Metabolic Relationships, Dietary Sources, and Typical Intakes
There are two main families of PUFAs, the n-6 and the n-3 families. The simplest members of
these families are linoleic acid (18:2n-6; LA) and α-linolenic acid (18:3n-3; ALA), respectively. LA and
ALA cannot be synthesized by mammals, including humans, and so they are described as essential
fatty acids. Both are synthesised by plants and are therefore found in plant tissues, like leaves, nuts,
seeds, and seed oils. LA is found in significant quantities in many commonly consumed vegetable
oils, like corn, sunflower, and soybean oils, and in products made from such oils, like margarines.
ALA is found in green plant tissues, in some common vegetable oils, including soybean and rapeseed
(canola) oils, in some nuts (e.g., walnuts), and in flaxseeds (also known as linseeds), and flaxseed oil.
LA and ALA together contribute over 95% of PUFAs in most Western diets, with LA intake most often
being in considerable excess of ALA intake. The intake of LA in Western countries increased greatly
over the second half of the 20th century, following the introduction and marketing of cooking oils and
margarines as an alternative to animal based fats and spreads [12]. The changed pattern of consumption
of LA during the 20th century resulted in a marked increase in the ratio of n-6 to n-3 PUFAs in the
Western diet, with this ratio currently being between 5 and 20 in most Western populations.
Although they are not synthesized by humans, LA and ALA can be metabolized to other fatty
acids by humans (Figure 1). This metabolic conversion, which mainly occurs in the liver, involves the
insertion of new double bonds into the hydrocarbon chain, called desaturation, and the elongation
of this chain (Figure 1). This pathway enables the conversion of LA to γ-linolenic acid (18:3n-6),
di-homo-γ-linolenic acid (20:3n-6) and arachidonic acid (20:4n-6; AA) (Figure 1). The same pathway
and the same enzymes enable the conversion of ALA to eicosapentaenoic acid (20:5n-3; EPA). Both AA
and EPA can be further metabolised. EPA can be converted to docosapentaenoic acid (22:5n-3) and on
to docosahexaenoic acid (22:6n-3; DHA) (Figure 1). Dietary intakes of AA, EPA, and DHA are much
lower than intakes of LA and ALA [13].
Figure 1. Overview of the pathway of conversion of linoleic and α-linolenic acids to longer chain more
unsaturated n-6 and n-3 polyunsaturated fatty acids (PUFAs).
In contrast to their precursors, AA, EPA, and DHA are not found in high amounts in plant tissues.
Instead, they are found in animal tissues. The most important sources of AA are eggs, meat, and organ
meats (offal). The daily intake of AA is estimated to be between 50 and 500 mg among adults in
Western countries, with higher intake in people who eat alot of red meat compared to those who do
not. EPA and DHA are found in most seafoods, and in the highest amounts in so-called “oily” or
“fatty” fish like tuna, salmon, mackerel, herring, and sardines. One serving of oily fish can provide
between 1.5 and 3.5 g of EPA plus DHA [13]. A lean fish serving (e.g., of cod) can provide about one
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tenth of this amount. Fish oil supplements also contain EPA and DHA. A standard fish oil supplement
contains about 30% EPA plus DHA; thus, a one gram capsule of such a supplement would contain
about 300 mg of EPA plus DHA. In the absence of oily fish consumption or use of fish oil supplements,
the dietary intake of EPA and DHA together is likely to be <100 mg/day [13].
3. Arachidonic Acid, Lipid Mediators, Inflammation, and Allergic Disease
PUFAs are important components of the phospholipids found in all cell membranes.
Phospholipids and their constituent PUFAs play roles in providing the environment that enables
membrane proteins to function, by influencing membrane order (“fluidity”) and by promoting specific
protein–lipid and protein–protein interactions. As a result of these actions, PUFAs regulate cell
signaling, gene expression, and cellular function. Through such membrane-mediated actions, PUFAs
can modulate immune cell function [14–16], including the inflammatory component [17], and may
influence the development and manifestations of allergic diseases [18,19]. However, the key link
between PUFAs and the immunological processes related to allergic diseases are the eicosanoids.
Eicosanoids are a family of lipid mediators synthesised from 20-carbon PUFAs released from membrane
phospholipids upon cell stimulation. Eicosanoids include prostaglandins (PGs), thromboxanes (TXs),
and leukotrienes (LTs) (Figure 2). Immune cell membranes usually contain a high proportion of
the n-6 PUFA AA and low proportions of other 20-carbon PUFAs like EPA. Therefore, the major
substrate for synthesis of eicosanoids is usually AA. PGs and TXs are synthesised from the precursor
PUFA by the cyclooxygenase (COX) pathway while LTs are synthesised by lipoxygenase (LOX)
pathways (Figure 2). The precise mixture of eicosanoids that is produced is determined by the
nature, timing, and duration of the initiating stimulus and by the particular cell involved [20–23].
Some eicosanoids, including PGE2, play a role in promoting sensitisation to allergens as a result of
their actions on dendritic cells, on T cell differentiation and on immunoglobulin (Ig) class switching
in B cells [9,10,18,24]. Other eicosanoids, like the 4-series LTs, are involved in the immunologic features
and clinical manifestations of allergic diseases, as a result of their actions on inflammatory, smooth
muscle and epithelial cells [9,10,18]. Animal models of allergic inflammation involve increased
production of PGs and LTs from AA, suggesting a role of these eicosanoids in the pathology of allergy.
However, individual PGs might have different effects, with some enhancing, and others suppressing,
allergic inflammation. For example, while PGD2, PGF2α, and TXA2 appear to increase allergic
inflammation, PGE2 and PGI2 appear to inhibit it [25–27]. Mast cells and activated macrophages are
important sources of PGD2. PGD2 is a potent bronchoconstrictor, promotes vascular permeability,
and activates eosinophils and a pro-allergic Th2-type response [27]. TXA2 is a bronchoconstrictor and
stimulates acetylcholine release. PGE2 is a vasodilator, promotes vascular permeability, inhibits the
production of Th1-type cytokines, and primes naïve T cells to produce pro-allergic interleukin (IL)-4
and IL-5 [24]. PGE2 also promotes Ig class switching in uncommitted B cells towards the production of
pro-allergic IgE [24]. Despite these effects, which are suggestive that PGE2 would promote allergic
responses, it seems to be protective towards inflammation of the airways [25,26]. It is possible that PGE2
has opposing roles, promoting sensitisation via its effects on T cell phenotype and B cells, but protecting
against the subsequent manifestations of inflammation upon re-exposure to allergen. PGI2 can suppress
the activity of Th2 lymphocytes and recruitment of eosinophils, explaining its “anti-allergy” effects.
LTB4 is chemotactic for leukocytes, increases vascular permeability, induces the release of lysosomal
enzymes and reactive oxygen species by neutrophils and of inflammatory cytokines (e.g., tumour
necrosis factor-α) by macrophages, and promotes IgE production by B cells. The cysteinyl-LTs (LTC4, D4
and E4) may be either vasoconstrictors or vasodilators depending upon the situation and the location of
their synthesis. They cause smooth muscle contraction and bronchoconstriction, and promote vascular
permeability, eosinophil recruitment, and mucus secretion. The central role of these eicosanoids in
allergic inflammation is indicated by the effective treatment of asthma by LT antagonists. The complex
nature of the role of eicosanoids in allergic disease is further illustrated by the interactions that
exist amongst these mediators. For example, PGE2 inhibits 5-LOX activity so down-regulating LT
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production [28]. This may be one mechanism by which PGE2 is protective towards established
allergic disease. Furthermore, PGE2 induces 15-LOX, leading to production of lipoxin A4 which is
anti-inflammatory [29–31].
Figure 2. Outline of the pathway of conversion of arachidonic acid to eicosanoids. Abbreviations
used: COX, cyclooxygenase; Cyt P450, cytochrome P450; HETE, hydroxyeicosatetraenoic acid;
LOX, lipoxygenase.
The role of AA as the main substrate for the synthesis of eicosanoids and the link between these
eicosanoids and inflammation, have lead to suggestions of a causal association between the increased
dietary intake of n-6 PUFA (mainly as the AA precursor LA) during the second half of the 20th
century [12], and the increased incidence and prevalence of allergic diseases over that period [9,10].
The proposed link between dietary n-6 PUFA, cell membrane AA, and pro-atopic and pro-allergic
eicosanoids is summarised in Figure 3.
In support of the proposed biological mechanism (Figure 3), a high dietary intake of LA has
been linked with increased risk of allergic diseases in several studies. Differences in the prevalence
of asthma and allergic rhinitis and differences in blood concentrations of allergen-specific IgE in
former East and West Germany were related to differences in consumption of LA-poor butter and
LA-rich margarine in the two countries [32]. Differences in the prevalence of bronchial asthma, allergic
rhinitis, and atopic dermatitis among Finnish schoolchildren were related to levels of LA in plasma
cholesteryl esters, an indicator of dietary LA intake [33]. Margarine consumption among German
schoolchildren was associated with higher hayfever risk compared with not consuming margarine [34].
Margarine consumption was higher among Australian schoolchildren with atopic dermatitis or with
other manifestations of allergic disease compared with controls [35] and high PUFA consumption was
associated with increased risk of recent asthma compared with low PUFA consumption [36]. In another
study, boys with high margarine consumption were at increased risk of allergic sensitization and of
allergic rhinitis compared with those who did not consume margarine [37]. For reasons that are not
clear, this relationship was not seen in girls [37]. Swedish children with high consumption of PUFA-rich
oils had increased risk of wheeze than those with low consumption [38], while a high dietary n-6 to
n-3 PUFA ratio was associated with increased risk of asthma in Australian schoolchildren [39]. Each of
these studies has associated dietary intake and disease at the same point in time. Few studies have
attempted to associate early LA exposure to later allergic disease, although there are some studies
reporting that LA is higher in breast milk consumed by infants who go on to develop allergic disease
in infancy, although not all such studies have found this reviewed in Ref [40]. Furthermore, umbilical
cord lipids from neonates who go on to develop allergic disease in early childhood contain a higher
amount of LA than normally seen [40], suggesting an early programming effect of higher, compared
with lower, LA exposure. A more recent Finnish study reported that a higher ratio of n-6 to n-3 PUFAs
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in the diet of pregnant women was associated with higher risk of rhino-conjunctivitis in the offspring
at 5 years of age [41].
Figure 3. Proposed relationship between increased linoleic acid exposure and increased allergic disease.
Abbreviation used: PG, prostaglandin.
4. Omega-3 Fatty Acids, Lipid Mediators, and Inflammatory Processes
Increased consumption of EPA and DHA (in studies this is usually through use of fish oil
supplements) results in enhanced incorporation of EPA and DHA into the phospholipids of immune
cell membranes resulting in an elevated proportion of these fatty acids [42–45]. The incorporation of
EPA and DHA into human immune cells is partly at the expense of n-6 PUFAs, including AA [42–44,46].
This decreases the amount of substrate available for synthesis of 2-series PGs and TXs and 4-series
LTs [17,47]. In addition to the reduced production of eicosanoids from AA, EPA is a substrate for
COX and LOX enzymes, producing eicosanoids with a slightly different structure to those formed
from AA, and the EPA-derived eicosanoids are frequently much less potent than the AA-derived
ones [17,47,48]. As an example, LTB5 is 10- to 100-fold less potent as a neutrophil chemotactic agent
than LTB4. In addition to n-3 PUFAs decreasing the metabolism of AA to eicosanoids and to EPA
acting as substrate for the generation of alternative eicosanoids, another family of lipid mediators is
produced from EPA and DHA (Figure 4). This family, termed specialised pro-resolving mediators,
includes the D- and E-series resolvins, produced from DHA and EPA, respectively, as well as protectins
and maresins produced from DHA. All of these compounds have potent anti-inflammatory and
inflammation resolving properties [49–51].
The role of some resolvins in allergic inflammation has been examined in animal models.
Transgenic fat-1 mice can endogenously synthesise n-3 PUFAs from n-6 PUFAs, a process that is
not usually possible in animals [52]. Compared with wild-type mice, fat-1 mice that had been
sensitized to ovalbumin had lower infiltration of leukocytes into the airways, lower concentrations
of a range of pro-allergic cytokines including IL-5 and IL-13 in lung lavage fluid, increased resolvin
E1 and D1 in lung tissue, and showed resistance of the airways to methacholine challenge [53].
These observations suggest that n-3 PUFAs might be protective towards allergic inflammation as
a result of the synthesis and actions of resolvins. Some other studies have assessed the therapeutic role
of resolvins in ovalbumin-sensitised Balb/C mice. In one study resolvin E1 decreased infiltration of
eosinophils and lymphocytes into the airways, decreased production of the Th2 cytokine IL-13, lowered
circulating ovalbumin-specific IgE concentrations, and reduced airway hyperresponsiveness to inhaled
methacholine [54]. In another study, resolvin E1 promoted the resolution of inflammatory airway
responses by directly suppressing the production of IL-23 and IL-6 in the lung [55]. More recently
resolvin D1 and its epimer aspirin-triggered resolvin D1 were both shown to decrease eosinophil
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recruitment to the airways, to reduce the production of pro-allergic cytokines and to improve airway
hyperresponsiveness to methacholine challenge [56]. These observations suggest that, in contrast
to the effects of high intake of n-6 PUFAs, a high intake of EPA and DHA will be protective against
allergic diseases perhaps acting in part through pro-resolving mediators.
Figure 4. Overview of the pathways of synthesis of specialised pro-resolving mediators
from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Abbreviations used:
AT, aspirin-triggered; MaR, maresin; PD, protectin D; Rv, resolvin.
5. Omega-3 Fatty Acids and Allergic Disease in Infants and Children
There is some evidence that higher intake of fish, especially fatty fish, in pregnant women is
associated with lower risk of allergic disease in the offspring during infancy and childhood [57], but not
all studies show this [58]. A Finnish study reported that a low intake of ALA or of total n-3 PUFAs in
pregnancy was associated with an increased risk of asthma in the offspring at the age of 5 years [59].
Likewise, Miyake et al. [60] found that high maternal ALA intake was associated with reduced risk
of wheeze in 16 to 24 months old Japanese children. Pike et al. [61] reported that higher EPA, DHA,
and total n-3 PUFAs in blood plasma of women in late pregnancy was associated with reduced risk of
non-atopic persistent/late wheeze in the offspring. A small number of studies found that infants who
go on to develop allergic diseases in infancy consume breast milk with lower EPA and DHA than those
who remain healthy, but this finding is not consistent across all studies [40]. Furthermore, umbilical
cord blood lipids from neonates who went on to develop allergic disease in early childhood often had
lower than normal amounts of EPA and DHA [40].
A small number of studies of maternal fish oil supplementation during pregnancy have been
conducted in the context of early immune responses and allergic outcomes in the offspring (studies
reporting clinical outcomes [62–70] are summarised in Table 1). Several studies have reported that
maternal fish oil modifies immune markers in umbilical cord blood [62,71–74]. These immunologic
effects might modify allergic sensitization and the risk of allergic diseases. Indeed, Dunstan et al. [62]
reported less severe atopic dermatitis and lower risk of sensitisation to egg in one year old infants
whose mothers had consumed fish oil supplements during pregnancy. Some other clinical outcomes
were numerically lower in the infants whose mothers had taken fish oil, but the differences were
not statistically significant. Olsen et al. [63] reported that fish oil supplementation in late pregnancy
was associated with a marked reduction in asthma-related diagnoses in the offspring at age 16 years,
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suggesting a long term effect of any immunologic changes that occurred in pregnancy and early
life. Furthermore, follow-up at age 24 years showed a reduced likelihood of having been prescribed
anti-asthma medication in the fish oil group [64], suggesting a long term effect of any immunologic
changes that occurred in pregnancy and early life. Fish oil supplementation during both pregnancy
and lactation resulted in lower PGE2 production by stimulated maternal blood [75], which might
influence Th2 polarization in the fetus. In the same study, infants whose mothers had taken fish oil had
a lower risk of developing allergic sensitization to egg, less IgE-associated eczema and less food allergy
during the first year of life [65]. Over the period of 0 to 24 months there was a lower risk of developing
any IgE-mediated disease or IgE-associated eczema or being sensitised to egg or to any allergen that
was tested [66]. Palmer et al. [67] found less sensitisation to hens’ egg at age 12 months in offspring
of mothers who consumed a DHA-rich oil during pregnancy. There was also a strong trend to less
IgE-associated eczema, but there was no difference in “any IgE-mediated disease”. Over the period
to age 3 years there was no effect of the DHA-rich oil on any clinical outcome including asthma [68].
However, sensitization to one species of house dust mite was lower at age 6 years [69]. In 2016
Best et al. [76] reported a meta-analysis of offspring clinical outcomes from trials of maternal fish oil
supplementation in pregnancy. The results are summarised in Table 2. They identified that maternal
fish oil supplementation results in a lower risk of atopic eczema, and less likelihood of having a positive
skin prick test to any allergen tested, to hens’ egg, or to any food extract, all in the first 12 months
of life. Recently, Bisgaard et al. [70] reported significantly reduced incidence of persistent wheeze or
asthma at ages 3 to 5 years in children whose mothers took fish oil during pregnancy (Figure 5). The
higher dose of EPA + DHA used, especially of EPA, may explain why these recent findings [70] differ
from those of Palmer et al. [67,68] and Best et al. [69]. Furthermore, the studies of Palmer et al. [67,68]
and Best et al. [69] reported disease with sensitization (i.e., atopic disease), as opposed the study of
Bisgaard et al. [70] which reported wheeze irrespective of sensitization as skin prick testing was only
conducted at 6 and 18 months of age. One interesting finding from Bisgaard et al. [70] is that the
beneficial effect of maternal EPA + DHA on offspring persistent wheeze or asthma (Figure 5) was
seen mainly in the subset of children whose mothers had the lowest EPA + DHA status at study entry,
but was less apparent in the subset of children whose mothers had the highest EPA + DHA status at
study entry. This observation suggests that n-3 PUFAs will be of most benefit to those with the lowest
status and may be less effective in those who already have a high status.
Table 1. Summary of randomized controlled trials of n-3 PUFAs in pregnancy reporting on allergic
outcomes in the offspring.
Publication Particpants Intervention Details Outcomes
Differences from Control in
n-3 PUFA Group
Dunstan et al. [62]
atopic, non-
smoking pregnant
women (n = 98)
fish oil providing 3.7 g n-3
PUFAs daily including
1.02 g EPA and 2.07 g DHA;
control group received olive
oil; from 20 weeks of
gestation until delivery
skin prick test positivity (hens’
egg; cows’ milk; peanut; house
dust mite; cat), asthma, atopic
eczema, food allergy all at
12 months of life
less sensitisation to hens’ egg
(odds ratio 0.34; p = 0.05); less
severe atopic eczema (odds
ratio 0.09; p = 0.045); less
recurrent wheeze, persistant
cough and diagnosed asthma
but these were not significant
Olsen et al. [63] pregnant women;n = 553
fish oil providing 2.7 g n-3
PUFAs daily including
0.86 g EPA and 0.62 g DHA;
control group received olive
oil; a third group received no
intervention; from 30 weeks
of gestation until delivery
asthma-related diagnoses at
16 years of life
less incidence of “any asthma”
(3.04% vs 8.08%; p = 0.03) and
“allegic asthma” (0.76% vs.
5.88%; p = 0.01)
Hansen et al. [64] as above as above
prescription of asthma or
allergic rhinitis medication at
age 24 years
less prescription of asthma
medication (hazard ratio 0.54;
p = 0.02); trend to less
prescription of allerfgic
rhinitis medication (hazard
ratio 0.70; p = 0.10)
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Table 1. Cont.
Publication Particpants Intervention Details Outcomes





with fetus at high
allergic risk;
n = 145
fish oil providing 2.7 g n-3
PUFAs daily including 1.6 g
EPA and 1.1 g DHA; control
group received soybean oil;
from 25 weeks of gestation
until 3.5 months post-natally
skin prick test positivity (hens’
egg; cows’ milk; wheat),
IgE-antibodies (hens’ egg;
cows’ milk; wheat), food
allergy, eczema at 3, 6 and
12 months of life
less IgE-associated eczema up
to 6 months of life
(8% vs. 20%; p = 0.06); less
IgE-associated eczema
(7.7% vs. 20.8%; p = 0.02),
sensitisation to hens’ egg
(11.5% vs. 25.4%; p = 0.02), any
positive skin prick test (15,4%
vs. 31.7%; p = 0.04) up to
12 months of life
Furuhjelm et al.
[66] as above as above
skin prick test positivity (hens’
egg; cows’ milk; wheat; cat;
tomothy; birch), food allergy,
eczema at 24 months of life
less IgE-mediated disease
(11.1% vs. 30.6%; p = 0.01),
IgE-mediated food reactions
(5.6% vs. 21.5%; p = 0.01),
sensitisation to hens’ egg
(13.4% vs. 29.5%; p = 0.04), any
positive skin prick test
(19.2% vs. 36.1%; p = 0.048),
IgE-associated eczema
(9.3% vs. 23.8%; p = 0.04) up
to 24 months of life
Palmer et al. [67]
pregnant women
with fetus at high
atopy risk; n = 706
fish oil providing 0.9 g n-3
PUFAs daily including 0.1 g
EPA and 0.8 g DHA; control
group received mixed
vegetable oils; from




cows’ milk; peanut; wheat;
tuna; grass pollen; perennial
ryegrass; olive tree pollen;
Alternaria tenuis; cat;
house dust mite), asthma,
food allergy, eczema at
12 months of life
less sensitisation to hens’ egg
(9% vs. 15%; p = 0.02); less
IgE-associated eczema
(7% vs. 12%; p = 0.06)
Palmer et al. [68] as above as above
skin prick test positivity (hens’
egg; cows’ milk; peanut;
wheat; tuna; cashew; sesame;
grass pollen; perennial
ryegrass; olive tree pollen;
alternaria tenuis; cat; house
dust mite), asthma, food
allergy, allergic rhinitis,
eczema at 3 years of life
-
Best et al. [69] as above as above
skin prick test positivity (hens’
egg; peanut; cashew; perennial
ryegrass pollen; olive tree
pollen; alternaria tenuis; cat;
dog; 2 species of house dust
mite), IgE-associated allergic
disease symptoms (eczema,
wheeze, or rhinitis) with
sensitization at 6 years of life
less sensitisation to one
species of house dust mite
(13.4% vs. 20.3%; p = 0.049)
Bisgaard et al. [70] pregnant women;n = 736
fish oil providing 2.4 g n-3
PUFAs daily including
1.32 g EPA and 0.89 g DHA;
control group received olive
oil; from 24 weeks of
gestation until delivery
asthma, allergy, eczema;
parental report of lung, skin,
lower respiratory tract related
symptoms; skin prick test
positivity (hens’ egg; cows’
milk; cat; dog) at 6 and
18 months of life
less persistant wheeze/asthma
from 3 to 5 years of life
(hazard ratio 0.68; p = 0.02)
One study has looked at maternal fish oil supplementation during lactation and immune outcomes
in the offspring [77]. Mononuclear cells from 2.5 years old children of mothers who received fish
oil supplements during lactation produced higher amounts of interferon-γ. This observation was
interpreted by the authors to reflect faster maturation of the immune system. Unfortunately, the study
did not assess clinical outcomes.
One study has investigated the effect of fish oil given to infants from birth until 6 months
of age on immune outcomes [78] and allergic disease [79]. The infants were at high-risk of
developing allergy. Mononuclear cells from infants who had received fish oil produced less of the Th2
cytokine IL-13 when stimulated ex vivo with housedust mite [78]. They also produced more of the
Th1 cytokines interferon-γ and tumour necrosis factor when stimulated with phytohaemagglutinin.
These observations would suggest a favourable shift in the Th1 vs. Th2 balance with fish oil
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supplementation. The study found that low plasma DHA and low red blood cell EPA were both
predictive of eczema by age 12 months [78]. At 12 months of age, clinical outcomes (any allergic
disease, total or any specific sensitization, eczema, food allergy, wheeze) were not different between
infants who had received fish oil or placebo [79]. However, infants who were most complaint to the
intervention had a lower risk of eczema at age 12 months. Furthermore, infants with a higher red blood
cell EPA, red blood cell ratio of EPA to ARA or plasma DHA at 6 months of age were less likely to
develop eczema by 12 months of age [79]. Infants with higher plasma DHA or EPA + docosapentaenoic
acid + DHA at 6 months were less likely to develop recurrent wheeze by 12 months of age [79].
Table 2. Summary of the findings of the meta-analysis of Best et al. [76] of randomized controlled trials
of n-3 PUFAs in pregnancy reporting on allergic outcomes in the offspring.
Outcome
Finding (Risk Ratio; 95%
Confidence Interval; p) Studies Included
atopic eczema (eczema with positive skin
prick test) in the first 12 months of life 0.53; 0.35–0.81; 0.004 [65,67]
any eczema (eczema with or without a
positive skin prick test) in the first
12 months of life
0.85; 0.67–1.07; 0.16 [65,67]
cumulative incidence of IgE-mediated
rhino-conjunctivitis (rhino-conjuctivitis
with a postive skin prick test) in the first
3 years of life
0.81; 0.44–1.47; 0.49 [66,68]
positive skin prick test to any allergen in the
first 12 months of life 0.68; 0.52–0.89; 0.006 [62,65,67]
positive skin prick test to hens’ egg in the
first 12 months of life 0.54; 0.39–0.75; 0.0003 [62,65,67]
positive skin prick test to any food extract
in the first 12 months of life 0.58; 0.45–0.75; <0.0001 [62,65,67]
One study has examined the long-term effect on allergic diseases of fish oil supplementation of
infants [80–84]. There was decreased prevalence of wheeze in the fish oil group at 18 months of age
and higher plasma n-3 PUFA levels were associated with less bronchodilator use [80,81]. At 3 years of
age the fish oil group had reduced cough, but not wheeze and there was no effect of fish oil on other
outcomes such as eczema, serum IgE concentration, or doctor diagnosis of asthma [82]. At 5 years
of age there was no significant effect of fish oil on any of the clinical outcomes relating to lung
function [32], allergy [83], or asthma [84]. Reasons for the lack of beneficial effects of long chain n-3
PUFAs at 5 years of age may be suboptimal adherence to the intervention (50% and 56% compliance
in the intervention and control group, respectively), the low dose of fish oil used, loss to follow-up,
and lack of power.
Taken together, these studies provide evidence that early exposure to the n-3 PUFAs EPA and
DHA induces immune effects that may be associated with reduced allergic sensitization and with
a reduction in allergic manifestations. However, the data available are not fully consistent and so it
is not possible to draw a certain conclusion at this stage. More studies in this area are needed and,
where these are interventions, it is important that they be sufficiently powered, that they measure
both immune and clinical outcomes where possible, and that dose of n-3 PUFAs and duration are
carefully considered.
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Figure 5. Risk of persistent wheeze or asthma in children according to maternal use of fish oil or
placebo during pregnanacy. From New England Journal of Medicine, H. Bisgaard, J. Stokholm,
B.L. Chawes, N.H. Vissing, E. Bjarnadóttir, A.M. Schoos, H.M. Wolsk, T.M. Pedersen, R.K. Vinding,
S. Thorsteinsdóttir, N.V. Følsgaard, N.R. Fink, J. Thorsen, A.G. Pedersen, J. Waage, M.A. Rasmussen,
K.D. Stark, S.F. Olsen, K. Bønnelykke, Fish Oil-Derived Fatty Acids in Pregnancy and Wheeze and
Asthma in Offspring, Volume 375, Page 2530–2539. Copyright © 2016 Massachusetts Medical Society.
Reprinted with permission from Massachusetts Medical Society.
6. The Salmon in Pregnancy Study
A systematic review published in 2011 identified that intake of fish, fatty fish, and omega-3 fatty
acids in pregnancy is associated with reduced risk of allergic disease in the offspring infants [57].
As with its advice to other adults, the UK Government advises that pregnant women should consume
two portions of fish per week, at least one of which should be fatty [85]. The Salmon in Pregnancy
Study was a randomised, controlled dietary intervention testing this advice in the context of offspring
allergic disease. Pregnant women who were low consumers of fatty fish and who were at risk of giving
birth to an infant who would become allergic were recruited [86]. The women were randomized to
two groups: one group maintained their habitual diet while the other included salmon twice per week
in their diet from week 19 of pregnancy until delivery. Women in the salmon group had a higher
dietary intake of EPA and DHA: intake of EPA + DHA from the diet was equivalent to 0.03 g/day
in the control group and was 0.4 g/day in the salmon group [86]. Women in the control group
showed a decline in the percentage of both EPA and DHA in plasma phosphatidylcholine from week
19 to week 38 pregnancy [86], consistent with other reports [87,88]. However, in the salmon group
this decline did not occur and EPA and DHA were seen to increase in plasma phosphatidylcholine
over the course of pregnancy [86]. Furthermore, both EPA and DHA were significantly higher in
the umbilical cord plasma phosphatidylcholine in the salmon group compared with the control
group [86]. Thus, by consuming salmon twice per week mothers were providing more EPA and DHA
to their growing fetus. There were also some differences in umbilical cord blood immune cell responses
between the two groups, including a lower production of pro-allergic PGE2 by cord blood mononuclear
cells in response to inflammatory stimuli in the salmon group [89]. Breast milk DHA was higher from
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women in salmon group at days 1, 5, 14, and 28 after birth, even though women ceased consuming
salmon at birth [90]. Thus, women in the salmon group were most likely able to provide a greater
amount of DHA to their newborn infant during the early weeks of lactation. Despite, these important
findings, at 6 months of age there was no significant difference between the two groups in the number
of infants with atopic eczema or in the severity of atopic eczema, in the number of infants showing
positive skin prick test responses to common allergens, or in various allergic manifestations [89].
However, the number of infants affected was low in both groups. It is possible that the amount of EPA
and DHA provided through two servings of salmon per week (equivalent to 0.4 g/day) was too low to
influence the clinical outcomes despite the higher n-3 PUFA status in cord blood and the altered cord
blood immune cell responses.
7. Summary and Conclusions
There are two main families of PUFAs, the n-6 and the n-3 families. Intake of the major plant n-6
PUFA LA increased over the second half of the 20th century. This increase in LA intake coincided
with increased incidence and prevalence of allergic diseases. A causal link between n-6 PUFA intake
and allergic disease has been suggested and this is supported by biologically plausible mechanisms,
largely related to the roles of eicosanoid mediators produced from the n-6 PUFA AA. There is some
evidence that high LA intake is associated with increased risk of allergic sensitization and allergic
manifestations. Fish and fish oils are sources of the long chain n-3 PUFAs EPA and DHA. These fatty
acids act to oppose the actions of n-6 PUFAs particularly with regard to eicosanoid synthesis. Thus, n-3
PUFAs may protect against allergic sensitisation and allergic manifestations. Epidemiological studies
investigating the association between maternal fish intake during pregnancy and allergic outcomes in
infants/children of those pregnancies suggest protective associations, but findings from these studies
are not consistent. Fish oil provision to pregnant women is associated with immunologic changes
in cord blood and such changes may persist. Studies performed to date indicate that provision of
fish oil during pregnancy may reduce sensitisation to common food allergens and reduce prevalence
and severity of atopic dermatitis in the first year of life, with a possible persistence until adolescence.
A recent study reported that fish oil consumption in pregnancy reduces persistent wheeze and asthma
in the offspring at ages 3 to 5 years. Eating oily fish or fish oil supplementation in pregnancy may be
a strategy to prevent infant and childhood allergic disease. Further studies of increased long chain
n-3 PUFA provision during pregnancy, lactation, and infancy are needed to more clearly identify
the immunologic and clinical effects in infants and children and to identify protective effects and
their persistence.
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Abstract: Consumption of raw cow’s milk instead of industrially processed milk has been reported to
protect children from developing asthma, allergies, and respiratory infections. Several heat-sensitive
milk serum proteins have been implied in this effect though unbiased assessment of milk proteins
in general is missing. The aim of this study was to compare the native milk serum proteome
between raw cow’s milk and various industrially applied processing methods, i.e., homogenization,
fat separation, pasteurization, ultra-heat treatment (UHT), treatment for extended shelf-life (ESL),
and conventional boiling. Each processing method was applied to the same three pools of raw milk.
Levels of detectable proteins were quantified by liquid chromatography/tandem mass spectrometry
following filter aided sample preparation. In total, 364 milk serum proteins were identified.
The 140 proteins detectable in 66% of all samples were entered in a hierarchical cluster analysis.
The resulting proteomics pattern separated mainly as high (boiling, UHT, ESL) versus no/low
heat treatment (raw, skimmed, pasteurized). Comparing these two groups revealed 23 individual
proteins significantly reduced by heating, e.g., lactoferrin (log2-fold change = −0.37, p = 0.004),
lactoperoxidase (log2-fold change = −0.33, p = 0.001), and lactadherin (log2-fold change = −0.22,
p = 0.020). The abundance of these heat sensitive proteins found in higher quantity in native cow’s
milk compared to heat treated milk, renders them potential candidates for protection from asthma,
allergies, and respiratory infections.
Keywords: proteomics; heat stability; milk serum proteins; immune-active proteins
1. Introduction
Consuming raw milk has been associated with a reduction in risk of childhood asthma and
atopy [1,2] as well as respiratory infections [3]. However, consumption of raw milk poses significant
risks, due to potential presence of pathogens in raw milk [3]. As an alternative to raw milk, specific milk
ingredients for supplementing heat treated milk have become the focus of recent research, and a wide
range of components have been hypothesized to be related to the allergy and asthma protective
potential of raw milk versus commercially available milk [4].
Nutrients 2017, 9, 963 175 www.mdpi.com/journal/nutrients
Nutrients 2017, 9, 963
After industrial processing, cow’s milk considerably differs from raw milk in several aspects,
with fat content and heat-treatment being the most obvious. Although the effects of fat content
and heat treatment on reduction of asthma partially overlap, both factors exert strong independent
effects [2]. The effect of fat content was mainly attributed to the levels of ω-3 polyunsaturated fatty
acids [2]. Similarly, heat treatment reduced the levels of milk serum proteins such as β-lactoglobulin
and α-lactalbumin, which in turn were found to be inversely related to asthma risk in children of the
GABRIELA study with statistical significance [1].
Although it remains open whether these proteins actually reduce the asthma risk themselves,
these findings suggest an allergy preventive potential by heat-sensitive proteins in general.
Generally whey proteins are susceptible to heat treatment [5,6], particularly immunoactive proteins
such as lactoferrin or lactadherin [7]. Heating of heat-labile proteins results in denaturation and
aggregation processes [8] and thereby leads to a loss of biological functionality (e.g., lactoferrin [9]).
Denatured and aggregated proteins can be extracted from the milk with a combination of pH reduction
and ultracentrifugation [10], after which remaining levels of non-aggregated milk serum proteins can be
determined [7]. Besides denaturation and aggregation, heating may also lead to chemical modifications,
especially the Maillard reaction [11]. During industrial milk processing, relatively short heating times
are applied, thus we expect relatively low levels of such chemical modifications, although especially for
UHT processing a certain level of chemical modifications has previously been observed [12]. The aim
of this study was to assess the native protein profile of bovine milk serum after different industrially
applied processing steps with varying heating intensity for the identification of potential asthma- and
allergy-protective candidate proteins.
2. Materials and Methods
2.1. Milk Samples
The milk samples used for this analysis were derived from three different farms located in
Southern Germany. The origins and characteristics of these three milk batches are shown in Table 1.
Each milk batch was processed on three consecutive days in a pilot plant. From milk collection to
the last processing step, milk samples were stored at 1 ◦C. After processing, the milk samples were
stored at −20 ◦C until proteomics analysis. The milk types resulting from the various processing
procedures are listed in Table 2. Industrial milk processing was not done with technical replicates
because these procedures are laborious, expensive, and time-consuming and there were biological
replicates represented by the three milk batches from the respective farms. In total, eight milk samples
from each of the three milk batches were assessed for proteomics. The same 24 milk samples were
previously used to assess the effect of different processing methods on microRNA (miRNA) levels [13].
The subsequent proteomics analyses of the 24 samples including sample preparation and mass
spectrometry were performed without technical replicates since technical reproducibility proved to
be high in previous experiments [14] and most of the variation was expected to come from the three
separate batches of milk.




No. of cows 13 60 30
Time point of milking for
pooled samples Morning and evening Morning and evening Morning and evening
No. of detectable milk serum
proteins in raw milk samples 143 153 158
176
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Table 2. Processing details of the milk samples.





RAW Native raw milk - Wednesday No-low heat
PAS Pasteurized
72 ◦C for 20 s Wednesday No-low heatTotal processing time *** 60 s
SKI Skim milk Separation at 50 ◦C Tuesday No-low heat
FAT Fat fraction/cream Separation at 50 ◦C Tuesday -
HOM Homogenized milk Preheating to 55
◦C, 2-stage
homogenization at 250/50 bar Tuesday -
ESL Extended shelf life milk
Preheating at 95 ◦C for 20 s, direct
steam injection at 127 ◦C for 5 s Monday High heat
Total processing time *** 60 s
UHT Ultra-high heat treated
Preheating at 93 ◦C for 23 s, direct
steam injection at 142 ◦C for 5 s Monday High heat
Total processing time *** 85 s
BOI Boiled milk
Preheating at >80 ◦C for >300 s,
boiling at 100 ◦C for 30 s Tuesday High heat
Total processing time *** 2000 s
* Milk samples were collected on a Monday and stored at 1 ◦C until they were processed. Processing occurred on
the same day or the two subsequent days. After processing samples were frozen to −20 ◦C and stored until analysis.
** For further analysis of heat treatment on milk proteins, grouping of milk types according to the heat treatment
was conducted; homogenized milk was excluded due to additional treatment with pressure; cream was excluded
because it contains only the milk fat fraction. *** Total processing time includes heating and cooling stage.
2.2. Removal of Fat and Denatured Protein
All samples were centrifuged at 1500× g for 10 min at 10 ◦C (with a rotor 25.15, Avanti Centrifuge
J-26 XP, Beckman Coulter, Miami, FL, USA). After centrifugation, all skimmed milk samples were
acidified by drop-wise addition of 1 M HCl under stirring, until a pH of 4.6 was reached. The samples
were then kept at 4 ◦C for 30 min to equilibrate. When needed, pH was adjusted before the final pH
reading. This pH adjustment was done to separate the denatured serum proteins from the native
serum proteins during ultracentrifugation, as previously described [7,10]. The acidified skim milk
was transferred to ultracentrifuge tubes followed by ultracentrifugation at 100,000× g for 90 min at
30 ◦C (Beckman L-60, rotor 70 Ti). After ultracentrifugation, samples were separated into three phases.
The top layer was remaining milk fat, the middle layer was milk serum, and the bottom layer (pellet)
was casein with denatured proteins. Milk serum was used for filter aided sample preparation (FASP)
as described below.
2.3. Filter Aided Sample Preparation (FASP)
FASP method was carried out according to Wisniewski et al., 2009 [15], with adaptations according
to Zhang et al., 2016 [7]. Milk serum samples (20 μL) were diluted in SDT-lysis buffer (4% SDS with
0.1 M dithiotreitol and 100 mM Tris/HCl pH 8.0) to get a 1 μg/μL protein solution. Samples were
then incubated for 10 min at 95 ◦C. They were centrifuged at 21,540× g for 10 min after being
cooled down to room temperature. Of each sample 20 μL were directly added to the middle of
180 μL 0.05 M iodoacetamide (IAA) in 8 M urea with 100 mM Tris/HCl pH 8.0 (called UT) in a low
binding Eppendorf tube and incubated for 10 min while mildly shaking at room temperature. The entire
volume of the sample (200 μL) was transferred to a Pall 3K omega filter (10–20 kDa cutoff, OD003C34;
Pall, Washington, NY, USA) and centrifuged at 20,000× g for 30 min. Another three centrifugations at
20,000× g for 30 min were carried out after adding three times 100 μL UT. Afterwards 110 μL 0.05 M
NH4HCO3 (ABC) in water was added to the filter unit and centrifuged at 20,000× g for 30 min.
Then, the filter was transferred to a new low-binding Eppendorf tube. On the filter, 100 μL ABC
containing 0.5 μg trypsin was added and centrifuged at 20,000× g for 30 min after incubation overnight.
Finally, the filter was removed and 5 μL 10% trifluoroacetic acid (TFA) was added to adjust the pH of
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the sample to around 2. These samples were ready for analysis by liquid chromatography/tandem
mass spectrometry (LC-MS/MS).
2.4. LC-MS/MS Analysis
A volume of 18 μL of the trypsin digested milk fractions was injected in a 0.10 × 30 mm Magic
C18AQ 200A 5 μm beads (Bruker Nederland B.V., Leiderdorp, The Netherlands) pre-concentration
column (prepared in house) at a maximum pressure of 270 bar. Peptides were eluted from the
pre-concentration column onto a 0.10 × 200 mm Magic C18AQ 200A 3 μm beads analytical column
with an acetonitrile gradient at a flow of 0.5 μL/min, using gradient elution from 8 to 33% acetonitrile
in water with 0.5 v/v % acetic acid in 50 min. The column was washed using an increase in the
percentage of acetonitrile to 80% (with 20% water and 0.5 v/v % acetic acid in the acetonitrile and the
water) in 3 min. Between the pre-concentration and analytical columns, an electrospray potential of
3.5 kV was applied directly to the eluent via a stainless steel needle fitted into the waste line of a P777
Upchurch microcross. Full scan positive mode FTMS spectra were measured between m/z 380 and
1400 on a LTQ-Orbitrap XL (Thermo electron, San Jose, CA, USA) in the Orbitrap at high resolution
(60,000). IT and FT AGC targets were set to 10,000 and 500,000, respectively, or maximum ion times
of 100 μs (IT) and 500 ms (FT) were used. Collision-induced dissociation (CID) fragmented MS/MS
scans (isolation width 2 m/z, 30% normalized collision energy, activation Q 0.25 and activation time
15 ms) of the four most abundant 2+ and 3+ charged peaks in the FTMS scan were recorded in data
dependent mode in the linear trap (MS/MS threshold = 5.000, 45 s exclusion duration for the selected
m/z ±25 ppm).
2.5. Data Analysis
Each run with all MS/MS spectra obtained was analysed with Maxquant 1.3.0.5 with
Andromeda search engine [16]. Carbamidomethylation of cysteines was set as a fixed modification
(enzyme = trypsin, maximally 2 missed cleavages, peptide tolerance for the first search 20 ppm,
fragment ions tolerance 0.5 amu). Oxidation of methionine, N-terminal acetylation and de-amidation
of asparagine or glutamine were set as variable modification for both identification and quantification.
The bovine reference database for peptides and protein searches was downloaded as fasta file
from Uniprot with reverse sequences generated by Maxquant (fasta file downloaded from Uniprot
2013 [17]). A set of 31 protein sequences of common contaminants was used as well, which included
Trypsin (P00760, bovine), Trypsin (P00761, porcine), Keratin K22E (P35908, human), Keratin K1C9
(P35527, human), Keratin K2C1 (P04264, human), and Keratin K1C1 (P35527, human). A maximum of
two missed cleavages were allowed and a mass deviation of 0.5 Da was set as limit for MS/MS peaks
and maximally 6 ppm deviation on the peptide m/z during the main search. The false discovery rate
(FDR) was set to 1% on both peptide and protein levels. The length of peptides was set to at least seven
amino acids. Finally, proteins were displayed based on minimally 2 distinct peptides of which at least
one unique and at least one unmodified. Match between runs was used with a time window of 10 min.
Both unmodified and modified peptides were used for quantification. Only unique or razor peptides
were used for quantification. Minimum ratio count for label-free quantification (LFQ) was set as 2.
The quantification of the full proteome is based on the extracted ion current and is taking
the whole three-dimensional isotope pattern into account, using peak volumes of all measured
isotopes for quantification [16]. At least two quantitation events were required for a quantifiable
protein. MaxQuant was used with the Intensity based absolute quantification (IBAQ) algorithms for
quantification [18]. The IBAQ algorithm estimates the absolute amount of a protein as the sum of the
intensities of all peptides (based on peak volumes), divided by the number of tryptic peptides that can
theoretically be generated. Proteins had to have at least three valid IBAQ intensities in the individual
samples for counting of the number of identified proteins.
The function of the identified proteins was checked in the UniprotKB database released
February 2014 [17].
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2.6. Statistical Analysis
Statistical analysis was performed with R 3.3.2 software [19]. The average number of measurable
proteins in raw milk was calculated and related to the respective numbers of milks after different
processing methods.
Proteins with ≤33% non-detects were included in further analysis. Non-detects of these
proteins were either simply replaced by zero or imputed by simple imputation. For the imputation
firstly the mean and standard deviation of each protein was estimated including the non-detected
values as censored observations by a linear Tobit model to determine protein specific distributions.
Subsequently, non-detects were replaced by random samples from the lower tail of the respective
distribution, i.e., below the protein specific detection limit as defined by the minimum of the measured
protein levels. The quality of imputation was examined via Wilcoxon tests, comparing median protein
levels of the imputed data against the raw data. For subsequent analyses, the imputed data were used.
Hierarchical clustering of milk samples was based on Pearson’s correlation of the specific protein
profiles following imputation.
For assessment of the effect of heating, milks were categorized in two groups by temperatures
above and below 80 ◦C [20]; high heated milk samples, defined as UHT, ESL and boiled milk and
no-/low heat treated milks, represented by pasteurized, skimmed and raw milk samples (Table 2).
A logistic regression model adjusted for the milk origin (Traunstein, Freising, Starnberg) was
used to calculate the differences in high vs. low heat treated milks. The log2 fold-changes of the
protein levels in low versus high heat treated milks were calculated to rank the proteins according
to their heat sensitivity, and plotted against the corresponding negative decadic logarithm of the
p-values in a volcano plot. Resulting p-values were adjusted for the false discovery rate according to
Benjamini–Hochberg, and a corrected p-value < 0.05 was considered statistically significant.
3. Results
A total of 364 milk serum proteins were identified and quantified in at least one of the 24 milk
samples, of which 44 could be quantified in all 24 samples. Subsequent analyses were based on the
169 proteins found in at least three different milk samples; 130 of those proteins were detected in all
three raw milk samples and further 28 proteins in two raw milk samples. The average LFQ levels
of proteins in the raw milk samples did not differ significantly between the three farms (p = 0.49),
thereby ruling out major differences in original milk batches.
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Figure 1. Proportion of number of detectable proteins in milk samples (each sample per farm
individually and averaged over the three different samples) after different processing compared
to raw cow’s milk. * No. of detectable native proteins in raw milk is the reference, i.e., 151 distinct
proteins were detected in the three raw milk samples on average.
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For further statistical analysis, proteins with >33% non-detects were excluded. Non-detects
in the remaining proteins (n = 140) were either replaced by imputed values below detection limit
or simply by zeros. Figure 2 shows the superiority of the imputation method in contrast to the
simple replacement of missing values by zero. The median of the individual protein LFQ levels
averaged over all 24 samples is solely slightly reduced after imputation compared to the raw data set
(median value was calculated after exclusion of missing values). In contrast, replacement of non-detects
by zero resulted in a clear distortion of the distribution and was not considered for further analysis.
Figure 2. Boxplots of average protein LFQ levels after different NA replacement. Comparison of mean
LFQ protein values in different data (raw, imputed, and NAs replaced by 0). Replacement by 0 differed
significantly from the raw data (p < 0.0001).
Similar protein patterns resulted from similar heating temperatures of the milk samples as
demonstrated by hierarchical clustering of the specific protein profiles (Figure 3): raw, skimmed and
pasteurized milk samples formed one cluster, whereas UHT, ESL, and boiled milk samples formed
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another cluster with the exception of one boiled milk sample, which differed substantially from both
main clusters. Under the assumption that this milk was partially overcooked, it was excluded from
subsequent analyses.
Figure 3. Heat map for protein levels and milk types. Rows reflect individual samples, whereas
individual proteins are given in columns. Their LFQ values are represented by different colors
according to the color code from low (blue) to high (red) expression.
Comparison of milks in the high heat versus the low heat treated group revealed a significant
reduction of the total protein LFQ levels in high heated milks compared to no/low heat treated milks,
as shown in Figure 4. Boiled milk showed the lowest protein levels; other heat treated milks contained
total protein LFQ levels ranging between boiled and raw milk and were inversely related to heating
temperatures (Figure 4).
When focusing on individual proteins, a significant reduction in quantity of at least 10% was
found in 23 proteins after high heat treatment compared to low heat treatment (Figure 5).
Ten of these proteins were related to immune functions (Table 3).
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Figure 4. Total protein contents (sum of LFQ values per sample) in differently processed milks.
* p-value derived from a logistic regression with adjustment for milk batch.
Figure 5. Volcano plot for the comparison of proteins in low- versus high-heat treated milk samples.
The log two-fold change of protein expression between low- and high-heat treated milk samples is
plotted against the corresponding p-values from a t-test given as negative decadic logarithm. A negative
log two-fold change indicates a decrease in LFQ levels.
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p-Value * Log2 Fold Change
(95% CI)
Protein Name Protein Function
P80457 67 0.001 −0.44 (−0.56; −0.31) Xanthine dehydrogenase/oxidase immunity
P24627 71 0.004 −0.37 (−0.51; −0.22) Lactoferrin immunity
G3X6N3 57 0.006 −0.35 (−0.50; −0.20) Serotransferrin transport
F1MR22 42 0.004 −0.34 (−0.47; −0.21) Polymeric immunoglobulin receptor immunity
P80025 37 0.001 −0.33 (−0.43; −0.23) Lactoperoxidase immunity
G3N1R1 4 0.002 −0.32 (−0.44; −0.21) Uncharacterized protein unknown
F1MGU7 7 0.04 −0.30 (−0.52; −0.07) Fibrinogen gamma-B chain Blood coagulation
G3X7A5 80 0.002 −0.29 (−0.41; −0.18) Complement C3 immunity
F1MZ96 10 0.002 −0.27 (−0.36; −0.18) Uncharacterized protein unknown
F1MX50 4 0.01 −0.27 (−0.40; −0.13) Uncharacterized protein cell
F1MM32 8 0.026 −0.26 (−0.43; −0.08) Sulfhydryl oxidase enzyme
P81265 42 0.006 −0.24 (−0.35; −0.14) Polymeric immunoglobulin receptor immunity
F1N076 12 0.001 −0.23 (−0.30; −0.15) Ceruloplasmin cell
F1MXX6 26 0.02 −0.22 (−0.35; −0.08) Lactadherin cell
Q08DQ0 6 0.017 −0.21 (−0.34; −0.08) Plakophilin-3 cell
P07589 6 0.004 −0.20 (−0.30; −0.11) Fibronectin immunity
A6QNL0 6 0.01 −0.20 (−0.32; −0.09) Monocyte differentiation antigen CD 14 immunity
P10152 11 0.048 −0.20 (−0.37; −0.04) Angiogenin-1 (ribonuclease 5) cell
F1MMD7 5 0.031 −0.20 (−0.34; −0.06) Inter-alpha-trypsin inhibitor heavy chain H4 Protease inhibitor
Q3MHN2 6 0.043 −0.20 (−0.35; −0.04) Complement component C9 immunity
P00735 7 0.028 −0.18 (−0.30; −0.05) Prothrombin immunity
F1MCF8 9 0.001 −0.17 (−0.22; −0.12) Uncharacterized protein immunity
P17690 9 0.005 −0.16 (−0.23; −0.09) Beta-2-glycoprotein 1 Blood coagulation
* p-values are adjusted for multiple testing.
4. Discussion
Heat treatment of milk led to a considerable decrease in number of detectable proteins and their
levels of quantification with a clear relationship to the applied heat load. The most intensive treatment,
i.e., boiling, reduced the number of proteins that could be detected by about 50% compared to raw
milk, with the other heating types ranging in between. The various processing methods led to specific
proteomic patterns covering 140 individual proteins as demonstrated by a cluster analysis. Of these,
23 distinct proteins were found to be substantially diminished in high heat treated milks. The majority
of these heat-sensitive proteins were related to immune functions.
Typically, people in Westernized countries consume industrially processed milk and, increasingly,
milk types with an extended shelf life. In addition, UHT milk with its very long storage duration of
three months or more is nowadays very popular. Traditionally, commercially available milk had been
pasteurized, i.e., heated at 72 ◦C for 20 s to inactivate potential hazardous microorganisms with only
small gain in shelf life.
Despite the potential risk of life-threatening infections, a minority of people still consume raw
cow’s milk, which has repeatedly been reported to protect against asthma, allergies, and respiratory
infections in childhood [1,3,21,22]. The wide consumption of cow’s milk thus renders it an attractive
strategy for prevention if the risk of infections were to be overcome. An option might be the isolation
and purification of the protective milk ingredients, and various studies have focused on the impact of
industrial processing on the potentially beneficial molecules. At the same time, reducing heat load of
commercially available dairy products may already lead to an increase in the availability of potentially
immunoactive proteins.
Of the industrially applied processing steps, predominantly fat separation for adjusting
milk fat levels, and homogenization for preventing fat creaming, affect the milk lipid fraction.
However, homogenization also leads to a massive increase in fat globule surface, which will be covered
by milk proteins, leading to a reduction of milk proteins in serum.
Waser at al., 2007 [23] found an asthma and wheeze protective effect of milk fat containing
products such as full cream milk and butter. In addition, Brick et al., 2016 [2] implied the higher fat
content and more precisely the higher content of anti-inflammatory omega-3 fatty acids in raw milk in
the asthma protective effect of full cream milk obtained directly from a farm. Despite mild heating to
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55 ◦C, high pressure treatment of milk (250 bar) used during the homogenization process has been
found to profoundly rearrange protein quantity and structure [22,24,25]. In addition, in the present
study homogenization reduced total protein LFQ levels and specific protein detectability markedly.
Another major processing step is heating for destroying hazardous microorganisms and increasing
shelf life. Thermo-labile milk components such as miRNAs [13] and proteins may thus be involved
in the protective effect of raw milk. Particularly protein functionality, solubility and quantity are all
affected by intensity of heat treatment [7,8,18,26]. Previously specific miRNA species were identified
as possible contributors to the asthma-protective effect of farm milk [11]. This notion is not in conflict
with our current findings; rather both molecule classes might add to the effect or might even interact.
Loss et al., 2011 [1] found inverse associations of asthma with higher levels of several milk whey
proteins, i.e., bovine serum albumin, alpha-lactalbumin and beta-lactoglobulin. However, it remains
unclear whether these specific proteins confer the effect themselves or whether they are proxies of heat
labile proteins in general. Therefore, we quantified heat-induced alterations of the entire milk proteome
by a comprehensive, standardized, and unbiased approach, i.e., without preselection of proteins.
First, we observed a considerable decrease of detectable proteins after heat treatment in a
dose-dependent manner. Boiled cow’s milk contained the lowest number of detectable proteins,
which is explained by the high heat load applied. The lower temperature of boiling compared to ESL
or UHT is more than compensated by the much longer duration of the heating (Table 2). In addition,
the long heating time of boiling may also lead to more extensive chemical modification compared to
industrial processes [11], further reducing protein levels in these samples.
For further investigation in the impact of heating on the protein quantity and heat sensitivity,
milk samples were categorized into high heat and no/low heat treated milk groups according to the
clusters presented in the heat map (Figure 3). This dichotomization was in line with findings on the
first marginal transition of bovine whey proteins at about 81 ◦C [20]. Actually, the difference between
high and no/low heat treated samples was more than 25 ◦C with pasteurization not exceeding 72 ◦C
and high heat treatment starting with 100 ◦C.
Figures 1 and 4 describe some variance within milk types between the three farms, e.g., one of
the UHT samples had a higher percentage of detectable proteins and a higher summed LFQ value
than the respective other two UHT samples. Nevertheless, the heat map (Figure 3) still groups all
the high-heated samples together. Even though this UHT sample contains a higher overall protein
intensity, and a higher number of identified proteins, the proteome profile still reflects a high heated
sample. This might be due to a similar pattern in decrease of individual, heat sensitive proteins.
The exact underlying mechanisms for these individual variations however cannot be explained in
this study. Further investigations on a larger scale are needed to better understand the variability in
proteome profile after heat processing.
The sum over all proteins, and more specifically the levels of 23 individual proteins were
substantially lower in high heat treated samples as expected by previous work from Zhang et al.,
2016 [7]. Interestingly, most of these 23 particularly heat-sensitive proteins were related to immune
functions (Table 3), and several proteins have already been mentioned in the context of asthma and
allergies. Under the assumption that some proteins withstand the acidity of the stomach milieu,
they may be resorbed in the gut and exert physiologic functions. At least this has been suggested for
e.g., lactoferrin (LTF) [27], protease inhibitors [28] and IgG [29].
Among the most promising candidates was lactoferrin, which is known to stimulate the immune
system by counteracting pathogenic invaders and injuries and preventing harmful overreactions of
the immune system [30,31].
Lactoperoxidase is a peroxidase enzyme secreted from the mammary gland that operates as a
natural antibacterial agent [32]. Asthmatic patients who were treated with lactoperoxidase aerosol
showed lower disease activity and reduced damaging effects of hydrogen peroxide (H2O2), which is
mainly generated by neutrophils and eosinophils in asthma and contributes to airway damages and
inflammation [33].
184
Nutrients 2017, 9, 963
Xanthine dehydrogenase/oxidase (XOR) might contribute to the formation of NO in the intestinal
lumen and thereby exert antimicrobial properties [34]. In our study we were unable to differentiate the
rather similar variants, dehydrogenase and oxidase, as the only difference is an intramolecular change
of two cysteines in the disulfide bond, whereas the amino acid chain, analyzed with the LC-MS/MS
analysis, is identical.
In addition, a number of acute phase proteins such as fibrinogen, prothrombin, complement C3
and C9 were found to be highly heat-sensitive. How they may be involved in the anti-inflammatory
effects ascribed to raw milk remains unclear, although the complement pathway, and specifically C3,
has been implied in the development of allergy and asthma [35–37].
Plakophilin-3 acts protective in both local and systemic inflammatory diseases [38] and
inter-alpha-trypsin inhibitor has anti-inflammatory, anti-scarring and anti-angiogenic properties [39].
Protease inhibitors, including several inter alpha-trypsin inhibitors, have been found to be upregulated
in the breast milk of allergic mothers and have been related to the pathogenesis of allergy and
asthma [40,41].
Lactadherin expression is found to be markedly reduced in asthmatic patients compared to
healthy subjects, and suppresses airway smooth muscle hypercontractility [42].
Polymeric immunoglobulin receptor may influence eosinophilic inflammation by binding
secretory immunoglobulins [43]. In addition, secretory components, which are part of the polymeric
immunoglobulin receptor that can be cleaved off, have shown individual effects in mucosal
immunity [44].
Ultimately, the discovery of the CD14 molecule, a receptor of bacterial endotoxin, is interesting as
gene–environment interactions of raw milk consumption and polymorphisms associated with this
gene have been discussed controversially for childhood onset asthma [45,46]. Similar to the human
CD14 molecule, its bovine counterpart might transmit signals elicited by endotoxin, and thereby have
an effect on the development or prevention of allergy and asthma.
Despite the plausible involvement of several proteins in the beneficial health effects we have
to acknowledge that we cannot provide a direct link to disease status in this study. However, the
palette of immune-active milk components detected in the present study can be seen as an extension
to the findings by Loss et al., 2011 [1], which explicitly linked protein levels to disease. In addition,
this study only shows a decrease in native proteins, due to either denaturation or heat-induced
chemical modification, without direct evidence for a loss-of-function. However, heating of milk has
been shown to reduce biological activity of milk, including antibacterial capacity [6] and previous
studies showed a loss-of-function of milk immune proteins upon denaturation (e.g., Paulson, 1993 [47];
Marin et al., 2003 [48]). However, future studies are needed to investigate in the biological function of
milk’s immunoactive proteins after applying heat treatments.
Another limitation of this analysis is the omission of the milk fat globule membrane (MFGM)
fraction [49]; their relatively low abundance in cow’s milk, however, precludes a major contribution to
the effects by the entirety of immunoactive proteins present in milk. Our analyses were made after one
freezing cycle; resulting alterations, however, seem to be very limited [7,50].
5. Conclusions
Taken together, we have performed a comprehensive search for proteins most likely to be affected
by industrial processing methods. Their higher abundance in native cow’s milk as compared to
industrially processed milks renders them potential candidates for protection from asthma, allergies,
and respiratory infections. However, in this study, we solely analyzed protein patterns of differently
processed milks, thus associations of found potential protein candidates with disease status have to be
investigated in population based studies.
Supplementary Materials: The supplementary file is available online at www.mdpi.com/2072-6643/9/9/963/s1.
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Abstract: The majority of foods that are consumed in our developed society have been processed.
Processing promotes a non-enzymatic reaction between proteins and sugars, the Maillard reaction
(MR). Maillard reaction products (MRPs) contribute to the taste, smell and color of many food
products, and thus influence consumers’ choices. However, in recent years, MRPs have been linked
to the increasing prevalence of diet- and inflammation-related non-communicable diseases including
food allergy. Although during the last years a better understanding of immunogenicity of MRPs has
been achieved, still only little is known about the structural/chemical characteristics predisposing
MRPs to interact with antigen presenting cells (APCs). This report provides a comprehensive review
of recent studies on the influence of the Maillard reaction on the immunogenicity and allergenicity of
food proteins.
Keywords: Maillard reaction; advanced glycation end products (AGEs); Maillard reaction products
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1. Food Processing
Most of the food consumed nowadays by developed societies is processed. The diversity of
processed food products increased exponentially during the last century, along with the need for more
safe, convenient and varied food products. Methods used for food processing can be categorized into
two processing types: conventional thermal methods, including pasteurization, sterilization, drying
and roasting [4,5] and non-thermal, novel methods such as high pressure treatment [6], electric field
treatment [7,8], irradiation [9] or applications of cold plasma [10]. Foods are subjected to thermal
processing mainly to preserve them by inactivating microbes (high temperature treatment), to improve
their sensory qualities (e.g., flavor, texture, taste, and smell) or to obtain another food product or
ingredient from a food source (e.g., protein isolates, cheese, oils). From a biochemical perspective,
thermal processing promotes chemical and physical changes of food proteins, and affects protein
conformation—and therefore also immunogenicity and allergenicity—by promoting interactions of
food proteins with other components present in the food matrix.
2. Thermal Processing Induces Conformational Changes in Food Proteins
Native proteins are folded into specific and compact 3D structures. This is determined by
primary structure (sequence of amino acids), secondary structure (formation of α-helixes and
β-sheets) and tertiary structure. The formation of α-helixes and β-sheets is driven by interactions
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between polypeptide chains linked together by hydrophobic and hydrophilic interactions, electrostatic
interactions and disulfide bonds [11]. All these chemical interactions create a unique protein
conformation that is reorganized at all structural levels during heat treatment. Changes in α-helix
and β-sheet structures start to occur at heating temperatures above 55 ◦C, and almost complete loss
of secondary and tertiary structure as well as cleavage of disulfide bonds occurs at temperatures
above 70–80 ◦C [12,13]. At the same time, because of protein denaturation, irreversible intermolecular
interactions may result in protein aggregation and cross-linking reactions between amino acids,
e.g., through formation of lysinoalanine (LAL) [14]. These heat-induced conformational changes
of food proteins may further affect digestion and absorption of proteins/peptides by the intestinal
epithelium, as well as their recognition by immune cells. Moreover, if sugars are present during the
heat treatment, the free amino groups of side chains of amino acids can be blocked due to the Maillard
reaction [11,13].
3. The Maillard Reaction in Food Processing
One of the best-known interactions between proteins and sugars occurring during heat processing
of food is the Maillard reaction (MR), also known as glycation. During the MR, sugars are linked to
proteins by a covalent bond between free amino groups of amino acids (mostly lysine and arginine)
and the carbonyl groups of a reducing sugar (simplified scheme on Figure 1).
Figure 1. Simplified scheme of the formation of Maillard reaction product during food processing.
Amadori rearrangement leads to the formation of a number of advanced glycation end products,
among others: (a) Nε-(carboxymethyl)lysine; (b) pyrraline and (c) pentosidine.
The MR occurs naturally during regular food processing and meal preparation (cooking,
frying, and baking) [15–17]. However, the chemistry of the reaction is extremely complex.
A cascade of chemical rearrangements including condensation, oxidation and hydration, leads to
formation of numerous Maillard reaction products (MRPs). The Schiff bases formed as the first
products of the reaction are followed by their Amadori rearrangement and subsequent oxidative
modifications (glycoxidations) resulting in the formation of advanced glycation end products (AGEs).
The chemical nature of many of the AGEs is unknown due to their heterogeneous and unstable
nature. However, a growing number of structurally defined AGEs such as pyrraline, pentosidine and
Nε-carboxymethyllysine (CML) have been found in processed food [18,19].
Moreover, the type and amounts of MRPs formed are under the control of factors such as the
structural diversity of (poly)saccharides and proteins, reaction temperature and time, ratio of amino
190
Nutrients 2017, 9, 835
group and reducing sugar, pH and water activity [15,20]. MRPs are known to confer functional
characteristics to food proteins such as appearance, smell, taste and texture. For this reason, the MR is
a relevant reaction for consumers therefore also for the food industry [17,21]. In addition to functional
changes of proteins, many studies in the last decade have revealed that the MR also affects biological
properties of food proteins such as their digestibility, bioavailability, immunogenicity and consequently
their allergenicity. Biochemical and conformational changes of proteins caused by MR may result
in masking of existing antibody binding epitopes, but also in creating new structures that are more
immunogenic and are thus able to promote the initiation of IgE-mediated allergies [22–25].
4. Influence of Maillard Reaction of Digestibility of Proteins
In order to elicit an allergic immune response, food proteins (or peptides thereof) must survive
digestion and remain in the gastrointestinal tract for a period of time that is sufficient to induce
sensitization. From that perspective, the susceptibility of food proteins to enzymatic hydrolysis seems
to be an important factor determining their allergenicity [26–28]. Even so, not all food allergens are
resistant to digestion [29,30]. As described above, both heating and the MR can alter the susceptibility
of proteins to gastrointestinal digestion due to unfolding, heat-induced disulfide bond interchanges,
aggregation, the formation of lactulosyllysine, and formation of AGEs, thereby affecting the availability
of enzymatic cleavage sites on the protein backbone.
Heating itself causes unfolding of protein and exposure of linear epitopes and may result in
enhanced susceptibility to enzymatic proteolysis as described for β-lactoglobulin heated at the
temperature of 90 ◦C [31]. However, Corzo-Martínez and colleagues demonstrated that denaturation
and aggregation of heated β-lactoglobulin caused by MR led to decreased β-LG proteolysis [32].
A band corresponding to intact β-LG was observed on SDS-PAGE picture after trypsin/chymotrypsin
digestion of β-LG glycated with galactose and tagatose at 40 ◦C for one day, even after 1 h of digestion.
Resistance to gastrointestinal digestion was more evident in β-LG glycated with galactose than
tagatose which was shown previously to be a less efficient sugar in formation of MRPs [33]. Therefore,
the results of that study revealed that higher degrees of glycation of bovine β-LG lead to a higher
resistance to proteolysis. This could be explained by lower susceptibility of glycated lysine and arginine
residues to trypsin/chymotrypsin proteolysis by masking the sites of cleavage [18]. In addition,
Maillard reaction-induced protein aggregates may protect proteins during in vitro gastrointestinal
digestion, which was shown by inhibition of aggregation of β-LG in the presence of pyridoxamine [32],
an effective inhibitor of formation of MRPs on all stages [34]. Those results are in line with a number
of other studies that demonstrated impaired enzymatic hydrolysis in vitro due to the MR observed
together with decreased protein solubility caused by denaturation, structural rearrangements and
aggregation of proteins heated with sugar [25,35–37]. In contrast, glycation has also been reported to
increase protein solubility [38,39] as well as protein digestibility as it has been shown for lysozyme [40]
and codfish parvalbumin [41], suggesting that an effect of MR on protein digestibility may be connected
with structural characteristic of the protein that is studied. Moreover, the diversity of conditions used
for glycation in the different experiments as pH, time of heating, temperature of heating, ionic strength
of the medium, water activity and type of sugar may also explain the disparity often observed in
the literature on the influence of MR on protein digestibility. Liu and colleagues showed that the
glycation of whey proteins at different conditions of water activity and pH alternates the peptide
profiles observed on HPLC chromatograms [42]. The local environment of lysine changes in differently
unfolded proteins at pH 5, 7 or 9, which affected the susceptibility for glycation, the type of formed
MRPs (e.g., formation of agglomerates), and subsequently modified the protease action, resulting in a
different peptide composition after enzymatic hydrolysis [42].
The number of studies involving in vivo experiments investigating an effect of MR on digestibility
of food proteins is limited to date. A recently published study performed on humans compared
the effects of diets with different MRP contents on dietary protein utilization in adolescent males.
The study revealed that a diet high in the MRPs limits the digestibility of proteins since 47% higher
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fecal nitrogen excretion, 12% lower apparent nitrogen absorption and 6% lower nitrogen digestibility
was observed in the group consuming diet high in MRPs [43]. Hellwig and colleagues [44] have shown
that the human colonic microbiota are able to degrade the following MRPs: Nε-fructosyllysine, CML
and pyrraline. This suggests that the released glycated peptides and amino acids may be used by
microbes as the source of energy or can be transported via intestinal barrier as it was proposed for
small pyrraline peptides [45]. This shows the relevance of microbiota in the degradation process of
Maillard reaction-modified proteins and therefore also their absorption in the intestine.
5. Absorption of MRPs in Intestine
The question if the glycated protein/peptide can have immunological effect in vivo depends on
whether these molecules are available in the gastrointestinal mucosa to be absorbed into the circulation
and subsequently to get in contact with the immune system. Dietary MPRs were shown to appear in the
circulation and/or urine of human subjects after consumption of MRPs rich diet [18,46–52]. The study
performed by Hellwig and colleagues on glycated casein samples revealed that fructoselysine and
(CML) are released after digestion bound to peptides smaller than 1000 Da, which makes them
available for absorption [52]. This was confirmed in the studies performed in the rat model showing
that advanced MRP such as CML, pyrraline and pentosidine may be absorbed by the gut. Ingested
dietary CML in rats appeared to be approximately 26.0–29.0% excreted in the urine, and 15.0–22.0%
excreted in feces [14,53]. Approximately 1.7% of dietary CML accumulated in the circulation, kidney
and liver and approximately 50.0% of the ingested CML was not recovered. This was later confirmed
in a human study where 31.2% of ingested dietary CML was excreted in the feces, 14.4% in the
urine, and 54.4% left unrecovered [48]. More than 60% of dietary pyrraline and approximately 2.0%
of dietary pentosidine were excreted in urine in humans [49,50]. Different percentage of recovery
of total diet amount of AGEs found in urine suggest different resorption and metabolic pathways
of individual Maillard products [50]. In addition, LAL, a compound formed by cross-linking of
protein, was found in the urine, plasma, liver and kidneys of rats fed with the diet with low and high
LAL-content [14] although it has been reported to be released during digestion process into larger
peptides of at least 30–40 amino acids [52].
Cross-linking of proteins seems to reduce an epithelial uptake of proteins although promote
an uptake through Peyer’s patches as was shown for crossed-linked β-lactoglobulin and
α-lactalbumin [54,55]. In addition, the larger agglomerates, as well as other MRPs can be further
metabolised by intestinal microbes [44,56,57] resulting in formation of new bioactive compounds but
also modulating the intestinal microbiota composition in humans [58,59]. The fact that the dietary
protein-bond AGEs, such as CML, pentosidine and pyrraline, are available in the gastrointestinal tract
and circulation means that they can also interact with the immune cells.
6. Influence of Maillard Reaction on Immunogenicity of Proteins
6.1. MR-Modified Proteins and Allergic Sensitization
Even though the role of AGEs in chronic inflammatory diseases is more well-known and
studied [47,60,61], evidence is emerging that AGEs also play a role in allergy. As this paper focuses on
allergy, the role of AGEs in chronic inflammation will not be discussed in details.
Allergy is commonly divided in two phases. An initial phase of allergic sensitization represents
principally a particular immune reaction leading to the formation of allergen-specific IgE antibodies.
IgE antibodies can crosslink adjacent cell-bound IgE molecules on basophils and mast cells upon
repeated exposure to allergens, leading to degranulation and the release of mediators, including
histamine, prostaglandins, leukotriens and tromboxanes. These mediators cause the typical symptoms
of a type 1 (within 20 min) IgE-mediated allergy, including rhinitis, atopic dermatitis, allergic asthma,
and occasionally even anaphylaxis [62].
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Immunogenicity of proteins is thus dependent on their ability to eventually induce adaptive
T-and B-lymphocyte responses during the allergic sensitization phase (see Figure 2). This is strongly
influenced by the efficiency of antigen uptake and processing, as well as by the activation status and
production of cytokines by myeloid antigen presenting cells (APC: monocytes, macrophages, and
dendritic cells). Receptor-mediated endocytosis—as opposed to pinocytosis—is an efficient way of
antigen uptake that facilitates adaptive immune responses at low antigen exposure and also induces
activation and cytokine production by antigen presenting cells. APCs such as dendritic cells (DC)
can use Fc receptors [63], RAGE (receptor for advanced glycation end products) [64,65], dectin-1, 2
and 3 [66,67], DC-SIGN [68], galectin-3 [69] and mannose receptors [70] for efficient antigen uptake.
For example, it is known that IgG-immune complexes are more immunogenic because they are targeted
to CD32/Fc RII receptors on APCs [71]. This was also shown for an uptake of allergen-IgE complexes
via CD23/FcεRII, resulting in efficient T cell activation at 100-fold lower antigen concentrations [72].
These findings suggest that interaction with specific receptors on APC may be of importance to
understand an immunogenic character of dietary AGEs (see Figure 2).
Figure 2. Schematic contribution of dietary Advanced glycation end products in the allergic
sensitization process. Dietary Maillard reaction products (MRP) are taken up in the gut by crossing the
epithelial barrier (I), leading to antigen uptake by mucosal dendritic cells and presentation of peptides
to specific T-cells (II). Activated antigen-specific helper Th cells differentiate into pro-inflammatory and
allergy-inducing Th17 and Th2 subsets (III). Allergen-specific B-cells become activated upon ligand
binding and start the production of allergen-specific IgE antibodies (IV) that bind to mast cells and
basophils and become detectable in the circulation.
6.2. Interaction of MR-Modified Proteins with Receptors Present on APCs
To induce an allergic immune response the MR-modified protein need to be recognized and
taken up by antigen presenting cells (APCs) and subsequently presented to T-cells [24]. Recently
more evidence has been found that some MRPs may function as activators of dendritic cells (DCs)
via targeting AGE receptors [23,73–75]. Several receptors mediating antigen uptake, activation and
maturation in DCs were identified as potential receptors for dietary MRPs, including AGE-receptor
complex (AGE-R1/OST-48, AGE-R2/80K-H, AGE-R3/galectin-3) [76–78], members of the scavenger
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receptor family A (SR-A) and B (SR-B) [23,24,75,79–81] as well as mannose receptor [82–84]. Dry
roasted Ara h1 was bound to the scavenger receptor, CD36 and the receptor for advanced glycation
end products (RAGE) [24,85].
RAGE is the most studied receptor that can recognize and bind dietary AGEs [24,42,85–88].
Cellular signaling due to AGE–RAGE interactions seem to be a key component in pro-oxidative and
pro-inflammatory condition [89] and this may be involved in enhanced allergic sensitization [85].
Soluble RAGE (sRAGE), the extracellular ligand-binding domains of RAGE present in the circulation,
competes with membrane RAGE in binding AGEs acting as a decoy domain receptor [90,91]. Binding
of AGEs to sRAGE, in contrast to interactions with membrane form of RAGE, does not result
in inflammatory signal transduction therefore sRAGE acts as inhibitor of RAGE-AGE signaling
and is potentially applicable for the treatment of various AGE-related diseases including diabetic
cardiovascular complications [92,93], diabetic kidney disease [94] and a number of aging-related
diseases including atherosclerosis, cataracts, Alzheimer’s disease and Parkinson’s disease [95,96].
The recent study of Liu and colleagues revealed that whey proteins glycated by dry heating
(at 130 ◦C) interacts with sRAGE. The strength of binding was positively correlated with the time of
heating and the formation of agglomerates and was more prominent in the samples with lower water
activity [86]. These findings are in line with other studies showing binding of AGE-modified peanut
allergens to recombinant form of RAGE [24]. The study performed by Zill and colleagues [85,97]
revealed RAGE-mediated activation of both Caco-2 cells and RAGE-transfected HEK-293 cells by
chemically defined food-derived products, both, AGEs and non-AGEs. This suggests that diet-derived
AGEs may activate the antigen presenting cells via RAGE. The study performed by Hou and colleagues
suggest a positive correlation between the level of AGEs accumulated in the circulation of patients with
chronic kidney disease and the expression of RAGE on monocytes isolated from these patients [98].
The enhanced expression of RAGE was strongly correlated with plasma levels of pentosidine, plasma
levels of tumor necrosis factor alpha (TNF-α), monocyte activation markers, and the systemic acute
phase reactant, C-reactive protein [98]. Hilmenyuk and colleagues demonstrated activation of RAGE
on immature DC via interaction with AGE-modified ovalbumin (OVA). Increased expression of RAGE
on immature DCs exposed to AGE-modified OVA was seen as well as enhanced activation of the
transcription factor NF-κB compared to DCs exposed to non-modified OVA [83]. The ligation of
RAGE by CML was shown to upregulate the RAGE expression in human neuroblastoma cell line
SH-SY5Y [87] as well as enhance the expression of vascular cell adhesion molecule-1 (VCAM-1) on
endothelial cells [99]. These data suggest that AGE-RAGE interaction may result in NF-κB activation as
well as upregulation of RAGE expression on immune cells what in consequence may result in secretion
of pro-inflammatory cytokines and thus activation of APCs. In opposite to these results other studies
show that CML-modified proteins [100] as well as Maillard-reaction modified β-lactoglobulin [101]
and coffee [102] are not able to stimulate inflammatory signaling pathways in RAGE-expressing human
cell lines [100,101]. Interestingly, ovalbumin modified by pyrraline, the other AGE, was also not shown
to interact with RAGE [23]. Thus, the discussion on the ligation of RAGE with food-derived AGEs
and its physiological consequences remains open and more data on activation of RAGE by AGEs are
needed to prove the role of RAGE in the activation of APCs during the allergic sensitization process.
6.3. Influence of MR-Modified Proteins on T-Cell Activation and Polarization
Interaction of AGEs with receptors present on APCs may result in internalization and therefore
presentation of antigen to T-cells. Ilchman and colleagues demonstrated that AGE-modified OVA
was taken up much more efficiently by bone marrow-derived murine myeloid dendritic cells (mDCs)
than native OVA, and enhanced activation of OVA-specific CD4+ T cells [75]. Scavenger receptor
class A type I and II (SR-AI/II) were identified as receptors mediating the uptake of AGE-OVA [75].
These results are in line with a study using human DCs as a model for an uptake of FITC-labeled
AGE-modified OVA. Enhanced uptake of AGE-modified OVA was mediated by mannose receptor,
scavenger receptor and macropinocytosis. Co-culturing of CD4+ T cells with AGE-OVA-loaded mature
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DCs induced greater Th2 cytokine production (IL-5, IL-4, and IL-6), while OVA-loaded DCs induced a
significant Th1 or regulatory cytokine profile [83]. The study of Moghaddam and colleagues performed
on dry roasted peanut proteins confirm the ability of dietary AGEs to target antigen presenting cells
via RAGE and CD36. Moreover, mice sensitized with dry-roasted peanut extract showed higher IL-4,
IL-5 and IL-13 secretion by mesenteric lymph node cells showing skewing of T cell response into Th2
when compared with mice sensitized with non-treated peanut extract. High reactivity of mice primed
with dry roasted peanut to raw peanut antigens suggest that roasting enhances immunogenicity of
peanut extract having an important impact on the priming step of sensitization [24].
Heilmann and colleagues aimed to identify glycation structures enhancing T-cell immunogenicity
of a food allergen by modification of OVA with different AGEs such as CML, CEL and pyrraline.
To assess the T-cell immunogenicity of glycated OVAs, murine OVA-specific CD4+ T-cells were
co-cultured with bone marrow-derived DCs in the presence of differently processed OVA samples.
Pyrraline modified OVA enhanced CD4+ T-cell immunogenicity, as evidenced by increased IL-2
production, higher production of IFN-γ and IL-17A when compared with native OVA. Moreover,
pyrraline-OVA and AGE-OVA were efficiently taken up by BMDCs via SR-A. In addition to antigen
uptake, cell maturation is required for DCs to gain their full T-cell stimulatory capacity. However, no
differences in expression of co-stimulatory molecules CD40, CD80, CD86, and MHC class II on the cell
surface of DC were seen suggesting that pyrraline modification does not induce BMDC maturation.
This is in line with observations of Moghaddam and colleagues [24], who suggested enhanced targeting
and presentation via AGE receptors rather than conventional DC maturation may be implicated in
the increased immunogenicity of DR peanut antigens in vivo. However, this is in contrast with the
work of Buttari and colleagues who showed that AGEs of plasma β2 glycoprotein I (β2 GPI) triggered
the maturation of monocyte-derived human DCs and polarized allogenic naive CD4+ T-cells into
Th2 cells in a co-culture with matured DCs [73]. These different observations could be explained by
heterogeneity of the structures MRPs and the expression profiles of receptors in these human and
murine DCs.
6.4. Role of Agglomeration in Immunogenicity of MR-Modified Proteins
These results raise the question which structural changes triggered by MRPs can explain
the immunogenicity of AGEs and capabilities to initiate the polarization of allogenic naive CD4+
T-cells into Th2 cells. Maillard reaction caused agglomeration of proteins was excluded as a major
contributor to increased immunogenicity of proteins in the studies of Moghaddam and colleagues [24]
and Heilmann and colleagues [23] since the samples underwent multiple rounds of filtration and
centrifugation that depleted cross-linked species. However, the agglomeration of MR-modified
proteins and level of cross-linking were not measured in these studies. Moreover, food processing of
proteins promotes the formation of β-sheet-rich, fibrillar structures [103] known to possess high affinity
binding to RAGE [104] and CD36 [105]. Pasteurization caused aggregation of beta-lactoglobulin and
alpha-lactalbumin enhanced uptake of cross-linked proteins via Peyer’s patches, which promoted
significantly higher Th2-associated antibody and cytokine production in mice than their native
counterparts [54,55]. These results suggest that not only Maillard reaction but also protein cross-linking
can enhance immunogenicity of proteins and their sensitizing capacity.
The research outcomes discussed above provide strong evidence that some dietary AGEs
can bind to receptors on antigen presenting cells and thus modify T-cell immunogenicity (the
schematic contribution of dietary AGEs in the allergic sensitization process is presented on Figure 2).
However, information about selectivity of AGEs structures binding to AGEs receptors is very limited.
The heterogeneity of AGEs and the diversity of their receptors indicate that more study is required
to elucidate the precise receptors and pathways implicated in enhanced DC-mediated uptake and
presentation of antigens to T cells.
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6.5. Influence of MR-Modified Proteins on B-Cells Switching and the Production of Antigen Specific IgG
and IgE
When membrane-bound immunoglobulin (Ig) of naïve B cells come in contact with specific
dietary antigens, and are activated by ligation of the surface molecule CD40 to CD40L on activated
Th2 cells that produce IL-4 and IL-13 , the B cells are induced to switch to produce IgE. Naïve
B cells further differentiate and proliferate into activated plasma cells synthesizing and secreting
antigen-specific IgE (see Box 2). Lymphocytes activated in the GALT leave through the draining
lymphatics and reach the MLN, where they stay for a period for further differentiation, before migration
into the bloodstream [62,106]. Moghaddam and colleagues demonstrated that BALB/c mice primed
subcutaneously with soluble fractions of peanut protein extract from raw or dry roasted (DR) peanuts
show enhanced peanut-specific IgG titers in DR-primed groups. These results were confirmed in
intra-gastric gavages of DR and raw peanut extracts showing 100-fold higher IgG titers, enhanced titers
of anti-peanut IgE as well as functional basophil degranulation in DR group. Moreover, mesenteric
lymph node cells from DR but not raw peanut protein-primed mice proliferated robustly in response
to raw and DR peanut extract with the dominance of IL-4 and IL-5 over IFN-γ and TNF-α. The authors
suggested that the observed increased immunogenicity of DR peanut antigens can be explained by
selective targeting, activation and presentation of antigen via binding to AGE receptors on DCs [24].
7. Influence of Maillard Reaction on Recognition of Food Allergens by Specific IgE
MR induced during food processing may also modulate binding potential of specific IgE to
food allergens. This can be induced by: (a) disruption of the conformational and linear epitopes
accompanied with the changes of the tertiary and secondary structure that impair the IgE binding
potential of the protein [12,106,107]; (b) formation of agglomerates carrying high number of epitopes
that cause enhanced degranulation capacity of basophils [108]; or (c) formation of new epitopes due to
aggregation and/or Maillard reaction [24] (Figure 3). These new epitopes called neo-allergens are able
to target APCs resulting in antigen presentation and subsequently modulating T-cell differentiation as
well as a production of antigen-specific IgE. Production of specific IgE is therefore a consequence of
sensitization phase by interaction of immunogenic MRPs with APCs (see Boxes 1 and 2). Moghaddam
and colleagues observed that enhanced anti-raw peanut IgE titers in mice sensitized with dried peanut
extract versus those sensitized with raw peanut extract was also reflected in enhanced degranulation
of basophils [24].
The MR was shown to either reduce or enhance IgG and/or IgE binding capacities of some food
allergens [25,109–113]. For instance, the proteins that belong to pathogenesis-related (PR) protein
family and being the homologous to birch pollen allergen Bet v 1 show reduced IgE binding capacity
after processing with sugar as it was shown for Pru av 1 [109] and Cor a 1 [114]. This can be explained
by a masking effect of carbohydrates reducing an accessibility of epitopes for IgE binding (Figure 3).
In contrast to (PR) protein family MR was shown to enhance IgE binding capacity to peanut proteins
and scallop tropomyosin [115–117]. Thus, the influence of MR on IgE binding seems to depend on
physicochemical properties of proteins (hydrophobicity, size, amino acid composition, charge) as well
as on conditions of MR (type of sugar, time, water activity, pH, temperature, presence of salts) [118,119].
The study of Vissers and colleagues showed reduced allergenicity of MR-modified peanut allergen
Ara h 1 in IgE binding test while enhanced β-hexosaminidase release from basophils upon incubation
with the same MR-modified allergen [113]. The authors suggest that MR-induced agglomeration of Ara
h 1 may be responsible for the observed increased capacity of antigen to cross-link the IgE and initiate
the mediator release from RBL-2H3 cells (see Box 1). That indicates a need to include the functional
assays, next to the IgE binding tests, in the studies on allergenicity of MRPs to be able to link the results
to development of acute complaints of a clinically observable allergic response (see Box 3). Based on
the functional basophil activation test (BAT) Cucu et al. showed that two out of six hazelnut allergic
patients showed enhanced basophil activation after exposition to MR-modified hazelnut extract [114].
Other study revealed that 70% of the patients (out of 15) sensitized to soy showed enhanced basophil
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activation in BAT assay upon incubation of basophils with MR-modified soy proteins when compared
with soy proteins modified only by heating (without sugars) [22]. Moreover study of Vojdani and
colleagues revealed increased levels (3–8-fold) of specific IgE against processed food antigens in 31%
of the patients when compared to raw food antigens [120]. These results suggest that some of the
patients are sensitized against processed food rather than raw and the MR may play a crucial role in
the enhancing of immunogenic potential of food allergens as it was already showed by Moghaddam
and colleagues [24]. Therefore, the diagnosis of food allergy could be improved by incorporation of
processed and MR-modified food allergens next to the raw ones into the diagnostic tests.
Figure 3. Modulation of allergenicity of food proteins by the Maillard reaction. Upon food processing
using heating, reducing sugars will react with primary amino groups on amino acids from allergen
proteins to result in Maillard reaction products (MRP). Consequently, these MRP may block epitopes
thereby preventing IgE binding and crosslinking, and subsequent mediator release. This results in
reduced allergenicity of the altered food allergens. Alternatively, MRP may lead to the exposure of
neo-epitopes leading to enhanced uptake by antigen-presenting cells and exposure to specific T-cells
and this enhanced possibility for IgE cross-linking may lead to enhanced allergenicity. Lastly, MRP may
lead to the formation of agglomerates of allergen molecules resulting into enhanced IgE cross-linking
and increased allergenicity. The ratio between these several possibilities determines the final outcome
of the mediator release capacity of the MRP altered food allergens.
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Box 1. Immunochemical properties of allergens.
Allergens are generally proteins that, when exposing genetically susceptible individuals frequently and in
low doses (<1 μg) on a mucosal surface are able to induce a Th2 response associated with the production of IL-4,
IL-5, and IL-13 leading to the synthesis of allergen-specific IgE antibodies.
At present, no identified antibody characteristics and no identified structural features of IgE binding epitopes
seem to be associated with the phenotype of the food allergic disease. Potential allergens must necessarily
contain B-cell epitopes to which IgE can bind, and T-cell epitopes capable of inducing a Th2 type response.
Peptide sequences of T-cell epitopes (10–15 amino acid residues long) show no general homology across allergen
families and thus it has been proven impossible to identify a consensus sequence for an allergenic epitope [121].
IgE binding allergen epitopes generally comprise conformational and more hydrophobic patches present on
the allergen. A significant proportion of the IgE is directed against the glycosylated B-cell epitopes [122]. This
might be a consequence of the hundred-fold increased cellular uptake of glycosylated proteins and peptides by
antigen-presenting cells compared to their non-glycoslyated counterparts and resulting in enhanced immune
responses [123]. However, others suggest that glycosylation is not a common critical determinant of allergenicity
as food allergens comprise both glycoproteins as well as non-glycosylated proteins [124].
An epitope is identified by its ability to bind antibodies and is suggested to consist of a recognizable sequence
of 6–15 amino acids (covering a 11–13 nm distance) contributing to the binding between epitope and antibody
molecule [125]. Two of these identical epitopes need to span a distance between 8 and 24 nm, with a single amino
acid being in the order of about 0.5 nm [126,127]. A linear unit potentially leading to degranulation would then
comprise a distance of 20–54 nm equaling 40–108 amino acids (4.400 to 11.880 Da) [128]. In a 20 kDa allergen this
would represent 2–5 units, while a 200 kDa allergen would harbor 16–45 units. Indeed, most allergens have
only one to five immunodominant epitopes. A 40 amino acid unit would be sufficient to induce IgE antibody
formation and combine the potential to result in degranulation upon binding to IgE on sensitized mast cells.
Box 2. Immunochemical properties of IgE.
IgE molecules have a 12% carbohydrate content with oligosaccharides asparagine-linked at six places all in
the first three of the four constant region domains, they have a limited segmental flexibility [129]. Therefore, IgE
molecules are generally considered to be more rigid than IgG molecules putting emphasis on the importance
of the inter-epitope distance resulting in proper IgE binding. This way a binding stoichiometry of two can be
reached as closely as possible resulting in a high binding affinity of the allergen-specific IgE antibodies [130].
The relevance of IgE affinity is illustrated in studies showing that in allergic individuals, the peanut allergen
Ara h 2-specific IgE affinity correlated with the severity of the allergic disease, but not with the level of specific
IgE [129,131]. In allergic individuals, IgE concentrations in the circulation may reach over 10 times the normal
level (≈150 ng/mL), and who have an increased risk of developing allergies. However, the concentration of IgE
in the serum of healthy individuals is 104 times less than that of IgG.
These IgE antibodies have the capacity to bind to IgE Fc epsilon receptors with high affinity (Ka ≈ 1010 M−1).
This exceptionally high affinity is mainly a reflection of the very slow dissociation rate with a half-life of about
20 h for circulating IgE. The residence time on mast cells in tissues is further extended to more than 14 days by
restricted diffusion and rebinding to cell receptors [130].
Box 3. Advantage of functional tests on IgE binding assays in the diagnosis of food allergy.
Diagnosis of allergy is routinely based on binding of IgE antibodies to the relevant allergen in a serological
test. Principally, this binding of one Fab fragment to a single epitope results in a positive reading representing
immunogenicity. This mostly conformational monovalent binding interaction is not related to the capacity
to induce an allergic response resulting into mediator release. For this reaction it is essential to achieve
cross-linking of several specific IgE molecules bound to adjacent FcεRI on mast cells and basophils (hence
allergenicity). Principally, this elicitation phase requires a multivalent interaction between (mostly linear)
allergen multi-epitopes and multiple Fab fragments on IgE antibodies. This allergen capacity can be analyzed ex
vivo with blood-derived basophils or in vitro by using e.g., the rat basophilic leukemia (RBL)-HE3 cell line and
is generally called allergenicity of the allergen. To analyze the basophil degranulation capacity sensitive assays
are required as these cells comprise only 0–2% of leukocytes equaling 1–8 × 104 cells/mL [130]. This different
capacity of allergens should be taken into account when relating the functional activity of allergens to the clinical
symptoms of allergy. High affinity Fcε receptors are abundantly expressed (6000–600,000 receptors per cell) on
mast cells in tissues and basophils in the blood. The number of FcεRI per basophil varies between different
donors (range 29,000–680,000) and is also related to the IgE concentration in the serum [131]. Upon IgE binding
to their specific receptors, these cells are sensitized and therefore the individual is called sensitized. Minimally,
2000 of these FcεRI bound specific IgE molecules need to be cross-linked by the relevant epitopes on the allergen
in order to cause degranulation of the mast cell and/or basophil resulting in the release of the mediators and
the development of acute complaints of a clinically observable allergic response. Therefore, functional assays
such as histamine, β-hexosaminidase release assays or basophil activation tests should be included next to the
conventional IgE binding tests to study the influence of Maillard reaction on allergenicity of proteins.
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8. Conclusions
In conclusion, the MR can alter immunoreactivity towards food proteins, and MR-modified
proteins may enhance the immune response by selective interaction with APCs carrying receptors
for AGE. In addition, it has become clear that the presentation of MR-modified allergens to T-cells
may skew the subsequent T-cell differentiation into Th2 cells producing IL-4, IL-5 and IL-13, which
are responsible for the initiation of IgE antibody production. Some studies also observed enhanced
mediator release from basophils incubated with MR-modified proteins that may be resulting from:
(a) the immunogenic potential of MRPs enhancing the sensitization; and/or (b) agglomeration leading
to more efficient cross-linking and therefore mediator release. These findings reveal a need for better
understanding of the influence of MR on both the sensitization phase as well as the development of
the symptoms of the allergy. Understanding the mechanisms involved in immunoreactivity of AGEs
would help to improve the diagnostics of food allergy as well as develop optimized conditions for
food processing to control the rate of MR.
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Abstract: Background: Gal d 1 (ovomucoid) is the dominant allergen in the chicken egg white.
Hypoallergenic variants of this allergen can be used in immunotherapy as an egg allergy treatment
approach. We hypothesised that disruption of two of the nine cysteine-cysteine bridges by
site-directed mutagenesis will allow the production of a hypoallergenic variant of the protein;
Methods: Two cysteine residues at C192 and C210 in domain III of the protein were mutated to alanine
using site-directed mutagenesis, to disrupt two separate cysteine-cysteine bridges. The mutated
and non-mutated proteins were expressed in Escherichia coli (E. coli) by induction with isopropyl
β-D-1-thiogalactopyranoside (IPTG). The expressed proteins were analysed using sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting to confirm expression.
Immunoglobulin E (IgE) reactivity of the two proteins was analysed, by immunoblotting, against a
pool of egg-allergic patients’ sera. A pool of non-allergic patients’ sera was also used in a separate blot
as a negative control; Results: Mutant Gal d 1 showed diminished IgE reactivity in the immunoblot
by showing lighter bands when compared to the non-mutated version, although there was more
of the mutant protein immobilised on the membrane when compared to the wild-type protein.
The non-allergic negative control showed no bands, indicating an absence of non-specific binding of
secondary antibody to the proteins; Conclusion: Disruption of two cysteine bridges in domain III of
Gal d 1 reduces IgE reactivity. Following downstream laboratory and clinical testing, this mutant
protein can be used in immunotherapy to induce tolerance to Gal d 1 and in egg allergy diagnosis.
Keywords: allergens; egg allergy; immunotherapy; hypoallergens
1. Introduction
Hypersensitivity to chicken egg is caused by allergens present in the egg white and egg yolk.
Among these, Gal d 1 (ovomucoid) is known to be the most allergenic and predominant allergen and it
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is found in the chicken egg white [1,2]. This 28 kDa glycoprotein accounts for approximately 11% of the
total egg white protein. The tertiary structure of Gal d 1 is composed of 186 amino acids which form
three domains, with each domain containing approximately 60 amino acids. The tertiary structure is
robustly supported by nine intra-domain cysteine-cysteine disulphide bridges and five oligosaccharide
side chains. The function of Gal d 1 is known to be a trypsin inhibitor; however, the trypsin inhibitory
activity is limited to the second domain [1]. Hypersensitivity to Gal d 1 occurs because of its ability to
efficiently bind to immunoglobulin E (IgE). It has eight IgE binding epitopes [2], some of which are
linear while others are conformational. The highly IgE-reactive epitopes present in the third domain
make it the most allergenic domain of the three. The presence of linear IgE binding epitopes in Gal
d 1 makes it resistant to conditions such as heat and/or proteolytic digestion [3]. Since egg-allergic
patients are often allergic to cooked egg [4], it can be suggested that Gal d 1 plays a crucial role in
cooked egg allergy due to its rigidity. These specific features of Gal d 1 make it the prime allergen
when compared to other allergens in chicken egg and an ideal target for the development of egg allergy
treatment strategies.
There is no long-term cure for egg allergy. Strict avoidance of egg is the currently recommended
management strategy; however, avoidance is difficult and may cause malnutrition in children [5,6],
especially in financially disadvantaged families where procurement of more expensive nutritional
supplements or food that can replace eggs may be difficult. It is also problematic to completely avoid
eggs because of the presence of components or traces of egg in various food products, pharmaceutical
products and vaccines [7,8]. Allergen-specific oral immunotherapy (OIT) offers a potential treatment
strategy, not only for egg allergy but also for other types of food allergies. OIT essentially involves
the gradual oral feeding of an allergen to the patient in order to induce tolerance [9,10]. However,
OIT can be perilous for some patients, primarily because of the high allergenecity of some allergens
and the sensitivity of the patient, which may cause adverse conditions such as anaphylaxis that
can even lead to death [11–13]. Adverse reactions to OIT are currently a potential barrier to clinical
application [14,15]. Therefore, production of less allergenic versions, or hypoallergens, of allergens
has been the focus of many research groups [16–18], because these hypoallergens can offer improved
safety of oral immunotherapy.
Production of hypoallergenic Gal d 1 can be achieved by using mutagenesis as a tool in two
different strategies: the first is by mutating the sequences of the IgE binding epitopes and the second
is by targeting the secondary structure of the proteins. Drew et al. (2004) [19] successfully produced
a hypoallergenic variant of the major latex allergen Hev b 6.10 by disrupting the cysteine-cysteine
bonds of the protein to reduce its IgE reactivity. In this study, we have successfully produced a
hypoallergenic variant of Gal d 1 by targeting only two of the nine cysteine-cysteine bridges using
site-directed mutagenesis.
2. Methods
2.1. Site-Directed Mutagenesis of Gal d 1
The cDNA of Gal d 1 was cloned into pTrcHisA expression vector as discussed in
Dhanapala et al. 2015 [20]. This construct was used for site-directed mutagenesis of nucleotides
coding two cysteine residues, using QuickChange Lightning Multi Site-Directed Mutagenesis
kit (Agilent Technologies, Santa Clara, CA, USA). Two TGC triplicates coding for cysteine
192 and 210 (Figure 1) were targeted in order to disrupt two different cysteine-cysteine
bridges located in domain III of Gal d 1 (Figure 2). The TGC codons were changed to GCC
codons that code for alanine. Initially, mutagenic primer pairs were designed according to the
mutagenesis kit guidelines. The two pairs were named PM7 and PM9, because the mutations
were targeting the seventh and the ninth cysteine-cysteine bridges, respectively. The primers
are as follows; PM7 forward 5′-GGCAACAAGTGCAACTTCGCCAATG CAGTCGTGGAAAG-3′,
PM7 reverse 5′-CTTTCCACGACTGCATTGGCGAAGTTGCACTTGTTGCC-3′, PM9 forward
208
Nutrients 2017, 9, 171
5′-ACTCTCACTTTAAGCCATTTTGGAAAAGCCTGAAAGCTTGGCTGT-3′, PM9 reverse
5′-ACAGCCAAGCTTTCAGGCTTTTCCAAAATGGCTTAAAGTGAGAGT-3′. The bolded and
underlined GCC on forward primers show the mutations. To mutate the Gal d 1 cDNA in pTrcHisA
vector, the above mentioned primers and the cDNA constructs (as template DNA) were subjected to a
polymerase chain reaction (PCR). The PCR reaction was set up according to Table 1. The PCR was
then run according to the cycling parameters outlined in Table 2. Following the PCR, the reaction was
digested with Dpn I for 5 min at 37 ◦C, to digest the non-mutated template DNA.
Figure 1. The nucleotide and amino acid sequence of Gal d 1. The squared cysteine (C) residues at
positions C192 and C210 are the targeted residues. These were replaced with alanine by mutating the
nucleotides to GCC.
Table 1. Mutagenic polymerase chain reaction (PCR) master mix components.
Reaction Component Volume Used (μL)
10× QuickChange Lightning Multi reaction buffer 2.5
Double-distilled water 15.5
Template DNA 1 (50 ng)
Mutagenic primers 1 of each primer (100 ng of each primer)
Deoxy-nucleoside triphosphate (dNTP) mix 1
QuickChange Lightning Multi enzyme blend 1
Total 25
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Figure 2. The secondary structure of Gal d 1 showing the total number of cysteine bridges. The two
arrows show the two cysteine bridges that would be destroyed by the mutations shown in Figure 1.
Figure adapted from: Kato et al., 1987 [1].
Table 2. Mutagenic PCR conditions.
Segment Cycles Temperature Time
1 1 95 ◦C 2 min
2 30
95 ◦C 20 s
55 ◦C 30 s
65 ◦C 3 min (30 s/kb of plasmid length)
3 1 65 ◦C 5
2.2. Chemical Transformation into E. coli
The mutated plasmids were then transformed into XL10-Gold ultracompetent E. coli cells
following manufacturer’s guidelines provided with the mutagenesis kit. The reaction was incubated
with 0.5 mL of pre-heated Luria broth (LB) media at 37 ◦C for 1 h at 250 rpm. The transformant
was then spread-plated on LB agar with 50 μg/mL ampicillin and incubated overnight at 37 ◦C.
The next day, 6 clones were grown in fresh LB media with ampicillin and grown overnight. The cells in
overnight cultures were pelleted by centrifuging at 13,000 rpm for 5 min and subjected to a mini-prep
(Qiagen, Hildon, Germany) to isolate the plasmid constructs following manufacturer’s guidelines.
The isolated plasmids of the six clones were sequenced to confirm the mutations. The sequences
were aligned and compared with wild-type Gal d 1 using the NCBI BLAST tool. The clones that had
the correct sequence and the mutations were then transformed into Express Iq chemically competent
E. coli cells (New England BioLabs, Boston, MA, USA) following manufacturer’s guidelines. The
transformants were plated on LB agar with ampicillin and incubated overnight at 37 ◦C. In addition
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to the mutant transformants plate, a sample of glycerol-stocked E. coli containing the wild-type
ovoumucoid construct was also plated on LB agar with ampicillin.
2.3. Time-Course Expression of Mutant Gal d 1 to Determine Optimum Expression Time
A single colony of the mutant Gal d 1 was grown overnight in LB media with 50 μg/mL ampicillin.
The overnight culture was then subcultured in 10 mL of fresh LB media and grown to mid-log phase
(OD600 0.4–0.6). A 1 mL sample of the cells was pelleted to be used as the unexpressed control (0 h)
of the time-course expression. Expression was then induced with 40 μL of IPTG and the cells were
incubated for 6 h at 37 ◦C with shaking at 250 rpm. A 1 mL sample was collected every one hour for
the 6 h period. The pellets collected at time points 0, 2, 4, 5 and 6 were lysed using 400 μL of Cell Lytic
B (Sigma Aldrich, Natick, MA, USA) lysis reagent and centrifuged at 13,000× g for 5 min to separate
the pellet (insoluble fraction) and the supernatant (soluble fraction). The two fractions were analysed
using SDS-PAGE and western blot according to the methods described in Dhanapala et al. 2015 [20].
2.4. Expression and Immunoblotting of Wild-Type and Mutant Gal d 1 Using Three Different
Detection Antibodies
The wild-type and mutant Gal d 1 were expressed in E. coli to their optimum time points
as determined by the time-course expressions (wild-type Gal d 1 optimum time was determined
in Dhanapala et al. 2015 [20]). Cells were pelleted and lysed using Cell Lytic B as previously
described. The soluble fractions of both proteins were run on SDS-PAGE in equal amounts
(15 μL), along with a molecular weight marker. A gap lane was left between the two proteins to
avoid any cross-contamination between the two variants. The SDS gel was then transferred on to a
nitrocellulose membrane to be used for western blotting. A total of five nitrocellulose membranes were
prepared this way, of which two would be used in the analysis described in Section 2.5. Three prepared
nitrocellulose membranes were subjected to Western blotting using three different antibodies that can
detect the expressed protein (e.g., anti-Xpress antibody, tetra-His antibody and penta-His antibody).
2.5. Immunological Analysis of Wild-Type vs. Mutant Gal d 1 Using Western Blot
The two remaining nitrocellulose membranes from Section 2.4 were used for immunoblotting
using egg allergic and non-allergic patients’ sera to test for IgE reactivity. In a previous study, we used
a pool of egg allergic patients’ sera and a pool of non-allergic patients’ sera for immunological analysis
of recombinant egg white proteins [20]. In this study we used the same pooled serum preparations
and incubated one membrane with allergic patients’ sera and the other with non-allergic patient’s
sera, and incubated overnight at 4 ◦C. The blots were then incubated with anti-human IgE (alkaline
phosphatase conjugated) secondary antibody produced in goat at a dilution of 1:1000. The bands were
detected using a chromogenic substrate as used in the Western blots described in Section 2.4.
3. Results
3.1. Mutagenesis of Gal d 1
Following site-directed mutagenesis to alter C192 and C210, six clones were sequenced to confirm
the mutations. Five of the six clones had only one mutation present. One clone had both of the
mutations at the expected locations of the sequence. When the wild-type Gal d 1 sequence was aligned
with the mutant Gal d 1 sequence on NCBI BLAST, it was seen that the TGC codons (cysteine) for C192
and C210 had been changed to GCC, which in turn codes for alanine.
3.2. Time-Course Expression of Mutant Gal d 1 to Determine Optimum Expression Time
The mutant Gal d 1 protein was expressed in E. coli following IPTG induction for 6 h, and pellets
were collected every 1 h, including one before IPTG induction. The pellets from time points 0, 2, 4, 5
and 6 were lysed and the soluble and insoluble fractions were analysed using SDS-PAGE and Western
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blot. The results show that the optimum expression time point for mutant Gal d 1 is 5 h (Figure 3B),
as compared to 2 h for wild-type Gal d 1 (Figure 3A) [20]. It can also be seen that the expression level
of mutant Gal d 1 decreased after 5 h.
Figure 3. Time-course expression of the mutant Gal d 1. A time-course expression of the wild-type Gal
d 1 (A) was previously published in Dhanapala et al. 2015 [20]. The mutant Gal d 1 (B) was subjected
to a time-course expression to determine its optimal expression time and conditions and was compared
to the wild-type Gal d 1 expression shown in (A).
3.3. Expression and Immunoblotting of Wild-Type and Mutant Gal d 1 Using Three Different
Detection Antibodies
The wild-type and mutant recombinant Gal d 1 proteins were expressed in LB until their
respective optimum time points by induction with IPTG. The proteins were analysed by SDS-PAGE
and Western blotting using three different antibodies (anti-Xpress, Tetra-His and Penta-His antibodies).
The SDS-PAGE shows that similar amounts of both proteins were loaded on to the gel (Figure 4).
The Western blots show that there was a slightly higher amount of mutant protein present on the
nitrocellulose membrane (Figure 4).
Figure 4. Immunoblot comparison of the wild-type and mutant Gal d 1 immobilised on nitrocellulose.
Three Western blots were conducted using His-tag–specific antibodies (Tetra-His & Penta-His) and
anti-Xpress antibody to compare the expression level of wild-type and mutant (PM7/9) Gal d 1.
SDS-PAGE shows the profile of the loaded proteins.
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3.4. Immunological Analysis of Wild-Type vs. Mutant Gal d 1 Using Western Blot
Two nitrocellulose membranes were prepared using the same samples used for the blots shown in
Figure 4. The two membranes were subjected to Western blotting using egg-allergic patients’ sera and
non-allergic sera. The egg-allergic patients’ sera blot showed reduced binding (lighter colouration) for
the mutant Gal d 1 lane when compared to the wild-type Gal d 1 (Figure 5). The non-allergic sera blot
showed no detectable bands in either of the lanes representing wild-type or mutant Gal d 1 (Figure 5).
Figure 5. Immunological comparison of IgE reactivity of wild-type and mutant Gal d 1. Western blots
were conducted, with exactly the same amount of proteins loaded against egg-allergic and non-allergic
patients’ sera. Anti-human IgE produced in goat was used as the secondary antibody. Non-allergic
controls were used to test for any non-specific binding of secondary antibody. The blots show a loss of
IgE reactivity in the mutant PM7/9.
4. Discussion
Hypersensitivity to chicken egg white is mainly caused by four major egg white allergens.
Of these, Gal d 1 is known to be the most allergenic protein. Gal d 1 is known to cause hypersensitivity
in its natural or cooked form. This may primarily be due to its rigid tertiary structure which allows
it to withstand harsh conditions such as heat and stomach/digestive acids. Due to the lack of an
effective curative treatment, strict avoidance is currently the standard method of managing egg allergy.
However, this strategy is not feasible due to the difficulty in achieving complete egg avoidance and
the high nutritional value of eggs in a balanced diet, especially for children. Induction of tolerance
to allergens is a well-established strategy for treatment of different types of allergies such as insect
venom or pollen allergy. Immunotherapy, specifically oral immunotherapy (OIT), which is a type
of allergen-specific immunotherapy (SIT), has been explored for the induction of tolerance to food
allergens. OIT involves feeding a patient increasing amounts of raw or cooked versions of the allergen
source, in order to induce desensitization or long-lasting tolerance to the allergen [21]. One barrier
to implementation of OIT in the clinical setting is the high rate of adverse reactions necessitating
discontinuation of therapy, which primarily involve immediate allergic reactions to the allergen [14,15].
Recombinant versions of allergens offer an approach to reduce adverse reactions, thereby allowing
improved effectiveness [22]. These recombinant allergens are purer and free from contamination
from other allergens of the food source, and thus may also be useful for the diagnosis of allergy
(e.g., skin prick tests or immunoassay).
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Food allergies, including allergy to chicken egg, may sometimes cause severe reactions such
as anaphylaxis. In such patients, use of natural allergens for diagnosis or immunotherapy may
be associated with unwanted allergic reactions. Therefore hypoallergenic, or less allergenic,
versions of allergens would be useful in such patients with severe allergic reactions. Production
of hypoallergenic variants has been rigorously pursued in allergy research, for example the production
of a hypoallergenic variant of the major latex allergen Hev b 6.01 by site-directed mutagenesis by Drew
et al., 2004 [19], and the development of a vaccine using hypoallergenic derivatives of the birch pollen
allergen Bet V 1 by Niederberger et al., 2004 [23]. In this study, we developed a hypoallergenic variant
of the major egg white allergen Gal d 1 (Gal d 1) which showed reduced IgE reactivity when compared
to its wild-type counterpart.
For mutagenesis, it was decided to use alanine as a replacement for cysteine residues at C192 and
C210 because it is the most common amino acid that does not have extreme electrostatic or steric effects
on the conformation of the protein [24]. The sequencing result of the six clones post-mutagenesis
showed that five clones had only one of the desired mutations present. The mutagenesis kit used in
this study allowed introducing multiple mutations in a single reaction. Therefore, the low efficiency
can be attributed to factors such as the quality of the template DNA or the efficiency of the mutagenic
primers. Nevertheless, one clone had both of the desired mutations at C192 and C210, replacing TGC
codons (cysteine) with GCC (alanine). The Gal d 1 secondary structure is made up of three tandem
domains (I–III), with domain III showing high IgE reactivity [25]. By targeting C192 and C210,
we aimed to destroy two cysteine-cysteine disulphide bridges in domain III, thus altering its
conformation. We hypothesised that altering the conformation of domain III may have a significant
effect on IgE reactivity of the whole protein.
The mutant Gal d 1 was successfully expressed in E. coli. A time-course expression was conducted
to determine the optimum time point for the expression of the mutant protein. We previously reported
that the wild-type recombinant Gal d 1 was best expressed at 2 h post-induction with IPTG [20].
However, the expression pattern of the mutant protein was different to that of the wild-type, as shown
in Figure 3. The mutant protein’s expression level increased with time up until 5 h, as opposed to the
wild-type protein’s which showed a reduction in expression after 2 h. Similar to the wild-type, the
mutant was highly expressed in the insoluble fraction, indicating that the expression of the protein
causes the formation of inclusion bodies in E. coli. Nonetheless, the amount expressed in the soluble
fraction was sufficient for the remainder of this study.
When analysing two proteins on an immunoblot to compare their reactivity for an antibody,
it is essential to immobilise similar amounts of the two proteins. When comparing recombinant
proteins, it is crucial that the proteins are purified to allow loading of similar amounts of proteins
to a gel to be transferred on to a nitrocellulose membrane. In this study, we did not have purified
recombinant versions of the wild-type or mutant Gal d 1. Therefore, after inducing expression until
the optimum time point of each variant, we loaded similar volumes of the crude E. coli extracts onto
gels, transferred on to nitrocellulose and subjected to detection using different antibodies to confirm
that both proteins are expressed and loaded at similar quantities. When analysed on SDS-PAGE
and Western blotted using Anti-Xpress, Tetra-His and Penta-His antibodies, it was evident that there
was more of the mutant protein immobilised on the nitrocellulose membrane when compared to
the wild-type protein. This was not a significant issue as we were testing the IgE reactivity of the
mutant against the wild-type Gal d 1. It was only vital to ensure that the wild-type protein did not
exceed the amount of mutant protein on the membrane. Following the aforementioned immunoassays,
the two proteins were compared against each other for IgE reactivity using egg-allergic patients’ sera.
The blot in Figure 5 clearly shows that there is a significantly visible reduction of IgE reactivity in
the mutant protein, although there is more of the mutant protein immobilised on the membrane.
One may argue that the IgE in the sera may have attached/reacted to E. coli protein; however, we have
previously shown that the IgE in the egg-allergic sera we used did not react to E. coli proteins [20].
The membrane incubated with non-allergic sera showed no bands, indicating that the secondary
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antibody, anti-human IgE produced in goat, does not non-specifically bind to the recombinant proteins.
Furthermore, breaking down and accumulation of the protein was evident by the presence of multiple
bands on the immunoblots on Figure 4. The presence of less bands in the Penta-His antibody blot,
compared to Tetra-His, can be attributed to the detection of proteins broken down at the histidine tag
by the Tetra-His antibody.
This study shows that disruption of only two out of nine cysteine-cysteine bridges in Gal d 1 by
targeting C192 and C210 significantly reduces its reactivity to egg-specific IgE. The result also suggests
that the structure of the protein plays a crucial role in its allergenecity. This mutant Gal d 1 has the
potential to be used in safer egg oral immunotherapy. This study provides preliminary results for
future research involving the production of hypoallergenic variants of egg allergens, in particular
Gal d 1. The result obtained from this study should be followed by further in vitro and in vivo
experimentation. The foremost next step is purification of the protein from the soluble fraction of E. coli.
We have expressed the protein with a 6× histidine tag; therefore, nickel affinity purification techniques
can be utilsed for this purpose. The purified protein can then be used in B-cell and T-cell activation
tests/assays. T-lymphocytes (T-cells) are known to be important in allergic desensitization [26,27];
therefore, it is imperative to test the ability of the hypoallergenic Gal d 1 produced in this study to
stimulate T-cells. Animal models also play a pivotal role in food allergen research [28], and therefore it
should be suggested that the hypoallergenic Gal d 1 we produced should undergo animal model–based
experimentation prior to clinical testing. We have previously shown that Gal d 1 is more reactive
in comparison to other allergens when tested against egg-allergic patients’ sera [20]. In addition,
the same study showed that patients show reactivity to more than one allergen, even the patients
showing high reactivity to Gal d 1. Therefore, it should be highlighted that a hypoallergenic variant of
Gal d 1 is only useful for reducing allergic response in patients allergic to multiple allergens during
immunotherapy, rather than complete abolition of reactivity, thus showing the importance of research
into the development of hypoallergenic variants of other allergens in the egg.
5. Conclusions
In summary, we have successfully produced a hypoallergenic variant of the major egg white
allergen Gal d 1 by disrupting two cysteine-cysteine bridges using site-directed mutagenesis.
This hypoallergenic variant, upon purification and further immunological analysis, may be used
as an excellent constituent in future immunotherapy vaccines for egg allergy.
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Abstract: Evidence suggests that reduced intake of fruit and vegetables may play a critical role in
the development of asthma and allergies. The present review aimed to summarize the evidence for
the association between fruit and vegetable intake, risk of asthma/wheeze and immune responses.
Databases including PubMed, Cochrane, CINAHL and EMBASE were searched up to June 2016.
Studies that investigated the effects of fruit and vegetable intake on risk of asthma/wheeze and
immune responses were considered eligible (n = 58). Studies used cross-sectional (n = 30), cohort
(n = 13), case-control (n = 8) and experimental (n = 7) designs. Most of the studies (n = 30) reported
beneficial associations of fruit and vegetable consumption with risk of asthma and/or respiratory
function, while eight studies found no significant relationship. Some studies (n = 20) reported
mixed results, as they found a negative association between fruit only or vegetable only, and asthma.
In addition, the meta-analyses in both adults and children showed inverse associations between
fruit intake and risk of prevalent wheeze and asthma severity (p < 0.05). Likewise, vegetable intake
was negatively associated with risk of prevalent asthma (p < 0.05). Seven studies examined immune
responses in relation to fruit and vegetable intake in asthma, with n = 6 showing a protective effect
against either systemic or airway inflammation. Fruit and vegetable consumption appears to be
protective against asthma.
Keywords: fruit; vegetable; antioxidant; asthma; wheezing; immune response
1. Introduction
Asthma is a chronic inflammatory lung disease, associated with airway constriction, inflammation,
bronchial hyper-responsiveness (BHR), as well as respiratory symptoms such as coughing, wheezing,
dyspnoea and chest tightness. The rise in incidence, prevalence and related medical and economic costs
of asthma across all age groups is a public health concern [1]. In Australia, one in every 10 adults has
asthma. It has been estimated that currently about 300 million people suffer from asthma worldwide,
with 250,000 annual deaths related to the disease. It is also estimated that the prevalence of asthma
will grow by more than 100 million by 2025 [2]. Asthma is the consequence of complicated interactions
between genetics and environmental factors. In genetically susceptible people, such interactions
can lead to the development of airway inflammation, atopy and/or BHR [3]. Environmental factors
including tobacco smoke, allergen exposure, pollen, mites, air pollution, chemical sprays, high ozone
levels, broad-spectrum antibiotic usage during the first years of life, small size at birth, having few
siblings, as well as respiratory infections such as Rhinovirus (RV) can play a major role in developing
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asthma exacerbations [4,5]. The considerable morbidity related to asthma may be ameliorated by
addressing modifiable risk factors such as diet [6]. It has been suggested that the increased prevalence of
asthma in recent decades may be associated with changes in dietary habits since the 1950s—particularly,
deficiency in dietary antioxidants [7]. The Western diet has shifted towards less fruit and vegetables,
and high intakes of convenience foods that are low in fibre and antioxidants and rich in saturated
fats [8,9].
Oxidative stress plays a major role in the pathophysiology of asthma, due to chronic activation
of airway inflammatory cells [10]. There is ample evidence that oxidative stress can have various
deleterious effects on airway function, including airway smooth muscle contraction, induction of
BHR, mucus hypersecretion, epithelial shedding and vascular exudation [11,12]. Moreover, reactive
oxygen species (ROS) can activate transcription factor nuclear factor-kappa B (NF-κB), which results
in a cascade of events involving upregulation of the transcription of various inflammatory cytokine
genes, such as interleukin-6 (IL-6) and eventually influx and degranulation of airway neutrophils [8].
Fresh fruit and vegetables provide rich sources of antioxidants and other biologically active substances
(such as flavonoids, isoflavonoids and polyphenolic compounds) [12]. Studies have shown that diets
with low average consumption of fruit and vegetables play a major role in the development of allergic
diseases [1,7], and may augment oxidative stress in asthma [13]. Antioxidants can reduce airway
inflammation via protecting the airways against oxidants by both endogenous (activated inflammatory
cells) and exogenous (such as air pollution, cigarette smoke) sources [7]. Moreover, dietary antioxidants
present in fruit and vegetables can scavenge ROS, and thus inhibit NFκB-mediated inflammation,
while diets low in antioxidants have reduced capacity to respond to oxidative stress [8].
Currently available asthma medications, such as glucocorticoids, are ineffective in some cases such
as viral-induced exacerbations [14]; and prolonged treatment with these therapeutic agents can result
in adverse effects, such as pneumonia, cataracts, and osteoporosis [15]. Therefore, non-pharmacological
interventions are required to reduce the burden of asthma in both adults and children. Understanding
the roles of dietary nutrients in asthma and asthma-related complications may help in the management
of this chronic inflammatory disease. Hence, a systematic review of the intake of fruits and vegetables
and their effects on immune responses and asthma risk is of interest. This paper aimed to describe
studies investigating the effects of fruit and vegetable consumption on risk of asthma and wheezing




PubMed, Cochrane, CINAHL and EMBASE databases were included in the literature search,
which was conducted in June 2016, including all previously published articles. Studies were limited to
humans with no language restrictions. Additional studies were identified by hand searching references
from the identified studies. See Figure 1 for an example of the search strategy.
2.2. Study Selection
Only original studies with the following designs were included: randomized controlled trials,
quasi-experimental studies, cohort studies, case-control studies, before and after studies, and cross
sectional studies. Case studies, case reports, animal studies, opinion papers, in vitro studies and
conference abstracts were excluded. Review articles were collected for the purposes of reviewing
the reference list and did not contribute to the final number of included studies. The target study
population was human of all age, gender or ethnicity, with asthma, wheeze, airway inflammation
or other related respiratory symptoms. The exposure of interest was intake of whole or extracted
fruit and vegetables. The study outcome measures were respiratory virus infection including human
rhinovirus, influenza virus, corona virus and adenovirus; markers of systemic inflammation such as ILs,
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C-reactive protein, tumour necrosis factor-α and intercellular adhesion molecule 1; and related clinical
outcomes including respiratory function such as forced expiratory volume in one second (FEV1),
forced vital capacity (FVC), asthma control and symptoms such as dyspnoea, coughing, wheezing and
chest tightness.
Figure 1. Example of search strategy using PubMed for studies investigating the effects of fruit and
vegetable consumption on immune responses (including immune responses to virus infection, and
inflammation) and clinical outcomes in asthma.
Citations from literature databases were imported into referencing software Endnote X7.7
(Clarivate Analytic, Philadelphia, PA, USA). All studies retrieved by the search strategy were initially
assessed for relevance to the review based on the title using inclusion and exclusion criteria. Articles
considered not relevant based on title were coded NR (not retrieve) with the reason noted. Articles
considered relevant, or unclear were coded R (retrieve). Further assessments of the retrieved articles
were according to the abstract, keywords and MeSH terms, using the inclusion and exclusion criteria.
Again, articles were coded as either NR with the reason or R. Retrieved full text articles were then
assessed for inclusion criteria. If there was doubt as to whether an article met the defined inclusion
criteria according to the title, abstract, keywords and MeSH term, the full article was assessed
for clarification.
2.3. Study Quality
Eligible studies were assessed in terms of the methodological quality based on a standardised
critical appraisal checklist designed by the American Dietetic Association [16]. The tool considered the
reliability, validity, as well as generalisability of the included studies. No study was excluded due to
poor quality. The two reviewers (BH and BB) then made final decisions on the included studies by
cross-checking results. In cases of disagreement on the inclusion of a study, the other independent
reviewers decided on the inclusion or exclusion of the study. Studies that were excluded at this stage
were recorded with the reason noted.
2.4. Data Extraction and Study Synthesis
Study details were extracted and recorded into a custom-designed database. Data extracted
included title, authors, country, study design, participant characteristics, study factor (e.g., dosage/
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dietary intake of fruits and vegetables), main outcome measures, findings including statistical
significance, analysis with adjustment for confounding factors, and limitations.
2.5. Statistical Methods
A meta-analysis was used to evaluate the association between fruit and vegetable intake and risk
of asthma and/or wheezing. Only studies that met the following inclusion criteria were included in
the meta-analysis: (a) fruit and vegetable intake reported; (b) the odds ratio (OR) or the relative risks
and the corresponding 95% confidence intervals (CI) were reported. However, due to the heterogeneity
of study designs and differences in exposure and outcome assessments, meta-analysis of all of these
studies were not possible. The analysis was performed for the total number of adults and children
together, and pregnant women. To assess the risk of asthma and/or wheezing, the risk estimate
from each study, weighted by the inverse of variance, was pooled. Appreciable heterogeneity was
assumed if I2 > 50 and p < 0.1. Meta-analysis was performed using random effect modelling if
I2 > 50 and fixed effect modelling was used if I2 < 50. Most studies assessed dietary intake with a
validated food frequency questionnaire (FFQ), and other studies used a dietary habit questionnaire,
food diaries or 24 h recall. Some studies used an FFQ with limited fruit and vegetable items such
as Rosenlund et al. [17], while other studies used an FFQ which included over 50 items, such as
Shaheen et al. [18] (>200 items), Romieu et al. [19] (108 items), and Protudjer et al. [20] (72 items).
In addition, some of the FFQs were modified for use in children [21]. Since the included studies used
different methods in reporting fruit and vegetable intake (i.e., >4 times/week vs. never, quartile 4
vs. quartile 1, daily intake vs. never, etc.), in order to include more studies in the meta-analysis, two
terms were defined: high fruit and/or vegetable intake (the group that had the highest intake of fruit
and vegetables in each study) vs. low fruit and/or vegetable intake (the group that had the lowest
intake of fruit and vegetables in each study). Tables 1–3 show how the variables are contrasted in
different studies.
3. Results
Initially, 3194 abstracts were identified by the search strategy. After removing duplicates and
screening the titles, 142 articles were retrieved for abstract review. Based on the abstracts, 80 articles
were excluded based on outcomes (n = 16), exposures (n = 26) or study design (n = 38). After reviewing
the full-texts, five articles were excluded as fruit and vegetable intakes were not reported, and also one
study was additionally included during the review process. Finally, Fifty-eight articles were included
in the review (Figure 2).
3.1. Characteristics of Included Studies
More than half of the studies were performed in children (n = 28), adolescents (n = 3) or both
(n = 10), with only 17 conducted in adults. Cross-sectional design was most commonly used (Table 1)
with 8 case-control studies (Table 2), 13 cohort studies (Table 3) and 7 clinical trials (Table 4). The
majority of studies were conducted in UK (n = 8) [1,18,22–27], but also in Australia (n = 5) [28–32],
Greece (n = 5) [13,33–36], Spain (n = 4) [37–40], Italy (n = 4) [9,41–43], Brazil (n = 3) [44–46], Netherlands
(n = 3) [21,47,48], USA (n = 3) [9,49,50], Canada (n = 2) [20,51], Finland (n = 2) [52,53], India (n = 2) [54,55],
Japan (n = 2) [56,57], Mexico (n = 2) [19,58] Sweden (n = 2) [17,59], Taiwan [60,61] (n = 2), Albania [62],
China [63], Colombia [64], Germany [7], Ireland [65], Norway [66], Portugal [67], Saudi Arabia [68],
and Singapore [69]. In addition, one study [70] used data from 20 countries. A total of 496,741
participants were included from cross-sectional studies, 2139 cases and 2739 controls from case-control
studies, 105,789 individuals with the mean follow-up of 9.53 years from cohort studies. In total,
7109 participants were included in clinical trials with a mean intervention period of 141 days ranging
from 3 to 365 days. The methodological quality of 41 studies was positive, and 16 studies were neutral.
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Figure 2. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flowchart of
studies to include in systematic review of the association between fruit and vegetable intake and asthma.
3.2. Studies Conducted in Adults
Four cohort [22,52,58,59], two case-control [18,23], eight cross-sectional
studies [31,32,42,55,57,62,67,69] and three experimental trials [28–30] assessed the association
of fruit and vegetable intake and asthma or asthma-related symptoms in adults. Fruit and
vegetable intake was reported to have beneficial associations with wheeze, or asthma in eight
studies [18,22,28,29,42,55,59,62]; one study [69] found no significant relationship; and eight
studies [23,30–32,52,57,58,67] reported mixed results. Most of the studies measured total fruit and
vegetable intake; however, one cross-sectional study examined only vegetable intake [42], three cohort
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studies assessed only fresh fruit intake [22,59], and one study [52] analysed the consumption of orange,
apple, grapefruit, onion, white cabbage, berries, and juices.
3.2.1. Cohort Studies
In terms of prospective studies, two studies [22,59] reported fruit and vegetable intake was
inversely associated with asthma. Likewise, Knekt et al. [52] found that higher dietary flavonoid intake
(measured by intakes of orange, apple, grapefruit, onion, white cabbage, berries, juices) was associated
with lower incidence of asthma. The strongest associations were noted for apple and orange intakes
and asthma. Another study [58] reported inverse associations between intakes of tomato, carrots, leafy
vegetables and asthma. No cohort studies in adults reported associations between fruit and vegetable
intake and immune function in asthma.
3.2.2. Case-Control Studies
Two case-control studies [18,23] reported that fruit and/or vegetables intake was inversely
associated with asthma risk in adults. No case-control studies in adults reported associations between
fruit and vegetable intake and immune function in asthma.
3.2.3. Cross-Sectional Studies
In line with these findings, a cross-sectional study by La vecchia et al. [42] reported that vegetable
consumption was inversely associated with bronchial asthma. While Priftanji et al. [62] reported
that fruit and vegetable intake between meals can have protective effects against possible allergic
asthma. Another cross-sectional study [31] showed that apple and pear intake was inversely associated
with current asthma, ever asthma, and BHR, and no significant association was observed regarding
vegetable intake and asthma. In contrast, another cross-sectional study [69] failed to observe any
significant association between fruit and vegetable intake and FEV1 and FVC. Barros et al. [67] found no
significant associations between fruit and vegetable intake and exhaled nitric oxide (FENO) in adults.
3.2.4. Experimental Trial
We have previously investigated the effects on both lung function and airway inflammation
following a LOA (low antioxidant) diet, which involved restriction of dietary fruit and vegetable
intake [28]. FEV1 and FVC % predicted values decreased (p < 0.01) and sputum neutrophils % increased
(p < 0.05) following the diet. The study also reported that treatment with tomato juice and tomato
extract reduced airway neutrophils and sputum neutrophil elastase activity. Similarly, Baines et al. [29]
showed that antioxidant withdrawal, via fruit and vegetable restriction, leads to upregulation of
genes involved in the inflammatory and immune responses including the innate immune receptors
TLR2, IL1R2, CD93, ANTXR2, and the innate immune signalling molecules IRAK2, 3, MAP3K8 and
neutrophil proteases. In another trial [30], we found that subjects on a LAO diet (involving fruit
and vegetable restriction) were 2.26 times as likely to have an asthma exacerbation at any time in
comparison with the high antioxidant diet group. Lung function also decreased following antioxidant
withdrawal in this study. There were no improvements in airway and systemic inflammation, lung
function and asthma control after tomato extract supplementation in this study.
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3.3. Studies Conducted in Children and Adolescents
Forty-one studies including nine cohort [21,33,37,41,47,48,53,56,65], six case-control [19,20,44,45,49,68],
22 cross-sectional studies [1,7,9,13,17,26,27,34–36,39,40,43,46,50,51,54,61,63,64,66,70], and four experimental
trials [24,25,38,60] assessed the effects of fruit and vegetable intake on asthma or asthma-related
symptoms in children and adolescents. An inverse association of fruit and vegetable intake and asthma
or wheeze was reported in 22 studies [1,9,13,19,21,26,33,35,38,39,41,43,45,49,50,54,60,63,65,66,70,71],
while seven studies [7,24,27,34,36,53,56] did not observe any significant association.
Twelve studies [17,20,37,40,44,46–48,51,61,64,68] found mixed results. Four studies [9,19,25,49]
reported on immune responses to fruit and vegetable intake in children in relation to asthma, with
all studies showing a protective effect on systemic or airway inflammation. The majority of studies
analysed total fruit and vegetable intake, though five cross-sectional studies assessed the consumption
of fruit only [1,27,43,64] or citrus fruit plus vegetables [7]. Additionally, one cohort study [41] assessed
the intake of cooked vegetables, salads, tomatoes, fresh fruit, citrus fruit and kiwi, and one birth cohort
study [53] measured food-based antioxidant intake.
3.3.1. Cohort Studies
In a one-year prospective study [41], intake of tomatoes and all fruits and citrus fruit alone had a
protective effect on shortness of breath. Similarly, a cohort study [33] that followed children from birth
up to 18 years of age reported that daily consumption of fruit and vegetables over the last 12 months
was inversely associated with current asthma at 18 years. Another birth cohort study [48] showed
that intakes of fresh fruit were inversely associated with asthma symptoms, while, no significant
association was observed between cooked vegetable intake and asthma symptoms. No cohort studies
in children reported associations between fruit and vegetable intake and immune function in asthma
Four cohort studies addressed the association between maternal fruit and vegetable intake during
pregnancy and risk of asthma-related outcomes in their children. One study [65] reported an inverse
association between asthma incidence in children and maternal fruit and vegetable intake in pregnancy.
Another study [21] reported that maternal apple intake had protective effects on ever wheeze, ever
asthma, and doctor-confirmed asthma in the children; however, no consistent associations were
observed between childhood outcomes and maternal vegetable consumption. In contrast, a study
conducted by Chatzi et al. [37] showed that consumption of vegetables more than eight times per
week was inversely correlated with persistent wheeze, while, no association was found regarding fruit
intake and wheeze. Two studies [53,56] found no significant association regarding maternal fruit or
vegetable intake and risk of wheeze in the offspring. Willers et al. [47] demonstrated that fruit intake
had a borderline significant association with wheeze. This study also reported that vegetable intake
was positively associated with asthma symptoms in children.
3.3.2. Case-Control Studies
In terms of case-control studies, four studies [20,44,49,68] reported that consumption of vegetables
was negatively associated with odds of asthma; however, no difference was observed regarding fruit
intake among the groups. In contrast, one study [45] found that regular consumption of fruit in the last
month was associated with lower risk of having persistent asthma, while there was no difference in
vegetable consumption between the two groups. A follow-up case-control study by Romieu et al. [19]
reported that the fruit and vegetable index (FVI) was positively related to FEV1 and FVC. A 1-point
increase in FVI was associated with a 105 mL (nearly 5%) increase in FVC. For each one-unit increase
in FVI there was a significant decrease in IL-8 levels in nasal lavage. Similarly, a recent study [49]
reported that increased vegetable consumption is negatively associated with serum IL-17F.
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3.3.3. Cross-Sectional Studies
The majority of cross-sectional studies reported beneficial associations of fruit and vegetable
intake with lung function (FEV1 and FVC) [26,50], wheeze [13,35,43,54] and asthma [1,9,39,63,66] as
well as with FENO levels [9] as a marker of eosinophilic airway inflammation. However, some studies
did not observe any association between fruit and vegetable intake and asthma in children [7,17,27,36].
Several cross-sectional studies found an inverse association between vegetable consumption and
asthma-related symptoms, although, they did not observe any significant association regarding
fruit intake and asthma [37,40,51,61]. In contrast, a recent study [46] reported fruit intake was
inversely related to odds of asthma, while, no association was found between vegetable intake and
asthma. Garcia et al. [64] found a negative association between fruit intake and asthma in adolescents.
An international study of 20 countries [70] reported consumption of cooked green vegetables and raw
green vegetables was significantly associated with fewer wheezers in non-affluent countries, and fruit
intake was associated with a low prevalence of current wheeze in affluent and non-affluent countries.
3.3.4. Experimental Studies
Lee et al. [60] described a 16-week trial of 192 children with asthma who received fruit and
vegetable capsules + fish oil + probiotic vs. placebo and reported the supplement group had a
significantly higher increase in FEV1, FVC and FEV1:FVC ratio compared to placebo. The proportion of
children using inhaled glucocorticoids decreased following the supplementation, though increased in
the placebo group. In another trial by Garcia et al. [25] 32 asthmatic children were randomly allocated
to one of four groups: having an apple or a banana or an apple + banana in addition to their normal
diet, or the control group (usual diet). The study reported 18% lower FeNO levels in Groups 2 (adding
banana) and 3 (adding banana + apple) following the intervention. In a study by Calatayud et al. [38],
104 children aged 1–5 years with current asthma participated in a nutritional education programme
based on the traditional Mediterranean diet for one year. The authors reported that fruit and vegetable
intake increased significantly with a concomitant decrease in inhaled glucocorticoids use. In contrast,
a one-year trial by Fogarty et al. [24] conducted in asthmatic children found that there was no difference
in the prevalence of wheezing, exercise-induced wheeze, or nocturnal cough between children who
were instructed to add an extra piece of fruit to their diet compared to the control group.
3.4. Findings from Meta-Analysis
Primary prevention studies that reported the OR associated with the risk of prevalent
asthma/wheeze were analysed separately to secondary prevention studies that reported the OR
associated with asthma severity (n = 2) or wheeze severity (n = 1). Meta-analyses of 17 primary
prevention studies revealed no significant association between fruit intake and risk of prevalent
asthma (OR = 0.98; 95% CI: 0.96–1.0, p = 0.09, I2 = 8) (Figure 3). However, intake of fruit was inversely
associated with the severity of asthma in secondary prevention studies [45,67] (OR = 0.61; 95% CI:
0.44–0.87, p = 0.005, I2 = 0) (Figure 4). Vegetable intake was negatively related to the prevalence of
asthma (OR = 0.95; 95% CI: 0.92–0.98, p = 0.003, I2 = 8) (Figure 5), while it was not related to the
severity of asthma in secondary prevention studies [45,67] (OR = 1.11; 95% CI: 0.63–1.94, p = 0.72,
I2 = 0) (Figure 6). Fruit intake was also negatively associated with risk of prevalent wheeze
(OR = 0.94; 95% CI: 0.91–0.97, p < 0.0001, I2 = 0%) (Figure 7). However, no significant relationship
was found between vegetable intake and risk of prevalent wheeze (OR = 0.98; 95% CI: 0.94–1.03,
p = 0.41, I2 = 0%) (Figure 8). Meta-analysis of the association between total fruit and total vegetable
intake with the severity of wheeze was not possible as there was only one secondary prevention
study [37]. A meta-analysis of six primary prevention studies that reported fruit and vegetable intake
together showed no significant relationship with the risk of prevalent asthma (OR = 0.90; 95% CI:
0.80–1.01, p = 0.07, I2 = 65%) (Figure 9). No meta-analysis was possible for immune markers as well as
respiratory infection, due to the lack of available studies. Moreover, meta-analysis on the association
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between fruit and/or vegetable intake and respiratory function was not possible, as studies used
heterogeneous methods in reporting these outcomes.
Figure 3. Meta-analysis of the association between fruit intake and risk of prevalent asthma.
Figure 4. Meta-analysis of the association between fruit intake and severity of asthma.
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Figure 5. Meta-analysis of the association between vegetable intake and risk of prevalent asthma.
Figure 6. Meta-analysis of the association between vegetable intake and severity of asthma.
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Figure 7. Meta-analysis of the association between fruit intake and risk of prevalent wheeze.
Figure 8. Meta-analysis of the association between vegetable intake and risk of prevalent wheeze.
235
Nutrients 2017, 9, 341
Figure 9. Meta-analysis of the association between fruit and vegetable intake and risk of
prevalent asthma.
4. Discussion
This systematic review and meta-analysis is the first aimed at investigating the effects of fruit and
vegetable consumption on risk of asthma and wheezing and immune responses (including immune
responses to virus infection and inflammation) in asthma and wheezing. We found that the majority of
studies (n = 8 in adults and n = 22 in children) reported a protective effect of a high fruit and vegetable
diet on asthma and/or wheeze. Twenty studies (n = 8 in adults and n = 12 in children) reported mixed
results, as they found a negative association between intake of fruit only or vegetable only and risk
of asthma and/or wheeze. Eight studies (n = 1 in adults and n = 7 in children) failed to show any
beneficial effects of fruit and vegetable intakes on risk of asthma and wheeze. In the meta-analysis, fruit
intake was not associated with the risk of prevalent asthma (p > 0.05); however, a negative relationship
was observed between consumption of fruit and asthma severity. Intake of vegetables was inversely
associated with the prevalence of asthma, while there was no association in secondary prevention
studies. In addition, fruit intake was negatively associated with the risk of prevalent wheeze, while
no significant relationship was found between vegetable consumption and wheeze prevalence. Fruit
and vegetable intake together showed no significant relationship with the risk of prevalent asthma.
Meta-analyses of immune response parameters and respiratory infections were not possible due to
lack of studies reporting on these markers.
Several mechanisms for the protective effects of fruit and vegetables on asthma and lung function
have been suggested. Fresh fruit and vegetables are rich dietary sources of antioxidants such as
vitamin C, E and β-carotene as well as flavonoids, isoflavonoids and polyphenolic compounds [1,7].
It has been reported that oxidative stress is elevated in asthma and increases further during acute
asthma exacerbations [72–74], so a high intake of antioxidants may be beneficial. Vitamin C is a major
antioxidant in the extracellular respiratory lining fluid that protects immune cells from oxidative stress,
and may also contribute to lung growth and development and reduce airway hyper-reactivity, both
of which are determinants of childhood and adult lung function [50]. The potential for vitamin C to
prevent asthma-related outcomes is illustrated by a cross-sectional study that documents the protective
effects of dietary vitamin C against wheezing and shortness of breath [43]. Vitamin E can be found in
various fruits and vegetables, including corn, tomato, spinach, broccoli, kiwifruit, and mango [75]. One
study reported that consumption of vitamin E was negatively correlated with forced expiratory flow,
which is a measure of small airway flow [50]. Another group of low molecular weight antioxidants
found in fruits and vegetables are carotenoids. Lycopene, present in high concentrations in tomatoes,
red fruits, watermelons, apricots and pink grapefruit, is the most potent antioxidant among the
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carotenoids [76]. It has been suggested that oral intakes of lycopene reduce both oxidative stress and
the pathophysiological features of asthma such as airway smooth muscle contraction, induction of BHR,
and mucus hypersecretion [76]. Flavonoids are a group of polyphenols found in fruits and vegetables
that have potent antioxidant as well as anti-inflammatory effects. One study showed that the incidence
of asthma was lower at higher total intakes of flavonoids [52]. Moreover, it has been reported that a
specific type of flavonoid, called “khellin”, was used traditionally in asthma treatment because of its
bronchodilator activity [52]. It is likely that the positive effects of fruit and vegetables can be attributed
to the combination of these nutrients, which are present in high concentrations in this natural food
source. Moreover, evidence indicates that paediatric asthma, which is allergic in 80% of cases [77], may
benefit from fruit and vegetable intake, as several studies reported lower rates of wheezing and allergic
rhinitis in children who consumed antioxidant-rich foods daily [36,48,78]. Similarly, high antioxidant
intake is related to enhanced pulmonary function and reduced chronic respiratory symptoms in
children, especially those exposed to high amounts of air or smoke pollution [36]. Studies also suggest
that antioxidants might affect immune function and allergic reactions [36,78]. A study of school-aged
children [79] reported that asthma and allergic rhinitis were inversely correlated with serum levels of
antioxidants compared to healthy children. Similar results were also observed in adults [80].
This systematic review has highlighted the lack of available data regarding the effects of fruit
and vegetable intake on immune responses in asthma. Asthma is a chronic inflammatory disease,
involving activation of a variety of immune cell types and increased oxidative stress. Oxidative stress
occurs in asthma due to the excessive release of free radicals from activated inflammatory cells and
is regarded as one of the critical factors involved in the chronic inflammatory process in both the
airways and in the systemic circulation of asthmatics [9,11,74]. Viral respiratory infections are a key
contributor to inflammation and oxidative stress in asthma and it has been shown that innate immune
responses are impaired in asthmatic adults and children [81], therefore, patients with asthma are more
vulnerable to virus infections compared with non-asthmatic controls [81,82]. Consequently, food such
as fruits and vegetables, which have the potential to reduce inflammation and oxidative stress due
to their anti-inflammatory and anti-oxidative properties, may be beneficial in asthma. Data from
three observational studies [9,19,49] in children examined the association between fruit and vegetable
intake and inflammation. In each case, there was an association between airway and/or systematic
inflammation and intake of fruit and/or vegetable. A cross-sectional study by Cardinale et al. [9]
reported that salad intake was negatively associated with FENO levels. Similarly, an inverse association
between fruit and vegetable intake and IL-8 levels in nasal lavage [19], and between vegetable intake
and serum IL-17F [49] was reported by two case-control studies. Only one intervention study in
children [25] has examined effects of fruit on inflammation, and reported that having a banana or a
banana and apple for one month resulted in a statistically significant 18% reduction in FENO levels.
However, fruit and vegetable intake was not related to FENO levels in adults [67]. In addition, two
intervention studies have examined the effect of withdrawal of antioxidant-rich foods (in particular
fruit and vegetables) from the diet, on immune responses in adults with asthma [28,30]. In one
study, antioxidant withdrawal resulted in increased airway neutrophils [28] and upregulation of
inflammatory and immune response genes in sputum cells, including the innate immune receptors
TLR2, IL1R2, CD93, ANTXR2, the innate immune signalling molecules IRAK2, IRAK3, MAP3K8 and
neutrophil proteases MMP25 and CPD [29]. The major dietary change in these studies was a decrease
in fruit and vegetable consumption to a level, which is representative of the typical western diet, which
is alarming considering the negative consequences in the airways [28].
There are several additional points that warrant consideration. Firstly, several proteins from fruits
and vegetables are similar to pollen allergens and may play a critical role in the pollen–fruit/vegetable
cross-reactivity. For instance, some allergens in apples, pears, various stone fruits, carrots, and
peanuts are homologous to the major birch pollen allergen, and can cause allergic symptoms when
consumed [17]. Therefore, children are less likely to eat them if they cause immediate symptoms. Such
disease-related modification of diet may affect the observed associations between intake of certain
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fruits or vegetables and asthma [17]. In one study [17], 45% of asthmatic children had sensitization
to birch pollen, and the authors reported that all negative associations between fruit and vegetable
intake and asthma were no longer significant when children with food-related allergic symptoms were
excluded; Secondly, it should be noted that fruit and vegetable consumption is associated with an
overall healthier lifestyle. In particular, it has been reported that people with higher fruit and vegetable
intakes are more likely to be non-smokers or ex-smokers [83], or perform more physical activity [84].
However, most of the included studies were adjusted for important lifestyle factors, such as smoking
and/or physical activity status (see Supplementary Materials).
The present systematic review has limitations that should be considered. Primarily, the criteria
used for asthma diagnosis were inconsistent. Skin-prick testing and different questionnaires were used
in some studies, while in other studies, asthma was diagnosed by a physician. Dietary assessment
methods also varied among the studies. Some studies used a FFQ, whereas, the other studies used
7-day food records, 24 h recalls or other questionnaires. Various methods were also used to define
and compare high and low intakes of fruit and vegetables (i.e., daily versus never, >3 times/week
versus <3 times/week, lowest versus highest tertile of intake, >3 times/day versus <2 times/day), and
thus dose-response relationships could not be assessed. Estimation of diet was also varied across the
included studies, as some studies reported individual foods, while a few studies reported the dietary
pattern, such as Mediterranean diet. However, only studies that reported data on fruit and vegetable
intake were included. Dissimilar populations (i.e., children, adolescents, young adults and elderly)
were also observed among the studies, and more than half of the studies were performed in children.
The results have been presented according to study population and age, and birth cohort studies were
assessed separately in the meta-analysis; however, due to the limited number of studies available
for inclusion in the meta-analyses, separating the analyses for adults and children was not possible.
Moreover, unmatched categories of diet exposure were observed; for example, some studies addressed
the effects of total fruit and vegetable consumption [26,31,50,62], while a few studies [1,27,43,64]
investigated the association between intake of a specific type of fruit and/or vegetable and asthma.
Some studies also reported only total fruit intake or total vegetable intake. Therefore, only studies that
reported total fruit and/or total vegetable intake were included and assessed in the meta-analysis.
Moreover, some studies investigated diet as a risk factor for asthma (primary prevention), while
other studies investigated diet as a disease modifier (secondary prevention). However, these different
study types were assessed separately in the meta-analyses. In addition, adjustment for confounders
in individual studies was performed using different covariates (see Supplementary Materials). For
example, gender and physical activity were adjusted in some studies, and not adjusted for in other
studies. As such, it is not surprising that the protective effect of fruit and vegetables was not reported by
all included studies [7,17,24,34,53,56]. Furthermore, one cohort [48] and one cross-sectional study [61]
demonstrated an increased risk of asthma as vegetable or fruit consumption increased. Nonetheless,
there were enough studies to see a significant protective effect of fruit and vegetables against asthma
and/or wheeze using meta-analysis. Finally, we cannot rule out the possible influences of potential
factors such as genetics, race and ethnicity on the association between fruit and vegetable intake
and asthma. Moreover, since most of the included studies had cross-sectional design, the results
could be influenced by reverse causality bias. The main strength of this systematic review is the
extensive systematic literature search, clear inclusion criteria and an explicit approach to collecting
data, thorough examination of the evidence, inclusion of both adults and children, inclusion of studies
with various designs and meta-analysis.
5. Conclusions
In summary, overall, the findings suggest that high intakes of fruit and vegetables may have
beneficial effects in asthma. However, some studies failed to attain similar results. Further studies with
cohort design that differ in regards to genetic susceptibility and ethnicity/race as well as well-designed
intervention trials are warranted to accurately address the effects of fruit and vegetable consumption
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on risk of asthma development and their role in managing asthma. More evidence is also needed
from laboratory studies to identify the biological mechanisms responsible for the effects of fruit and
vegetable intake on the development and management of asthma.
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Abstract: Introduction: Different clinical and molecular patterns of food allergy have been reported
in different areas of the world. The aim of the study is to evaluate differences in allergen patterns
among nut-allergic patients in two different areas of Spain. Material and methods: A total of
77 patients with nut allergy from two different regions of Spain (Madrid and Asturias) were evaluated.
Results: Hazelnut, peanut, and walnut were the three most frequent nuts eliciting allergy in both
regions, but in a different order. Patients from Madrid experienced systemic reactions more often
than patients from Asturias (73.5% Madrid vs. 50.0%, p < 0.05). The percentage of sensitizations to
LTP (Lipid Transfer Protein) was higher than Bet v 1 (p < 0.05) in the Madrid area. The percentage
of sensitizations in Asturias area was similar to LTP than Bet v 1 (Pru p 3 46.4%, Bet v 1 42.9%, ns).
Bet v 1 was the predominant allergen involved among hazelnut-allergic patients (56.2%), while LTP
was more common in peanut-allergic patients (61.5%). Conclusion: Walnut, hazelnut, and peanut
were the most frequent nuts eliciting allergy in Spain. Despite this, important differences in molecular
pattern were appreciated not only between both regions, but also among nut-allergic patients in
Asturias. The different molecular pattern was linked to the frequency of systemic symptoms.
Keywords: nut allergy; peanut; walnut; hazelnut; Bet v 1; LTP; Pru p 3; Phl p 12
1. Introduction
Traditionally, the term anaphylaxis has referred to a systemic, immediate hypersensitivity reaction
caused by IgE-mediated immunologic release of mediators from mast cells and basophils [1] and
expressed by systemic symptoms (i.e., cutaneous, respiratory, gastrointestinal, or vascular symptoms).
Food-induced anaphylaxis is a leading cause of anaphylaxis treated in emergency departments and
hospitals around the world [2]. Nuts (including peanut and tree nuts) are one of the most common
foods causing acute allergic reactions in children and adults, and nearly all nuts have been associated
with fatal allergic reactions [3]. McWilliam et al. [3] evaluated the prevalence of tree nut allergy in
different regions of the world by means of a systematic review. The results of the study proved that
prevalence of individual nut allergies varied significantly by region, with hazelnut being the most
common tree nut allergy in Europe, walnut and cashew in the USA, and Brazil nut, almond, and
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walnut most commonly reported in the UK. In addition, peanut allergy was the leading cause of death
related to food-induced anaphylaxis in the United States [4].
Component resolved diagnosis allows the study of the molecules or allergens involved in the nut
allergic reactions. Many allergens have been reported from nuts [5,6] and in many cases cross-reactivity
has being found among them [7].
Although most nuts (i.e., almond, hazelnut, pine nut, walnut, peanut, etc.) belong to different
botanical families without taxonomical relationships, cross-reactivity can occur due to shared
homologue proteins, since most of the nut allergens belong to a small number of protein families
sharing a 3-D structure, biologic function, and sequence identity to varying degrees. Along with
that, different protein families have been associated to different risks of systemic reactions or
anaphylaxis [8,9]. In this sense, different clinical and molecular patterns of food allergy have been
reported in different areas of the world [10,11].
Nut allergy has been associated with Bet v 1 sensitization in Europe, and in Spain, nut allergy has
been associated with LTP sensitization [10,12,13]. In this study we describe differences in nut allergy in
two different areas of Spain in which allergy was clearly associated with different molecular patterns
of sensitization and differing risks of systemic symptoms.
2. Material and Methods
2.1. Study Population
A total of 77 patients with nut allergy from two different regions of Spain participated in the study:
Madrid (n: 49; Fundación Jiménez Díaz Hospital; Tables 1 and 2) and Asturias (n: 28; Hospital Central
de Asturias; Tables 3 and 4). Inclusion criteria were patients diagnosed with nut allergy recruited
during 2013–2016. Nut allergy was diagnosed in patients having a clear history of adverse reactions
due to any nut (peanut, tree nut allergy, etc.) suggestive of IgE-mediated allergy, showing positive
skin prick tests, or specific IgE and/or food challenge tests, following the diagnostic algorithm of
the Food Adverse Reaction Committee of Sociedad Española de Alergia e Inmunología Clínica [14].
Patients suffering severe systemic reactions to nuts, as well as patients with typical, recent, repeated,
and unequivocal reactions who had positive skin tests/specific IgE, did not undergo an oral challenge
test to diagnose plant-food allergy [14].
Table 1. Nut allergic patients from Madrid.
No. Age Sex
Specific IgE
Pru p 3 Phl p 12 Bet v 1 Peanut Hazelnut Walnut
1 37 years old F 6.02 ND 0.00 1.17 2.88 5.09
2 20 years old M 0.42 0.40 0.00 0.96 2.79 0.25
3 50 years old M 4.00 0.18 0.02 1.37 0.94 2.94
4 26 years old F 0.01 0.00 0.00 0.04 0.02 0.00
5 22 years old M 19.20 0.08 0.01 4.65 3.22 12.30
6 20 years old F 9.35 0.00 0.00 2.42 0.85 4.77
7 20 years old M 0.02 15.70 0.01 8.84 0.69 1.88
8 23 years old M 4.35 0.00 0.00 3.19 0.72 3.01
9 45 years old M 38.30 ND ND 11.1 1.77 13.9
10 21 years old F 5.75 0.00 0.00 1.97 1.17 2.66
11 22 years old M 1.40 ND 2.06 0.73 0.62 8.81
12 27 years old M 1.11 0.47 0.00 0.47 0.00 0.42
13 12 years old M 1.11 0.47 0.00 0.47 0.00 0.42
14 34 years old M 7.83 ND 1.67 4.14 0.78 0.65
15 40 years old M 1.26 0.01 0.00 0.65 0.39 1.08
16 32 years old F 4.12 0.16 0.02 1.78 1.36 2.67
17 29 years old M 1.79 0.02 0.02 0.62 0.28 0.67
18 40 years old M 2.40 0.02 0.01 2.31 0.85 3.12
19 32 years old F 12.60 0.03 ND 5.73 4.09 10.9
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Pru p 3 Phl p 12 Bet v 1 Peanut Hazelnut Walnut
20 32 years old M 0.11 0.02 ND 0.13 0.07 0.08
21 25 years old F 0.22 20.20 ND 20.8 1.19 1.87
22 29 years old M 27.10 0.05 ND 9.58 5.59 18.8
23 25 years old F 3.02 0.00 6.84 0.41 16.6 1.95
24 60 years old F 32.30 0.10 ND 5.44 2.15 19.6
25 28 years old F 0.72 0.03 0.01 1.22 0.14 0.52
26 39 years old F 0.01 6.01 0.00 3.22 0.54 0.87
27 44 years old F 1.20 0.66 0.00 0.93 0.65 1.28
28 38 years old F 0.01 0.00 0.00 0.00 0.09 0.00
29 17 years old F 0.23 0.02 0.03 0.04 0.84 5.84
30 16 years old M 3.90 0.34 0.00 1.95 0.98 3.13
31 39 years old F 0.27 0.05 0.00 0.12 0.05 0.14
32 40 years old F 2.86 0.01 0.00 1.23 0.12 2.03
33 4 years old M 0.04 ND 0.00 0.03 0.13 ND
34 12 years old F 0.03 0.01 0.04 100 0.17 2.24
35 26 years old M 23.70 0.10 0.10 3.00 11.30 19.9
36 40 years old M 100.00 0.22 0.20 33.3 22.60 59.1
37 66 years old F 7.58 0.00 0.00 2.20 2.79 6.76
38 3 years old M 12.90 ND ND 19.5 ND 5.73
39 53 years old F 1.00 0.09 1.25 0.03 0.61 0.01
40 33 years old M 5.87 8.79 5.09 8.47 3.54 6.17
41 7 years old M 0.19 0.02 0.06 1.82 0.85 ND
42 39 years old M 3.34 0.00 2.21 3.17 6.18 4.99
43 52 years old F 0.04 1.35 0.01 0.56 0.21 0.19
44 29 years old F 0.15 5.96 0.08 3.64 1.41 1.52
45 25 years old M 2.03 0.00 0.01 0.12 0.18 0.87
46 29 years old F 44.40 0.00 0.00 24.20 14.5 33.6
47 29 years old M 95.50 0.07 0.04 1.95 3.36 3.28
48 13 years old F 0.00 0.03 0.00 100.00 2.08 3.11
49 31 years old M 3.18 0.30 0.01 2.01 1.66 2.61
F: Female; M: Male; ND: Not done.
Table 2. Nut allergic patients from Madrid.
No.
Specific IgE
Ara h 9 Cor a 8 Almond Chestnut Pistachio Pinenut
1 1.42 3.51 0.93 0.78 0.03 0.14
2 0.53 3.18 0.38 0.26 0.18 0.12
3 1.81 2.58 0.25 1.26 0.05 0.11
4 0 0 0.02 0.05 0.02 0.03
5 14.6 8.85 2.22 1.45 2.14 0.11
6 3.2 2.89 0.81 0.05 0.06 0
7 0.01 0 0.37 4.48 0.67 0.92
8 3.33 1.59 0.73 1.1 0.04 0.32
9 ND ND 5.34 3.31 0 ND
10 1.46 ND 1.04 1.58 0 0
11 ND ND 0.46 0.81 2.2 0
12 0.39 0 0 0 0 0
13 0.39 0 0 0 0 0
14 4.43 ND 2.01 1.42 0.94 ND
15 0.76 0.46 0.22 0.28 0.02 0
16 1.05 2.81 0.56 0.58 0.13 0.03
17 0.29 0.1 0.3 0.5 0.41 0.3
18 2.35 0.46 1.88 1.91 0.62 ND
19 7.38 4.2 4.28 4.07 0.51 0.06
20 0.05 0.01 0.12 0.1 0.07 0.83
21 0 0 0.65 8.73 1.32 4.46
22 18.6 11.5 2.73 4.26 0.38 2.18
23 0.39 0.39 0.42 0 0 0
24 18.1 16 0.56 6.71 0.24 0.12
25 0.43 0.22 0.14 0.2 0.04 0.07
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Ara h 9 Cor a 8 Almond Chestnut Pistachio Pinenut
26 0 0 0.64 3.15 0.71 1.68
27 1.27 0.67 0.28 0.5 0.13 0.28
28 0.01 0 0.03 0.02 0.01 0.03
29 0.09 0 0.02 0.14 0.04 0.02
30 3.2 1.98 0.9 1.77 0.14 0.09
31 0.13 0.07 0.04 0.06 0.1 0
32 4.16 0.03 0.11 0.79 0.03 0.03
33 0 0 0.02 0.05 85.6 0
34 0 0 0.5 0.08 2.08 0.05
35 17.6 13.9 1.75 1.7 0.87 0.51
36 100 46.8 15.8 12.8 7.35 3
37 6.58 5.93 1.01 1 0.08 0
38 11.3 ND 7.72 ND 0.85 ND
39 0 0 0.4 0.21 0.1 0.01
40 0.53 0.12 3.56 8.47 1.58 1.74
41 0.01 0 0.13 1.88 0.84 0.65
42 5.56 1.46 1.28 1.83 0.63 0.47
43 0.02 0 3.72 0.53 0.76 0.12
44 0.07 0.07 1.76 3.03 2.21 1.97
45 0.16 0.21 0.12 0.03 0.31 0.01
46 40.6 15.5 5.93 13.3 1.18 1.83
47 44.4 3.64 4.6 4.56 1.8 0.75
48 0 0 3 0.12 1.6 0.11
49 1.86 1.87 1.38 1.7 0.7 0.31
F: Female; M: Male; ND: Not done.
Table 3. Nut allergic patients from Asturias.
No. Age Sex
Specific IgE
Pru p 3 Phl p 12 Bet v 1 Peanut Hazelnut Walnut
1 58 years old F 0.00 0.00 4.99 0.26 2.50 0.00
2 79 years old F 0.06 ND ND 0.06 0.04 ND
3 42 years old F 0.09 0.04 85.40 0.37 57.9 0.04
4 35 years old F 0.01 0.00 14.00 0.01 4.74 0.00
5 39 years old M 1.09 0.02 0.92 0.31 0.66 0.42
6 30 years old M 0.54 0.49 3.12 2.30 2.07 0.69
7 14 years old M 0.03 0.01 0.00 0.02 0.04 1.22
8 6 years old M 0.02 0.02 0.00 1.33 0.81 48.40
9 6 years old M 0.53 0.03 0.03 0.32 22.5 7.36
10 29 years old M 56.5 0.11 0.06 8.41 14.8 38.8
11 8 years old F 0.15 0.11 0.14 0.54 1.48 3.69
12 27 years old M 9.07 0.06 0.03 1.66 1.90 5.06
13 24 years old F 0 0.04 1.87 0.53 1.81 0.04
14 41 years old M 1.76 0.01 0.00 1.13 1.08 1.69
15 44 years old M 9.66 0.01 0.01 0.25 0.58 0.84
16 37 years old M 0.3 0.00 00.00 0.02 0.05 0.06
17 30 years old M 26.8 0.06 0.03 4.66 3.79 5.15
18 16 years old M 0.04 0.03 34.4 8.63 24.50 0.09
19 40 years old F 2.64 0.00 2.46 0.07 1.18 0.29
20 31 years old M 11 0.04 0.06 4.48 5.36 4.95
21 16 years old M 0.05 0.03 0.02 16.2 0.04 1.50
22 12 years old F 0.13 0.81 17.40 4.29 9.54 2.85
23 61 years old F 0.03 0.61 12.00 0.55 5.09 0.07
24 51 years old M 0.17 3.21 18.90 2.14 7.69 0.19
25 47 years old F 4.54 0.00 0.00 1.30 0.52 3.17
26 33 years old F 14 0.00 0.00 3.06 2.31 8.27
27 45 years old F 0 0.00 0.82 0.19 0.77 0.02
28 33 years old M 1.62 0.00 0.00 0.30 0.02 1.03
F: Female; M: Male; ND: Not done.
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Table 4. Nut allergic patients from Asturias.
No.
Specific IgE
Ara h 9 Cor a 8 Almond Chestnut Pistachio Pinenut
1 0 0 0.21 0.73 0.01 0
2 0 0 0.83 0.06 0.14 0.06
3 0.06 0 2.02 10.1 0.04 0.02
4 0 0 0.19 0.66 0.01 0
5 0.33 0.25 0.19 0.41 0.03 0.13
6 0.12 0.08 0.1 1.12 2.12 0.18
7 0 0 0.01 0.04 0.02 0.01
8 0 0 0.1 0.16 0.15 0.01
9 0.13 8.83 0.26 2.91 0.28 0.4
10 27.1 12.1 7.98 5.46 0.91 3.19
11 0.06 0.04 0.43 0.57 0.45 0.44
12 3.43 1.26 0.85 3.02 1.66 0.62
13 ND 0 0.03 0.45 0.06 ND
14 1.62 0.94 0.34 1.35 0.1 0.05
15 0.69 0.22 0.49 0.19 0.08 0.02
16 0.06 0.13 0 0.03 0.02 0
17 8.76 1.36 1.09 1.09 0.17 0.1
18 0.05 0.02 1.6 6.95 0.11 0.1
19 5.44 0.77 0.93 0.2 0.11 0
20 4.71 9.38 1.1 1.39 0.34 0.09
21 0 0 0.21 0.1 0.03 0.02
22 0.08 0 0.29 2.28 5.65 0.07
23 0 0 0.35 0.4 0.18 0.07
24 0 0.07 0.1 0.79 0.09 0.18
25 2.25 1.23 0.27 0.07 0.14 0.99
26 7.54 5.99 2.9 2.51 0.15 0.05
27 0 0 0 0.17 0.16 0
28 1.31 0 0.05 0.5 0.08 0
F: Female; M: Male; ND: Not done.
Exclusion criteria were pregnancy or breastfeeding, extensive skin disease, serious
psychiatric/psychological disturbances, contraindication to adrenaline treatment, alcohol or drug
addiction, treatment with β-blockers, as well as any other condition which could either hamper
protocol compliance or for which an oral challenge test is contraindicated [15].
2.2. Allergen-Specific IgE
Allergen-specific IgE was measured with the ImmunoCAP System FEIA (ThermoFisher Scientific
AB, Uppsala, Sweden) following the manufacturer’s recommendations. Venous blood samples were
analyzed for IgE to nuts (peanut, hazelnut, almond, chestnut, pistachio, pine nut, and walnut), as well
as to Pru p 3, Bet v 1, Phl p 12, Ara h 9, and Cor a 8.
2.3. Skin Prick-Prick Test
Skin prick tests were performed with a commercial battery (C.B.F. LETI, S.A; Tres Cantos, Spain)
of nut extracts (almond, hazelnut, peanut, chestnut, sunflower seed, pine nut, walnut, pistachio)
and prick-by-prick test with nuts (almond, hazelnut, peanut, chestnut, sunflower seed, pine nut,
walnut, pistachio, and cashew), as well as a commercial battery (ALK-Abelló, Madrid, Spain) of pollen
extracts, including Lollium perenne, Betula verrucosa, Cupressus sempervirens, Platanus acerifolia, Artemisia
vulgaris, Parietaria judaica, Salsola kali, Plantago lanceolata, and Olea europaea. The ALK-Lancet needle
(ALK-Lancet; ALK-Abelló, Horsholm, Denmark) was used for skin tests, which were performed
according to EAACI guidelines [16]. Histamine phosphate at 10 mg/mL and normal saline solution
were used as positive and negative controls, respectively. A weal with a diameter at least 3 mm larger
than the negative control was considered a positive reaction.
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2.4. Ethical Consent
The Fundación Jiménez Díaz Ethic Committee approved this study and written informed consent
was obtained from all subjects.
2.5. Statistical Analysis
Statistical analysis was performed with SPSS (SPSS Inc., Chicago, IL, USA). The qualitative
variables were expressed as a percentage (without taking into account the missing cases).
For quantitative variables, means and standard deviation (SD) were calculated, and for specific
IgE and SPT results, medians and 25th (Q1) and 75th (Q3) percentiles were given. A X2 test was used
for comparisons of frequencies. Values were considered significant at a p value of less than 0.05.
3. Results
A total of 77 patients (Table 5) with nut allergy took part in the study: 49 patients from Madrid
and 28 from Asturias. Patients from Madrid had a mean age of 30 years: 46.9% female (23 out of the
49 patients) and 53.1% male (26 out of the 49 patients). The mean age in Asturias was 33.4 years: 42.9%
female (12 out of the 28 patients) and 57.1% male (16 out of the 28 patients). Fifteen patients younger
than eighteen years participated in the study (eight in Madrid and seven in Asturias).
Table 5. General characteristics of nut allergic patients.
Characteristics Madrid Asturias
Nut allergic patients 49 28
Age (mean ± SD) 30.1 ± 13.5 33.4 ± 17.4
Sex 46.9% ♀/53.1% ♂ 42.9% ♀/57.1% ♂
Nut Allergy
Walnut 32 (65.5%) 14 (50.0%)
Hazelnut 28 (57.0%) 16 (57.1%)
Peanut 23 (46.9%) 13 (46.4%)
Almond 21 (42.0%) 3 (10.7%)
Symptoms
OAS 13 (25.6%) 14 (50.0%)
SS 36 (73.5%) 14 (50.0%)
SD: standard deviation; OAS: Oral Allergy Syndrome; SS: Systemic Symptoms.
The study results were focused on hazelnut, peanut and walnut because of they were the
three most frequent nuts eliciting allergy in both regions. The most frequent in Madrid was
walnut (32 patients—65.3%), followed by hazelnut (28 patients—57.1%), peanut (23 patients—46.9%),
and almond (21 patients—42%); while in Asturias the most frequent nut was hazelnut
(16 patients—7.1%), followed by walnut (14 patients—50.0%), peanut (13 patients—46.4%), and
almond (three patients—10.7%). Other nuts elicited allergy less frequently.
Respiratory symptoms affected 81.6% of the patients in Madrid and 56.6% in Asturias. All patients
from Madrid had associated asthma and rhinitis while in Asturias rhinitis was the most prevalent
respiratory symptom (47% rhinitis, 29% rhinitis and asthma, and 23.5% asthma).
In Madrid, 77.5% of the patients were sensitized to grass pollen and 47% to birch pollen, but 44%
of the patients were sensitized to both. In Asturias, 57.1% and 42.8% were sensitized to grass pollen
and birch pollen, respectively, although only 3.6% were sensitized to both grass and birch pollens
in Asturias.
Interestingly, 36 of the 49 nut allergic patients (73.5%) from Madrid had systemic symptoms, while
only 14 of the 28 patients (50.0%) studied in Asturias experienced systemic reactions, the difference being
statistically significant (p < 0.05). 26.5% patients from Madrid and 50% from Asturias had isolated OAS
symptoms (p < 0.05). In both regions walnut was the nut that elicited systemic symptoms in a larger
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number of patients (22 patients in Madrid, seven patients in Asturias), while walnut elicited OAS in
a larger number of patients from Madrid (10 patients) and hazelnut in Asturias (10 patients) (Table 6).
Table 6. Symptoms to nuts in patients from Madrid and Asturias.
Symptoms
Madrid Asturias
n % n %
Hazelnut 28 16
OAS 9 32.1% 10 62.5%
SS 19 67.9% 6 37.5%
Peanut 23 13
OAS 5 21.7% 8 61.5%
SS 18 78.3% 5 38.5%
Walnut 32 14
OAS 10 31.2% 7 50.0%
SS 22 68.8% 7 50.0%
On evaluating the pattern of sensitizations at the molecular level, we found important and
interesting differences (Figures 1 and 2 and Table 7). In Madrid, sensitization to Pru p 3 was 71.4%
followed by Ara h 9 (61.2%), Cor a 8 (44.9%), Phl p 12 (20.4%), and Bet v 1 (12%). In the patient group
from Asturias, 46.4% were sensitized to Pru p 3, 42.9% to Bet v 1, 33.3% to Ara h 9, 30% to Cor a 8, and
14.3% to Phl p 12.
Figure 1. Differences in molecular pattern between Madrid and Asturias.
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Figure 2. Specific IgE to LTP (Pru p 3) and Bet v 1 from both regions (median, Q1, and Q3).
Table 7. Differences in specific IgE levels to purified allergens between Madrid and Asturias
(Median, Q1, Q3).
Allergen Asturias Madrid p
Pru p 3 0.23 (0.04, 3.11) 2.40 (0.23, 7.58) 0.037
Phl p 12 0.03 (0.00, 0.06) 0.05 (0.01, 0.32) 0.205
Bet v 1 0.06 (0.00, 4.05) 0.01 (0.00, 0.04) 0.005
In the Madrid region, the percentage of sensitizations to LTP was higher than sensitizations to
Bet v 1 (LTP 71.4%; Bet v 1 12%; p < 0.05). This pattern of molecular sensitization was repeated in
patients allergic to walnut (78.0% LTP vs. 12.5% Bet v 1), hazelnut (78.6% LTP vs. 12.0% Bet v 1), and
peanut (78.6% LTP vs. 8.7% Bet v 1). Surprisingly, this situation was very different with respect to
analyzing the molecular pattern of sensitization to different nut allergies in Asturias. Bet v 1 was the
predominant allergen involved among patients allergic to hazelnuts (56.2% to Bet v 1 vs. 31.2% to
LTP), while LTP was the predominant allergen among patients allergic to peanut (61.5% to LTP vs.
30.8% to Bet v 1). Sensitization to walnut-allergic patients was equivalent to LTP (42.9%) and Bet v 1
(42.9%) (Figure 3).
Figure 3. Differences in molecular pattern between Madrid and Asturias for patients allergic to
hazelnut, peanut, or walnut.
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On evaluating the frequency of allergy to nuts in Asturias (Figure 4) among patients sensitized to LTP,
peanut (61.5%) was the most frequent nut-eliciting allergy, followed by walnut (46.1%) and then hazelnut
(38.5%). On evaluating the frequency of allergy to nuts among patients sensitized to Bet v 1, hazelnut
(75%) was the most frequent nut-eliciting allergy, followed by walnut (50%) and then peanut (33%).
Figure 4. Frequency of nut allergies in patients sensitized to LTP and Bet v 1 from Asturias.
4. Discussion
This study found that walnut, hazelnut, and peanut were the most frequent nuts eliciting allergy
in both regions of Spain. Despite this consistency, important differences in molecular pattern were
seen not only between both regions, but also among different nuts in Asturias. The different molecular
pattern was linked to the frequency of systemic symptoms suffered by patients.
Nut is a frequent cause of food allergy worldwide and is responsible for severe and near-fatal
anaphylactic reactions [2]. Spain is probably one of the most typical examples of plant food allergy
due to LTP sensitizations [10–13,17,18].
In this study we have evaluated the most frequent nut-eliciting allergy in two different regions
from Spain. While, a distance of only 400 km separate them, Madrid has a continental climate and
Asturias a maritime climate. An interesting result to be emphasized was that percentage of positive
skin prick test results to birch pollen was similar in both regions (47% in Madrid and 42.8% in Asturias)
without statistically significant differences. Curiously, on evaluating primary sensitizations, 12% of the
patients from Madrid were sensitized to Bet v 1, while 42.8% were sensitized in Asturias, the difference
being now statistically significant (p < 0.05). In this sense, we should remember that Madrid is an area
with absence or low atmospheric level of birch tree pollen. The considerable percentage of patients
sensitized to birch pollen in the Madrid area with a low percentage of sensitization to Bet v 1 have
been previously reported [17].
Walnut, peanut, and hazelnut were the most frequent nuts eliciting allergy in both regions
of Spain and, as a result, the study was focused on the analysis of differences of these three nuts.
Walnut was more frequent in Madrid, but there were small differences among the tree nut prevalence
in Asturias, with hazelnut being more frequent in this case but without significant statistical differences.
These results were different from those reported by McWilliam et al., who analyzed the prevalence of
nut allergy worldwide [3]. These differences might be explained by the allergen molecule involved in
the allergic reactions, since, as previously stated, LTP was usually the major allergen involved in food
allergy in Spain [10,12,13,18].
Another important result to be emphasized was the allergen pattern involved in the allergic
reactions. On the one hand, there was a predominant pattern of LTP sensitization in the Madrid region,
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which was in accordance with previously-reported studies [10,12,13,18]. This pattern was similar to
the evaluated individual nuts (i.e., walnut, hazelnut and peanut). On the other hand, a mix of LTP
and Bet v 1 sensitizations highlighted the pattern in Asturias region, however, the pattern changed
depending on the nut evaluated. A predominant pattern of LTP was found in peanut allergy, Bet v 1
pattern in hazelnut allergy, and a mixed pattern (LTP and Bet v 1) to walnut allergy. These data are
especially relevant because, to the best of our knowledge, this is the first time in which the predominant
allergen family eliciting allergy in the same area changed from one nut to another. Nonetheless, we are
conscious that it should be confirmed in studies with a higher number of patients.
Results of this report, along with other nut allergy studies from Spain [10–13,17,18], indicate that
three different patterns of nut allergy coexist in Spain: LTP pattern, the most frequent pattern in most
places for older children (>5 years old) and adult nut allergic patients; Bet v 1 pattern, which was
significant in areas with patients sensitized to Bet v 1 dominated by hazelnut allergy; and, finally,
storage protein pattern (2S albumin) in nut allergic children (<5 years old).
5. Conclusions
In this study we found that walnut, hazelnut, and peanut were the most frequent nuts eliciting
allergy in both regions of Spain. Despite this, important differences in molecular pattern were
appreciated not only between both regions, but also among nuts in Asturias. The different molecular
pattern was linked to the frequency of anaphylaxis.
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